{"65ea761c7d7cafc62d68454ebf79a2804d28174f": [["Most prominent examples include severe acute respiratory syndrome (SARS) and pneumonic plague (smallpox is discussed in the chapter by Saks and Karras elsewhere in this issue).", [["acute respiratory syndrome", "DISEASE", 39, 65], ["SARS", "DISEASE", 67, 71], ["pneumonic plague", "DISEASE", 77, 93], ["smallpox", "DISEASE", 95, 103], ["severe acute respiratory syndrome", "PROBLEM", 32, 65], ["SARS", "PROBLEM", 67, 71], ["pneumonic plague", "PROBLEM", 77, 93], ["severe", "OBSERVATION_MODIFIER", 32, 38], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["respiratory syndrome", "OBSERVATION", 45, 65], ["pneumonic", "OBSERVATION_MODIFIER", 77, 86], ["plague", "OBSERVATION_MODIFIER", 87, 93]]]], "24a8d61289ce1c542917b246a732649ef52d254b": [["Later, the extended models, such as the susceptible-exposed-infectious-recovered (SEIR) model 7 , are proposed.", [["infectious", "OBSERVATION_MODIFIER", 60, 70]]], ["With neural networks [8] [9] [10] [11] , researchers can generate predictions with the training data 9 , and the artificial intelligence (AI) methodology has deeply changed the modeling methods but avoiding the overfitting problems is another important topic.", [["neural", "ANATOMY", 5, 11], ["the training data", "TEST", 83, 100], ["the modeling methods", "TREATMENT", 173, 193], ["the overfitting problems", "PROBLEM", 207, 231]]]], "PMC6780103": [], "9eada110e2edb3036dafe9bfb49ab481bc2da9ac": [["IntroductionThe developing practice of using neonatal organs and tissues for research raises specific ethical and legal questions that beg for rational and transparent guidelines with which to evaluate referrals.", [["neonatal organs", "ANATOMY", 45, 60], ["tissues", "ANATOMY", 65, 72], ["organs", "ORGAN", 54, 60], ["tissues", "TISSUE", 65, 72]]], ["This is especially true because of the rapidly increasing use of neonatal organs for research.", [["organs", "ANATOMY", 74, 80], ["organs", "ORGAN", 74, 80], ["neonatal organs", "TREATMENT", 65, 80]]], ["To this end, a working group of scholars representing disciplines including bioethics, neonatology, obstetrics, and law, as well as professionals from Organ Procurement Organizations (OPO) and tissue banks including IIAM was formed.", [["tissue", "ANATOMY", 193, 199], ["tissue", "TISSUE", 193, 199], ["IIAM", "TREATMENT", 216, 220]]], ["Its task was to consider the myriad of issues and to develop algorithms and policies for screening potential neonatal donors.", [["donors", "ORGANISM", 118, 124]]], ["Our primary goals were: (a) to ensure that referrals were evaluated in compliance with all applicable federal and state laws, regulations, and institutional protocols; and (b) to follow acceptable ethical standards.BackgroundThe donation of organs and tissues from neonates (birth to 28 days) for transplantation has been a relatively infrequent occurrence for a number of reasons, including a relative scarcity of recipients who are size matched to these small donors (Stiers et al. 2015; Boucek et al. 2018) .", [["organs", "ANATOMY", 241, 247], ["tissues", "ANATOMY", 252, 259], ["organs", "ORGAN", 241, 247], ["tissues", "TISSUE", 252, 259], ["recipients", "ORGANISM", 415, 425], ["donors", "ORGANISM", 462, 468], ["transplantation", "TREATMENT", 297, 312], ["organs", "ANATOMY", 241, 247], ["tissues", "ANATOMY", 252, 259], ["size", "OBSERVATION_MODIFIER", 434, 438], ["small", "OBSERVATION_MODIFIER", 456, 461]]], ["Director of Research from the United Network for Organ Sharing Robert Carrico shares that since 2010, annual totals of neonatal organ donors in the United States, both from donation after brain death (DBD) and donation after circulatory death (DCD), have ranged from 3 to 21 donors annually.", [["organ", "ANATOMY", 128, 133], ["brain", "ANATOMY", 188, 193], ["circulatory", "ANATOMY", 225, 236], ["brain death", "DISEASE", 188, 199], ["circulatory death", "DISEASE", 225, 242], ["DCD", "DISEASE", 244, 247], ["organ", "ORGAN", 128, 133], ["brain", "ORGAN", 188, 193], ["donors", "ORGANISM", 275, 281], ["brain death", "PROBLEM", 188, 199], ["donation", "TREATMENT", 210, 218], ["circulatory death", "PROBLEM", 225, 242]]], ["This represents between 0.03 and 0.21% of organ donors recovered in any given year.", [["organ", "ANATOMY", 42, 47], ["organ", "ORGAN", 42, 47], ["donors", "ORGANISM", 48, 54], ["organ donors", "TREATMENT", 42, 54]]], ["The donation of neonatal organs and tissues for research is even less common than for transplantation, primarily because family members who receive a prenatal diagnosis of a lethal anomaly (LA) or experience the death of a neonate are not routinely offered information about research donation.", [["neonatal organs", "ANATOMY", 16, 31], ["tissues", "ANATOMY", 36, 43], ["anomaly", "DISEASE", 181, 188], ["LA", "CHEMICAL", 190, 192], ["death", "DISEASE", 212, 217], ["organs", "ORGAN", 25, 31], ["tissues", "TISSUE", 36, 43], ["neonate", "ORGANISM", 223, 230], ["transplantation", "TREATMENT", 86, 101], ["a lethal anomaly", "PROBLEM", 172, 188], ["research donation", "TREATMENT", 275, 292]]], ["Moreover, until recently researchers rarely sought neonatal organs and tissues.BackgroundIn the mid-2010s, some families who received a pre-natal diagnosis of a LA such as anencephaly decided to carry their pregnancy to term regardless of the poor prognosis for long-term survival, often wishing to donate after the anticipated natural death of their neonate (Gray 2016a, b, c, d, e, f, g; Young 2017) .", [["neonatal organs", "ANATOMY", 51, 66], ["tissues", "ANATOMY", 71, 78], ["LA", "CHEMICAL", 161, 163], ["anencephaly", "DISEASE", 172, 183], ["death", "DISEASE", 336, 341], ["organs", "ORGAN", 60, 66], ["tissues", "TISSUE", 71, 78], ["neonate", "ORGANISM", 351, 358], ["anencephaly", "PROBLEM", 172, 183], ["tissues", "ANATOMY", 71, 78]]], ["Social media, blogs, and websites, including www.purposefulgift.org and www.anencephaly.info, have increasingly connected parents who receive a diagnosis of a LA.", [["anencephaly", "DISEASE", 76, 87], ["LA", "CHEMICAL", 159, 161], ["anencephaly", "PROBLEM", 76, 87]]], ["Some expectant parents began contacting the International Institute for the Advancement of Medicine (IIAM) with requests for assistance.BackgroundIIAM is among the largest 501c3 non-profit organizations in the U.S. that coordinates the placement of non-transplantable organs and tissues with Organ Procurement Organizations (OPOs) and researchers.", [["organs", "ANATOMY", 268, 274], ["tissues", "ANATOMY", 279, 286], ["organs", "ORGAN", 268, 274], ["tissues", "TISSUE", 279, 286], ["the placement of non-transplantable organs and tissues", "TREATMENT", 232, 286], ["largest", "OBSERVATION_MODIFIER", 164, 171], ["organs", "ANATOMY", 268, 274]]], ["IIAM is a division of MTF Biologics, one of the largest non-profit providers of donated human tissues (e.g., musculoskeletal, dermal and placental).", [["tissues", "ANATOMY", 94, 101], ["musculoskeletal", "ANATOMY", 109, 124], ["dermal", "ANATOMY", 126, 132], ["placental", "ANATOMY", 137, 146], ["human", "ORGANISM", 88, 93], ["tissues", "TISSUE", 94, 101], ["dermal", "TISSUE", 126, 132], ["placental", "ORGAN", 137, 146], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 88, 93], ["MTF Biologics", "TREATMENT", 22, 35], ["donated human tissues", "PROBLEM", 80, 101], ["largest", "OBSERVATION_MODIFIER", 48, 55], ["donated human tissues", "OBSERVATION", 80, 101], ["musculoskeletal", "ANATOMY", 109, 124], ["placental", "ANATOMY", 137, 146]]], ["Founded in 1986, IIAM annually receives over 15,000 referrals of non-transplantable organs and tissues authorized for research from donors from U.S. OPOs.", [["organs", "ANATOMY", 84, 90], ["tissues", "ANATOMY", 95, 102], ["organs", "ORGAN", 84, 90], ["tissues", "TISSUE", 95, 102], ["donors", "ORGANISM", 132, 138], ["organs", "ANATOMY", 84, 90]]], ["In the past 20 years, they have placed more than 14,000 research organs.", [["organs", "ANATOMY", 65, 71], ["organs", "ORGAN", 65, 71]]], ["Matching donors and research projects is a challenging process, as researchers have very specific donor criteria and logistics requirements.", [["donors", "OBSERVATION", 9, 15]]], ["Research organs provided by IIAM are used by academic researchers as well as by pharmaceutical and medical device companies in the U.S. and abroad.BackgroundAt the same time, academic researchers began requesting neonatal organs through IIAM.", [["organs", "ANATOMY", 9, 15], ["organs", "ANATOMY", 222, 228], ["organs", "ORGAN", 9, 15], ["organs", "ORGAN", 222, 228]]], ["Prior to this time, researchers had limited access to such organs and relied either on organs from adult donors or fetal tissue.", [["organs", "ANATOMY", 59, 65], ["organs", "ANATOMY", 87, 93], ["fetal tissue", "ANATOMY", 115, 127], ["organs", "ORGAN", 59, 65], ["organs", "ORGAN", 87, 93], ["donors", "ORGANISM", 105, 111], ["fetal tissue", "TISSUE", 115, 127], ["such organs", "PROBLEM", 54, 65], ["adult donors or fetal tissue", "PROBLEM", 99, 127], ["fetal tissue", "OBSERVATION", 115, 127]]], ["No national guidelines or standards existed for the coordination of neonatal donation for research so referrals of potential neonatal donors were sporadic and managed on an ad hoc basis.", [["donors", "ORGANISM", 134, 140], ["neonatal donation", "TREATMENT", 68, 85], ["potential neonatal donors", "PROBLEM", 115, 140]]], ["After a brief discussion of ethical and legal issues as well as clinical ramifications of neonatal donation, we will explain how they helped shape our policy recommendations.", [["ethical and legal issues", "PROBLEM", 28, 52], ["neonatal donation", "TREATMENT", 90, 107]]], ["Although neonatal organs and tissues can be used for both transplantation and research, we will mainly focus on donation for research.Ethical and Legal PerspectivesNeonatal organ and tissue donation represent a desire to make an altruistic gift and can play a key role in the care and support provided to families by hospital staff around the time of a neonate's death.", [["neonatal organs", "ANATOMY", 9, 24], ["tissues", "ANATOMY", 29, 36], ["organ", "ANATOMY", 173, 178], ["tissue", "ANATOMY", 183, 189], ["death", "DISEASE", 363, 368], ["organs", "ORGAN", 18, 24], ["tissues", "TISSUE", 29, 36], ["organ", "ORGAN", 173, 178], ["tissue", "TISSUE", 183, 189], ["both transplantation", "TREATMENT", 53, 73], ["Neonatal organ and tissue donation", "TREATMENT", 164, 198], ["a neonate's death", "PROBLEM", 351, 368], ["organ", "ANATOMY", 173, 178], ["tissue", "ANATOMY", 183, 189]]], ["Indeed, many families who have donated the organs and tissues of their deceased neonate reported that the decision brought them solace and comfort (Gray 2016a, b, c, d, e, f, g; Rhodes 2014; Purposeful Gift) .", [["organs", "ANATOMY", 43, 49], ["tissues", "ANATOMY", 54, 61], ["organs", "ORGAN", 43, 49], ["tissues", "TISSUE", 54, 61], ["neonate", "ORGANISM", 80, 87], ["comfort", "TEST", 139, 146], ["Gray", "TEST", 148, 152]]], ["Moreover, neonatal donation is proving increasingly important for research into a variety of areas, including determining the causes of neural tube defects (NTD); treating vision impairment; diabetes; organ system development; rheumatoid arthritis; pancreatic cancer; treatment of MRSA infection; pediatric emergency resuscitation (Gray 2016a, b, c, d, e, f, g; Aguayo-Mazzucato et al. 2017; Gregg et al. 2012; Ardini-Poleske et al. 2017; Cogger et al. 2017) .Ethical and Legal PerspectivesThe primary goal of families with whom some of the authors (GDS, JO, MA, SBG) have interacted was to carry a fetus diagnosed with LA to term (or as close to term as possible) in order to achieve a live birth, knowing that aggressive treatment after birth would be futile.", [["neural tube", "ANATOMY", 136, 147], ["organ system", "ANATOMY", 201, 213], ["pancreatic cancer", "ANATOMY", 249, 266], ["fetus", "ANATOMY", 599, 604], ["neural tube defects", "DISEASE", 136, 155], ["NTD", "DISEASE", 157, 160], ["vision impairment", "DISEASE", 172, 189], ["diabetes", "DISEASE", 191, 199], ["rheumatoid arthritis", "DISEASE", 227, 247], ["pancreatic cancer", "DISEASE", 249, 266], ["MRSA infection", "DISEASE", 281, 295], ["LA", "CHEMICAL", 620, 622], ["neural tube", "MULTI-TISSUE_STRUCTURE", 136, 147], ["organ", "ORGAN", 201, 206], ["pancreatic cancer", "CANCER", 249, 266], ["fetus", "ORGANISM", 599, 604], ["MRSA", "SPECIES", 281, 285], ["neonatal donation", "TREATMENT", 10, 27], ["neural tube defects", "PROBLEM", 136, 155], ["vision impairment", "PROBLEM", 172, 189], ["diabetes", "PROBLEM", 191, 199], ["organ system development", "PROBLEM", 201, 225], ["rheumatoid arthritis", "PROBLEM", 227, 247], ["pancreatic cancer", "PROBLEM", 249, 266], ["MRSA infection", "PROBLEM", 281, 295], ["pediatric emergency resuscitation", "TREATMENT", 297, 330], ["Gray", "TEST", 332, 336], ["Aguayo", "TEST", 362, 368], ["Ardini", "TEST", 411, 417], ["aggressive treatment", "TREATMENT", 712, 732], ["neural", "OBSERVATION", 136, 142], ["tube defects", "OBSERVATION", 143, 155], ["rheumatoid arthritis", "OBSERVATION", 227, 247], ["pancreatic", "ANATOMY", 249, 259], ["cancer", "OBSERVATION", 260, 266], ["MRSA", "OBSERVATION_MODIFIER", 281, 285], ["infection", "OBSERVATION", 286, 295]]], ["The possibility of organ and tissue donation was a secondary goal and provided an opportunity to find something positive in the midst of a tragic situation.Ethical and Legal PerspectivesLegal and ethical questions that must be addressed require adherence to a variety of laws, regulations, and ethical principles.", [["organ", "ANATOMY", 19, 24], ["tissue", "ANATOMY", 29, 35], ["organ", "ORGAN", 19, 24], ["tissue", "TISSUE", 29, 35], ["organ and tissue donation", "TREATMENT", 19, 44], ["something positive", "PROBLEM", 102, 120], ["possibility of", "UNCERTAINTY", 4, 18], ["organ", "ANATOMY", 19, 24], ["tissue donation", "OBSERVATION", 29, 44]]], ["Various state and federal laws regulate the donation of organs and tissues regardless of the age of a potential donor.", [["organs", "ANATOMY", 56, 62], ["tissues", "ANATOMY", 67, 74], ["organs", "ORGAN", 56, 62], ["tissues", "TISSUE", 67, 74]]], ["Federal law does not contain any restrictions that are uniquely relevant to neonatal organ and tissue donation.", [["organ", "ANATOMY", 85, 90], ["tissue", "ANATOMY", 95, 101], ["organ", "ORGAN", 85, 90], ["tissue", "TISSUE", 95, 101]]], ["The federal National Organ Transplant Act (NOTA) and related regulations prohibit the sale of organs or tissues and creates a framework to facilitate and standardize the donation and recovery process (42 U.S.C. \u00a7 273 et seq).", [["organs", "ANATOMY", 94, 100], ["tissues", "ANATOMY", 104, 111], ["organs", "ORGAN", 94, 100], ["tissues", "TISSUE", 104, 111]]], ["At the state level, there are laws that may affect tissue and organ donation for research.", [["tissue", "ANATOMY", 51, 57], ["organ", "ANATOMY", 62, 67], ["tissue", "TISSUE", 51, 57], ["organ", "ORGAN", 62, 67]]], ["All states have adopted the Uniform Determination of Death Act (DDA), which describes the events that trigger the possibility of organ and tissue donation (DDA 1980) .", [["organ", "ANATOMY", 129, 134], ["tissue", "ANATOMY", 139, 145], ["Death", "DISEASE", 53, 58], ["organ", "ORGAN", 129, 134], ["tissue", "TISSUE", 139, 145], ["organ and tissue donation", "TREATMENT", 129, 154]]], ["Organ and tissue donation must conform to the so-called Dead Donor Rule, which states that no patient's death may be caused by organ recovery (Robertson 1999) .Ethical and Legal PerspectivesUnder the policies stipulated by the Organ Procurement and Transplant Network, it is mandatory to separate the medical care of a patient and the determination of death from the recovery of organs or tissues in all cases of donation (Organ Procurement and Transplant Network Policies (pp. 28-29) Available at: https://optn.transplant.hrsa.gov/media/1200/ optn_policies.pdf).", [["Organ", "ANATOMY", 0, 5], ["tissue", "ANATOMY", 10, 16], ["organ", "ANATOMY", 127, 132], ["organs", "ANATOMY", 379, 385], ["tissues", "ANATOMY", 389, 396], ["death", "DISEASE", 104, 109], ["death", "DISEASE", 352, 357], ["Organ", "TISSUE", 0, 5], ["tissue", "TISSUE", 10, 16], ["patient", "ORGANISM", 94, 101], ["organ", "ORGAN", 127, 132], ["patient", "ORGANISM", 319, 326], ["organs", "ORGAN", 379, 385], ["tissues", "TISSUE", 389, 396], ["patient", "SPECIES", 94, 101], ["patient", "SPECIES", 319, 326], ["Organ and tissue donation", "TREATMENT", 0, 25], ["Dead Donor Rule", "TEST", 56, 71], ["patient's death", "PROBLEM", 94, 109], ["death", "PROBLEM", 352, 357], ["tissue", "ANATOMY", 10, 16], ["donation", "OBSERVATION", 17, 25]]], ["If life-sustaining treatment is withdrawn, donation may occur if the patient dies and organ and tissue recovery can occur within a time period specified by the intended researcher.Ethical and Legal PerspectivesObtaining authorization for donation from parents of neonatal patients can be complex, and has received significant attention in previous studies (Martin et al. 2015) .", [["organ", "ANATOMY", 86, 91], ["tissue", "ANATOMY", 96, 102], ["patient", "ORGANISM", 69, 76], ["organ", "ORGAN", 86, 91], ["tissue", "TISSUE", 96, 102], ["patients", "ORGANISM", 272, 280], ["patient", "SPECIES", 69, 76], ["patients", "SPECIES", 272, 280], ["treatment", "TREATMENT", 19, 28], ["donation", "TREATMENT", 238, 246], ["previous studies", "TEST", 339, 355]]], ["Typically, OPO staff conduct the authorization process, but they are not involved in the routine care of the neonate, or in determining or pronouncing the death of the neonate.", [["death", "DISEASE", 155, 160], ["neonate", "ORGANISM", 109, 116], ["neonate", "ORGANISM", 168, 175]]], ["Family members are given the latitude to determine which organs or tissues they wish to donate, and whether they wish to donate solely for transplantation or transplantation and research.Ethical and Legal PerspectivesSome families may wish to donate organs in the context of actively terminating a pregnancy with an ultimately lethal outcome.", [["organs", "ANATOMY", 57, 63], ["tissues", "ANATOMY", 67, 74], ["organs", "ANATOMY", 250, 256], ["organs", "ORGAN", 57, 63], ["tissues", "TISSUE", 67, 74], ["organs", "ORGAN", 250, 256], ["transplantation", "TREATMENT", 139, 154], ["transplantation", "TREATMENT", 158, 173]]], ["The American College of Obstetricians and Gynecologists (ACOG) has established guidelines regarding medically acceptable indications for pre-term delivery for maternal or newborn benefit, but such a choice raises the legally and ethically fraught issue of abortion (Nicholson 2015; Committee Opinion No. 560 2013) .", [["pre-term delivery", "TREATMENT", 137, 154]]], ["Many state laws have unique implications for the legality of neonatal organ donation in certain circumstances.", [["organ", "ANATOMY", 70, 75], ["organ", "ORGAN", 70, 75], ["neonatal organ donation", "TREATMENT", 61, 84]]], ["In particular, laws forbidding donation of, or research upon, tissue resulting from an abortion may be relevant in cases in which a pre-term delivery technically meets the statelaw definition of abortion.", [["tissue", "ANATOMY", 62, 68], ["tissue", "TISSUE", 62, 68], ["a pre-term delivery", "TREATMENT", 130, 149], ["abortion", "PROBLEM", 195, 203]]], ["Although abortion is a legal medical procedure in the United States, for purposes of this project we rejected the possibility of accepting donations that resulted from abortions.", [["abortions", "DISEASE", 168, 177], ["a legal medical procedure", "TREATMENT", 21, 46], ["abortions", "PROBLEM", 168, 177]]], ["Our guidelines do, however, allow acceptance of donations from some neonates who are delivered pre-term-but only if the delivery would not qualify as an abortion under applicable law.Ethical and Legal PerspectivesFinally, we considered federal and state laws governing the withholding or withdrawing of lifesustaining care from disabled neonates.", [["neonates", "ORGANISM", 68, 76], ["neonates", "ORGANISM", 337, 345], ["withdrawing of lifesustaining care", "TREATMENT", 288, 322], ["disabled neonates", "PROBLEM", 328, 345]]], ["These laws, most specifically the Baby Doe Regulations (BDR) and the Born Alive Infant Protection Act (BAIPA), apply primarily to clinicians and hospitals that are directly involved in the pre-term delivery and subsequent care of a neonate, and do not constrain organ donation.Ethical and Legal PerspectivesBDR and BAIPPA are federal laws that apply to pre-term delivery and resuscitation.", [["organ", "ANATOMY", 262, 267], ["organ", "ORGAN", 262, 267], ["pre-term delivery", "TREATMENT", 353, 370], ["resuscitation", "TREATMENT", 375, 388]]], ["States are required to enact procedures for reporting and responding to ''medical neglect,'' which is defined to include withholding treatment (including appropriate nutrition, hydration, and medication) from neonates with disabilities and life-threatening conditions (42 U.S.C. \u00a7 5106a(b)(2)(C)).", [["disabilities", "DISEASE", 223, 235], ["''medical neglect", "PROBLEM", 72, 89], ["withholding treatment", "TREATMENT", 121, 142], ["appropriate nutrition", "TREATMENT", 154, 175], ["hydration", "TREATMENT", 177, 186], ["medication", "TREATMENT", 192, 202]]], ["This requirement imposes a fairly sweeping mandate to provide care for neonates born with potentially lethal conditions.", [["neonates", "ORGANISM", 71, 79], ["potentially lethal conditions", "PROBLEM", 90, 119]]], ["There are, however, three exceptions to the requirement of providing medically indicated treatment.", [["treatment", "TREATMENT", 89, 98]]], ["Treatment is not required if, ''in the treating physician's or physicians' reasonable medical judgment:Ethical and Legal Perspectives\u2022 The neonate is chronically and irreversibly comatose''; \u2022 Providing treatment would only prolong the death of the neonate, would not be effective in correcting or ameliorating the conditions, or would ''otherwise be futile in terms of the survival of the neonate'' and, \u2022 The treatment ''would be virtually futile in terms of the survival of the neonate'' and ''the treatment itself under such circumstances would be inhumane'' (42 U.S.C. \u00a7 5106 g(a) (5)).Ethical and Legal PerspectivesThe American Academy of Pediatrics and the Ethics Committee of the American College of Critical Care Medicine have both affirmed that it is ethically and legally justifiable to withhold or withdraw aggressive life-sustaining treatment in neonates when the burdens of such treatment far outweigh its benefits (Ethics Committee 2001; Committee on Bioethics 2013; Sarnaik 2015; AAP policy Statement 2010; Kon et al. 2016; Gries et al. 2013) .Ethical and Legal PerspectivesBAIPA is a second federal law that has an intent similar to that of BDR.", [["comatose", "DISEASE", 179, 187], ["death", "DISEASE", 236, 241], ["neonate", "ORGANISM", 139, 146], ["neonate", "ORGANISM", 249, 256], ["neonate", "ORGANISM", 481, 488], ["neonates", "ORGANISM", 859, 867], ["treatment", "TREATMENT", 203, 212], ["the neonate''", "TREATMENT", 477, 490], ["the treatment", "TREATMENT", 497, 510], ["aggressive life", "TREATMENT", 819, 834], ["sustaining treatment", "TREATMENT", 835, 855], ["such treatment", "TREATMENT", 888, 902], ["BDR", "PROBLEM", 1158, 1161], ["chronically", "OBSERVATION_MODIFIER", 150, 161]]], ["BAIPA states that any infant who is ''born alive,'' at any stage of development, must be treated as a person for purposes of the protections of federal law (1 U.S.C. \u00a7 8).", [["infant", "SPECIES", 22, 28], ["person", "SPECIES", 102, 108]]], ["It might, however, mean that the Emergency Medical Treatment and Active Labor Act's (EMTALA) requirement of stabilizing patients who arrive at the hospital in an emergency condition would apply to very premature infants as well (42 U.S.C.A. \u00a7 1395dd) EMTALA, combined with the BAIPA, may therefore be understood to require some treatment of extremely premature infants who are born with a heartbeat or other signs of life.", [["patients", "ORGANISM", 120, 128], ["infants", "ORGANISM", 212, 219], ["infants", "ORGANISM", 361, 368], ["patients", "SPECIES", 120, 128], ["infants", "SPECIES", 212, 219], ["infants", "SPECIES", 361, 368], ["the Emergency Medical Treatment", "TREATMENT", 29, 60], ["Active Labor Act's", "TREATMENT", 65, 83], ["the BAIPA", "TREATMENT", 273, 282], ["some treatment", "TREATMENT", 323, 337], ["a heartbeat", "PROBLEM", 387, 398]]], ["Futile or non-medically-indicated treatment would not likely be required for a very premature infant, since such treatment would not, within reasonable medical probability, prevent the neonate's condition from deteriorating.Ethical and Legal PerspectivesThus, as long as it is appropriate to characterize any care withheld from very premature neonates as being futile (in reasonable medical judgment), there is little danger of running afoul of BDR or BAIPA, as applied to EMTALA.Clinical PerspectiveIn 2015, there were 15,652 total U.S. neonatal deaths (3.93 per 1000 live births) (Murphy et al. 2017) .", [["deaths", "DISEASE", 547, 553], ["neonates", "ORGANISM", 343, 351], ["EMTALA", "PROTEIN", 473, 479], ["treatment", "TREATMENT", 34, 43], ["a very premature infant", "PROBLEM", 77, 100], ["such treatment", "TREATMENT", 108, 122], ["the neonate's condition", "PROBLEM", 181, 204], ["very premature neonates", "PROBLEM", 328, 351], ["BAIPA", "TREATMENT", 452, 457]]], ["Congenital malformations, deformations, and chromosomal abnormalities were noted to be primary causes of neonatal death.", [["chromosomal", "ANATOMY", 44, 55], ["Congenital malformations", "DISEASE", 0, 24], ["deformations", "DISEASE", 26, 38], ["chromosomal abnormalities", "DISEASE", 44, 69], ["neonatal death", "DISEASE", 105, 119], ["chromosomal", "CELLULAR_COMPONENT", 44, 55], ["Congenital malformations", "PROBLEM", 0, 24], ["deformations", "PROBLEM", 26, 38], ["chromosomal abnormalities", "PROBLEM", 44, 69], ["neonatal death", "PROBLEM", 105, 119], ["malformations", "OBSERVATION", 11, 24]]], ["One such congenital malformation is anencephaly, one of the most common central nervous system disorders.", [["central nervous system", "ANATOMY", 72, 94], ["congenital malformation", "DISEASE", 9, 32], ["anencephaly", "DISEASE", 36, 47], ["central nervous system disorders", "DISEASE", 72, 104], ["central nervous system", "ANATOMICAL_SYSTEM", 72, 94], ["One such congenital malformation", "PROBLEM", 0, 32], ["anencephaly", "PROBLEM", 36, 47], ["the most common central nervous system disorders", "PROBLEM", 56, 104], ["congenital", "OBSERVATION_MODIFIER", 9, 19], ["malformation", "OBSERVATION", 20, 32], ["anencephaly", "OBSERVATION", 36, 47], ["common", "ANATOMY_MODIFIER", 65, 71], ["central", "ANATOMY_MODIFIER", 72, 79], ["nervous system", "ANATOMY", 80, 94]]], ["Anencephaly is a neural tube defect that occurs when the cephalic (head) end of the neural tube fails to close, usually between the 23rd and 26th days of pregnancy; this results in the absence of the major portion of the brain, skull, and scalp.", [["neural tube", "ANATOMY", 17, 28], ["cephalic", "ANATOMY", 57, 65], ["head", "ANATOMY", 67, 71], ["neural tube", "ANATOMY", 84, 95], ["brain", "ANATOMY", 221, 226], ["skull", "ANATOMY", 228, 233], ["scalp", "ANATOMY", 239, 244], ["Anencephaly", "DISEASE", 0, 11], ["neural tube defect", "DISEASE", 17, 35], ["neural tube", "TISSUE", 17, 28], ["head", "ORGANISM_SUBDIVISION", 67, 71], ["neural tube", "TISSUE", 84, 95], ["brain", "ORGAN", 221, 226], ["skull", "ORGAN", 228, 233], ["scalp", "ORGAN", 239, 244], ["Anencephaly", "PROBLEM", 0, 11], ["a neural tube defect", "PROBLEM", 15, 35], ["the neural tube", "TREATMENT", 80, 95], ["neural", "OBSERVATION", 17, 23], ["tube defect", "OBSERVATION", 24, 35], ["cephalic", "ANATOMY", 57, 65], ["head", "ANATOMY", 67, 71], ["neural tube", "OBSERVATION", 84, 95], ["major portion", "ANATOMY_MODIFIER", 200, 213], ["brain", "ANATOMY", 221, 226], ["skull", "ANATOMY", 228, 233], ["scalp", "ANATOMY", 239, 244]]], ["Some rudimentary forebrain, a part of the brain consisting mainly of the cerebrum, may exist.", [["forebrain", "ANATOMY", 17, 26], ["brain", "ANATOMY", 42, 47], ["cerebrum", "ANATOMY", 73, 81], ["forebrain", "ORGAN", 17, 26], ["brain", "ORGAN", 42, 47], ["cerebrum", "ORGAN", 73, 81], ["Some rudimentary forebrain", "PROBLEM", 0, 26], ["rudimentary", "OBSERVATION", 5, 16], ["forebrain", "ANATOMY_MODIFIER", 17, 26], ["brain", "ANATOMY", 42, 47], ["cerebrum", "ANATOMY", 73, 81]]], ["A functioning brainstem is usually present.", [["brainstem", "ANATOMY", 14, 23], ["brainstem", "ORGAN", 14, 23], ["brainstem", "ANATOMY", 14, 23]]], ["Prenatal diagnosis of anencephalic neonates typically occurs at 12-14 weeks.", [["neonates", "ORGANISM", 35, 43], ["anencephalic neonates", "PROBLEM", 22, 43], ["anencephalic neonates", "OBSERVATION", 22, 43]]], ["The majority of anencephalic pregnancies are terminated early in the pregnancy (Brierley 2010; Stiers et al. 2015) .", [["anencephalic", "CANCER", 16, 28], ["anencephalic pregnancies", "PROBLEM", 16, 40], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["anencephalic pregnancies", "OBSERVATION", 16, 40]]], ["The CDC estimates that anencephaly annually affects approximately 3 pregnancies in every 10,000, or 1206 pregnancies (CDC 2015) .", [["anencephaly", "DISEASE", 23, 34], ["anencephaly", "OBSERVATION", 23, 34]]], ["Most anencephalic neonates die within days or weeks without life-supporting interventions (Shewmon 1989) .Clinical PerspectiveThe care of a mother carrying a baby with a LA can be complex, requiring close coordination between the obstetrician, neonatologist, and other healthcare professionals.", [["LA", "CHEMICAL", 170, 172], ["neonates", "ORGANISM", 18, 26]]], ["In some instances, mothers experience a typical pregnancy except for the fact that they have received a diagnosis of a LA; those who receive minimal or no prenatal care are unaware of a LA until the baby is born.", [["LA", "CHEMICAL", 119, 121], ["LA", "CHEMICAL", 186, 188], ["mothers", "ORGANISM", 19, 26]]], ["In many cases, the syndrome or condition afflicting the fetus may cause concern for maternal, fetal, and/or both maternal and fetal health and may lead to a decision to induce pre-term (iatrogenic) labor.", [["fetus", "ANATOMY", 56, 61], ["fetal", "ANATOMY", 94, 99], ["fetal", "ANATOMY", 126, 131], ["pre-term (iatrogenic) labor", "DISEASE", 176, 203], ["fetus", "ORGANISM", 56, 61], ["fetal", "ANATOMICAL_SYSTEM", 94, 99], ["fetal", "ANATOMICAL_SYSTEM", 126, 131], ["the syndrome", "PROBLEM", 15, 27], ["pre-term (iatrogenic) labor", "PROBLEM", 176, 203], ["syndrome", "OBSERVATION", 19, 27]]], ["Alternatively, pre-term delivery may occur spontaneously without intervention.", [["intervention", "TREATMENT", 65, 77]]], ["Spontaneous labor with intact membranes 2.", [["membranes", "ANATOMY", 30, 39], ["Spontaneous labor", "DISEASE", 0, 17], ["Spontaneous labor", "PROBLEM", 0, 17], ["labor", "OBSERVATION", 12, 17], ["intact membranes", "OBSERVATION", 23, 39]]], ["Pre-term premature rupture of membranes (PPROM) 3.", [["membranes", "ANATOMY", 30, 39], ["premature rupture", "DISEASE", 9, 26], ["PPROM", "DISEASE", 41, 46], ["Pre-term premature rupture of membranes", "PROBLEM", 0, 39], ["premature", "OBSERVATION_MODIFIER", 9, 18], ["rupture", "OBSERVATION", 19, 26]]], ["Delivery for maternal or fetal indications (Thakor et al. 2008 ).Clinical PerspectiveTucker reports that 15-25% of pre-term infants are iatrogenically delivered early because of maternal or fetal pregnancy complications (Tucker and McGuire 2004) .", [["fetal", "ANATOMY", 25, 30], ["fetal", "ANATOMY", 190, 195], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 25, 30], ["infants", "ORGANISM", 124, 131], ["fetal", "ORGANISM_SUBDIVISION", 190, 195], ["infants", "SPECIES", 124, 131], ["Delivery", "TREATMENT", 0, 8], ["maternal or fetal indications", "PROBLEM", 13, 42], ["maternal or fetal pregnancy complications", "PROBLEM", 178, 219]]], ["Complications may include hypertension, preeclampsia or eclampsia, polyhydramnios, oligohydramnios, gestational diabetes, intrauterine growth restrictions, infection, and twin-to-twin transfusion syndrome.Clinical PerspectiveDespite the recent widespread use of hypothermia therapy, Hypoxic Ischemic Encephalopathy (HIE) is a major cause of neurologic disabilities in term neonates.", [["intrauterine", "ANATOMY", 122, 134], ["neurologic", "ANATOMY", 341, 351], ["hypertension", "DISEASE", 26, 38], ["preeclampsia", "DISEASE", 40, 52], ["eclampsia", "DISEASE", 56, 65], ["polyhydramnios", "DISEASE", 67, 81], ["oligohydramnios", "DISEASE", 83, 98], ["gestational diabetes", "DISEASE", 100, 120], ["intrauterine growth restrictions", "DISEASE", 122, 154], ["infection", "DISEASE", 156, 165], ["hypothermia", "DISEASE", 262, 273], ["Hypoxic Ischemic Encephalopathy", "DISEASE", 283, 314], ["HIE", "DISEASE", 316, 319], ["neurologic disabilities", "DISEASE", 341, 364], ["neonates", "ORGANISM", 373, 381], ["hypertension", "PROBLEM", 26, 38], ["preeclampsia", "PROBLEM", 40, 52], ["eclampsia", "PROBLEM", 56, 65], ["polyhydramnios", "PROBLEM", 67, 81], ["oligohydramnios", "PROBLEM", 83, 98], ["gestational diabetes", "PROBLEM", 100, 120], ["intrauterine growth restrictions", "PROBLEM", 122, 154], ["infection", "PROBLEM", 156, 165], ["twin transfusion syndrome", "PROBLEM", 179, 204], ["hypothermia therapy", "TREATMENT", 262, 281], ["Hypoxic Ischemic Encephalopathy", "PROBLEM", 283, 314], ["neurologic disabilities in term neonates", "PROBLEM", 341, 381], ["may include", "UNCERTAINTY", 14, 25], ["hypertension", "OBSERVATION", 26, 38], ["preeclampsia", "OBSERVATION", 40, 52], ["eclampsia", "OBSERVATION", 56, 65], ["polyhydramnios", "OBSERVATION", 67, 81], ["oligohydramnios", "OBSERVATION", 83, 98], ["gestational", "OBSERVATION_MODIFIER", 100, 111], ["diabetes", "OBSERVATION", 112, 120], ["intrauterine", "OBSERVATION_MODIFIER", 122, 134], ["growth", "OBSERVATION_MODIFIER", 135, 141], ["infection", "OBSERVATION", 156, 165], ["widespread", "OBSERVATION_MODIFIER", 244, 254], ["hypothermia", "OBSERVATION", 262, 273], ["Hypoxic", "OBSERVATION_MODIFIER", 283, 290], ["Ischemic", "OBSERVATION_MODIFIER", 291, 299], ["Encephalopathy", "OBSERVATION", 300, 314]]], ["The incidence of HIE ranges from 1 to 8 per 1000 live births in developed countries and is as high as 26 per 1000 live births in underdeveloped countries (Douglas-Escobar and Weiss 2015).", [["HIE", "DISEASE", 17, 20], ["HIE ranges", "TEST", 17, 27]]], ["HIE neonates frequently receive ventilation, hypothermia, or other therapy, until brain death is confirmed or until a decision is made to withdraw treatment and to allow for a natural death, also known as ''AND''.Clinical PerspectiveMedical literature is scant regarding discussion about neonates with HIE who became organ donors for transplantation or research.", [["brain", "ANATOMY", 82, 87], ["organ", "ANATOMY", 317, 322], ["HIE", "DISEASE", 0, 3], ["hypothermia", "DISEASE", 45, 56], ["brain death", "DISEASE", 82, 93], ["death", "DISEASE", 184, 189], ["HIE", "DISEASE", 302, 305], ["neonates", "ORGANISM", 4, 12], ["brain", "ORGAN", 82, 87], ["neonates", "ORGANISM", 288, 296], ["organ", "ORGAN", 317, 322], ["HIE neonates", "PROBLEM", 0, 12], ["ventilation", "TREATMENT", 32, 43], ["hypothermia", "PROBLEM", 45, 56], ["other therapy", "TREATMENT", 61, 74], ["brain death", "PROBLEM", 82, 93], ["treatment", "TREATMENT", 147, 156], ["a natural death", "PROBLEM", 174, 189], ["organ donors", "TREATMENT", 317, 329], ["transplantation", "TREATMENT", 334, 349], ["hypothermia", "OBSERVATION", 45, 56]]], ["There are anecdotal reports of neonatal organ donation from HIE donors, including one author's center.", [["organ", "ANATOMY", 40, 45], ["organ", "ORGAN", 40, 45], ["neonatal organ donation", "TREATMENT", 31, 54]]], ["Jadcherla, et al., reported a case of neonatal organ donation in a fullterm neonate with severe HIE complicated by multiorgan dysfunction who underwent therapeutic hypothermia (Bokisa et al. 2015) .", [["organ", "ANATOMY", 47, 52], ["multiorgan", "ANATOMY", 115, 125], ["HIE", "DISEASE", 96, 99], ["multiorgan dysfunction", "DISEASE", 115, 137], ["hypothermia", "DISEASE", 164, 175], ["organ", "ORGAN", 47, 52], ["multiorgan", "ORGAN", 115, 125], ["neonatal organ donation", "TREATMENT", 38, 61], ["severe HIE", "PROBLEM", 89, 99], ["multiorgan dysfunction", "PROBLEM", 115, 137], ["therapeutic hypothermia", "TREATMENT", 152, 175], ["multiorgan dysfunction", "OBSERVATION", 115, 137], ["therapeutic", "OBSERVATION_MODIFIER", 152, 163], ["hypothermia", "OBSERVATION", 164, 175]]], ["In non-ventilated cases, palliative care is provided to the neonate (hydration, comfort, etc.) allowing for a natural death (AND).", [["death", "DISEASE", 118, 123], ["palliative care", "TREATMENT", 25, 40]]], ["It is at that point that criteria for DCD may be applied.Clinical PerspectiveMedical challenges include working with hospital staff who may have inadequate information or awareness about the potential of neonates to become donors.", [["DCD", "DISEASE", 38, 41], ["neonates", "ORGANISM", 204, 212], ["donors", "ORGANISM", 223, 229], ["DCD", "TREATMENT", 38, 41]]], ["Because transplant surgeons normally perform organ recovery only for transplant, OPO staff need to be trained in organ recovery for research.", [["organ", "ANATOMY", 45, 50], ["organ", "ANATOMY", 113, 118], ["organ", "ORGAN", 45, 50], ["organ", "ORGAN", 113, 118], ["transplant", "TREATMENT", 69, 79]]], ["Specific details of the delivery of neonates can have a significant effect on the donation process-i.e., whether delivery occurred at term or prior to term; whether the neonate was delivered by natural delivery or whether labor was induced; the indications for medical intervention if labor was induced.Clinical PerspectiveThe criteria used for the acceptance of organ donors for research may vary, based on the type of research and individual research protocols.", [["organ", "ANATOMY", 363, 368], ["neonates", "ORGANISM", 36, 44], ["neonate", "ORGANISM", 169, 176], ["organ", "ORGAN", 363, 368], ["the delivery of neonates", "TREATMENT", 20, 44], ["the donation process", "TREATMENT", 78, 98], ["natural delivery", "TREATMENT", 194, 210], ["labor", "PROBLEM", 222, 227], ["medical intervention", "TREATMENT", 261, 281], ["labor", "PROBLEM", 285, 290], ["organ donors", "TREATMENT", 363, 375], ["individual research protocols", "TREATMENT", 433, 462]]], ["A neonate with LA may be considered as a potential donor for liver, lung, heart, kidney, pancreas, intestine, thymus, or tissue (skin, eyes, bone marrow, musculoskeletal and reproductive tissues).", [["liver", "ANATOMY", 61, 66], ["lung", "ANATOMY", 68, 72], ["heart", "ANATOMY", 74, 79], ["kidney", "ANATOMY", 81, 87], ["pancreas", "ANATOMY", 89, 97], ["intestine", "ANATOMY", 99, 108], ["thymus", "ANATOMY", 110, 116], ["tissue", "ANATOMY", 121, 127], ["skin", "ANATOMY", 129, 133], ["eyes", "ANATOMY", 135, 139], ["bone marrow", "ANATOMY", 141, 152], ["musculoskeletal", "ANATOMY", 154, 169], ["tissues", "ANATOMY", 187, 194], ["LA", "CHEMICAL", 15, 17], ["neonate", "ORGANISM", 2, 9], ["LA", "SIMPLE_CHEMICAL", 15, 17], ["liver", "ORGAN", 61, 66], ["lung", "ORGAN", 68, 72], ["heart", "ORGAN", 74, 79], ["kidney", "ORGAN", 81, 87], ["pancreas", "ORGAN", 89, 97], ["intestine", "ORGAN", 99, 108], ["thymus", "ORGAN", 110, 116], ["tissue", "TISSUE", 121, 127], ["skin", "ORGAN", 129, 133], ["eyes", "ORGAN", 135, 139], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 141, 152], ["musculoskeletal", "ORGANISM_SUBDIVISION", 154, 169], ["reproductive tissues", "TISSUE", 174, 194], ["liver, lung, heart, kidney, pancreas, intestine, thymus", "PROBLEM", 61, 116], ["tissue (skin, eyes, bone marrow, musculoskeletal and reproductive tissues", "PROBLEM", 121, 194], ["liver", "ANATOMY", 61, 66], ["lung", "ANATOMY", 68, 72], ["heart", "ANATOMY", 74, 79], ["kidney", "ANATOMY", 81, 87], ["pancreas", "ANATOMY", 89, 97], ["intestine", "ANATOMY", 99, 108], ["thymus", "ANATOMY", 110, 116], ["skin", "ANATOMY", 129, 133], ["eyes", "ANATOMY", 135, 139], ["bone marrow", "ANATOMY", 141, 152], ["musculoskeletal", "ANATOMY", 154, 169]]], ["Multiple recipients or research studies can often benefit from a single donation.", [["research studies", "TEST", 23, 39], ["a single donation", "TREATMENT", 63, 80], ["recipients", "OBSERVATION", 9, 19]]], ["The researcher (or the protocol) needs to establish requirements such as minimum gestational age of the neonate.", [["neonate", "ORGANISM", 104, 111], ["the protocol", "TREATMENT", 19, 31]]], ["Exact time of death and a clear plan for organ recovery surgery have to be determined and documented.", [["organ", "ANATOMY", 41, 46], ["death", "DISEASE", 14, 19], ["organ", "ORGAN", 41, 46], ["organ recovery surgery", "TREATMENT", 41, 63]]], ["Donation must occur in a timely manner because of concern regarding the effect of warm ischemic time (WIT) on organ viability; this concern should be balanced with the family's need for time with their neonate after the neonate has passed away.OPO PerspectiveNeonatal donors, especially anencephalic donors, provide a unique set of challenges to an OPO.", [["organ", "ANATOMY", 110, 115], ["organ", "ORGAN", 110, 115], ["neonate", "ORGANISM", 202, 209], ["neonate", "ORGANISM", 220, 227], ["donors", "ORGANISM", 268, 274], ["donors", "ORGANISM", 300, 306], ["Donation", "TREATMENT", 0, 8], ["warm ischemic time", "PROBLEM", 82, 100], ["organ viability", "PROBLEM", 110, 125], ["OPO PerspectiveNeonatal donors", "TREATMENT", 244, 274], ["anencephalic donors", "TREATMENT", 287, 306]]], ["Whether the donation will ultimately result in transplanted organs or tissues, research organs or tissues, or some combination of these outcomes is often unclear until the surgical recovery occurs.", [["organs", "ANATOMY", 60, 66], ["tissues", "ANATOMY", 70, 77], ["organs", "ANATOMY", 88, 94], ["tissues", "ANATOMY", 98, 105], ["organs", "ORGAN", 60, 66], ["tissues", "TISSUE", 70, 77], ["organs", "ORGAN", 88, 94], ["tissues", "TISSUE", 98, 105], ["transplanted organs or tissues", "PROBLEM", 47, 77]]], ["The lack of formation of cerebral cortex and exposed brain structure make it impossible to determine brain death in anencephalic neonates.", [["cerebral cortex", "ANATOMY", 25, 40], ["brain", "ANATOMY", 53, 58], ["brain", "ANATOMY", 101, 106], ["brain death", "DISEASE", 101, 112], ["anencephalic", "DISEASE", 116, 128], ["cerebral cortex", "MULTI-TISSUE_STRUCTURE", 25, 40], ["brain", "ORGAN", 53, 58], ["brain", "ORGAN", 101, 106], ["neonates", "ORGANISM", 129, 137], ["cerebral cortex and exposed brain structure", "PROBLEM", 25, 68], ["brain death in anencephalic neonates", "PROBLEM", 101, 137], ["cerebral cortex", "ANATOMY", 25, 40], ["brain", "ANATOMY", 53, 58], ["anencephalic neonates", "OBSERVATION", 116, 137]]], ["In other circumstances, such as HIE, it may be possible because the cerebral cortex is formed, and the skull structure is intact.", [["cerebral cortex", "ANATOMY", 68, 83], ["skull", "ANATOMY", 103, 108], ["HIE", "DISEASE", 32, 35], ["cerebral cortex", "MULTI-TISSUE_STRUCTURE", 68, 83], ["skull", "ORGAN", 103, 108], ["may be possible", "UNCERTAINTY", 40, 55], ["cerebral cortex", "ANATOMY", 68, 83], ["formed", "OBSERVATION", 87, 93], ["skull", "ANATOMY", 103, 108], ["intact", "OBSERVATION", 122, 128]]], ["In ventilated neonatal donors, including neonates with HIE, the process will often unfold in the same way as in older donors.", [["HIE", "DISEASE", 55, 58], ["donors", "ORGANISM", 23, 29], ["neonates", "ORGANISM", 41, 49], ["donors", "ORGANISM", 118, 124]]], ["Thus, coordinating neonatal anencephalic donation requires flexibility and establishment of contingency plans to maximize successful donation.OPO PerspectiveThe challenges faced by OPOs in coordinating anencephalic donors fall largely into one of three categories: donor identification and referral; family and staff counseling; donation logistics.", [["donors", "ORGANISM", 215, 221], ["coordinating neonatal anencephalic donation", "TREATMENT", 6, 49], ["successful donation", "TREATMENT", 122, 141], ["anencephalic donation", "OBSERVATION", 28, 49]]], ["A brief discussion of each follows.Donor Identification and ReferralIn the United States, OPOs are to receive referrals on all in-hospital and imminent deaths.", [["deaths", "DISEASE", 152, 158]]], ["Most OPOs have established ''clinical triggers'' for referral, which include variables such as Glasgow Coma Scale 5 or below, discussion of withdrawal of care, initiation of brain death testing, or cardiac arrest.", [["brain", "ANATOMY", 174, 179], ["cardiac", "ANATOMY", 198, 205], ["brain death", "DISEASE", 174, 185], ["cardiac arrest", "DISEASE", 198, 212], ["OPOs", "CANCER", 5, 9], ["brain", "ORGAN", 174, 179], ["Glasgow Coma Scale", "TREATMENT", 95, 113], ["withdrawal of care", "TREATMENT", 140, 158], ["brain death testing", "TEST", 174, 193], ["cardiac arrest", "PROBLEM", 198, 212], ["cardiac", "ANATOMY", 198, 205], ["arrest", "OBSERVATION", 206, 212]]], ["In the context of ventilated neonatal donors, these clinical triggers may apply; in anencephalic donors, who are typically nonventilated, they will not.", [["donors", "ORGANISM", 38, 44], ["donors", "ORGANISM", 97, 103], ["ventilated neonatal donors", "TREATMENT", 18, 44], ["ventilated", "OBSERVATION", 18, 28], ["neonatal donors", "OBSERVATION", 29, 44]]], ["The challenge, therefore, is to establish referral processes for practitioners working with the families of anencephalic neonates, to educate both OPO staff and donor hospital professionals about neonatal donation, and to implement protocols for both OPO and hospital staff to manage these cases.", [["neonatal donation", "TREATMENT", 196, 213]]], ["Sample protocols are available upon request to IIAM (www.iiam.org).Family and Staff CounselingThe standard approach for OPOs in terms of counseling donor family and hospital staff regarding donation begins with the initial referral and after an evaluation of the clinical suitability for donation.", [["Sample protocols", "TEST", 0, 16], ["an evaluation", "TEST", 242, 255]]], ["First, the donor family may be several months short of the actual delivery and will have much more time to consider their options for donation.", [["donation", "TREATMENT", 134, 142]]], ["Second, the context of the discussions with perinatal and neonatal practitioners regarding the pregnancy and other related decisions is quite different from traditional organ donor situations, in which the discussion centers around brain death, withdrawal of care in a patient who is not brain dead and helping the family come to grips with the finality of the patient's brain injury.Family and Staff CounselingWith anencephalic neonates, the family is addressing a far different set of issues, such as whether to carry to term and development of an appropriate birth plan.", [["organ", "ANATOMY", 169, 174], ["brain", "ANATOMY", 232, 237], ["brain", "ANATOMY", 288, 293], ["brain", "ANATOMY", 371, 376], ["brain death", "DISEASE", 232, 243], ["brain injury", "DISEASE", 371, 383], ["organ", "ORGAN", 169, 174], ["brain", "ORGAN", 232, 237], ["patient", "ORGANISM", 269, 276], ["brain", "ORGAN", 288, 293], ["patient", "ORGANISM", 361, 368], ["brain", "ORGAN", 371, 376], ["patient", "SPECIES", 269, 276], ["patient", "SPECIES", 361, 368], ["the pregnancy", "PROBLEM", 91, 104], ["brain death", "PROBLEM", 232, 243], ["the patient's brain injury", "PROBLEM", 357, 383], ["brain", "ANATOMY", 371, 376], ["injury", "OBSERVATION", 377, 383]]], ["The process typically proceeds as with any organ/tissue donor referral in scenarios with HIE or LA.Donation LogisticsIn standard DBD or DCD scenarios, regardless of the age of the potential donor, OPOs obtain authorization for donation, evaluate organ function, attempt to maximize organ function, match organs to recipients, and then coordinate the surgical recovery, which may include allowing teams from distant centers to fly to the hospital for the surgical recovery.", [["organ", "ANATOMY", 43, 48], ["tissue", "ANATOMY", 49, 55], ["organ", "ANATOMY", 246, 251], ["organ", "ANATOMY", 282, 287], ["organs", "ANATOMY", 304, 310], ["HIE", "DISEASE", 89, 92], ["LA", "CHEMICAL", 96, 98], ["organ", "ORGAN", 43, 48], ["tissue", "TISSUE", 49, 55], ["organ", "ORGAN", 246, 251], ["organ", "ORGAN", 282, 287], ["organs", "ORGAN", 304, 310], ["Donation Logistics", "TREATMENT", 99, 117], ["DCD scenarios", "TREATMENT", 136, 149], ["donation", "TREATMENT", 227, 235], ["organ function", "TEST", 246, 260], ["the surgical recovery", "TREATMENT", 450, 471]]], ["Surgical recovery is scheduled after organ evaluation and preliminary acceptance by a transplant center or, in the case of research donation, by a researcher.", [["organ", "ANATOMY", 37, 42], ["organ", "ORGAN", 37, 42], ["organ evaluation", "TEST", 37, 53], ["research donation", "TREATMENT", 123, 140]]], ["Donor blood type, height, weight, and many other data factor into this process.Donation LogisticsA ventilated neonatal donor will follow much the same path.", [["blood", "ANATOMY", 6, 11], ["blood", "ORGANISM_SUBSTANCE", 6, 11], ["Donor blood type", "TEST", 0, 16], ["height", "TEST", 18, 24], ["weight", "TEST", 26, 32], ["Donation LogisticsA ventilated neonatal donor", "TREATMENT", 79, 124]]], ["Anencephalic donors are not typically intubated.", [["donors", "ORGANISM", 13, 19], ["Anencephalic donors", "TREATMENT", 0, 19], ["donors", "OBSERVATION", 13, 19]]], ["It is vital to underscore that no donation can take place until death has occurred, through the pronouncement of death either by neurological criteria (i.e., brain death) or by circulatory death.", [["brain", "ANATOMY", 158, 163], ["circulatory", "ANATOMY", 177, 188], ["death", "DISEASE", 64, 69], ["death", "DISEASE", 113, 118], ["brain death", "DISEASE", 158, 169], ["circulatory death", "DISEASE", 177, 194], ["brain", "ORGAN", 158, 163], ["death", "PROBLEM", 64, 69], ["circulatory death", "PROBLEM", 177, 194], ["circulatory death", "OBSERVATION", 177, 194]]], ["OPOs can implement a few key strategies to maximize the benefit of the donation for the neonatal donor family, transplant recipients, and researchers.", [["OPOs", "SIMPLE_CHEMICAL", 0, 4], ["the donation", "TREATMENT", 67, 79], ["transplant recipients", "TREATMENT", 111, 132]]], ["They include:Donation Logistics1.", [["Donation Logistics1", "TREATMENT", 13, 32]]], ["Proactively identify centers where these potentially complex cases may be referred and transplant centers willing to consider neonatal organs for transplant.", [["organs", "ANATOMY", 135, 141], ["organs", "ORGAN", 135, 141], ["transplant centers", "TREATMENT", 87, 105], ["transplant", "TREATMENT", 146, 156], ["transplant", "OBSERVATION", 146, 156]]], ["Have research outlets for all possible organs and tissues since transplantation rarely occurs with these potential donors.", [["organs", "ANATOMY", 39, 45], ["tissues", "ANATOMY", 50, 57], ["organs", "ORGAN", 39, 45], ["tissues", "TISSUE", 50, 57], ["donors", "ORGANISM", 115, 121], ["transplantation", "TREATMENT", 64, 79]]], ["Closely collaborate with the specialists caring for the mother and neonate.", [["neonate", "ORGANISM", 67, 74]]], ["It is not uncommon for these cases to unfold over months.", [["not uncommon", "UNCERTAINTY", 6, 18]]], ["The prolonged process of neonatal donation and the importance of bonding with the family require a team approach in order to avoid compassion fatigue (Nicely and Delario 2011; Maloney and Wolfelt 2011; Larowe 2005) .Experience with Neonatal Donors for ResearchIn 2012, Bethany C., who was pregnant with an anencephalic baby, contacted IIAM.", [["fatigue", "DISEASE", 142, 149], ["neonatal donation", "TREATMENT", 25, 42], ["a team approach", "TREATMENT", 97, 112], ["compassion fatigue", "PROBLEM", 131, 149], ["anencephalic", "OBSERVATION", 306, 318]]], ["She wanted to donate her son's organs and tissues following his death.", [["organs", "ANATOMY", 31, 37], ["tissues", "ANATOMY", 42, 49], ["death", "DISEASE", 64, 69], ["organs", "ORGAN", 31, 37], ["tissues", "TISSUE", 42, 49], ["his death", "PROBLEM", 60, 69], ["organs", "ANATOMY", 31, 37]]], ["She found IIAM's website and contacted IIAM just days before her scheduled C-section.", [["her scheduled C-section", "TREATMENT", 61, 84]]], ["Within 2 h, IIAM found researchers who were willing to accept her baby's liver and pancreas, and another researcher who was interested in receiving his entire body after organ donation.", [["liver", "ANATOMY", 73, 78], ["pancreas", "ANATOMY", 83, 91], ["body", "ANATOMY", 159, 163], ["organ", "ANATOMY", 170, 175], ["liver", "ORGAN", 73, 78], ["pancreas", "ORGAN", 83, 91], ["body", "ORGANISM_SUBDIVISION", 159, 163], ["organ", "ORGAN", 170, 175], ["organ donation", "TREATMENT", 170, 184], ["liver", "ANATOMY", 73, 78], ["pancreas", "ANATOMY", 83, 91]]], ["The OPO performed the organ recovery after his death.", [["organ", "ANATOMY", 22, 27], ["death", "DISEASE", 47, 52], ["organ", "ORGAN", 22, 27], ["OPO", "PROTEIN", 4, 7], ["his death", "PROBLEM", 43, 52]]], ["As a result of his donation, researchers were able to evaluate pancreatic beta cells in their earliest stages of development, leading them to understand why some people develop Type 1 Diabetes; other researchers studied hepatocytes, which is critical to understanding cell generation.", [["pancreatic beta cells", "ANATOMY", 63, 84], ["hepatocytes", "ANATOMY", 220, 231], ["cell", "ANATOMY", 268, 272], ["Type 1 Diabetes", "DISEASE", 177, 192], ["pancreatic beta cells", "CELL", 63, 84], ["people", "ORGANISM", 162, 168], ["hepatocytes", "CELL", 220, 231], ["cell", "CELL", 268, 272], ["pancreatic beta cells", "CELL_TYPE", 63, 84], ["hepatocytes", "CELL_TYPE", 220, 231], ["people", "SPECIES", 162, 168], ["his donation", "TREATMENT", 15, 27], ["pancreatic beta cells", "PROBLEM", 63, 84], ["Type 1 Diabetes", "PROBLEM", 177, 192], ["pancreatic", "ANATOMY", 63, 73], ["Diabetes", "OBSERVATION", 184, 192], ["hepatocytes", "ANATOMY", 220, 231], ["cell generation", "OBSERVATION", 268, 283]]], ["Images generated by his body led to FDA clearance for a medical device used for rapid pediatric resuscitation (Ardini-Poleske et al. 2017; Gray 2016a, b, c, d, e, f, g) .", [["body", "ANATOMY", 24, 28], ["body", "ORGANISM_SUBDIVISION", 24, 28], ["a medical device", "TREATMENT", 54, 70], ["rapid pediatric resuscitation", "TREATMENT", 80, 109], ["Gray", "TEST", 139, 143]]], ["Between 2012 and 2017, IIAM coordinated the recovery of organs and tissues from 86 donors, placing 281 organs and tissues.", [["organs", "ANATOMY", 56, 62], ["tissues", "ANATOMY", 67, 74], ["organs", "ANATOMY", 103, 109], ["tissues", "ANATOMY", 114, 121], ["organs", "ORGAN", 56, 62], ["tissues", "TISSUE", 67, 74], ["donors", "ORGANISM", 83, 89], ["organs", "ORGAN", 103, 109], ["tissues", "TISSUE", 114, 121], ["organs", "ANATOMY", 56, 62], ["tissues", "ANATOMY", 114, 121]]], ["Most neonates who became donors were anencephalic (60%), followed by neonates who died because of anoxia or HIE (23%).", [["anencephalic", "DISEASE", 37, 49], ["anoxia", "DISEASE", 98, 104], ["HIE", "DISEASE", 108, 111], ["neonates", "ORGANISM", 5, 13], ["donors", "ORGANISM", 25, 31], ["neonates", "ORGANISM", 69, 77], ["anoxia", "PROBLEM", 98, 104], ["HIE", "TEST", 108, 111]]], ["Other causes of death included Trisomy 18, fatal cardiac and renal anomalies, trauma, and other genetic and neurological conditions.", [["cardiac", "ANATOMY", 49, 56], ["renal", "ANATOMY", 61, 66], ["neurological", "ANATOMY", 108, 120], ["death", "DISEASE", 16, 21], ["Trisomy 18", "DISEASE", 31, 41], ["cardiac and renal anomalies", "DISEASE", 49, 76], ["trauma", "DISEASE", 78, 84], ["cardiac", "ORGAN", 49, 56], ["renal", "ORGAN", 61, 66], ["death", "PROBLEM", 16, 21], ["Trisomy 18", "PROBLEM", 31, 41], ["fatal cardiac and renal anomalies", "PROBLEM", 43, 76], ["trauma", "PROBLEM", 78, 84], ["other genetic and neurological conditions", "PROBLEM", 90, 131], ["renal", "ANATOMY", 61, 66], ["anomalies", "OBSERVATION", 67, 76]]], ["Pre-term deliveries (20 0/7 weeks-36 6/7 weeks) often occurred for medically indicated reasons (either maternal or fetal health or both); the majority of these deliveries were iatrogenic.", [["fetal", "ANATOMY", 115, 120], ["fetal", "ANATOMICAL_SYSTEM", 115, 120], ["Pre-term deliveries", "PROBLEM", 0, 19], ["iatrogenic", "PROBLEM", 176, 186], ["iatrogenic", "OBSERVATION", 176, 186]]], ["One was referred following miscarriage at 16 weeks and was able to donate skin.Experience with Neonatal Donors for ResearchAll of the families who pursued donation did so with the intent of having a live birth, spending as much time as possible with the neonate, and donating, if possible, after the neonate's death.", [["skin", "ANATOMY", 74, 78], ["miscarriage", "DISEASE", 27, 38], ["death", "DISEASE", 310, 315], ["skin", "ORGAN", 74, 78], ["miscarriage", "PROBLEM", 27, 38], ["the neonate's death", "PROBLEM", 296, 315], ["skin", "ANATOMY", 74, 78]]], ["The time elapsed from birth to death ranged from minutes to days (See Fig. 2) .", [["death", "DISEASE", 31, 36]]], ["In most cases, the neonate remained in the Labor and Delivery area; on one occasion, the neonate was taken home, given hospice care, and then her body was returned to the hospital following her death at 5 days.", [["body", "ANATOMY", 146, 150], ["death", "DISEASE", 194, 199], ["neonate", "ORGANISM", 19, 26], ["neonate", "ORGANISM", 89, 96], ["body", "ORGANISM_SUBDIVISION", 146, 150], ["hospice care", "TREATMENT", 119, 131], ["Labor", "OBSERVATION", 43, 48]]], ["Considering the legal, medical, ethical and practical issues surrounding these donation opportunities, the working group developed a set of algorithms designed to guide staff from OPOs and IIAM in evaluating potential donors.", [["donors", "ORGANISM", 218, 224]]], ["Three separate algorithms were developed: one for neonates being delivered at term with a LA (See Fig. 3) ; one for neonates being born pre-term with a LA (See Fig. 4) ; one for neonates who die as a result of other conditions, such as HIE or trauma (See Fig. 5 ).", [["LA", "CHEMICAL", 90, 92], ["LA", "CHEMICAL", 152, 154], ["HIE", "DISEASE", 236, 239], ["trauma", "DISEASE", 243, 249], ["neonates", "ORGANISM", 50, 58], ["neonates", "ORGANISM", 116, 124], ["neonates", "ORGANISM", 178, 186], ["other conditions", "PROBLEM", 210, 226], ["trauma", "PROBLEM", 243, 249]]], ["Reasons for declining referrals of potential neonatal donors include:Experience with Neonatal Donors for Research\u2022 Iatrogenic labor planned to terminate a pregnancy, not for maternal and/or fetal health (1%) \u2022 GA less than 24 weeks (3%) Researchers who accepted neonatal organs and tissues through this program study such diverse areas as regenerative medicine, diabetes, chronic kidney disease, cancer, congenital organ malformation, abnormal lung development, and fertility (See Fig. 6 ).", [["fetal", "ANATOMY", 190, 195], ["neonatal organs", "ANATOMY", 262, 277], ["tissues", "ANATOMY", 282, 289], ["kidney", "ANATOMY", 380, 386], ["cancer", "ANATOMY", 396, 402], ["organ", "ANATOMY", 415, 420], ["lung", "ANATOMY", 444, 448], ["Iatrogenic labor", "DISEASE", 115, 131], ["diabetes", "DISEASE", 362, 370], ["chronic kidney disease", "DISEASE", 372, 394], ["cancer", "DISEASE", 396, 402], ["congenital organ malformation", "DISEASE", 404, 433], ["abnormal lung development", "DISEASE", 435, 460], ["donors", "ORGANISM", 54, 60], ["fetal", "ORGAN", 190, 195], ["organs", "ORGAN", 271, 277], ["tissues", "TISSUE", 282, 289], ["kidney", "ORGAN", 380, 386], ["cancer", "CANCER", 396, 402], ["organ", "ORGAN", 415, 420], ["lung", "ORGAN", 444, 448], ["Neonatal Donors", "TREATMENT", 85, 100], ["Iatrogenic labor", "PROBLEM", 115, 131], ["neonatal organs and tissues", "PROBLEM", 262, 289], ["this program study", "TEST", 298, 316], ["regenerative medicine", "TREATMENT", 339, 360], ["diabetes", "PROBLEM", 362, 370], ["chronic kidney disease", "PROBLEM", 372, 394], ["cancer", "PROBLEM", 396, 402], ["congenital organ malformation", "PROBLEM", 404, 433], ["abnormal lung development", "PROBLEM", 435, 460], ["chronic", "OBSERVATION_MODIFIER", 372, 379], ["kidney", "ANATOMY", 380, 386], ["disease", "OBSERVATION", 387, 394], ["cancer", "OBSERVATION", 396, 402], ["organ", "ANATOMY", 415, 420], ["malformation", "OBSERVATION", 421, 433], ["abnormal", "OBSERVATION_MODIFIER", 435, 443], ["lung", "ANATOMY", 444, 448]]], ["Pulmonary research in particular, has been advanced using donated neonatal lungs.", [["Pulmonary", "ANATOMY", 0, 9], ["lungs", "ANATOMY", 75, 80], ["Pulmonary", "ORGAN", 0, 9], ["lungs", "ORGAN", 75, 80], ["research", "OBSERVATION", 10, 18], ["lungs", "ANATOMY", 75, 80]]], ["Over 75 neonatal donors have been provided to the Biorepository for the Investigation for Diseases of the Lung (BRINDL)/University of Rochester Medical Center (URMC) Human Tissue Core and distributed to more than 10 other academic laboratories.", [["Lung", "ANATOMY", 106, 110], ["donors", "ORGANISM", 17, 23], ["Lung", "ORGAN", 106, 110], ["Human", "ORGANISM", 166, 171], ["Human", "SPECIES", 166, 171], ["Human", "SPECIES", 166, 171], ["Diseases", "PROBLEM", 90, 98], ["Lung", "ANATOMY", 106, 110]]], ["BRINDL and the URMC Human Tissue Core are responsible for all the human data that currently appears on LungMAP.net.", [["Human", "ORGANISM", 20, 25], ["Tissue", "TISSUE", 26, 32], ["human", "ORGANISM", 66, 71], ["BRINDL", "DNA", 0, 6], ["URMC", "DNA", 15, 19], ["Human", "SPECIES", 20, 25], ["human", "SPECIES", 66, 71], ["Human", "SPECIES", 20, 25], ["human", "SPECIES", 66, 71], ["all the human data", "TEST", 58, 76]]], ["Papers and presentations arising from the LungMAP project primarily focus on characterization of neonatal lung cells, and clinical and translational studies in rare lung diseases.", [["neonatal lung cells", "ANATOMY", 97, 116], ["lung", "ANATOMY", 165, 169], ["lung diseases", "DISEASE", 165, 178], ["neonatal lung cells", "CELL", 97, 116], ["lung", "ORGAN", 165, 169], ["neonatal lung cells", "CELL_TYPE", 97, 116], ["neonatal lung cells", "PROBLEM", 97, 116], ["clinical and translational studies", "TEST", 122, 156], ["rare lung diseases", "PROBLEM", 160, 178], ["lung", "ANATOMY", 106, 110], ["cells", "OBSERVATION", 111, 116], ["rare", "OBSERVATION_MODIFIER", 160, 164], ["lung", "ANATOMY", 165, 169], ["diseases", "OBSERVATION", 170, 178]]], ["This project has also explored why neonates and infants frequently progress to severe lung failure when exposed to Respiratory Syncytial Virus (RSV) versus adults whose systems respond to RSV in a less severe manner.", [["lung", "ANATOMY", 86, 90], ["lung failure", "DISEASE", 86, 98], ["Respiratory Syncytial Virus", "DISEASE", 115, 142], ["RSV", "DISEASE", 188, 191], ["neonates", "ORGANISM", 35, 43], ["infants", "ORGANISM", 48, 55], ["lung", "ORGAN", 86, 90], ["Respiratory Syncytial Virus", "ORGANISM", 115, 142], ["RSV", "ORGANISM", 144, 147], ["RSV", "ORGANISM", 188, 191], ["infants", "SPECIES", 48, 55], ["Respiratory Syncytial Virus", "SPECIES", 115, 142], ["RSV", "SPECIES", 144, 147], ["RSV", "SPECIES", 188, 191], ["severe lung failure", "PROBLEM", 79, 98], ["Respiratory Syncytial Virus", "PROBLEM", 115, 142], ["adults whose systems", "PROBLEM", 156, 176], ["RSV", "PROBLEM", 188, 191], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["lung", "ANATOMY", 86, 90], ["failure", "OBSERVATION", 91, 98], ["Respiratory Syncytial", "ANATOMY", 115, 136]]], ["This information is expected to provide new options for treatment and prevention (Taylor et al. 2019; Jiang et al. 2019; Wang et al. 2019; Lal et al. 2018; Whitsett 2018; Kyle et al. 2018; Bandyopadhyay et al. 2018; Luo et al. 2018; Zhu et al. 2018; Zhou et al. 2018; Ardini-Poleske et al. 2017; Warburton 2017; Du et al. 2017 ).", [["treatment", "TREATMENT", 56, 65], ["Ardini", "TEST", 268, 274]]], ["Research findings from other projects using neonatal organs have been presented at scientific conferences and published in scientific journals (Gray 2016a, b, c, d, e, f, g; Ardini-Poleske et al. 2017; Gittinger 2015) .", [["neonatal organs", "ANATOMY", 44, 59], ["organs", "ORGAN", 53, 59], ["Gray", "TEST", 144, 148], ["Ardini", "TEST", 174, 180]]], ["Placements of research organs and tissues range from one organ per donor to over ten organs and tissues per donor.ConclusionDonation of organs and tissues for research from neonates who die following a live birth has recently become an option some families wish to consider.", [["organs", "ANATOMY", 23, 29], ["tissues", "ANATOMY", 34, 41], ["organ", "ANATOMY", 57, 62], ["organs", "ANATOMY", 85, 91], ["tissues", "ANATOMY", 96, 103], ["organs", "ANATOMY", 136, 142], ["tissues", "ANATOMY", 147, 154], ["organs", "ORGAN", 23, 29], ["tissues", "TISSUE", 34, 41], ["organ", "ORGAN", 57, 62], ["organs", "ORGAN", 85, 91], ["tissues", "TISSUE", 96, 103], ["organs", "ORGAN", 136, 142], ["tissues", "TISSUE", 147, 154], ["neonates", "ORGANISM", 173, 181], ["organs", "ANATOMY", 23, 29], ["tissues", "ANATOMY", 34, 41], ["tissues", "ANATOMY", 96, 103], ["organs", "ANATOMY", 136, 142]]], ["Pursuing this donation option requires careful attention to legal, ethical, medical, and procedural issues.", [["this donation option", "TREATMENT", 9, 29]]], ["It is vital to ensure that the integrity of the donation process be safeguarded, and that the desire to support neonatal donor families does not compromise ethical and legal standards.", [["the donation process", "TREATMENT", 44, 64], ["neonatal donor families", "TREATMENT", 112, 135]]], ["The comfort and solace that donation provides following the death of a neonate can be vital to families' healing processes and should be Post-natal fetal defect supported whenever possible.", [["fetal", "ANATOMY", 148, 153], ["death", "DISEASE", 60, 65], ["neonate", "ORGANISM", 71, 78], ["fetal", "ORGAN", 148, 153], ["solace", "TREATMENT", 16, 22], ["Post-natal fetal defect", "PROBLEM", 137, 160], ["defect", "OBSERVATION", 154, 160]]], ["Given the potential legal and ethical barriers to donation and the fact that not all OPOs are currently equipped to provide this service even if the request falls within acceptable standards, it is important that families have realistic expectations with respect to donation opportunities.", [["ethical barriers", "TREATMENT", 30, 46]]], ["Coordinating neonatal referrals requires careful collaboration between hospital administration, health care professionals, OPO staff, staff of the agency interfacing with researchers and OPOs, and the researchers themselves.ConclusionThe uses of neonatal organs and tissues have led to remarkable breakthroughs in science.", [["neonatal organs", "ANATOMY", 246, 261], ["tissues", "ANATOMY", 266, 273], ["organs", "ORGAN", 255, 261], ["tissues", "TISSUE", 266, 273], ["remarkable", "OBSERVATION_MODIFIER", 286, 296], ["breakthroughs", "OBSERVATION", 297, 310]]], ["Family donation of organs and tissues from a neonate represents a desire to make an altruistic gift and can play a key role in the care and support provided to families by hospital staff at the time of a neonate's pending death.", [["organs", "ANATOMY", 19, 25], ["tissues", "ANATOMY", 30, 37], ["death", "DISEASE", 222, 227], ["organs", "ORGAN", 19, 25], ["tissues", "TISSUE", 30, 37], ["organs", "ANATOMY", 19, 25]]], ["Family members who suffer the tragic loss of a newborn through either congenital abnormalities such as anencephaly, or situations arising from a traumatic birth or HIE, have found ''unexplainable peace, joy and healing'' in their ability to donate, thereby allowing their child to make an ''impact on the world'' (Rhodes 2014 ).ConclusionAuthor's contribution MA: conceptualization, research, writing, RDS: conceptualization, research, writing, SGB: research, writing, BJH: conceptualization, research, writing, RRN: research, writing, JPOi: research, writing, SY: conceptualization, research, writing.ConclusionFunding MTF Biologics provided funding for the development of the project.The authors wish to thank Wee Siang Tay for his assistance with references.", [["congenital abnormalities", "DISEASE", 70, 94], ["anencephaly", "DISEASE", 103, 114], ["HIE", "DISEASE", 164, 167], ["RDS", "DISEASE", 402, 405], ["congenital abnormalities", "PROBLEM", 70, 94], ["anencephaly", "PROBLEM", 103, 114]]]], "PMC7427614": [["Introduction\u201cSevere Acute Respiratory Syndrome coronavirus type 2 (SARS-CoV-2),\u201d responsible for an infection termed the coronavirus disease (COVID-19), is a newly discovered pathogen in humans.", [["Acute Respiratory Syndrome coronavirus", "DISEASE", 20, 58], ["infection", "DISEASE", 100, 109], ["coronavirus disease", "DISEASE", 121, 140], ["\u201cSevere Acute Respiratory Syndrome coronavirus type 2", "ORGANISM", 12, 65], ["SARS-CoV-2", "ORGANISM", 67, 77], ["coronavirus", "ORGANISM", 121, 132], ["humans", "ORGANISM", 187, 193], ["coronavirus", "SPECIES", 121, 132], ["humans", "SPECIES", 187, 193], ["Severe Acute Respiratory Syndrome coronavirus type 2 (SARS-CoV-2", "SPECIES", 13, 77], ["humans", "SPECIES", 187, 193], ["Severe Acute Respiratory Syndrome coronavirus type 2", "PROBLEM", 13, 65], ["SARS", "PROBLEM", 67, 71], ["CoV", "TEST", 72, 75], ["an infection", "PROBLEM", 97, 109], ["the coronavirus disease", "PROBLEM", 117, 140], ["COVID", "TEST", 142, 147], ["a newly discovered pathogen in humans", "PROBLEM", 156, 193], ["Severe", "OBSERVATION_MODIFIER", 13, 19], ["Acute", "OBSERVATION_MODIFIER", 20, 25], ["Respiratory Syndrome", "OBSERVATION", 26, 46], ["infection", "OBSERVATION", 100, 109], ["coronavirus disease", "OBSERVATION", 121, 140], ["pathogen", "OBSERVATION", 175, 183]]], ["On March 11, 2020, COVID-19 was declared a pandemic by the World Health Organization (WHO).", [["COVID", "TEST", 19, 24]]], ["As of 24 March 2020, the number of confirmed cases was 372,755 cases and 16,231 deaths, which increased to 2,160,207 cases and 146,088 deaths as of 18 April 2020 (WHO Situation reports; Zhu et al., 2020).", [["deaths", "DISEASE", 80, 86], ["deaths", "DISEASE", 135, 141]]], ["In this context, the WHO recommended the adoption of various protective, behavioral, and non-pharmacological measures (such as avoiding physical contact, handshakes, hugs and kisses; banning social gatherings and major events; closing universities and schools; and implementing self-isolation, social/physical distancing, confinement, and quarantine) to curb the spread of the virus as well as preventive approaches [including practicing physical activity (PA), sleeping well, etc.] to keep oneself healthy during the ongoing outbreak.IntroductionGovernments of all countries ordered their people to self-isolate (stay at home).", [["people", "ORGANISM", 590, 596], ["people", "SPECIES", 590, 596], ["various protective", "TREATMENT", 53, 71], ["non-pharmacological measures", "TREATMENT", 89, 117]]], ["However, long-term isolation or home-confinement may have negative effects on psychosocial and mental health, especially causing stress, negative emotions, and impaired cognition (Hawkley and Capitanio, 2015).", [["impaired cognition", "DISEASE", 160, 178]]], ["If prolonged, they may suppress immune system and physiological functions (Kiecolt-Glaser et al., 2002), which may increase the risk of exposure to SARS-CoV-2 and the likelihood of contracting the infection.", [["immune system", "ANATOMY", 32, 45], ["SARS", "DISEASE", 148, 152], ["infection", "DISEASE", 197, 206], ["SARS-CoV-2", "ORGANISM", 148, 158], ["SARS-CoV", "SPECIES", 148, 156], ["SARS", "PROBLEM", 148, 152], ["CoV", "TEST", 153, 156], ["the infection", "PROBLEM", 193, 206], ["infection", "OBSERVATION", 197, 206]]], ["For instance, the WHO suggested that people stay physically active at home in order to optimize their health status, decrease the negative psychosocial consequences of confinement, and maintain their immune system function.IntroductionMany studies have reported positive effects of PA on psychosocial status, such as quality of life (QoL), outside of confinement (Anokye et al., 2012; Vagetti et al., 2014; Krzepota et al., 2018; Ho et al., 2019).", [["immune system", "ANATOMY", 200, 213], ["people", "ORGANISM", 37, 43], ["immune system", "ANATOMICAL_SYSTEM", 200, 213], ["PA", "GENE_OR_GENE_PRODUCT", 282, 284], ["people", "SPECIES", 37, 43], ["Many studies", "TEST", 235, 247]]], ["However, no study has so far investigated the relationship between PA and QoL during a period of confinement, such as the quarantine caused by COVID-19.", [["PA", "GENE_OR_GENE_PRODUCT", 67, 69], ["study", "TEST", 12, 17], ["COVID", "TEST", 143, 148]]], ["Therefore, we aimed to explore the relationship between PA and QoL in the general population of Tunisia during the first 4 weeks of the confinement implemented by the government to curtail the COVID-19 pandemic.", [["PA", "GENE_OR_GENE_PRODUCT", 56, 58], ["the COVID", "TEST", 189, 198], ["pandemic", "PROBLEM", 202, 210]]], ["This may help the community members to improve their QoL in the face of a future pandemic, such as the COVID-19 outbreak or potential secondary waves/relapses, should the virus not be completely eradicated and suppressed by means of pharmacological interventions (drugs and vaccines).Participants ::: Materials and MethodsA non-probabilistic sampling approach was utilized.", [["Participants", "SPECIES", 284, 296], ["the COVID", "TEST", 99, 108], ["potential secondary waves/relapses", "PROBLEM", 124, 158], ["the virus", "PROBLEM", 167, 176], ["pharmacological interventions", "TREATMENT", 233, 262], ["drugs", "TREATMENT", 264, 269], ["vaccines", "TREATMENT", 274, 282], ["MethodsA non-probabilistic sampling approach", "TREATMENT", 315, 359]]], ["Subjects were considered eligible to take part into the study if meeting the following inclusion criteria: (i) age in the range 18\u201330 years; (ii) not using alcohol, drugs, or other substances; and (iii) no co-morbidities and/or orthopedic limitations that could interfere with the perceived QoL or level of PA.Participants ::: Materials and MethodsA link to the online questionnaires was sent via mail to 242 potential participants, of which 216 returned valid questionnaires (participation rate of 89.3%).", [["alcohol", "CHEMICAL", 156, 163], ["alcohol", "CHEMICAL", 156, 163], ["Subjects", "ORGANISM", 0, 8], ["alcohol", "SIMPLE_CHEMICAL", 156, 163], ["PA", "GENE_OR_GENE_PRODUCT", 307, 309], ["Participants", "SPECIES", 310, 322], ["participants", "SPECIES", 419, 431], ["the study", "TEST", 52, 61], ["co-morbidities", "PROBLEM", 206, 220], ["orthopedic limitations", "PROBLEM", 228, 250], ["participation rate", "TEST", 477, 495]]], ["Thus, 216 participants were included in the analysis.", [["participants", "ORGANISM", 10, 22], ["participants", "SPECIES", 10, 22], ["the analysis", "TEST", 40, 52]]], ["All measures were collected on the same day, to avoid any bias in the study, considering the constantly evolving situation of the pandemic.Participants ::: Materials and MethodsMost participants in the current survey were men (n = 112, 51.9%), and the mean age at the time of the study was 27.9 years (SD = 8.1).", [["participants", "ORGANISM", 182, 194], ["men", "ORGANISM", 222, 225], ["Participants", "SPECIES", 139, 151], ["participants", "SPECIES", 182, 194], ["men", "SPECIES", 222, 225], ["the study", "TEST", 66, 75], ["the pandemic", "PROBLEM", 126, 138], ["the study", "TEST", 276, 285], ["SD", "TEST", 302, 304], ["pandemic", "OBSERVATION", 130, 138]]], ["Participants were divided into three groups [i.e., inactive group (IG): less than 600 metabolic equivalent of tasks (METs), n = 131; minimally active group (MAG): from 600 to 2,999 METs, n = 49; and health-enhancing PA group (HEPAG): 3,000 + METs, n = 36] based on their habitual PA level in the period of quarantine, as recommended by previous research (Lee et al., 2011).Participants ::: Materials and MethodsWe excluded participants who were not compliant to government guidelines at home during the COVID-19 epidemic.", [["PA", "GENE_OR_GENE_PRODUCT", 280, 282], ["Participants", "SPECIES", 0, 12], ["Participants", "SPECIES", 373, 385], ["participants", "SPECIES", 423, 435], ["METs", "TEST", 117, 121], ["minimally active group (MAG)", "TEST", 133, 161], ["METs", "TEST", 181, 185], ["METs", "PROBLEM", 242, 246], ["the COVID", "TEST", 499, 508]]], ["Participants completed the online PA and QoL questionnaires.", [["Participants", "SPECIES", 0, 12]]], ["They were thoroughly advised of the aims of the study.", [["the study", "TEST", 44, 53]]], ["All participants signed a free and informed consent form.", [["participants", "SPECIES", 4, 16]]], ["Local institutional ethical approval was provided for this study, which was conducted in accordance with the 1964 Declaration of Helsinki and its subsequent amendments.Physical Activity ::: Measures ::: Materials and MethodsPA was assessed using the International Physical Activity Questionnaire-BREF (IPAQ-BREF; Lee et al., 2011).", [["this study", "TEST", 54, 64]]], ["This questionnaire comprised of seven questions which assessed the frequency and duration of vigorous intensity, moderate intensity, and walking PA for at least 10 min during the past week.", [["moderate intensity", "PROBLEM", 113, 131], ["moderate", "OBSERVATION_MODIFIER", 113, 121], ["intensity", "OBSERVATION_MODIFIER", 122, 131]]], ["Participants were asked to respond to one of the frequency options: from 1 to 7 days.", [["Participants", "SPECIES", 0, 12]]], ["Participants who had not undertaken any PA in the previous 7 days responded only to the question \u201cDuring the last 7 days, how much time did you spend sitting on a week day?\u201dPhysical Activity ::: Measures ::: Materials and MethodsThe IPAQ assessed total PA and total sedentary time, whereas the intensity of activity was converted to MET units (MET-h\u00b7week\u22121), as recommended by previous study (Ainsworth et al., 2000).Quality of Life ::: Measures ::: Materials and MethodsQoL was measured using the self-administered WHO Quality of Life Instrument-Short Form (WHOQOL-BREF; Skevington et al., 2004).", [["PA", "GENE_OR_GENE_PRODUCT", 253, 255], ["Participants", "SPECIES", 0, 12], ["The IPAQ", "TEST", 229, 237], ["total PA", "TEST", 247, 255], ["MethodsQoL", "TREATMENT", 464, 474]]], ["It comprised 26 items including domains and facets (or sub-domains).", [["26 items", "OBSERVATION_MODIFIER", 13, 21], ["facets", "OBSERVATION_MODIFIER", 44, 50]]], ["The participants marked a response using a 5-point Likert scale [ranging from 1 (very dissatisfied/very poor) to 5 (very satisfied/very good)].", [["participants", "SPECIES", 4, 16], ["Likert scale", "TEST", 51, 63], ["marked", "OBSERVATION_MODIFIER", 17, 23]]], ["The domain scores of the WHOQOL-Bref were computed according to the guideline of the WHO (WHO, 1998).Statistical Analysis ::: Materials and MethodsStatistical analyses were performed by means of the commercial software \u201cStatistical Package for the Social Sciences\u201d (SPSS for Windows, version 20.0, SPSS Inc., Chicago, Illinois, USA).", [["WHOQOL", "PROTEIN", 25, 31], ["MethodsStatistical analyses", "TEST", 140, 167]]], ["Kolmogorov-Smirnov test was used to assess if data were normally distributed.", [["Kolmogorov-Smirnov test", "TEST", 0, 23]]], ["Differences in PA level and QoL domains were determined by using Mann-Whitney U tests.", [["PA", "GENE_OR_GENE_PRODUCT", 15, 17], ["PA level", "TEST", 15, 23], ["QoL domains", "TEST", 28, 39], ["Mann-Whitney U tests", "TEST", 65, 85]]], ["To assess a difference between different categories of participants based on their PA level, Kruskal-Wallis tests were used.", [["participants", "SPECIES", 55, 67], ["their PA level", "TEST", 77, 91], ["Kruskal-Wallis tests", "TEST", 93, 113]]], ["In the case of significant differences, post hoc comparisons with Bonferroni corrections were applied using the Mann-Whitney U test.", [["Bonferroni corrections", "TREATMENT", 66, 88], ["the Mann-Whitney U test", "TEST", 108, 131], ["significant", "OBSERVATION_MODIFIER", 15, 26]]], ["Furthermore, bivariate correlations were computed by using Spearman\u2019s Rho to examine the relationship between PA level and QoL domains.ResultsAn overview of the participants\u2019 METs and QoL domain scores is shown in Table 1.", [["Rho", "GENE_OR_GENE_PRODUCT", 70, 73], ["PA", "GENE_OR_GENE_PRODUCT", 110, 112], ["Rho", "PROTEIN", 70, 73], ["participants", "SPECIES", 161, 173], ["PA level", "TEST", 110, 118], ["METs", "PROBLEM", 175, 179], ["QoL domain scores", "TEST", 184, 201]]], ["Most of the time was spent with participants being sedentary, followed by light-, moderate-, and high-intensity activities, regardless of the group.", [["participants", "SPECIES", 32, 44], ["moderate", "OBSERVATION_MODIFIER", 82, 90]]], ["In general, all dependent variables differed among the groups (Kruskal-Wallis test, p < 0.001; Table 1), except being sedentary.", [["all dependent variables", "PROBLEM", 12, 35], ["Kruskal-Wallis test", "TEST", 63, 82], ["sedentary", "OBSERVATION", 118, 127]]], ["Post hoc analyses revealed that the differences between groups were significant in all comparisons and by the pattern, where the IG accumulated less light-, moderate-, and high-intensity activities when compared to HEPAG (Table 1).", [["Post hoc analyses", "TEST", 0, 17], ["the IG", "TEST", 125, 131], ["high-intensity activities", "PROBLEM", 172, 197], ["significant", "OBSERVATION_MODIFIER", 68, 79], ["moderate", "OBSERVATION_MODIFIER", 157, 165], ["high-intensity", "OBSERVATION_MODIFIER", 172, 186]]], ["When compared to the MAG, the IG did not differ in total time spent at light activities only.ResultsRegarding QoL, the IG reported lower scores compared to the MAG and HEPAG for all four domains, while the MAG and HEPAG did not differ (p = 0.950).", [["MAG", "GENE_OR_GENE_PRODUCT", 21, 24], ["MAG", "GENE_OR_GENE_PRODUCT", 160, 163], ["MAG", "GENE_OR_GENE_PRODUCT", 206, 209], ["MAG", "PROTEIN", 21, 24], ["MAG", "PROTEIN", 160, 163], ["HEPAG", "PROTEIN", 168, 173], ["MAG", "PROTEIN", 206, 209], ["the MAG", "TEST", 17, 24], ["lower scores", "PROBLEM", 131, 143], ["the MAG", "TEST", 156, 163], ["HEPAG", "TREATMENT", 168, 173], ["the MAG", "TEST", 202, 209], ["HEPAG", "TEST", 214, 219]]], ["The same pattern was observed for QoL total score, where the IG reported lower scores compared to the MAG and HEPAG, while the MAG and HEPAG did not differ (p = 0.659; Table 1).ResultsCorrelation analysis showed that total PA (MET) had a small to moderate relationship with QoL domains (Table 2).", [["MAG", "GENE_OR_GENE_PRODUCT", 102, 105], ["MAG", "GENE_OR_GENE_PRODUCT", 127, 130], ["PA", "GENE_OR_GENE_PRODUCT", 223, 225], ["MAG", "PROTEIN", 102, 105], ["HEPAG", "PROTEIN", 110, 115], ["MAG", "PROTEIN", 127, 130], ["QoL total score", "TEST", 34, 49], ["the MAG", "TEST", 98, 105], ["HEPAG", "TREATMENT", 110, 115], ["the MAG", "TEST", 123, 130], ["HEPAG", "TEST", 135, 140], ["ResultsCorrelation analysis", "TEST", 177, 204], ["total PA (MET)", "PROBLEM", 217, 231], ["a small to moderate relationship with QoL domains", "PROBLEM", 236, 285], ["small to moderate", "OBSERVATION_MODIFIER", 238, 255]]], ["More in-detail, small to moderate correlations (r ranging from 0.14 to 0.42) between all PA intensities and QoL domains were observed (Table 2).DiscussionThe present study aimed to determine the relationship between PA and QoL during the confinement caused by the COVID-19 outbreak.", [["PA", "GENE_OR_GENE_PRODUCT", 89, 91], ["PA", "GENE_OR_GENE_PRODUCT", 216, 218], ["small to moderate correlations", "PROBLEM", 16, 46], ["all PA intensities", "TEST", 85, 103], ["QoL domains", "TEST", 108, 119], ["The present study", "TEST", 154, 171], ["the COVID", "TEST", 260, 269], ["small to moderate", "OBSERVATION_MODIFIER", 16, 33]]], ["The main findings of the present study showed that MAG and HEPAG groups have better total PA, physical, psychological, social, and environmental domains scores than the IG.", [["MAG", "GENE_OR_GENE_PRODUCT", 51, 54], ["MAG", "PROTEIN", 51, 54], ["the present study", "TEST", 21, 38], ["MAG", "TEST", 51, 54], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Small to large correlations were also observed between total PA, total walking activity, total moderate-intensity PA, total vigorous-intensity PA, and the QoL domains.DiscussionThe relationship between active living and QoL is well studied in patients with different diseases and also in healthy participants (Ellingson and Conn, 2000; Brown et al., 2003; Anokye et al., 2012; Ha et al., 2014; Krzepota et al., 2018; Ho et al., 2019).", [["patients", "ORGANISM", 243, 251], ["patients", "SPECIES", 243, 251], ["participants", "SPECIES", 296, 308], ["total PA", "TEST", 55, 63], ["total walking activity", "TEST", 65, 87], ["total moderate-intensity PA", "TREATMENT", 89, 116], ["total vigorous-intensity PA", "TREATMENT", 118, 145], ["large", "OBSERVATION_MODIFIER", 9, 14]]], ["However, the current study showed that total PA (MET) was correlated with all QoL domains during a period of government directed confinement and a limiting of personal freedom.", [["PA", "GENE_OR_GENE_PRODUCT", 45, 47], ["the current study", "TEST", 9, 26]]], ["Specifically, large correlations were observed between total PA and psychological and social QoL domains.", [["total PA", "TREATMENT", 55, 63], ["large", "OBSERVATION_MODIFIER", 14, 19]]], ["Accordingly, some studies have also reported a positive correlation between PA and QoL domains (Mourady et al., 2017).", [["PA", "GENE_OR_GENE_PRODUCT", 76, 78], ["some studies", "TEST", 13, 25]]], ["For instance, some authors have reported positive correlations between total PA and physical and mental domains (Stewart et al., 2003; Wendel-Vos et al., 2004; Fox et al., 2007; Shibata et al., 2007), while others have shown positive correlations between PA and some QoL domains, namely general QoL; functional capacity; mental health; autonomy, past, present, and future activities; death and dying; intimacy; vitality; and psychological domain (Vagetti et al., 2014).", [["death", "DISEASE", 384, 389], ["PA", "GENE_OR_GENE_PRODUCT", 77, 79], ["PA", "GENE_OR_GENE_PRODUCT", 255, 257], ["total PA", "TEST", 71, 79]]], ["Mourady et al. (2017) reported that total PA was significantly correlated with physical and psychological health, general QoL, social relationships, and the environmental domains in healthy participants.", [["PA", "GENE_OR_GENE_PRODUCT", 42, 44], ["participants", "SPECIES", 190, 202], ["total PA", "TEST", 36, 44]]], ["On the contrary, in one study, sedentary PA was significantly associated with the social relationship domains (Mourady et al., 2017).", [["PA", "GENE_OR_GENE_PRODUCT", 41, 43], ["one study", "TEST", 20, 29]]], ["The last finding is not in agreement with our study result regarding the correlation between sedentary and QoL domains (e.g., in our study total sedentary mostly had non-significant relationships with QoL domains).", [["our study", "TEST", 42, 51], ["sedentary and QoL domains", "PROBLEM", 93, 118], ["our study", "TEST", 129, 138]]], ["This contradiction may be explained by the differences in the study contexts.", [["the study", "TEST", 58, 67], ["may be explained", "UNCERTAINTY", 19, 35]]], ["Participants in the present study practiced social distancing to avoid the spread of COVID-19.", [["COVID-19", "CHEMICAL", 85, 93], ["Participants", "SPECIES", 0, 12], ["COVID", "TEST", 85, 90]]], ["In addition, by staying at home, without practicing PA, they may feel insecure.DiscussionRegarding the dose-response relationship between PA and QoL domains, the current study reported small to moderate correlations between all PA intensities and QoL domains.", [["PA", "GENE_OR_GENE_PRODUCT", 52, 54], ["PA", "GENE_OR_GENE_PRODUCT", 138, 140], ["PA", "GENE_OR_GENE_PRODUCT", 228, 230], ["PA and QoL domains", "TEST", 138, 156], ["the current study", "TEST", 158, 175], ["all PA intensities", "TEST", 224, 242], ["QoL domains", "TEST", 247, 258], ["small", "OBSERVATION_MODIFIER", 185, 190], ["moderate", "OBSERVATION_MODIFIER", 194, 202]]], ["More in-detail, moderate correlations were observed between low- and moderate-intensities and psychological and social domains.", [["low- and moderate-intensities and psychological and social domains", "PROBLEM", 60, 126], ["moderate", "OBSERVATION_MODIFIER", 16, 24], ["moderate", "OBSERVATION_MODIFIER", 69, 77]]], ["Previous studies have reported positive relationships between moderate to vigorous PA and several SF-36 domains in participants attending a behavior change service within primary care, with these domains including: (a) general health and vitality, (b) physical functioning, and (c) the role of physical activity (Blom et al., 2019).", [["participants", "SPECIES", 115, 127], ["Previous studies", "TEST", 0, 16], ["positive relationships", "PROBLEM", 31, 53], ["moderate", "OBSERVATION_MODIFIER", 62, 70]]], ["Light PA was also associated with the aforementioned domains and the emotional sphere (Blom et al., 2019).", [["PA", "GENE_OR_GENE_PRODUCT", 6, 8]]], ["This is not surprising, since a lot of studies showed the beneficial effect of light, moderate, and vigorous physical activities on all QoL domains (Gillison et al., 2009; Gill et al., 2013).DiscussionRegarding the correlation between PA and QoL domains, in our study, total PA, total walking activity, total moderate-intensity PA, and total vigorous-intensity PA were positively correlated with all QoL domains in both males and females.", [["PA", "GENE_OR_GENE_PRODUCT", 235, 237], ["PA", "GENE_OR_GENE_PRODUCT", 361, 363], ["a lot of studies", "TEST", 30, 46], ["PA and QoL domains", "TEST", 235, 253], ["our study", "TEST", 258, 267], ["total PA", "TEST", 269, 277], ["total walking activity", "TEST", 279, 301], ["total moderate-intensity PA", "PROBLEM", 303, 330], ["not surprising", "UNCERTAINTY", 8, 22], ["moderate", "OBSERVATION_MODIFIER", 86, 94], ["vigorous", "OBSERVATION_MODIFIER", 100, 108], ["moderate", "OBSERVATION_MODIFIER", 309, 317], ["both males", "ANATOMY", 415, 425]]], ["These findings are in agreement in part with Nakamura et al. (2014), who reported that leisure-time PA, moderate-intensity PA, and vigorous-intensity PA were associated with physical health domains.", [["PA", "GENE_OR_GENE_PRODUCT", 150, 152], ["PA", "TEST", 100, 102], ["moderate-intensity PA", "PROBLEM", 104, 125], ["moderate", "OBSERVATION_MODIFIER", 104, 112]]], ["Moderate intensity and total activity leisure-time PA were also correlated with mental health in men (Nakamura et al., 2014).", [["PA", "GENE_OR_GENE_PRODUCT", 51, 53], ["men", "ORGANISM", 97, 100], ["men", "SPECIES", 97, 100], ["Moderate intensity", "PROBLEM", 0, 18], ["intensity", "OBSERVATION_MODIFIER", 9, 18], ["total", "OBSERVATION_MODIFIER", 23, 28], ["activity", "OBSERVATION_MODIFIER", 29, 37]]], ["However, our study showed large correlations between psychological and social domains and all intensities of PA.", [["PA", "GENE_OR_GENE_PRODUCT", 109, 111], ["our study", "TEST", 9, 18], ["large correlations between psychological and social domains", "PROBLEM", 26, 85], ["large", "OBSERVATION_MODIFIER", 26, 31]]], ["In addition, a previous study reported that light-intensity of PA was positively correlated with psychological health and social relationship domains in healthy participants (Mourady et al., 2017).", [["PA", "GENE_OR_GENE_PRODUCT", 63, 65], ["participants", "SPECIES", 161, 173], ["a previous study", "TEST", 13, 29]]], ["These studies and the current investigation support the latest guidelines issued by the WHO suggesting that people attain 150 min of moderate-intensity, 75 min of vigorous-intensity PA per week, or a combination of both to improve health, well-being, and QoL during the confinement.DiscussionDespite its novelty and methodological rigor, the present study is not without any limitations that should be properly acknowledged.", [["people", "ORGANISM", 108, 114], ["people", "SPECIES", 108, 114], ["These studies", "TEST", 0, 13], ["methodological rigor", "PROBLEM", 316, 336], ["the present study", "TEST", 338, 355]]], ["A further drawback is represented by the study design that being cross-sectional does not allow causal inferences to be drawn from the data.", [["the study", "TEST", 37, 46], ["the data", "TEST", 131, 139]]], ["Given the preliminary nature of the present report, further research is needed to confirm our conclusions among different populations, using representative samples.", [["representative samples", "TEST", 141, 163]]], ["In particular, longitudinal studies are needed to better understand the relationship between PA levels and perceived QoL during the confinement measures and after their lifting.DiscussionFrom the present findings, we can conclude that there is an association between PA levels and perceived QoL during the confinement period and the COVID-19 outbreak.", [["PA", "GENE_OR_GENE_PRODUCT", 93, 95], ["PA", "GENE_OR_GENE_PRODUCT", 267, 269], ["longitudinal studies", "TEST", 15, 35], ["PA levels", "TEST", 93, 102], ["the confinement measures", "TREATMENT", 128, 152], ["PA levels", "TEST", 267, 276], ["the COVID", "TEST", 329, 338]]], ["If longitudinal studies replicate our data, PA with light-, moderate-, and vigorous intensities can be well recommended as an important method to improve QoL and to decrease/counteract the negative psychosocial effects of confinement.", [["PA", "GENE_OR_GENE_PRODUCT", 44, 46], ["longitudinal studies", "TEST", 3, 23], ["our data", "TEST", 34, 42], ["PA", "TEST", 44, 46], ["moderate-, and vigorous intensities", "PROBLEM", 60, 95], ["moderate", "OBSERVATION_MODIFIER", 60, 68]]], ["However, based on the above-mentioned limitations, along with the impact that disease-caused confinement has on people physically and psychologically, further research in the field is urgently warranted.Data Availability StatementThe datasets presented in this article are readily available from the corresponding author (maamer2011@hotmail.fr).Ethics StatementThe studies involving human participants were reviewed and approved by local institutional ethical approval provided for this study, which was conducted in accordance with the 1964 Declaration of Helsinki.", [["people", "ORGANISM", 112, 118], ["human", "ORGANISM", 383, 388], ["people", "SPECIES", 112, 118], ["human", "SPECIES", 383, 388], ["participants", "SPECIES", 389, 401], ["human", "SPECIES", 383, 388], ["this study", "TEST", 482, 492], ["disease", "OBSERVATION", 78, 85]]], ["Written informed consent to participate in this study was provided by the participants\u2019 legal guardian/next of kin.Conflict of Interest ::: Author ContributionsThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [["participants", "SPECIES", 74, 86], ["this study", "TEST", 43, 53]]]], "PMC7094983": [["MainThe emergence of SARS in southern China in 2002, which was caused by a previously unknown coronavirus (SARS-CoV)11\u201315 and has led to more than 8,000 human infections and 774 deaths (http://www.who.int/csr/sars/en/), highlights two new frontiers in emerging infectious diseases.", [["SARS", "DISEASE", 21, 25], ["SARS", "DISEASE", 107, 111], ["infections", "DISEASE", 159, 169], ["deaths", "DISEASE", 178, 184], ["infectious diseases", "DISEASE", 261, 280], ["SARS-CoV", "ORGANISM", 107, 115], ["human", "ORGANISM", 153, 158], ["human", "SPECIES", 153, 158], ["SARS-CoV", "SPECIES", 107, 115], ["human", "SPECIES", 153, 158], ["SARS", "PROBLEM", 21, 25], ["infections", "OBSERVATION", 159, 169], ["infectious", "OBSERVATION", 261, 271]]], ["First, it demonstrates that coronaviruses are capable of causing fatal diseases in humans.", [["coronaviruses", "ORGANISM", 28, 41], ["humans", "ORGANISM", 83, 89], ["humans", "SPECIES", 83, 89], ["humans", "SPECIES", 83, 89], ["coronaviruses", "PROBLEM", 28, 41], ["fatal diseases in humans", "PROBLEM", 65, 89], ["coronaviruses", "OBSERVATION", 28, 41], ["fatal", "OBSERVATION_MODIFIER", 65, 70], ["diseases", "OBSERVATION", 71, 79]]], ["Second, the identification of bats as the reservoir for SARS-related coronaviruses, and the fact that SARS-CoV3\u201310 probably originated in bats, firmly establishes that bats are an important source of highly lethal zoonotic viruses, such as Hendra, Nipah, Ebola and Marburg viruses16.MainHere we report on a series of fatal swine disease outbreaks in Guangdong province, China, approximately 100 km from the location of the purported index case of SARS.", [["SARS", "DISEASE", 56, 60], ["SARS-CoV3\u201310", "CHEMICAL", 102, 114], ["zoonotic viruses", "DISEASE", 214, 230], ["Hendra, Nipah, Ebola and Marburg viruses", "DISEASE", 240, 280], ["swine disease", "DISEASE", 323, 336], ["SARS", "DISEASE", 447, 451], ["bats", "ORGANISM", 30, 34], ["SARS-related coronaviruses", "ORGANISM", 56, 82], ["SARS-CoV3\u201310", "ORGANISM", 102, 114], ["bats", "ORGANISM", 168, 172], ["Hendra", "ORGANISM", 240, 246], ["Ebola", "ORGANISM", 255, 260], ["Marburg viruses16", "ORGANISM", 265, 282], ["Nipah", "SPECIES", 248, 253], ["swine", "SPECIES", 323, 328], ["Marburg viruses", "SPECIES", 265, 280], ["swine", "SPECIES", 323, 328], ["the reservoir", "TREATMENT", 38, 51], ["SARS", "PROBLEM", 56, 60], ["coronaviruses", "PROBLEM", 69, 82], ["SARS", "PROBLEM", 102, 106], ["highly lethal zoonotic viruses", "PROBLEM", 200, 230], ["fatal swine disease outbreaks", "PROBLEM", 317, 346], ["SARS", "PROBLEM", 447, 451]]], ["Most strikingly, we found that the causative agent of this swine acute diarrhoea syndrome (SADS) is a novel HKU2-related coronavirus that is 98.48% identical in genome sequence to a bat coronavirus, which we detected in 2016 in bats in a cave in the vicinity of the index pig farm.", [["acute diarrhoea syndrome", "DISEASE", 65, 89], ["SADS", "DISEASE", 91, 95], ["coronavirus", "DISEASE", 121, 132], ["swine", "ORGANISM", 59, 64], ["HKU2", "GENE_OR_GENE_PRODUCT", 108, 112], ["coronavirus", "ORGANISM", 121, 132], ["bat coronavirus", "ORGANISM", 182, 197], ["pig", "ORGANISM", 272, 275], ["swine", "SPECIES", 59, 64], ["bat coronavirus", "SPECIES", 182, 197], ["pig", "SPECIES", 272, 275], ["swine acute diarrhoea syndrome (SADS", "SPECIES", 59, 95], ["bat coronavirus", "SPECIES", 182, 197], ["pig", "SPECIES", 272, 275], ["this swine acute diarrhoea syndrome", "PROBLEM", 54, 89], ["a novel HKU2-related coronavirus", "PROBLEM", 100, 132], ["a bat coronavirus", "PROBLEM", 180, 197], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["diarrhoea", "OBSERVATION", 71, 80]]], ["This new virus (SADS-CoV) originated from the same genus of horseshoe bats (Rhinolophus) as SARS-CoV.MainFrom 28 October 2016 onwards, a fatal swine disease outbreak was observed in a pig farm in Qingyuan, Guangdong province, China, very close to the location of the first known index case of SARS in 2002, who lived in Foshan (Extended Data Fig. 1a).", [["swine disease", "DISEASE", 143, 156], ["SARS", "DISEASE", 293, 297], ["SADS-CoV", "ORGANISM", 16, 24], ["horseshoe bats", "ORGANISM", 60, 74], ["Rhinolophus", "ORGANISM_SUBDIVISION", 76, 87], ["SARS-CoV", "ORGANISM", 92, 100], ["pig", "ORGANISM", 184, 187], ["swine", "SPECIES", 143, 148], ["pig", "SPECIES", 184, 187], ["SADS-CoV", "SPECIES", 16, 24], ["SARS-CoV", "SPECIES", 92, 100], ["swine", "SPECIES", 143, 148], ["pig", "SPECIES", 184, 187], ["This new virus (SADS-CoV)", "PROBLEM", 0, 25], ["horseshoe bats", "PROBLEM", 60, 74], ["a fatal swine disease outbreak", "PROBLEM", 135, 165], ["virus", "OBSERVATION", 9, 14], ["horseshoe bats", "OBSERVATION", 60, 74], ["fatal", "OBSERVATION_MODIFIER", 137, 142]]], ["Porcine epidemic diarrhoea virus (PEDV, a coronavirus) had caused prior outbreaks at this farm, and was detected in the intestines of deceased piglets at the start of the outbreak.", [["intestines", "ANATOMY", 120, 130], ["Porcine epidemic diarrhoea virus", "DISEASE", 0, 32], ["coronavirus", "DISEASE", 42, 53], ["Porcine epidemic diarrhoea virus", "ORGANISM", 0, 32], ["intestines", "ORGAN", 120, 130], ["piglets", "ORGANISM", 143, 150], ["Porcine epidemic diarrhoea virus", "SPECIES", 0, 32], ["coronavirus", "SPECIES", 42, 53], ["piglets", "SPECIES", 143, 150], ["Porcine epidemic diarrhoea virus", "SPECIES", 0, 32], ["PEDV", "SPECIES", 34, 38], ["Porcine epidemic diarrhoea virus", "PROBLEM", 0, 32], ["PEDV", "PROBLEM", 34, 38], ["a coronavirus)", "PROBLEM", 40, 54], ["prior outbreaks", "PROBLEM", 66, 81], ["epidemic", "OBSERVATION_MODIFIER", 8, 16], ["diarrhoea virus", "OBSERVATION", 17, 32], ["intestines", "ANATOMY", 120, 130], ["deceased", "OBSERVATION", 134, 142]]], ["However, PEDV could no longer be detected in deceased piglets after 12 January 2017, despite accelerating mortality (Fig. 1a), and extensive testing for other common swine viruses yielded no results (Extended Data Table 1).", [["PEDV", "CHEMICAL", 9, 13], ["PEDV", "GENE_OR_GENE_PRODUCT", 9, 13], ["piglets", "ORGANISM", 54, 61], ["PEDV", "PROTEIN", 9, 13], ["swine", "SPECIES", 166, 171], ["PEDV", "SPECIES", 9, 13], ["swine viruses", "SPECIES", 166, 179], ["PEDV", "PROBLEM", 9, 13], ["extensive testing", "TEST", 131, 148], ["other common swine viruses", "PROBLEM", 153, 179], ["no longer", "UNCERTAINTY", 20, 29]]], ["These findings suggested that this was an outbreak of a novel disease.", [["a novel disease", "PROBLEM", 54, 69]]], ["Clinical signs are similar to those caused by other known swine enteric coronaviruses17, 18 and include severe and acute diarrhoea and acute vomiting, leading to death due to rapid weight loss in newborn piglets that are less than five days of age.", [["diarrhoea", "DISEASE", 121, 130], ["vomiting", "DISEASE", 141, 149], ["death", "DISEASE", 162, 167], ["weight loss", "DISEASE", 181, 192], ["piglets", "ORGANISM", 204, 211], ["swine", "SPECIES", 58, 63], ["piglets", "SPECIES", 204, 211], ["Clinical signs", "PROBLEM", 0, 14], ["other known swine enteric coronaviruses17", "PROBLEM", 46, 87], ["severe and acute diarrhoea", "PROBLEM", 104, 130], ["acute vomiting", "PROBLEM", 135, 149], ["death", "PROBLEM", 162, 167], ["rapid weight loss in newborn piglets", "PROBLEM", 175, 211], ["severe", "OBSERVATION_MODIFIER", 104, 110], ["acute", "OBSERVATION_MODIFIER", 115, 120], ["diarrhoea", "OBSERVATION", 121, 130], ["acute", "OBSERVATION_MODIFIER", 135, 140], ["vomiting", "OBSERVATION", 141, 149], ["rapid", "OBSERVATION_MODIFIER", 175, 180], ["weight loss", "OBSERVATION", 181, 192]]], ["Infected piglets died 2\u20136 days after disease onset, whereas infected sows suffered only mild diarrhoea and most sows recovered within two days.", [["diarrhoea", "DISEASE", 93, 102], ["piglets", "ORGANISM", 9, 16], ["sows", "ORGANISM", 69, 73], ["piglets", "SPECIES", 9, 16], ["disease onset", "PROBLEM", 37, 50], ["mild diarrhoea", "PROBLEM", 88, 102], ["mild", "OBSERVATION_MODIFIER", 88, 92], ["diarrhoea", "OBSERVATION", 93, 102]]], ["The disease caused no signs of febrile illness in piglets or sows.", [["febrile illness", "DISEASE", 31, 46], ["piglets", "ORGANISM", 50, 57], ["piglets", "SPECIES", 50, 57], ["The disease", "PROBLEM", 0, 11], ["febrile illness", "PROBLEM", 31, 46], ["disease", "OBSERVATION", 4, 11], ["no signs of", "UNCERTAINTY", 19, 30], ["febrile", "OBSERVATION_MODIFIER", 31, 38], ["illness", "OBSERVATION", 39, 46]]], ["The mortality rate was as high as 90% in piglets that were five days or younger, whereas in piglets that were older than eight days, the mortality dropped to 5%.", [["piglets", "ORGANISM", 41, 48], ["piglets", "ORGANISM", 92, 99], ["piglets", "SPECIES", 41, 48], ["piglets", "SPECIES", 92, 99], ["The mortality rate", "TEST", 0, 18]]], ["Subsequently, SADS-related outbreaks were found in three additional pig farms within 20\u2013150 km of the index farm (Extended Data Fig. 1a) and, by 2 May 2017, the disease had caused the death of 24,693 piglets at these four farms (Fig. 1a).", [["SADS", "CHEMICAL", 14, 18], ["death", "DISEASE", 184, 189], ["pig", "ORGANISM", 68, 71], ["piglets", "ORGANISM", 200, 207], ["pig", "SPECIES", 68, 71], ["piglets", "SPECIES", 200, 207], ["pig", "SPECIES", 68, 71], ["SADS", "TEST", 14, 18], ["outbreaks", "PROBLEM", 27, 36], ["the disease", "PROBLEM", 157, 168], ["the death", "PROBLEM", 180, 189]]], ["In farm A alone, 64% (4,659 out of 7,268) of all piglets that were born in February died.", [["piglets", "ORGANISM", 49, 56], ["piglets", "SPECIES", 49, 56]]], ["The outbreak has abated, and measures that were taken to control SADS included separation of sick sows and piglets from the rest of the herd.", [["SADS", "DISEASE", 65, 69], ["sows", "ORGANISM_SUBDIVISION", 98, 102], ["piglets", "ORGANISM", 107, 114], ["herd", "ORGANISM_SUBDIVISION", 136, 140], ["piglets", "SPECIES", 107, 114], ["sick sows", "PROBLEM", 93, 102]]], ["A qPCR test described below was used as the main diagnostic tool to confirm SADS-CoV infection.", [["infection", "DISEASE", 85, 94], ["SADS-CoV", "GENE_OR_GENE_PRODUCT", 76, 84], ["SADS-CoV", "SPECIES", 76, 84], ["A qPCR test", "TEST", 0, 11], ["SADS", "PROBLEM", 76, 80], ["CoV infection", "PROBLEM", 81, 94], ["CoV", "ANATOMY", 81, 84], ["infection", "OBSERVATION", 85, 94]]]], "1fdad648ea0b100b2f81c17e715113f94ede76e8": [["Introduction miRNAs are small molecules (17-24 nt) of non-coding, single-stranded RNA that inhibit the translation of mature messenger RNAs (mRNAs) [1] .", [["miRNAs", "DNA", 13, 19], ["17-24 nt", "RNA", 41, 49], ["non-coding, single-stranded RNA", "RNA", 54, 85], ["mature messenger RNAs", "RNA", 118, 139], ["mRNAs", "RNA", 141, 146], ["small molecules", "PROBLEM", 24, 39], ["non-coding, single-stranded RNA", "PROBLEM", 54, 85], ["small", "OBSERVATION_MODIFIER", 24, 29], ["stranded RNA", "OBSERVATION_MODIFIER", 73, 85], ["mature", "OBSERVATION_MODIFIER", 118, 124], ["messenger RNAs", "OBSERVATION", 125, 139]]], ["There are more than 1881 miRNA precursor sequences in the human genome, allowing the generation of 2588 mature miRNAs according to miRBase 21.0 [2] .", [["human", "ORGANISM", 58, 63], ["miRNA precursor sequences", "DNA", 25, 50], ["human genome", "DNA", 58, 70], ["2588 mature miRNAs", "RNA", 99, 117], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 58, 63], ["human genome", "ANATOMY", 58, 70]]], ["These molecules regulate around 60% of gene expression, they are present in a great number of biological processes, and their potential role as biomarkers in diagnosis and treatment is being explored [3] .", [["treatment", "TREATMENT", 172, 181]]], ["Among the biological functions of miRNAs are maintenance of the epithelial cell barrier in the respiratory tract and regulation of anti-viral host defense [4] .", [["epithelial cell", "ANATOMY", 64, 79], ["respiratory tract", "ANATOMY", 95, 112], ["epithelial cell barrier", "TISSUE", 64, 87], ["respiratory tract", "ORGANISM_SUBDIVISION", 95, 112], ["miRNAs", "DNA", 34, 40], ["the epithelial cell barrier", "TREATMENT", 60, 87], ["anti-viral host defense", "TREATMENT", 131, 154], ["epithelial cell", "OBSERVATION", 64, 79], ["respiratory tract", "ANATOMY", 95, 112], ["anti-viral host", "OBSERVATION", 131, 146]]], ["Viral acute respiratory infections (ARIs) are the most common cause of acute respiratory symptoms (e.g., flu and bronchitis), and many of these infections have been linked to the exacerbation of symptoms in chronic respiratory diseases such as asthma [5] .", [["respiratory", "ANATOMY", 12, 23], ["respiratory", "ANATOMY", 77, 88], ["respiratory", "ANATOMY", 215, 226], ["Viral acute respiratory infections", "DISEASE", 0, 34], ["ARIs", "DISEASE", 36, 40], ["acute respiratory symptoms", "DISEASE", 71, 97], ["flu", "DISEASE", 105, 108], ["bronchitis", "DISEASE", 113, 123], ["infections", "DISEASE", 144, 154], ["respiratory diseases", "DISEASE", 215, 235], ["asthma", "DISEASE", 244, 250], ["Viral acute respiratory infections (ARIs)", "PROBLEM", 0, 41], ["acute respiratory symptoms", "PROBLEM", 71, 97], ["flu", "PROBLEM", 105, 108], ["bronchitis", "PROBLEM", 113, 123], ["these infections", "PROBLEM", 138, 154], ["symptoms", "PROBLEM", 195, 203], ["chronic respiratory diseases", "PROBLEM", 207, 235], ["asthma", "PROBLEM", 244, 250], ["acute", "OBSERVATION_MODIFIER", 6, 11], ["respiratory", "ANATOMY", 12, 23], ["infections", "OBSERVATION", 24, 34], ["most common", "OBSERVATION_MODIFIER", 50, 61], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["respiratory", "ANATOMY", 77, 88], ["symptoms", "OBSERVATION", 89, 97], ["bronchitis", "OBSERVATION", 113, 123], ["infections", "OBSERVATION", 144, 154], ["chronic", "OBSERVATION_MODIFIER", 207, 214], ["respiratory diseases", "OBSERVATION", 215, 235], ["asthma", "OBSERVATION", 244, 250]]]], "55248fb2e12f9712b35a26e3fdb723baea0ac775": [["IntroductionPorcine epidemic diarrhea virus (PEDV), a member of the Coronaviridae family, and genus Alphacoronavirus, is an enveloped, single-stranded, positive-sense RNA virus, which causes infectious gastroenteritis in pigs [1] .", [["IntroductionPorcine epidemic diarrhea", "DISEASE", 0, 37], ["infectious gastroenteritis", "DISEASE", 191, 217], ["IntroductionPorcine epidemic diarrhea virus", "ORGANISM", 0, 43], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 100, 116], ["pigs", "ORGANISM", 221, 225], ["epidemic diarrhea virus", "SPECIES", 20, 43], ["pigs", "SPECIES", 221, 225], ["IntroductionPorcine epidemic diarrhea virus", "SPECIES", 0, 43], ["PEDV", "SPECIES", 45, 49], ["pigs", "SPECIES", 221, 225], ["IntroductionPorcine epidemic diarrhea virus (PEDV", "PROBLEM", 0, 49], ["genus Alphacoronavirus", "PROBLEM", 94, 116], ["sense RNA virus", "PROBLEM", 161, 176], ["infectious gastroenteritis", "PROBLEM", 191, 217], ["infectious", "OBSERVATION_MODIFIER", 191, 201]]], ["The virus has a~28 kb genome containing a 5 0 untranslated region (UTR), a 3 0 UTR, and at least seven open reading frames (ORFs).", [["~28 kb genome", "DNA", 15, 28], ["5 0 untranslated region", "DNA", 42, 65], ["UTR", "DNA", 67, 70], ["3 0 UTR", "DNA", 75, 82], ["open reading frames", "DNA", 103, 122], ["ORFs", "DNA", 124, 128], ["The virus", "PROBLEM", 0, 9], ["a 5 0 untranslated region (UTR)", "PROBLEM", 40, 71], ["a 3 0 UTR", "PROBLEM", 73, 82], ["virus", "OBSERVATION", 4, 9], ["28 kb", "OBSERVATION_MODIFIER", 16, 21], ["5 0 untranslated", "OBSERVATION_MODIFIER", 42, 58]]], ["The ORFs encode four structural proteins (spike (S), envelope (E), membrane (M), and nucleocapsid (N)), one hypothetical accessary protein (ORF3), and two polyproteins (1a and 1b), in the order of 5 0 UTR-ORF 1a/1b-S-ORF 3-E-M-N-3 0 UTR [2, 3] .IntroductionSince late 2010, PED outbreaks, which cause severe diarrhea and high mortality, have affected 80-100% of piglets in China [4] [5] [6] .", [["membrane", "ANATOMY", 67, 75], ["diarrhea", "DISEASE", 308, 316], ["spike (S), envelope (E)", "GENE_OR_GENE_PRODUCT", 42, 65], ["membrane", "CELLULAR_COMPONENT", 67, 75], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 85, 101], ["ORF3", "GENE_OR_GENE_PRODUCT", 140, 144], ["piglets", "ORGANISM", 362, 369], ["ORFs", "DNA", 4, 8], ["structural proteins", "PROTEIN", 21, 40], ["spike (S)", "PROTEIN", 42, 51], ["envelope (E), membrane (M)", "PROTEIN", 53, 79], ["nucleocapsid (N)", "PROTEIN", 85, 101], ["accessary protein", "PROTEIN", 121, 138], ["ORF3", "PROTEIN", 140, 144], ["polyproteins", "PROTEIN", 155, 167], ["1a and 1b", "PROTEIN", 169, 178], ["5 0 UTR-ORF 1a", "DNA", 197, 211], ["S", "DNA", 215, 216], ["ORF 3", "DNA", 217, 222], ["E-M-N-3 0 UTR", "DNA", 223, 236], ["piglets", "SPECIES", 362, 369], ["The ORFs", "TEST", 0, 8], ["UTR", "TEST", 201, 204], ["ORF", "TEST", 205, 208], ["ORF", "TEST", 217, 220], ["severe diarrhea", "PROBLEM", 301, 316], ["high mortality", "PROBLEM", 321, 335], ["severe", "OBSERVATION_MODIFIER", 301, 307], ["diarrhea", "OBSERVATION", 308, 316]]], ["Although a large proportion of the pig population had been vaccinated (using a vaccine derived from the CV777 strain), the protection was limited.", [["pig", "ORGANISM", 35, 38], ["pig", "SPECIES", 35, 38], ["pig", "SPECIES", 35, 38], ["the pig population", "PROBLEM", 31, 49], ["a vaccine", "TREATMENT", 77, 86], ["large", "OBSERVATION_MODIFIER", 11, 16], ["proportion", "OBSERVATION_MODIFIER", 17, 27]]], ["Consequently, the outbreaks caused serious economic loss to the pig industry [4] [5] [6] [7] .", [["pig", "ORGANISM", 64, 67], ["[4] [5] [6] [7]", "SIMPLE_CHEMICAL", 77, 92], ["pig", "SPECIES", 64, 67], ["pig", "SPECIES", 64, 67], ["serious economic loss", "PROBLEM", 35, 56], ["the pig industry", "TREATMENT", 60, 76]]], ["In the USA, the first case of PED emerged with very high mortality (90-95%) in suckling piglets in April 2013 [8] .", [["PED", "DISEASE", 30, 33], ["piglets", "ORGANISM", 88, 95], ["piglets", "SPECIES", 88, 95], ["very high mortality", "PROBLEM", 47, 66]]], ["Subsequently, the outbreak spread throughout North America, affecting more than 31 USA States as of July 2014 [9] .", [["outbreak", "OBSERVATION_MODIFIER", 18, 26], ["spread", "OBSERVATION_MODIFIER", 27, 33]]], ["In the analysis of the genomes of the PEDV strains detected in the USA, most were grouped in the high mortality type similar to the Chinese PEDV strain (AH2012), and the remaining strains were grouped in the INDEL type, which have specific insertions and deletions in the S gene [9, 10] .", [["PEDV strains", "ORGANISM", 38, 50], ["PEDV strain", "ORGANISM", 140, 151], ["AH2012", "CANCER", 153, 159], ["S gene", "DNA", 272, 278], ["PEDV", "SPECIES", 38, 42], ["Chinese PEDV strain", "SPECIES", 132, 151], ["the PEDV strains", "PROBLEM", 34, 50], ["the Chinese PEDV strain", "PROBLEM", 128, 151], ["the remaining strains", "PROBLEM", 166, 187], ["PEDV strains", "OBSERVATION", 38, 50], ["INDEL type", "OBSERVATION", 208, 218]]], ["During 2013-2014, PEDV was obtained from farms showing high infectivity and/or mortality in suckling piglets in many countries worldwide such as South Korea [11] , Japan [12] , Taiwan [13] , Canada [14] , Mexico [15] , Germany [16, 17] , and France [18] .", [["PEDV", "ORGANISM", 18, 22], ["piglets", "ORGANISM", 101, 108], ["piglets", "SPECIES", 101, 108], ["PEDV", "SPECIES", 18, 22], ["PEDV", "PROBLEM", 18, 22], ["high infectivity", "PROBLEM", 55, 71]]], ["The PEDV strains detected in these countries were grouped as US-like PEDV strains based on phylogenetic analysis using whole-genome sequences.", [["PEDV strains", "ORGANISM", 4, 16], ["whole-genome sequences", "DNA", 119, 141], ["PEDV", "SPECIES", 4, 8], ["PEDV", "SPECIES", 69, 73], ["The PEDV strains", "PROBLEM", 0, 16], ["US", "TEST", 61, 63], ["PEDV strains", "PROBLEM", 69, 81], ["phylogenetic analysis", "TEST", 91, 112], ["whole-genome sequences", "TEST", 119, 141], ["PEDV strains", "OBSERVATION", 4, 16]]], ["The high similarity of whole-genome sequences among these PEDV strains, rather than the past strains detected in each country, led to the hypothesis that the origin of these virulent strains may be common [12, 13] .IntroductionAlthough a phylogenetic analysis was conducted for the PEDV strains discovered in the recent outbreaks, inconsistencies have arisen when results were compared between different regions of the genome or between results using partial and whole genome sequences [9, [19] [20] [21] [22] [23] .", [["PEDV strains", "ORGANISM", 58, 70], ["[19] [20] [21] [22] [23]", "SIMPLE_CHEMICAL", 490, 514], ["whole-genome sequences", "DNA", 23, 45], ["PEDV", "SPECIES", 282, 286], ["these PEDV strains", "PROBLEM", 52, 70], ["the past strains", "PROBLEM", 84, 100], ["these virulent strains", "PROBLEM", 168, 190], ["a phylogenetic analysis", "TEST", 236, 259], ["the PEDV strains", "PROBLEM", 278, 294], ["partial and whole genome sequences", "TEST", 451, 485]]], ["Recombination has been suggested as a reason for these inconsistencies [9, 19, 22, 24, 25] , as it is assumed to play important roles in escaping from vaccine protection and adapting to the host species [21, 25, 26] .", [["vaccine protection", "TREATMENT", 151, 169]]], ["For instance, if a specific region of the genome sequence was inserted in parental strains as a result of recombination, the region will be passed on to the daughter strains.", [["genome sequence", "DNA", 42, 57], ["parental strains", "PROBLEM", 74, 90]]], ["The hypothetical existence of a partial genome sequence specific to the daughter strains incited us to explore partial genomic features shared by some PEDV strains as an indicator of the epidemiological association between PEDV strains detected in different locations.Ethic statementAll fecal samples of Japanese isolates were submitted from Livestock Hygiene Service Centers in each prefecture to National Institute of Animal Health during disease control activities of local official veterinarians during 2013-2014 epidemic [12] .", [["fecal samples", "ANATOMY", 287, 300], ["PEDV", "GENE_OR_GENE_PRODUCT", 151, 155], ["PEDV", "GENE_OR_GENE_PRODUCT", 223, 227], ["fecal samples", "ORGANISM_SUBSTANCE", 287, 300], ["partial genome sequence", "DNA", 32, 55], ["PEDV", "SPECIES", 223, 227], ["a partial genome sequence", "PROBLEM", 30, 55], ["partial genomic features", "PROBLEM", 111, 135], ["some PEDV strains", "PROBLEM", 146, 163], ["PEDV strains", "PROBLEM", 223, 235], ["All fecal samples", "TEST", 283, 300], ["Japanese isolates", "TREATMENT", 304, 321], ["fecal", "ANATOMY", 287, 292]]], ["Therefore, all fecal samples had been collected passively from pigs with clinical signs such as diarrhea, and no aggressive operation had been conducted against pigs for sampling purpose.", [["fecal samples", "ANATOMY", 15, 28], ["diarrhea", "DISEASE", 96, 104], ["fecal samples", "ORGANISM_SUBSTANCE", 15, 28], ["pigs", "ORGANISM", 63, 67], ["pigs", "ORGANISM", 161, 165], ["pigs", "SPECIES", 63, 67], ["pigs", "SPECIES", 161, 165], ["pigs", "SPECIES", 63, 67], ["pigs", "SPECIES", 161, 165], ["all fecal samples", "TEST", 11, 28], ["clinical signs", "TEST", 73, 87], ["diarrhea", "PROBLEM", 96, 104], ["aggressive operation", "TREATMENT", 113, 133], ["sampling purpose", "TEST", 170, 186]]], ["All samples were included in our previous study [12] under sample specific permissions from the local government which provided the relevant sample.", [["samples", "ANATOMY", 4, 11], ["All samples", "TEST", 0, 11], ["our previous study", "TEST", 29, 47]]], ["Submission of fecal samples was conducted under the supervision of Ministry of Agriculture, Forestry and Fisheries.", [["fecal samples", "ANATOMY", 14, 27], ["fecal samples", "ORGANISM_SUBSTANCE", 14, 27], ["fecal samples", "TEST", 14, 27], ["fecal", "ANATOMY", 14, 19]]], ["Sequences of non-Japanese isolates were downloaded from the GenBank database.Whole genome sequence of PEDV strainsFrom October 2013 to October 2014, intestinal samples from sows and/or piglets showing vomiting, anorexia, and watery diarrhea at 36 farms ware submitted from Livestock Hygiene Service Centers in 17 prefectures in Japan to National Institute of Animal Health (NIAH) during control activities against PEDV spread [12] .", [["intestinal samples", "ANATOMY", 149, 167], ["vomiting", "DISEASE", 201, 209], ["anorexia", "DISEASE", 211, 219], ["watery diarrhea", "DISEASE", 225, 240], ["PEDV", "CHEMICAL", 414, 418], ["intestinal samples", "MULTI-TISSUE_STRUCTURE", 149, 167], ["sows", "ORGANISM", 173, 177], ["piglets", "ORGANISM", 185, 192], ["sows", "SPECIES", 173, 177], ["piglets", "SPECIES", 185, 192], ["PEDV", "SPECIES", 102, 106], ["PEDV", "SPECIES", 414, 418], ["non-Japanese isolates", "TEST", 13, 34], ["the GenBank database", "TEST", 56, 76], ["PEDV strains", "PROBLEM", 102, 114], ["intestinal samples", "TEST", 149, 167], ["piglets", "PROBLEM", 185, 192], ["vomiting", "PROBLEM", 201, 209], ["anorexia", "PROBLEM", 211, 219], ["watery diarrhea", "PROBLEM", 225, 240], ["PEDV spread", "PROBLEM", 414, 425], ["intestinal", "ANATOMY", 149, 159]]], ["The virus isolation, RNA extraction, and sequencing were conducted in NIAH as described previously [12] .", [["The virus isolation", "TREATMENT", 0, 19], ["RNA extraction", "TREATMENT", 21, 35], ["sequencing", "TEST", 41, 51], ["virus isolation", "OBSERVATION", 4, 19]]], ["Whole genome sequences of PEDV detected in countries other than Japan were obtained from the GenBank database.", [["PEDV", "DNA", 26, 30], ["PEDV", "SPECIES", 26, 30], ["Whole genome sequences", "TEST", 0, 22], ["PEDV", "PROBLEM", 26, 30]]], ["To ensure the date of isolation of each PEDV strain was accurate, only the strains with sufficient information [9, 10, 14, 17, [27] [28] [29] [30] [31] were selected.", [["PEDV", "ORGANISM", 40, 44], ["[27] [28] [29] [30", "SIMPLE_CHEMICAL", 127, 145], ["PEDV", "SPECIES", 40, 44], ["isolation", "TREATMENT", 22, 31], ["each PEDV strain", "PROBLEM", 35, 51]]], ["As a result, 119 PEDV strains, including 36 Japanese and 83 foreign PEDV strains (76 from USA, 1 from Canada, 2 from Mexico, 1 from Germany, and 3 from Korea) were used in this study.", [["PEDV", "SPECIES", 17, 21], ["PEDV", "SPECIES", 68, 72], ["119 PEDV strains", "PROBLEM", 13, 29], ["foreign PEDV strains", "TEST", 60, 80], ["this study", "TEST", 172, 182]]], ["The origins of and the date the pig illness was diagnosed at the farm as PED (for Japanese PEDV strain) or the date of detection (for foreign strains) are summarized in S1 Table.", [["pig illness", "DISEASE", 32, 43], ["pig", "ORGANISM", 32, 35], ["pig", "SPECIES", 32, 35], ["pig", "SPECIES", 32, 35], ["the pig illness", "PROBLEM", 28, 43], ["Japanese PEDV strain", "PROBLEM", 82, 102], ["foreign strains", "PROBLEM", 134, 149]]], ["GenBank accession numbers of each PEDV strain are also included in S1 Table.", [["each PEDV strain", "PROBLEM", 29, 45], ["PEDV strain", "OBSERVATION", 34, 45]]], ["For further analysis, we aligned all 119 PEDV sequences using the ClustalW method [32] in the MEGA6 program [33] with default parameter settings.", [["PEDV sequences", "DNA", 41, 55], ["further analysis", "TEST", 4, 20], ["the ClustalW method", "TEST", 62, 81], ["default parameter settings", "TREATMENT", 118, 144]]], ["The length of the aligned sequences was 27,746 nt.", [["aligned sequences", "DNA", 18, 35], ["the aligned sequences", "TEST", 14, 35], ["nt", "PROBLEM", 47, 49], ["length", "OBSERVATION_MODIFIER", 4, 10]]], ["Phylogenetic analysis using the entire genome was performed by the MEGA6 program using the maximum-likelihood method with the general time reversible nucleotide substitution model.", [["nucleotide", "CHEMICAL", 150, 160], ["nucleotide", "CHEMICAL", 150, 160], ["Phylogenetic analysis", "TEST", 0, 21], ["the general time reversible nucleotide substitution model", "TREATMENT", 122, 179], ["substitution model", "OBSERVATION", 161, 179]]], ["The confidence level for each branch was tested by the bootstrap method with 1,000 replicates.Determination of a sequence motifA motif is generally defined as a nucleotide sequence that has some biological significance, such as a binding site on a regulatory protein.", [["nucleotide", "CHEMICAL", 161, 171], ["binding site", "DNA", 230, 242], ["regulatory protein", "PROTEIN", 248, 266], ["a sequence motifA motif", "TEST", 111, 134], ["a nucleotide sequence", "TEST", 159, 180], ["a binding site", "PROBLEM", 228, 242]]], ["A variety of computational tools [34, 35] have been developed for finding motifs on genome sequences.", [["genome sequences", "DNA", 84, 100], ["computational tools", "TEST", 13, 32], ["genome sequences", "TEST", 84, 100]]], ["In this study, we defined a motif as a highly conserved region at the same position in the genome that was exclusively shared between several of the PEDV strains, assuming that a region of the genome replaced as a result of recombination will be passed on to the daughter strains.", [["PEDV", "GENE_OR_GENE_PRODUCT", 149, 153], ["this study", "TEST", 3, 13], ["a motif", "PROBLEM", 26, 33], ["the PEDV strains", "PROBLEM", 145, 161], ["PEDV strains", "OBSERVATION", 149, 161]]], ["To find motifs based on our definition, we developed an original motif mining program using R software version 3.1.1 (R Core Team (2014), Vienna, Austria. http://www.R-project.org/) and \"ape\" package [36] .Determination of a sequence motifThe process of identifying motifs is further detailed here.", [["a sequence motif", "TREATMENT", 223, 239]]], ["First, we removed identical sites among the 119 PEDV strains, and then defined the remaining 1,071 sites as single nucleotide polymorphism sites (SNPs).", [["1,071 sites", "DNA", 93, 104], ["single nucleotide polymorphism sites", "DNA", 108, 144], ["the 119 PEDV strains", "PROBLEM", 40, 60], ["single nucleotide polymorphism sites", "TREATMENT", 108, 144]]], ["These sequences were then scanned using the defined window size (200 nt as a default value) starting from each SNP to find a motif and to determine the strains with the motif.", [["SNP", "CHEMICAL", 111, 114], ["These sequences", "TEST", 0, 15], ["a motif", "TEST", 123, 130], ["the motif", "TREATMENT", 165, 174], ["size", "OBSERVATION_MODIFIER", 59, 63]]], ["The difference between these groups was obtained as a minimum value of differences between all possible pairs of strains from each group.", [["strains", "PROBLEM", 113, 120]]], ["The difference between strains was calculated as the total number of transitions, transversions, insertions, and deletions in SNPs in the region.", [["SNPs", "DNA", 126, 130], ["The difference between strains", "PROBLEM", 0, 30], ["transversions, insertions", "TREATMENT", 82, 107], ["deletions in SNPs in the region", "TREATMENT", 113, 144], ["region", "ANATOMY_MODIFIER", 138, 144]]], ["The cutoff value for statistical significance was set as the upper 95% confidence limit of the Poisson distribution with the expected mean being equal to the mean of all prescribed pairwise differences in this window.", [["The cutoff value", "TEST", 0, 16]]], ["For each candidate motif region, the strains in the minor group were the strains possessing the motif.Determination of a sequence motifSince the candidate motifs were identified as genome regions and some of the windows analyzed contained multiple SNPs, continuous or adjacent candidate motifs were combined if they were shared with two or more strains that were identical in all relevant motifs.", [["genome regions", "DNA", 181, 195], ["the strains", "PROBLEM", 33, 44], ["multiple SNPs", "PROBLEM", 239, 252], ["multiple", "OBSERVATION_MODIFIER", 239, 247]]], ["Finally, to reflect the combination process of motifs, the presence of each combined motif was tested for all 119 PEDV strains.", [["PEDV", "SPECIES", 114, 118], ["all 119 PEDV strains", "PROBLEM", 106, 126]]], ["Starting and ending sites for each motif were identified with reference to the whole genome sequence of the referential PEDV strain, Colorado/USA/2013.BLAST search for the identified motifsIn order to explore the parental strain of the identified motifs, the nucleotide sequence within each motif of its reference strain was searched in GenBank by using BLAST (http://blast.ncbi. nlm.nih.gov) with its default parameters.", [["nucleotide", "CHEMICAL", 259, 269], ["nucleotide", "CHEMICAL", 259, 269], ["whole genome sequence", "DNA", 79, 100], ["BLAST search", "TEST", 151, 163], ["the nucleotide sequence", "TEST", 255, 278]]], ["Similarity of the motif between the reference strain and strains found by BLAST was calculated as a distance value as described previously.Overview of detected sequence motifsAs a result of the use of the motif mining program over the genome sequences, eight motifs defined as M1-M8 were identified.", [["M1-M8", "GENE_OR_GENE_PRODUCT", 277, 282], ["sequence motifs", "DNA", 160, 175], ["genome sequences", "DNA", 235, 251], ["M1", "DNA", 277, 279], ["strains", "PROBLEM", 57, 64], ["a distance value", "TEST", 98, 114], ["the motif mining program", "TREATMENT", 201, 225], ["the genome sequences", "TEST", 231, 251]]], ["These motifs are listed in Table 1 , and a summary table for the presence of these motifs in the 119 PEDV strains is shown in S2 Table.", [["these motifs", "TEST", 77, 89]]], ["The longest motif was M5 (2,032 nt, 79 SNPs), and the shortest motif was M8 (34 nt, 5 SNPs).", [["The longest motif", "TEST", 0, 17], ["SNPs", "TEST", 39, 43], ["the shortest motif", "TEST", 50, 68]]], ["Differences between the reference strain and the motif-positive and -negative strains was distinct.", [["motif-positive and -negative strains", "DNA", 49, 85], ["the reference strain", "TEST", 20, 40], ["the motif", "TEST", 45, 54]]], ["For example, the difference between the reference strain and the 14 strains having motif M6 was 0-7 (99.6-100.0% agreement), while that to the 105 strains without motif M6 was 149-153 (92.2-92.4% agreement).", [["motif M6", "TEST", 83, 91]]], ["The position of the detected motifs was identified in the reference genome of the USA PEDV strain, Colorado/USA/2013 (Fig 1) .", [["Colorado/USA/2013 (Fig 1", "SPECIES", 99, 123], ["the detected motifs", "PROBLEM", 16, 35], ["position", "OBSERVATION_MODIFIER", 4, 12]]], ["All eight motifs were distributed along with the ORF 1a, 1b, S, and ORF3 genes.", [["ORF 1a", "GENE_OR_GENE_PRODUCT", 49, 55], ["1b", "GENE_OR_GENE_PRODUCT", 57, 59], ["S", "GENE_OR_GENE_PRODUCT", 61, 62], ["ORF3", "GENE_OR_GENE_PRODUCT", 68, 72], ["ORF 1a, 1b, S, and ORF3 genes", "DNA", 49, 78], ["the ORF 1a", "TEST", 45, 55]]], ["M6 was the only motif spanning different genes (i.e., from the 3 0 end of the ORF 1b gene to the 5 0 end of the S gene).Motifs in the 119 PEDV strainsThe phylogenetic tree of whole genomes from all 119 PEDV strains is shown with the annotation of clades reported by Vlasova et al. [9] in Fig 2A.", [["ORF 1b", "GENE_OR_GENE_PRODUCT", 78, 84], ["M6", "DNA", 0, 2], ["3 0 end", "DNA", 63, 70], ["ORF 1b gene", "DNA", 78, 89], ["5 0 end", "DNA", 97, 104], ["S gene", "DNA", 112, 118], ["the ORF", "TREATMENT", 74, 81], ["phylogenetic", "OBSERVATION_MODIFIER", 154, 166], ["tree", "OBSERVATION_MODIFIER", 167, 171]]], ["Regarding the six motifs found in Indiana12.83/USA/2013 (M1-M6), the presence of nucleotides that were identical to those found in the reference strain (densely colored area) at the position of each motif was clearly consistent with the presence of the corresponding motif.", [["nucleotides", "CHEMICAL", 81, 92], ["Indiana12.83/USA/2013 (M1-M6", "SPECIES", 34, 62], ["nucleotides", "PROBLEM", 81, 92], ["densely", "OBSERVATION_MODIFIER", 153, 160], ["clearly consistent with", "UNCERTAINTY", 209, 232]]], ["Conversely, with respect to motifs M7 and M8, which were not found in Indiana12.83/USA/ 2013, nucleotides that were inconsistent with the nucleotides present in the reference strain (sparsely colored area) were found at the position of these motifs.BLAST search for the identified motifsSince the strain Indiana12.83/USA/2013 had six motifs (M1-M6), it was provisionally defined as the reference strain for the six motifs in the BLAST search.", [["nucleotides", "CHEMICAL", 94, 105], ["nucleotides", "CHEMICAL", 138, 149], ["M8", "GENE_OR_GENE_PRODUCT", 42, 44], ["Indiana12.83/USA/2013", "SPECIES", 304, 325], ["nucleotides", "TEST", 94, 105], ["the nucleotides", "PROBLEM", 134, 149], ["BLAST search", "TEST", 249, 261]]], ["The motifs M3, M4, and M5 were almost identical to the corresponding sequence in ZMDZY (KC196276), which was the PEDV strain detected in 2011 in China [37] .", [["M4", "GENE_OR_GENE_PRODUCT", 15, 17], ["ZMDZY", "GENE_OR_GENE_PRODUCT", 81, 86], ["M5", "PROTEIN", 23, 25], ["The motifs M3", "TEST", 0, 13], ["the PEDV strain", "PROBLEM", 109, 124], ["M3", "ANATOMY_MODIFIER", 11, 13]]], ["The differences between the reference strain and the strain ZMDZY at these three motifs were between 0-3 nt (i.e., 99.DiscussionElucidation of the relationship between strains of causative agents during a disease epidemic can help reveal transmission routes and allow for adequate control measures to be put in place to prevent further spread [40, 41] .", [["the reference strain", "PROBLEM", 24, 44], ["the strain ZMDZY", "PROBLEM", 49, 65], ["causative agents", "TREATMENT", 179, 195], ["a disease epidemic", "PROBLEM", 203, 221], ["transmission routes", "TREATMENT", 238, 257], ["adequate control measures", "TREATMENT", 272, 297]]], ["Phylogenetic tree analysis and whole-genome sequencing are the most recent and powerful tools for deciphering this relationship [40, 41] .", [["Phylogenetic tree analysis", "TEST", 0, 26], ["whole-genome sequencing", "PROBLEM", 31, 54], ["tree", "OBSERVATION_MODIFIER", 13, 17]]], ["However, the interpretation of the results obtained from phylogenetic analyses can be controversial, especially when results were compared between different regions of the genome or between results using partial and whole genome sequences [9, 19, 22] .", [["whole genome sequences", "DNA", 216, 238], ["phylogenetic analyses", "TEST", 57, 78], ["partial and whole genome sequences", "TEST", 204, 238]]], ["Thus, we utilized whole-genome sequencing to identify motifs that would reveal the genetic relationship between the 119 PEDV strains detected in PED outbreaks worldwide during 2013-2014.", [["PEDV", "GENE_OR_GENE_PRODUCT", 120, 124]]], ["The agreement between the prevalence of these motifs and the sequence similarity between strains (Fig 2C) suggests that these motifs reflect actual genetic similarity among these PEDV strains.", [["PEDV strains", "ORGANISM", 179, 191], ["these motifs", "TREATMENT", 40, 52], ["these PEDV strains", "PROBLEM", 173, 191]]], ["Considering the size of the motifs (34-2,032 nt) and the number of SNPs discontinuously included in each motif and identical to strains having the motif (smallest was 4 nt in motif M3), it is reasonable to suppose that the presence of these motifs was a result of an epidemiological connection between strains having the same motif and not the result of random genetic evolution in each distinct strain.", [["SNPs", "DNA", 67, 71], ["the motifs", "TEST", 24, 34], ["an epidemiological connection between strains", "PROBLEM", 264, 309], ["each distinct strain", "PROBLEM", 382, 402], ["size", "OBSERVATION_MODIFIER", 16, 20]]], ["Therefore, even if a motif is shared by strains in distant phylogenetic clusters, this analysis would suggest the presence of an epidemiological relationship between these strains.", [["this analysis", "TEST", 82, 95], ["these strains", "PROBLEM", 166, 179]]], ["Moreover, the interpretation of the results from a phylogenetic tree analysis sometimes requires arbitrary aggregation of a complicated structure of roots into inclusive subgroups such as clades [9] .", [["roots", "ANATOMY", 149, 154], ["roots", "ORGAN", 149, 154], ["a phylogenetic tree analysis", "TEST", 49, 77], ["arbitrary aggregation", "PROBLEM", 97, 118], ["a complicated structure of roots", "PROBLEM", 122, 154]]], ["However, utilizing sequence motifs is a more objective and explicit indicator of the relationships between strains and will provide new insights into the route of disease transmission.", [["sequence motifs", "TEST", 19, 34], ["strains", "PROBLEM", 107, 114], ["disease transmission", "PROBLEM", 163, 183], ["disease", "OBSERVATION", 163, 170]]], ["With regard to the features of motif-based analysis, its results were both consistent and inconsistent with the result of conventional phylogenic tree analysis.", [["motif-based analysis", "TEST", 31, 51], ["conventional phylogenic tree analysis", "PROBLEM", 122, 159], ["phylogenic tree", "OBSERVATION", 135, 150]]], ["Among the 119 PEDV strains included in this study, 72 strains from the USA and 2 strains from Mexico were already analyzed by phylogenic tree analysis in a previous study [9] .", [["PEDV", "SPECIES", 14, 18], ["PEDV strains", "PROBLEM", 14, 26], ["this study", "TEST", 39, 49], ["the USA", "TEST", 67, 74], ["a previous study", "TEST", 154, 170]]], ["An example of the consistency between the two methods can be observed with all eight strains grouped as a single clade named US INDEL strains by phylogenic analysis, which were also found to have the same motif M6 in this study (Fig 2B) .", [["all eight strains", "PROBLEM", 75, 92], ["INDEL strains", "PROBLEM", 128, 141], ["phylogenic analysis", "TEST", 145, 164], ["this study", "TEST", 217, 227]]], ["Although the five US strains, Ohio59/USA/2013, Ohio75/ USA/2013, Ohio60/USA/2013, Wisconsin55/USA/2013, and Iowa103/USA/2013, were grouped in the same sub-branch in North American clade I by phylogenic analysis, the difference between these five strains and the other strains in the same clade was not clear.", [["Ohio75", "GENE_OR_GENE_PRODUCT", 47, 53], ["USA", "GENE_OR_GENE_PRODUCT", 55, 58], ["Iowa103", "DNA", 108, 115], ["Ohio59/USA/2013, Ohio75/ USA/2013, Ohio60/USA/2013, Wisconsin55/USA/2013, and Iowa103/USA/2013", "SPECIES", 30, 124], ["North American clade I", "SPECIES", 165, 187], ["phylogenic analysis", "TEST", 191, 210], ["these five strains", "PROBLEM", 235, 253], ["the other strains", "PROBLEM", 258, 275], ["branch", "ANATOMY_MODIFIER", 155, 161], ["clear", "OBSERVATION", 302, 307]]], ["However, as a result of the motif-based analysis, these strains were found to exclusively share motif M3, which was also found in some INDEL strains such as Minnesota58/USA/2013.", [["the motif-based analysis", "TEST", 24, 48], ["these strains", "PROBLEM", 50, 63], ["some INDEL strains", "PROBLEM", 130, 148], ["INDEL strains", "OBSERVATION", 135, 148]]], ["This may suggest a possible epidemiological relationship between these strains although this was not obvious in the phylogenic tree analysis.DiscussionThe motifs M1-M6 were shared by the PEDV strains from two or more countries and the most frequently observed motif (M1) was found in the PEDV strains from all six countries included in this study.", [["M1-M6", "GENE_OR_GENE_PRODUCT", 162, 167], ["PEDV", "SPECIES", 288, 292], ["these strains", "PROBLEM", 65, 78], ["the PEDV strains", "PROBLEM", 183, 199], ["the PEDV strains", "PROBLEM", 284, 300], ["this study", "TEST", 336, 346], ["may suggest a possible", "UNCERTAINTY", 5, 27], ["phylogenic tree", "OBSERVATION", 116, 131]]], ["Consequently, the PED outbreaks in these countries in 2013-2014 might be closely related, and may be a result of multiple transmissions of PEDVs between these countries and not a single invasion across their borders.", [["PEDVs", "DISEASE", 139, 144], ["PEDVs", "GENE_OR_GENE_PRODUCT", 139, 144], ["the PED outbreaks", "PROBLEM", 14, 31], ["multiple transmissions of PEDVs", "PROBLEM", 113, 144], ["a single invasion across their borders", "PROBLEM", 177, 215], ["invasion", "OBSERVATION", 186, 194]]], ["This is similar to the results presented by Vlasova et al. [9] who suggested that there were multiple transmissions of PEDV from affected countries into USA by showing that several strains grouped into different clades were sourced from different countries.", [["PEDV", "CHEMICAL", 119, 123], ["PEDV", "SPECIES", 119, 123], ["PEDV", "PROBLEM", 119, 123], ["several strains", "PROBLEM", 173, 188]]], ["These results bring attention to the possibility of a non-accidental route of virus transmission between countries, such as commodities that are excluded from border control measures.DiscussionInterestingly, all six motifs (M1-M6) were found in the two strains: Indiana12.83/USA/ 2013 and L00719/GER/2014.", [["M1-M6", "GENE_OR_GENE_PRODUCT", 224, 229], ["M1", "PROTEIN", 224, 226], ["virus transmission", "TREATMENT", 78, 96], ["border control measures", "TREATMENT", 159, 182], ["virus", "OBSERVATION", 78, 83]]], ["Since Indiana12.83/USA/2013 was the first strain detected (in June 2013) among the 119 strains included in this study, this strain may be the source of all six motifs.", [["Indiana12.83/USA/2013", "SPECIES", 6, 27], ["the 119 strains", "PROBLEM", 79, 94], ["this study", "TEST", 107, 117]]], ["There were strains that were detected in the USA earlier than Indiana12.83/USA/2013 (i.e., Iowa/16465/2013, KF452322 and USA/Indiana/17846/2013, KF452323), which occurred in April and May of 2013, respectively [8] .", [["Iowa/16465/2013, KF452322 and USA/Indiana/17846/2013", "SPECIES", 91, 143], ["strains", "PROBLEM", 11, 18], ["USA", "TEST", 121, 124], ["strains", "OBSERVATION_MODIFIER", 11, 18]]], ["However, they were not genetically similar to Indi-ana12.83/USA/2013, but were similar to strains that had no motif in this study such as Iowa28/ USA/2013.", [["Indi-ana", "TEST", 46, 54], ["strains", "PROBLEM", 90, 97], ["this study", "TEST", 119, 129]]], ["We conducted a BLAST search for the parental strain of the motifs M1-M6, and the strain ZMDZY detected in China in 2011 was assumed as the parental strain for motifs M3, M4, and M5 but not for M1, M2, and M6.", [["M1-M6", "CELL", 66, 71], ["M2", "GENE_OR_GENE_PRODUCT", 197, 199], ["ZMDZY", "DNA", 88, 93], ["M4", "CELL_LINE", 170, 172], ["M5", "CELL_LINE", 178, 180], ["M1", "PROTEIN", 193, 195], ["M2", "PROTEIN", 197, 199], ["M6", "PROTEIN", 205, 207], ["a BLAST search", "TEST", 13, 27], ["the strain ZMDZY", "PROBLEM", 77, 93]]], ["The motifs M1 and M2 were thought to originate from the other Chinese strains detected in 2011-2012, such as PEDV-1C, GD-1, and PEDV-7C.", [["M2", "GENE_OR_GENE_PRODUCT", 18, 20], ["PEDV-1C", "GENE_OR_GENE_PRODUCT", 109, 116], ["GD-1", "GENE_OR_GENE_PRODUCT", 118, 122], ["PEDV-7C", "CELL", 128, 135], ["M2", "PROTEIN", 18, 20], ["PEDV", "TEST", 109, 113], ["GD", "TEST", 118, 120], ["PEDV", "TEST", 128, 132], ["M1", "OBSERVATION_MODIFIER", 11, 13], ["M2", "ANATOMY", 18, 20]]], ["The parental strain for M6 was not clear because no previous strain possessed a high identity with this motif.", [["M6", "SPECIES", 24, 26], ["previous strain", "PROBLEM", 52, 67], ["this motif", "TREATMENT", 99, 109]]], ["The inconsistency in the putative parent strains for each motif may suggest a complexity to the origin of these motifs found in the strain Indiana12.83/USA/2013.DiscussionSince the presence of motifs are the result of expression of certain unique genome sequence (s) in a subgroup of PEDV strains, their presence may influence viral characteristics of host strains.", [["PEDV strains", "ORGANISM", 284, 296], ["genome sequence", "DNA", 247, 262], ["PEDV", "SPECIES", 284, 288], ["PEDV strains", "PROBLEM", 284, 296], ["host strains", "PROBLEM", 352, 364], ["host strains", "OBSERVATION", 352, 364]]], ["For instance, the S gene of PEDV, in which two motifs (partial M6 and M7) were found (Fig 1) , is reported to regulate growth adaptation and pathogenicity [15, 42, 43] , as well as induce neutralizing antibodies [15, 42, 44] .", [["PEDV", "GENE_OR_GENE_PRODUCT", 28, 32], ["S gene", "DNA", 18, 24], ["PEDV", "DNA", 28, 32], ["neutralizing antibodies", "PROTEIN", 188, 211], ["PEDV", "PROBLEM", 28, 32], ["neutralizing antibodies", "TEST", 188, 211], ["PEDV", "OBSERVATION", 28, 32]]], ["Likewise, motif M8 was found in the ORF 3 gene, which is reported to related to attenuation and virulence [42, 45] .", [["ORF 3", "GENE_OR_GENE_PRODUCT", 36, 41], ["ORF 3 gene", "DNA", 36, 46], ["attenuation", "OBSERVATION_MODIFIER", 80, 91]]], ["In addition to the application of motifs as epidemiological markers, elucidation of the relationship between motifs and viral features should be a target for future study.DiscussionSome things should be considered when attempting to utilize sequence motifs as an indicator of the epidemiological relationship between causative agents of infectious diseases.", [["infectious diseases", "DISEASE", 337, 356], ["epidemiological markers", "TEST", 44, 67], ["the relationship between motifs and viral features", "PROBLEM", 84, 134], ["future study", "TEST", 158, 170], ["sequence motifs", "TREATMENT", 241, 256], ["infectious diseases", "PROBLEM", 337, 356]]], ["First, since uniqueness of the nucleotide sequence in a subgroup of examined strains is important in identifying a motif, the strains that are extremely different from the other strains should not be included in the examined strains.", [["nucleotide", "CHEMICAL", 31, 41], ["nucleotide", "CHEMICAL", 31, 41], ["the nucleotide sequence", "TEST", 27, 50], ["the strains", "PROBLEM", 122, 133], ["the other strains", "PROBLEM", 168, 185]]], ["The reason for this is that such strains may increase the number of inconsistent sites, which may not contribute to the discrimination of a motif.", [["such strains", "PROBLEM", 28, 40], ["inconsistent sites", "PROBLEM", 68, 86], ["may not contribute", "UNCERTAINTY", 94, 112]]], ["For this purpose, the year of isolation for the target strains in this study was limited to a short period of time between 2013 and 2014.", [["isolation", "TREATMENT", 30, 39], ["the target strains", "PROBLEM", 44, 62], ["this study", "TEST", 66, 76]]], ["In addition, in the case where strains form a single focal epidemic such as an outbreak of highly transmissible exotic disease within an area, finding a motif might be difficult because the difference between strains would be small throughout all strains and finding a significant difference that separates the strains into subgroups would be difficult.", [["exotic disease", "DISEASE", 112, 126], ["strains", "PROBLEM", 31, 38], ["a single focal epidemic", "PROBLEM", 44, 67], ["highly transmissible exotic disease", "PROBLEM", 91, 126], ["the difference between strains", "PROBLEM", 186, 216], ["small throughout all strains", "PROBLEM", 226, 254], ["the strains into subgroups", "PROBLEM", 307, 333], ["focal", "OBSERVATION_MODIFIER", 53, 58], ["epidemic", "OBSERVATION", 59, 67], ["highly", "OBSERVATION_MODIFIER", 91, 97], ["transmissible", "OBSERVATION_MODIFIER", 98, 111], ["exotic disease", "OBSERVATION", 112, 126], ["small", "OBSERVATION_MODIFIER", 226, 231], ["significant", "OBSERVATION_MODIFIER", 269, 280]]], ["Finally, estimation of a strain's evolutionary history based on the profile of detected motifs is not plausible in this study as some of the identified motifs are in close proximity to each other on the PEDV genome, and thus the possibility of more than one motif being inserted or removed on a single occasion cannot be discounted.", [["PEDV genome", "DNA", 203, 214], ["this study", "TEST", 115, 125], ["not plausible", "UNCERTAINTY", 98, 111], ["PEDV", "OBSERVATION", 203, 207]]], ["With this in mind, future studies will need to develop a reliable model to estimate the evolutionary history of these motifs from the difference in the pattern of the identified motifs.ConclusionsWe identified eight sequence motifs from the genomes of PEDV strains detected in six countries during the 2013-2014 epidemic.", [["PEDV", "ORGANISM", 252, 256], ["PEDV", "SPECIES", 252, 256], ["future studies", "TEST", 19, 33], ["these motifs", "PROBLEM", 112, 124], ["eight sequence motifs", "TEST", 210, 231], ["PEDV strains", "PROBLEM", 252, 264], ["PEDV strains", "OBSERVATION", 252, 264]]], ["Using the motifs as an indicator of an epidemiological relationship, we suggested that there may have been multiple transmissions of PEDV between these countries.", [["PEDV", "CANCER", 133, 137], ["PEDV", "SPECIES", 133, 137], ["PEDV", "PROBLEM", 133, 137], ["multiple", "OBSERVATION_MODIFIER", 107, 115]]], ["The analysis of sequence motifs shown here is a novel tool to evaluate the relationship between strains of causative agents using whole genome sequence data.ConclusionsSupporting Information S1 File.", [["The analysis of sequence motifs", "TEST", 0, 31], ["causative agents", "TREATMENT", 107, 123], ["whole genome sequence data", "TEST", 130, 156]]], ["\"SNP scan\" code is for finding candidate motifs from a set of viral sequences.", [["SNP", "CHEMICAL", 1, 4], ["viral sequences", "DNA", 62, 77], ["SNP scan", "TEST", 1, 9], ["a set of viral sequences", "TEST", 53, 77]]], ["The \"Motif scan\" code is for identifying motifs found by \"Motif scan\" code in each sequence.", [["Motif scan", "TEST", 58, 68]]], ["Sequences should be aligned and trimmed such that all sequences have the same length and should be saved in the fasta format (.fas file).", [["fas", "GENE_OR_GENE_PRODUCT", 127, 130], ["fas", "PROTEIN", 127, 130], ["Sequences", "TEST", 0, 9], ["all sequences", "TEST", 50, 63]]], ["(ZIP) S1 Table.", [["ZIP", "CHEMICAL", 1, 4]]], ["List of PEDV strains and motifs.", [["PEDV", "GENE_OR_GENE_PRODUCT", 8, 12], ["PEDV strains", "TREATMENT", 8, 20]]], ["Detail of 119 PEDV strains examined in this study with motifs in each strain.", [["PEDV strains", "TEST", 14, 26], ["this study", "TEST", 39, 49]]], ["Detail of nucleotides in the motifs.", [["nucleotides", "CHEMICAL", 10, 21]]], ["Excel workbook with spreadsheets for the detail of nucleotides in SNPs contained in each motif.", [["nucleotides", "CHEMICAL", 51, 62], ["SNPs", "DNA", 66, 70], ["spreadsheets", "TREATMENT", 20, 32], ["nucleotides in SNPs", "TREATMENT", 51, 70]]], ["Location of each SNP is shown as the number of nucleotides from the 5'UTR of PEDV strain Colorado/USA/2013.", [["SNP", "CHEMICAL", 17, 20], ["nucleotides", "CHEMICAL", 47, 58], ["5'UTR", "DNA", 68, 73]]], ["Nucleotides identical to the reference strain for each motif at each site is shown as dots.", [["Nucleotides", "TREATMENT", 0, 11]]], ["Notations for nucleotides follows IUPAC rule; a: adenine, g: guanine, c: cytosine, t: thymine, n: a, g, c or t, k: g or t, m: a or c, y: c or t.", [["adenine", "CHEMICAL", 49, 56], ["guanine", "CHEMICAL", 61, 68], ["cytosine", "CHEMICAL", 73, 81], ["thymine", "CHEMICAL", 86, 93], ["nucleotides", "CHEMICAL", 14, 25], ["adenine", "CHEMICAL", 49, 56], ["guanine", "CHEMICAL", 61, 68], ["cytosine", "CHEMICAL", 73, 81], ["thymine", "CHEMICAL", 86, 93], ["adenine", "SIMPLE_CHEMICAL", 49, 56], ["g: guanine", "SIMPLE_CHEMICAL", 58, 68], ["c: cytosine", "SIMPLE_CHEMICAL", 70, 81], ["t: thymine", "SIMPLE_CHEMICAL", 83, 93], ["n: a", "SIMPLE_CHEMICAL", 95, 99], ["c", "SIMPLE_CHEMICAL", 104, 105], ["nucleotides", "TEST", 14, 25]]]], "5037ed5d5d543b1aa6e2410a6c82df14247e7f27": [["IntroductionJapanese encephalitis virus (JEV), one of the causes for epidemic encephalitis, belongs to the family of Flaviviridae.", [["IntroductionJapanese encephalitis", "DISEASE", 0, 33], ["JEV", "DISEASE", 41, 44], ["encephalitis", "DISEASE", 78, 90], ["IntroductionJapanese encephalitis virus", "ORGANISM", 0, 39], ["JEV", "ORGANISM", 41, 44], ["Flaviviridae", "ORGANISM", 117, 129], ["IntroductionJapanese encephalitis virus", "SPECIES", 0, 39], ["IntroductionJapanese encephalitis virus", "SPECIES", 0, 39], ["JEV", "SPECIES", 41, 44], ["IntroductionJapanese encephalitis virus (JEV", "PROBLEM", 0, 44], ["epidemic encephalitis", "PROBLEM", 69, 90], ["Flaviviridae", "TREATMENT", 117, 129], ["epidemic", "OBSERVATION_MODIFIER", 69, 77], ["encephalitis", "OBSERVATION", 78, 90]]], ["It is widely distributed in Asia (Harris et al., 2006; Solomon, 2003; Tsai, 2000) .", [["widely", "OBSERVATION_MODIFIER", 6, 12], ["distributed", "OBSERVATION_MODIFIER", 13, 24]]], ["The outbreaks of emerging flaviviruses have made the prevention and treatment of flavivirus infection a global public health concern (Hanna et al., 1996; Mackenzie et al., 2004; Wang et al., 2007) .", [["flaviviruses", "DISEASE", 26, 38], ["flavivirus infection", "DISEASE", 81, 101], ["emerging flaviviruses", "PROBLEM", 17, 38], ["treatment", "TREATMENT", 68, 77], ["flavivirus infection", "PROBLEM", 81, 101], ["flaviviruses", "OBSERVATION", 26, 38], ["flavivirus", "OBSERVATION", 81, 91]]], ["The genome of JEV is a single-stranded and plus-sense RNA approximately 11 kb in length, encoding 3 structural and 7 non-structural proteins in the order of 5 0 -C-prM-E-NS1-NS2a-NS2b-NS3-NS4a-NS4b-NS5-3 0 (Chambers et al., 1990) .IntroductionThe cellular DEAD-box helicases family of RNA helicase utilizes the energy derived from nucleotide triphos phate (NTP) hydrolysis to modulate the unwinding of RNA.", [["cellular", "ANATOMY", 247, 255], ["nucleotide", "CHEMICAL", 331, 341], ["NTP", "CHEMICAL", 357, 360], ["nucleotide", "CHEMICAL", 331, 341], ["NTP", "CHEMICAL", 357, 360], ["JEV", "ORGANISM", 14, 17], ["cellular", "CELL", 247, 255], ["nucleotide triphos phate", "SIMPLE_CHEMICAL", 331, 355], ["NTP", "SIMPLE_CHEMICAL", 357, 360], ["single-stranded and plus-sense RNA", "RNA", 23, 57], ["3 structural and 7 non-structural proteins", "PROTEIN", 98, 140], ["prM", "PROTEIN", 164, 167], ["E", "PROTEIN", 168, 169], ["NS1", "PROTEIN", 170, 173], ["NS2a", "PROTEIN", 174, 178], ["NS2b", "PROTEIN", 179, 183], ["NS3", "PROTEIN", 184, 187], ["NS4a", "PROTEIN", 188, 192], ["NS4b", "PROTEIN", 193, 197], ["NS5", "PROTEIN", 198, 201], ["cellular DEAD-box helicases family", "PROTEIN", 247, 281], ["RNA helicase", "PROTEIN", 285, 297], ["RNA", "RNA", 402, 405], ["JEV", "SPECIES", 14, 17], ["NS1", "TEST", 170, 173], ["NS2a", "TEST", 174, 178], ["NS2b", "TREATMENT", 179, 183], ["NS3", "TREATMENT", 184, 187], ["NS4a", "TREATMENT", 188, 192], ["NS4b", "TREATMENT", 193, 197], ["NS5", "TREATMENT", 198, 201], ["RNA helicase", "TREATMENT", 285, 297], ["nucleotide triphos phate (NTP) hydrolysis", "TREATMENT", 331, 372], ["the unwinding of RNA", "PROBLEM", 385, 405]]], ["They are highly conserved from bacteria to humans and play important roles in all biological steps of RNA, such as RNA transcription, splicing, transport and decay, ribosome assembly and translation (Gustafson and Wessel, 2010; Lee et al., 2008) .", [["humans", "ORGANISM", 43, 49], ["ribosome", "CELLULAR_COMPONENT", 165, 173], ["humans", "SPECIES", 43, 49], ["humans", "SPECIES", 43, 49], ["bacteria", "PROBLEM", 31, 39]]], ["DDX5, one of the cellular DEAD helicase, acts as an important co-activator for a range of transcription factors (Endoh et al., 1999; Fuller-pace and Ali, 2008; Steimer and Klostermeier, 2012) .", [["cellular", "ANATOMY", 17, 25], ["DDX5", "CHEMICAL", 0, 4], ["DDX5", "GENE_OR_GENE_PRODUCT", 0, 4], ["cellular", "CELL", 17, 25], ["DDX5", "PROTEIN", 0, 4], ["cellular DEAD helicase", "PROTEIN", 17, 39], ["transcription factors", "PROTEIN", 90, 111], ["the cellular DEAD helicase", "TREATMENT", 13, 39], ["Ali", "ANATOMY", 149, 152]]], ["Moreover, DDX5 has been shown to be recruited to the promoters of responsive genes when these transcription factors are activated, consistent with its role in transcription initiation (Clark et al., 2008) .IntroductionTheoretically, a drug targeting the cellular factors important for the viral life cycle can be used to inhibit the virus infection.", [["cellular", "ANATOMY", 254, 262], ["DDX5", "CHEMICAL", 10, 14], ["infection", "DISEASE", 339, 348], ["DDX5", "GENE_OR_GENE_PRODUCT", 10, 14], ["cellular", "CELL", 254, 262], ["DDX5", "PROTEIN", 10, 14], ["promoters", "DNA", 53, 62], ["responsive genes", "DNA", 66, 82], ["transcription factors", "PROTEIN", 94, 115], ["cellular factors", "PROTEIN", 254, 270], ["a drug targeting the cellular factors", "PROBLEM", 233, 270], ["the viral life cycle", "TREATMENT", 285, 305], ["the virus infection", "PROBLEM", 329, 348]]], ["DDX5 attracts great interests in antiviral researches because several studies showed it is involved in the replication of several viruses such as HIV-1 (Zhou et al., 2013) , SARS-CoV, influenza virus and Hepatitis C virus (HCV) (Chen et al., 2009; Goh et al., 2004) .", [["DDX5", "CHEMICAL", 0, 4], ["SARS-CoV", "DISEASE", 174, 182], ["influenza virus and Hepatitis C", "DISEASE", 184, 215], ["DDX5", "GENE_OR_GENE_PRODUCT", 0, 4], ["HIV-1", "ORGANISM", 146, 151], ["SARS-CoV", "ORGANISM", 174, 182], ["influenza virus", "ORGANISM", 184, 199], ["Hepatitis C virus", "ORGANISM", 204, 221], ["HCV", "ORGANISM", 223, 226], ["DDX5", "PROTEIN", 0, 4], ["HIV-1", "SPECIES", 146, 151], ["influenza virus", "SPECIES", 184, 199], ["Hepatitis C virus", "SPECIES", 204, 221], ["HIV-1", "SPECIES", 146, 151], ["SARS-CoV", "SPECIES", 174, 182], ["Hepatitis C virus", "SPECIES", 204, 221], ["HCV", "SPECIES", 223, 226], ["antiviral researches", "TREATMENT", 33, 53], ["several studies", "TEST", 62, 77], ["several viruses", "PROBLEM", 122, 137], ["HIV", "TEST", 146, 149], ["SARS", "PROBLEM", 174, 178], ["CoV", "PROBLEM", 179, 182], ["influenza virus", "PROBLEM", 184, 199], ["Hepatitis C virus", "PROBLEM", 204, 221], ["antiviral researches", "OBSERVATION", 33, 53], ["several", "OBSERVATION_MODIFIER", 122, 129], ["viruses", "OBSERVATION", 130, 137], ["CoV", "ANATOMY", 179, 182], ["influenza virus", "OBSERVATION", 184, 199]]], ["DDX5 interacts with SARS-CoV helicase and SARS-CoV replication is significantly inhibited when expression of DDX5 was silenced by small interfering RNA (Chen et al., 2009) .", [["DDX5", "CHEMICAL", 0, 4], ["DDX5", "GENE_OR_GENE_PRODUCT", 0, 4], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 20, 28], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 42, 50], ["DDX5", "GENE_OR_GENE_PRODUCT", 109, 113], ["DDX5", "PROTEIN", 0, 4], ["SARS-CoV helicase", "PROTEIN", 20, 37], ["DDX5", "PROTEIN", 109, 113], ["SARS-CoV", "SPECIES", 20, 28], ["SARS-CoV", "SPECIES", 42, 50], ["SARS", "PROBLEM", 20, 24], ["CoV helicase", "TREATMENT", 25, 37], ["SARS", "PROBLEM", 42, 46], ["CoV replication", "TREATMENT", 47, 62], ["small interfering RNA", "PROBLEM", 130, 151], ["small", "OBSERVATION_MODIFIER", 130, 135]]], ["DDX5 also colocalizes with influenza virus RNP in the nucleus and interacts with influenza virus polymerase (Bortz et al., 2011) .", [["nucleus", "ANATOMY", 54, 61], ["DDX5", "CHEMICAL", 0, 4], ["DDX5", "GENE_OR_GENE_PRODUCT", 0, 4], ["influenza virus", "ORGANISM", 27, 42], ["nucleus", "CELLULAR_COMPONENT", 54, 61], ["influenza virus", "ORGANISM", 81, 96], ["DDX5", "PROTEIN", 0, 4], ["influenza virus RNP", "PROTEIN", 27, 46], ["influenza virus polymerase", "PROTEIN", 81, 107], ["influenza virus", "SPECIES", 27, 42], ["influenza virus", "SPECIES", 81, 96], ["influenza virus", "SPECIES", 27, 42], ["influenza virus", "SPECIES", 81, 96], ["influenza virus RNP", "PROBLEM", 27, 46], ["influenza virus polymerase", "PROBLEM", 81, 107], ["influenza virus RNP", "OBSERVATION", 27, 46], ["nucleus", "ANATOMY", 54, 61], ["influenza virus", "OBSERVATION", 81, 96]]], ["HCV RNA-dependent RNA polymerase can interact with DDX5 and transient expression of RdRp causes the redistribution of endogenous DDX5 from the nucleus to the cytoplasm (Goh et al., 2004) .IntroductionMeanwhile, other cellular helicases such as DDX1, DDX3 and DDX6 can act as the cofactors to promote HIV and HCV replication (Fang et al., 2004 (Fang et al., , 2005 Reed et al., 2012) .", [["nucleus", "ANATOMY", 143, 150], ["cytoplasm", "ANATOMY", 158, 167], ["cellular", "ANATOMY", 217, 225], ["HCV", "ORGANISM", 0, 3], ["DDX5", "GENE_OR_GENE_PRODUCT", 51, 55], ["RdRp", "GENE_OR_GENE_PRODUCT", 84, 88], ["DDX5", "GENE_OR_GENE_PRODUCT", 129, 133], ["nucleus", "CELLULAR_COMPONENT", 143, 150], ["cytoplasm", "ORGANISM_SUBSTANCE", 158, 167], ["cellular", "CELL", 217, 225], ["DDX1", "GENE_OR_GENE_PRODUCT", 244, 248], ["DDX3", "GENE_OR_GENE_PRODUCT", 250, 254], ["DDX6", "GENE_OR_GENE_PRODUCT", 259, 263], ["HIV", "ORGANISM", 300, 303], ["HCV", "ORGANISM", 308, 311], ["HCV RNA", "RNA", 0, 7], ["RNA polymerase", "PROTEIN", 18, 32], ["DDX5", "PROTEIN", 51, 55], ["RdRp", "PROTEIN", 84, 88], ["DDX5", "PROTEIN", 129, 133], ["cellular helicases", "PROTEIN", 217, 235], ["DDX1", "PROTEIN", 244, 248], ["DDX3", "PROTEIN", 250, 254], ["DDX6", "PROTEIN", 259, 263], ["HIV", "SPECIES", 300, 303], ["HCV", "SPECIES", 0, 3], ["HIV", "SPECIES", 300, 303], ["HCV", "SPECIES", 308, 311], ["HCV RNA-dependent RNA polymerase", "PROBLEM", 0, 32], ["transient expression of RdRp", "PROBLEM", 60, 88], ["endogenous DDX5", "PROBLEM", 118, 133], ["DDX3", "PROBLEM", 250, 254], ["HCV replication", "TREATMENT", 308, 323], ["RdRp", "OBSERVATION", 84, 88], ["redistribution", "OBSERVATION_MODIFIER", 100, 114], ["endogenous DDX5", "OBSERVATION", 118, 133], ["nucleus", "ANATOMY", 143, 150]]], ["DDX3 inhibits hepatitis B virus reverse transcription by incorporation into nucleocapsids (Wang et al., 2009b) .", [["hepatitis B", "DISEASE", 14, 25], ["DDX3", "GENE_OR_GENE_PRODUCT", 0, 4], ["hepatitis B virus", "ORGANISM", 14, 31], ["DDX3", "PROTEIN", 0, 4], ["hepatitis B virus", "SPECIES", 14, 31], ["hepatitis B virus", "SPECIES", 14, 31], ["DDX3", "PROBLEM", 0, 4], ["hepatitis B virus", "TREATMENT", 14, 31], ["hepatitis", "OBSERVATION", 14, 23]]], ["DDX1 can also stimulate the replication of IBV (Xu et al., 2010) .", [["DDX1", "CHEMICAL", 0, 4], ["DDX1", "GENE_OR_GENE_PRODUCT", 0, 4], ["IBV", "ORGANISM", 43, 46], ["DDX1", "PROTEIN", 0, 4], ["IBV", "SPECIES", 43, 46]]], ["It has been reported that DDX6, DDX28, DDX42, DHX15 and DDX56 are important for infectivity of West Nile virus (Chahar et al., 2013; Krishnan et al., 2008; Xu et al., 2011; Xu and Hobman, 2012) .", [["DDX6", "GENE_OR_GENE_PRODUCT", 26, 30], ["DDX28", "GENE_OR_GENE_PRODUCT", 32, 37], ["DDX42", "GENE_OR_GENE_PRODUCT", 39, 44], ["DHX15", "GENE_OR_GENE_PRODUCT", 46, 51], ["DDX56", "GENE_OR_GENE_PRODUCT", 56, 61], ["West Nile virus", "ORGANISM", 95, 110], ["DDX6", "PROTEIN", 26, 30], ["DDX28", "PROTEIN", 32, 37], ["DDX42", "PROTEIN", 39, 44], ["DHX15", "PROTEIN", 46, 51], ["DDX56", "PROTEIN", 56, 61], ["West Nile virus", "SPECIES", 95, 110], ["West Nile virus", "SPECIES", 95, 110]]], ["DDX6 is also involved in DENV, HCV, foamy virus and adenovirus replication (Greer et al., 2011; Jangra et al., 2010; Ward et al., 2011; Yu et al., 2011) .IntroductionIn this study, we demonstrated that DDX5 is required for JEV replication, and the helicase activity of DDX5 is crucial for JEV replication.", [["DDX5", "CHEMICAL", 202, 206], ["DDX6", "GENE_OR_GENE_PRODUCT", 0, 4], ["DENV", "ORGANISM", 25, 29], ["HCV", "ORGANISM", 31, 34], ["foamy virus", "ORGANISM", 36, 47], ["adenovirus", "ORGANISM", 52, 62], ["DDX5", "GENE_OR_GENE_PRODUCT", 202, 206], ["JEV", "ORGANISM", 223, 226], ["DDX5", "GENE_OR_GENE_PRODUCT", 269, 273], ["JEV", "ORGANISM", 289, 292], ["DDX6", "PROTEIN", 0, 4], ["DDX5", "PROTEIN", 202, 206], ["DDX5", "PROTEIN", 269, 273], ["DENV", "SPECIES", 25, 29], ["HCV", "SPECIES", 31, 34], ["foamy virus", "SPECIES", 36, 47], ["adenovirus", "SPECIES", 52, 62], ["JEV", "SPECIES", 223, 226], ["JEV", "SPECIES", 289, 292], ["DENV", "PROBLEM", 25, 29], ["HCV", "PROBLEM", 31, 34], ["this study", "TEST", 169, 179], ["DDX5", "TEST", 202, 206], ["JEV replication", "TREATMENT", 223, 238], ["JEV replication", "TREATMENT", 289, 304], ["DENV", "OBSERVATION", 25, 29], ["foamy virus", "OBSERVATION", 36, 47]]], ["DDX5 interacted and colocalized with JEV core, NS3, NS5 (MTase and RdRp domain) in the cytoplasm of the infected cells.", [["cytoplasm", "ANATOMY", 87, 96], ["cells", "ANATOMY", 113, 118], ["DDX5", "CHEMICAL", 0, 4], ["DDX5", "GENE_OR_GENE_PRODUCT", 0, 4], ["JEV", "ORGANISM", 37, 40], ["NS3", "GENE_OR_GENE_PRODUCT", 47, 50], ["NS5", "GENE_OR_GENE_PRODUCT", 52, 55], ["MTase", "GENE_OR_GENE_PRODUCT", 57, 62], ["cytoplasm", "ORGANISM_SUBSTANCE", 87, 96], ["cells", "CELL", 113, 118], ["DDX5", "PROTEIN", 0, 4], ["NS3", "PROTEIN", 47, 50], ["NS5", "PROTEIN", 52, 55], ["MTase", "PROTEIN", 57, 62], ["RdRp domain", "PROTEIN", 67, 78], ["infected cells", "CELL_TYPE", 104, 118], ["JEV", "SPECIES", 37, 40], ["JEV core", "TREATMENT", 37, 45], ["NS3", "TREATMENT", 47, 50], ["NS5 (MTase and RdRp domain", "TREATMENT", 52, 78], ["the infected cells", "PROBLEM", 100, 118], ["infected cells", "OBSERVATION", 104, 118]]], ["DDX5 was recruited from the nucleus to cytoplasm during virus infection.", [["nucleus", "ANATOMY", 28, 35], ["cytoplasm", "ANATOMY", 39, 48], ["infection", "DISEASE", 62, 71], ["DDX5", "GENE_OR_GENE_PRODUCT", 0, 4], ["nucleus", "CELLULAR_COMPONENT", 28, 35], ["cytoplasm", "ORGANISM_SUBSTANCE", 39, 48], ["DDX5", "PROTEIN", 0, 4], ["virus infection", "PROBLEM", 56, 71], ["nucleus", "ANATOMY", 28, 35], ["virus infection", "OBSERVATION", 56, 71]]], ["DDX5 can bind to the JEV 3 0 UTR and colocalizes with viral RNA.", [["DDX5", "CHEMICAL", 0, 4], ["DDX5", "GENE_OR_GENE_PRODUCT", 0, 4], ["DDX5", "PROTEIN", 0, 4], ["JEV 3 0 UTR", "DNA", 21, 32], ["viral RNA", "RNA", 54, 63], ["viral RNA", "PROBLEM", 54, 63], ["viral RNA", "OBSERVATION", 54, 63]]], ["Finally we used a JEV replicon system to confirm that DDX5 plays an important role in JEV RNA replication.Viruses, cells and transfectionBaby hamster kidney (BHK)-21 cells (C-13, American Type Culture Collection) was maintained in Dulbecco's minimal essential medium supplemented with 10% fetal bovine serum and penicillin (100 U/ml) and streptomycin (100 lg/ml) at 37\u00b0C in 5% CO 2 .", [["cells", "ANATOMY", 115, 120], ["hamster kidney (BHK)-21 cells", "ANATOMY", 142, 171], ["fetal bovine serum", "ANATOMY", 289, 307], ["DDX5", "CHEMICAL", 54, 58], ["penicillin", "CHEMICAL", 312, 322], ["streptomycin", "CHEMICAL", 338, 350], ["penicillin", "CHEMICAL", 312, 322], ["streptomycin", "CHEMICAL", 338, 350], ["CO 2", "CHEMICAL", 377, 381], ["JEV", "ORGANISM", 18, 21], ["DDX5", "GENE_OR_GENE_PRODUCT", 54, 58], ["JEV", "ORGANISM", 86, 89], ["cells", "CELL", 115, 120], ["transfectionBaby hamster kidney", "CELL", 125, 156], ["BHK)-21 cells", "CELL", 158, 171], ["C-13", "CELL", 173, 177], ["bovine", "ORGANISM", 295, 301], ["serum", "ORGANISM_SUBSTANCE", 302, 307], ["penicillin", "SIMPLE_CHEMICAL", 312, 322], ["streptomycin", "SIMPLE_CHEMICAL", 338, 350], ["DDX5", "PROTEIN", 54, 58], ["transfectionBaby hamster kidney (BHK)-21 cells", "CELL_LINE", 125, 171], ["C-13", "CELL_LINE", 173, 177], ["hamster", "SPECIES", 142, 149], ["bovine", "SPECIES", 295, 301], ["JEV", "SPECIES", 18, 21], ["JEV", "SPECIES", 86, 89], ["hamster", "SPECIES", 142, 149], ["bovine", "SPECIES", 295, 301], ["a JEV replicon system", "TREATMENT", 16, 37], ["JEV RNA replication", "TREATMENT", 86, 105], ["Viruses", "PROBLEM", 106, 113], ["transfectionBaby hamster kidney", "TEST", 125, 156], ["BHK", "TEST", 158, 161], ["C", "TEST", 173, 174], ["American Type Culture Collection", "TEST", 179, 211], ["Dulbecco", "TEST", 231, 239], ["10% fetal bovine serum", "TREATMENT", 285, 307], ["penicillin", "TREATMENT", 312, 322], ["streptomycin", "TREATMENT", 338, 350], ["kidney", "ANATOMY", 150, 156]]], ["JEV SA14-14-2 strain was propagated in the BHK-21 cells, and the viral titers were determined in BHK-21 cells by plaque assay.", [["BHK-21 cells", "ANATOMY", 43, 55], ["BHK-21 cells", "ANATOMY", 97, 109], ["plaque", "ANATOMY", 113, 119], ["JEV SA14-14-2", "ORGANISM", 0, 13], ["BHK-21 cells", "CELL", 43, 55], ["BHK-21 cells", "CELL", 97, 109], ["BHK-21 cells", "CELL_LINE", 43, 55], ["BHK-21 cells", "CELL_LINE", 97, 109], ["JEV", "SPECIES", 0, 3], ["BHK-21", "SPECIES", 43, 49], ["BHK-21", "SPECIES", 97, 103], ["JEV SA14", "TEST", 0, 8], ["strain", "PROBLEM", 14, 20], ["the viral titers", "TEST", 61, 77], ["BHK", "TEST", 97, 100], ["plaque assay", "TEST", 113, 125], ["viral titers", "OBSERVATION", 65, 77], ["plaque", "OBSERVATION", 113, 119]]], ["Cells were transfected using polyethylenimine (25 KD, Sigma-Aldrich).", [["Cells", "ANATOMY", 0, 5], ["polyethylenimine", "CHEMICAL", 29, 45], ["polyethylenimine", "CHEMICAL", 29, 45], ["Cells", "CELL", 0, 5], ["polyethylenimine", "SIMPLE_CHEMICAL", 29, 45], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 54, 67], ["polyethylenimine", "TREATMENT", 29, 45]]], ["The amounts of plasmid DNA with which cells were transfected (1 lg per 15.4 mm and 10 lg per 80 mm) were kept constant by the inclusion of DNA vector.", [["plasmid", "ANATOMY", 15, 22], ["cells", "ANATOMY", 38, 43], ["DNA", "CELLULAR_COMPONENT", 23, 26], ["cells", "CELL", 38, 43], ["DNA", "CELLULAR_COMPONENT", 139, 142], ["plasmid DNA", "DNA", 15, 26], ["DNA vector", "DNA", 139, 149], ["plasmid DNA", "PROBLEM", 15, 26], ["amounts", "OBSERVATION_MODIFIER", 4, 11], ["plasmid DNA", "OBSERVATION", 15, 26], ["15.4 mm", "OBSERVATION_MODIFIER", 71, 78]]], ["Transfection efficiencies of over 70% were routinely obtained when using the pEGFP-N2 (Novagen) plasmid to monitor the transfection efficiencies.PlasmidsTo construct HA-tagged DDX5 pcDNA3.1-DDX5 (1-614), pCold-I-DDX5 or pGEX-4T-3-DDX5 plasmids, the gene fragments were amplified using DDX5-HA plasmid (a gift from Prof. Ralf Janknecht) as the template by PCR using specific primers (Table 1) and were cloned in frame into pcDNA3.1(+) (Invitrogen), pGEX-4T-3(GE Healthcare) or pCold-I (Takara) vector respectively.", [["pEGFP", "GENE_OR_GENE_PRODUCT", 77, 82], ["Novagen", "GENE_OR_GENE_PRODUCT", 87, 94], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 181, 189], ["pCold-I-DDX5", "GENE_OR_GENE_PRODUCT", 204, 216], ["pGEX-4T-3", "GENE_OR_GENE_PRODUCT", 220, 229], ["DDX5", "GENE_OR_GENE_PRODUCT", 230, 234], ["DDX5", "GENE_OR_GENE_PRODUCT", 285, 289], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 422, 428], ["pGEX-4T-3", "GENE_OR_GENE_PRODUCT", 448, 457], ["pCold-I", "GENE_OR_GENE_PRODUCT", 476, 483], ["Takara", "GENE_OR_GENE_PRODUCT", 485, 491], ["pEGFP-N2 (Novagen) plasmid", "DNA", 77, 103], ["HA-tagged DDX5 pcDNA3.1-DDX5 (1-614", "DNA", 166, 201], ["pCold-I-DDX5 or pGEX-4T-3", "DNA", 204, 229], ["DDX5 plasmids", "DNA", 230, 243], ["gene fragments", "DNA", 249, 263], ["DDX5", "DNA", 285, 289], ["HA plasmid", "DNA", 290, 300], ["Ralf Janknecht", "DNA", 320, 334], ["pcDNA3.1(+) (Invitrogen), pGEX-4T-3", "DNA", 422, 457], ["GE Healthcare", "DNA", 458, 471], ["pCold-I (Takara) vector", "DNA", 476, 499], ["Transfection efficiencies", "TEST", 0, 25], ["the pEGFP-N2 (Novagen) plasmid", "TREATMENT", 73, 103], ["the transfection efficiencies", "PROBLEM", 115, 144], ["PlasmidsTo construct HA", "TEST", 145, 168], ["DDX5", "TEST", 190, 194], ["pCold", "TEST", 204, 209], ["DDX5", "TEST", 212, 216], ["pGEX", "TEST", 220, 224], ["DDX5 plasmids", "TREATMENT", 230, 243], ["the gene fragments", "PROBLEM", 245, 263], ["HA plasmid", "TREATMENT", 290, 300], ["pcDNA3", "TEST", 422, 428], ["Invitrogen", "TEST", 435, 445], ["pGEX", "TEST", 448, 452], ["transfection efficiencies", "OBSERVATION", 119, 144]]], ["JEV core, NS3, NS5-MTase (1-268) and were also subcloned into pcDNA3.1 (+) vector, the MYC tag was introduced during PCR by inclusion of the tag coding sequence in the antisense primer.", [["JEV", "ORGANISM", 0, 3], ["NS3", "GENE_OR_GENE_PRODUCT", 10, 13], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 15, 24], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 62, 70], ["MYC", "GENE_OR_GENE_PRODUCT", 87, 90], ["JEV core", "DNA", 0, 8], ["NS3", "PROTEIN", 10, 13], ["NS5", "PROTEIN", 15, 18], ["MTase", "PROTEIN", 19, 24], ["pcDNA3.1 (+) vector", "DNA", 62, 81], ["MYC tag", "DNA", 87, 94], ["tag coding sequence", "DNA", 141, 160], ["antisense primer", "DNA", 168, 184], ["JEV", "SPECIES", 0, 3], ["NS5-MTase", "TREATMENT", 15, 24], ["the MYC tag", "TREATMENT", 83, 94], ["the tag coding sequence", "TREATMENT", 137, 160], ["NS3", "ANATOMY", 10, 13]]], ["Kozak sequence was added in the sense primers (Table 1) .", [["Kozak sequence", "DNA", 0, 14], ["Kozak sequence", "TREATMENT", 0, 14]]], ["To express JEV viral proteins, the cDNA fragments of JEV SA14-14-2 strain encoding core, NS3, NS5-MTase and NS5-RdRp were all subcloned into pET-24a-(+) vector (Novagen) and pGEX-4T-3(GE Healthcare) by PCR using specific primers (Table 1) . pcDNA3.1-DDX5-K144E-HA, pcDNA3.1-DDX5-S279L -HA mutants were made with Quick-Change site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions using pcDNA3.1-DDX5-HA as the template by PCR using specific primers (Table 1) .", [["JEV", "ORGANISM", 11, 14], ["JEV SA14-14-2 strain", "ORGANISM", 53, 73], ["NS3", "GENE_OR_GENE_PRODUCT", 89, 92], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 94, 103], ["NS5-RdRp", "GENE_OR_GENE_PRODUCT", 108, 116], ["pET-24a", "GENE_OR_GENE_PRODUCT", 141, 148], ["Novagen", "GENE_OR_GENE_PRODUCT", 161, 168], ["pGEX-4T-3", "CELL", 174, 183], ["pcDNA3.1-DDX5-", "GENE_OR_GENE_PRODUCT", 241, 255], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 265, 273], ["DDX5", "GENE_OR_GENE_PRODUCT", 274, 278], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 419, 427], ["DDX5-HA", "GENE_OR_GENE_PRODUCT", 428, 435], ["JEV viral proteins", "PROTEIN", 11, 29], ["cDNA fragments", "DNA", 35, 49], ["JEV SA14-14-2 strain", "DNA", 53, 73], ["NS3", "PROTEIN", 89, 92], ["NS5", "PROTEIN", 94, 97], ["MTase", "PROTEIN", 98, 103], ["NS5", "PROTEIN", 108, 111], ["RdRp", "PROTEIN", 112, 116], ["pET-24a-(+) vector", "DNA", 141, 159], ["Novagen", "DNA", 161, 168], ["pGEX-4T-3", "DNA", 174, 183], ["pcDNA3.1-DDX5-K144E-HA, pcDNA3.1-DDX5-S279L -HA mutants", "DNA", 241, 296], ["pcDNA3.1", "DNA", 419, 427], ["DDX5", "DNA", 428, 432], ["HA", "DNA", 433, 435], ["JEV", "SPECIES", 11, 14], ["JEV viral proteins", "PROBLEM", 11, 29], ["the cDNA fragments", "TEST", 31, 49], ["JEV SA14", "TEST", 53, 61], ["NS3", "TEST", 89, 92], ["NS5", "TEST", 94, 97], ["NS5-RdRp", "TREATMENT", 108, 116], ["pET", "TEST", 141, 144], ["pGEX", "TEST", 174, 178], ["K144E", "TEST", 255, 260], ["HA", "TEST", 261, 263], ["DDX5", "TEST", 274, 278], ["HA mutants", "PROBLEM", 286, 296], ["Quick-Change site", "TREATMENT", 312, 329], ["directed mutagenesis kit (Stratagene)", "TREATMENT", 330, 367], ["pcDNA3.1", "TREATMENT", 419, 427], ["HA", "PROBLEM", 433, 435], ["JEV viral", "OBSERVATION", 11, 20]]], ["Oligonucleotides with the following sequence: CTCTAATGTGGAGTGCGAC was used to clone short hairpin RNA (shRNA)-encoding sequences against DDX5 in the pGPU6/Neo (Genepharma, China) vector, the Oligonucleotides encoding non-targeting shRNA was cloned into pGPU6/ Neo vector and the sequence is as follows: GTTCTCCGAACGTGT-CACGT which was used as the control shRNA.PlasmidsTo construct RNAi resistant pcDNA3.1-DDX5r, pcDNA3.1-DDX5r-K144E-HA and pcDNA3.1-DDX5r-S279L-HA mutants, the shRNA target sequence in DDX5 gene was changed into CCTTGATGTGGTCCGCTAC without introducing any residue change using QuikChange site-directed mutagenesis kit (Stratagene) using pcDNA3.1-DDX5-HA as the template by PCR using specific primers (Table 1 ).", [["DDX5", "GENE_OR_GENE_PRODUCT", 137, 141], ["Neo", "GENE_OR_GENE_PRODUCT", 155, 158], ["pGPU6", "GENE_OR_GENE_PRODUCT", 253, 258], ["Neo", "GENE_OR_GENE_PRODUCT", 260, 263], ["GTTCTCCGAACGTGT-CACGT", "GENE_OR_GENE_PRODUCT", 303, 324], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 397, 405], ["DDX5r", "GENE_OR_GENE_PRODUCT", 406, 411], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 413, 419], ["DDX5r", "GENE_OR_GENE_PRODUCT", 422, 427], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 441, 449], ["DDX5r", "GENE_OR_GENE_PRODUCT", 450, 455], ["DDX5", "GENE_OR_GENE_PRODUCT", 503, 507], ["pcDNA3.1-DDX5-HA", "GENE_OR_GENE_PRODUCT", 655, 671], ["clone short hairpin RNA (shRNA)-encoding sequences", "DNA", 78, 128], ["DDX5", "DNA", 137, 141], ["pGPU6", "DNA", 149, 154], ["Neo (Genepharma, China) vector", "DNA", 155, 185], ["non-targeting shRNA", "DNA", 217, 236], ["pGPU6", "DNA", 253, 258], ["Neo vector", "DNA", 260, 270], ["pcDNA3.1", "DNA", 397, 405], ["DDX5r", "DNA", 406, 411], ["pcDNA3", "DNA", 413, 419], ["1-DDX5r-K144E-HA and pcDNA3.1-DDX5r-S279L-HA mutants", "DNA", 420, 472], ["shRNA target sequence", "DNA", 478, 499], ["DDX5 gene", "DNA", 503, 512], ["pcDNA3.1", "DNA", 655, 663], ["DDX5", "DNA", 664, 668], ["HA", "DNA", 669, 671], ["Oligonucleotides", "TREATMENT", 0, 16], ["CTCTAATGTGGAGTGCGAC", "TREATMENT", 46, 65], ["clone short hairpin RNA", "TREATMENT", 78, 101], ["DDX5", "TEST", 137, 141], ["Neo (Genepharma, China) vector", "TREATMENT", 155, 185], ["the Oligonucleotides encoding non-targeting shRNA", "TREATMENT", 187, 236], ["Neo vector", "TREATMENT", 260, 270], ["GTTCTCCGAACGTGT-CACGT", "TREATMENT", 303, 324], ["Plasmids", "TREATMENT", 361, 369], ["pcDNA3", "TREATMENT", 413, 419], ["DDX5r", "TEST", 422, 427], ["K144E", "TEST", 428, 433], ["HA", "TEST", 434, 436], ["pcDNA3.1", "TEST", 441, 449], ["DDX5r", "TEST", 450, 455], ["HA mutants", "PROBLEM", 462, 472], ["the shRNA target sequence", "TREATMENT", 474, 499], ["any residue change", "PROBLEM", 570, 588], ["QuikChange site", "TREATMENT", 595, 610], ["directed mutagenesis kit (Stratagene)", "TREATMENT", 611, 648], ["pcDNA3.1", "TREATMENT", 655, 663], ["HA", "PROBLEM", 669, 671]]], ["All the nucleotide sequence was confirmed by using DNA sequence analysis.PlasmidsFor construct of templates for JEV 5 0 and 3 0 UTR RNA transcription, the JEV 5 0 and 3 0 UTR gene was amplified by PCR with specific primers.", [["nucleotide", "CHEMICAL", 8, 18], ["nucleotide", "CHEMICAL", 8, 18], ["DNA", "CELLULAR_COMPONENT", 51, 54], ["JEV 5", "ORGANISM", 112, 117], ["JEV 5", "ORGANISM", 155, 160], ["JEV 5 0", "DNA", 112, 119], ["JEV 5 0 and 3 0 UTR gene", "DNA", 155, 179], ["JEV", "SPECIES", 112, 115], ["All the nucleotide sequence", "TEST", 0, 27], ["DNA sequence analysis", "TEST", 51, 72], ["Plasmids", "TREATMENT", 73, 81], ["construct of templates", "TREATMENT", 85, 107], ["JEV", "TEST", 112, 115], ["UTR RNA transcription", "TREATMENT", 128, 149], ["the JEV", "TREATMENT", 151, 158], ["3 0 UTR gene", "TREATMENT", 167, 179]]], ["A control RNA was generated by PCR amplification of part of the ampicillin resistance gene (1-250 bp) using the primers (Vashist et al., 2012) (Table 1) .", [["ampicillin", "CHEMICAL", 64, 74], ["ampicillin", "CHEMICAL", 64, 74], ["ampicillin", "SIMPLE_CHEMICAL", 64, 74], ["ampicillin resistance gene", "DNA", 64, 90], ["A control RNA", "TREATMENT", 0, 13], ["PCR amplification", "TEST", 31, 48], ["the ampicillin resistance gene", "TREATMENT", 60, 90], ["the primers", "TREATMENT", 108, 119]]], ["T7 promoter and tobramycin aptamer tag (Hartmuth et al., 2004) sequences were included in sense and anti-sense primer respectively.", [["tobramycin", "CHEMICAL", 16, 26], ["tobramycin", "CHEMICAL", 16, 26], ["tobramycin", "SIMPLE_CHEMICAL", 16, 26], ["T7 promoter", "DNA", 0, 11], ["tobramycin aptamer tag", "DNA", 16, 38], ["anti-sense primer", "DNA", 100, 117], ["T7 promoter", "TREATMENT", 0, 11], ["tobramycin aptamer tag", "TREATMENT", 16, 38]]], ["The PCR products were subcloned into pMD-18T vector (Takara, China).PlasmidsThe JEV replicon with a Renilla luciferase reporter was generated by cloning JEV SA14-14-2 strain cDNA into pBluescript-II KS (Agilent Technologies) under the control of a T7 promoter as the previous study (Chien et al., 2011) .", [["JEV", "ORGANISM", 80, 83], ["luciferase", "GENE_OR_GENE_PRODUCT", 108, 118], ["JEV", "ORGANISM", 153, 156], ["PCR products", "DNA", 4, 16], ["pMD-18T vector", "DNA", 37, 51], ["Renilla luciferase reporter", "DNA", 100, 127], ["JEV SA14-14-2 strain cDNA", "DNA", 153, 178], ["T7 promoter", "DNA", 248, 259], ["pMD-18T", "SPECIES", 37, 44], ["JEV", "SPECIES", 80, 83], ["JEV", "SPECIES", 153, 156], ["The PCR products", "TREATMENT", 0, 16], ["The JEV replicon", "TREATMENT", 76, 92], ["a Renilla luciferase reporter", "TEST", 98, 127], ["cloning JEV SA14", "TEST", 145, 161], ["a T7 promoter", "TREATMENT", 246, 259], ["the previous study", "TEST", 263, 281], ["JEV replicon", "OBSERVATION", 80, 92]]], ["The Renilla luciferase gene was inserted after the first 102 bp of the JEV C gene, followed by the foot-and-mouth disease virus 2A self-cleaving protease (FMDV-2A), which enables the cleavage of the luciferase away from downstream nonstructural proteins (Lo et al., 2003; Varnavski and Khromykh, 1999) .", [["Renilla", "GENE_OR_GENE_PRODUCT", 4, 11], ["luciferase", "GENE_OR_GENE_PRODUCT", 12, 22], ["JEV C", "GENE_OR_GENE_PRODUCT", 71, 76], ["foot-and-mouth disease virus 2A", "ORGANISM", 99, 130], ["FMDV-2A", "GENE_OR_GENE_PRODUCT", 155, 162], ["luciferase", "GENE_OR_GENE_PRODUCT", 199, 209], ["Renilla luciferase gene", "DNA", 4, 27], ["JEV C gene", "DNA", 71, 81], ["foot-and-mouth disease virus 2A self-cleaving protease", "PROTEIN", 99, 153], ["FMDV", "PROTEIN", 155, 159], ["2A", "PROTEIN", 160, 162], ["luciferase", "PROTEIN", 199, 209], ["downstream nonstructural proteins", "PROTEIN", 220, 253], ["foot-and-mouth disease virus", "SPECIES", 99, 127], ["FMDV", "SPECIES", 155, 159], ["JEV", "SPECIES", 71, 74], ["foot-and-mouth disease virus", "SPECIES", 99, 127], ["The Renilla luciferase gene", "TREATMENT", 0, 27], ["the JEV C gene", "TREATMENT", 67, 81], ["mouth disease virus", "PROBLEM", 108, 127], ["cleaving protease", "TREATMENT", 136, 153], ["Renilla luciferase", "ANATOMY", 4, 22], ["foot", "ANATOMY", 99, 103], ["mouth", "ANATOMY", 108, 113]]], ["FMDV 2A was fused to the last 90 bp of the E gene which is necessary for the proper topology of the following viral proteins.", [["FMDV 2A", "ORGANISM", 0, 7], ["E", "GENE_OR_GENE_PRODUCT", 43, 44], ["FMDV 2A", "PROTEIN", 0, 7], ["E gene", "DNA", 43, 49], ["viral proteins", "PROTEIN", 110, 124], ["FMDV", "SPECIES", 0, 4], ["FMDV", "SPECIES", 0, 4]]], ["To ensure RNA stability and processing, a hepatitis delta virus ribozyme was placed immediately adjacent to the 3 0 end of the JEV cDNA followed by a bovine growth hormone (BGH) polyadenylation sequence.", [["hepatitis", "DISEASE", 42, 51], ["hepatitis delta virus", "ORGANISM", 42, 63], ["JEV", "ORGANISM", 127, 130], ["bovine growth hormone", "GENE_OR_GENE_PRODUCT", 150, 171], ["BGH", "GENE_OR_GENE_PRODUCT", 173, 176], ["3 0 end", "DNA", 112, 119], ["JEV cDNA", "DNA", 127, 135], ["bovine growth hormone (BGH) polyadenylation sequence", "DNA", 150, 202], ["hepatitis delta virus", "SPECIES", 42, 63], ["bovine", "SPECIES", 150, 156], ["hepatitis delta virus", "SPECIES", 42, 63], ["JEV", "SPECIES", 127, 130], ["RNA stability", "PROBLEM", 10, 23], ["a hepatitis delta virus ribozyme", "TREATMENT", 40, 72], ["the JEV cDNA", "TREATMENT", 123, 135], ["a bovine growth hormone", "TREATMENT", 148, 171], ["polyadenylation sequence", "TEST", 178, 202], ["RNA stability", "OBSERVATION", 10, 23]]], ["The control construct, a GAPDH 5 0 and 3 0 UTR-flanking luciferase reporter gene, was cloned into pMD-18T Vector (Takara, China).Protein expression and purificationThe expression plasmids of pCold-I-DDX5, pGEX-4T-3-core, pGEX-4T-3-NS3, pGEX-4T-3-NS5-MTase, pGEX-4T-3-NS5-RdRP, pGEX-4T-3-DDX5, pET-24a-core, pET-24a-NS3, pET-24a-NS5-MTase, and pET-24a-NS5-RdRP were transformed into Escherichia coli expression strain BL-21-Codon plus (DE3)-Rosetta 2 cells.", [["plasmids", "ANATOMY", 179, 187], ["DE3)-Rosetta 2 cells", "ANATOMY", 435, 455], ["GAPDH", "GENE_OR_GENE_PRODUCT", 25, 30], ["luciferase", "GENE_OR_GENE_PRODUCT", 56, 66], ["pCold-I-DDX5", "GENE_OR_GENE_PRODUCT", 191, 203], ["pGEX-4T-3", "GENE_OR_GENE_PRODUCT", 205, 214], ["pGEX-4T-3", "ORGANISM", 221, 230], ["NS3", "ORGANISM", 231, 234], ["pGEX-4T-3", "ORGANISM", 236, 245], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 246, 255], ["pGEX-4T-3", "ORGANISM", 257, 266], ["NS5", "ORGANISM", 267, 270], ["pGEX-4T-3-DDX5", "ORGANISM", 277, 291], ["pET-24a", "GENE_OR_GENE_PRODUCT", 293, 300], ["pET-24a-NS3", "ORGANISM", 307, 318], ["pET-24a", "GENE_OR_GENE_PRODUCT", 320, 327], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 328, 337], ["pET-24a", "GENE_OR_GENE_PRODUCT", 343, 350], ["NS5", "ORGANISM", 351, 354], ["RdRP", "ORGANISM", 355, 359], ["Escherichia coli", "ORGANISM", 382, 398], ["DE3)-Rosetta 2 cells", "CELL", 435, 455], ["GAPDH 5 0 and 3 0 UTR", "DNA", 25, 46], ["flanking luciferase reporter gene", "DNA", 47, 80], ["pMD", "PROTEIN", 98, 101], ["expression plasmids", "DNA", 168, 187], ["pCold", "DNA", 191, 196], ["I", "PROTEIN", 197, 198], ["DDX5", "DNA", 199, 203], ["pGEX", "DNA", 205, 209], ["4T", "DNA", 210, 212], ["pGEX", "DNA", 221, 225], ["4T", "DNA", 226, 228], ["NS3", "DNA", 231, 234], ["pGEX", "DNA", 236, 240], ["4T", "DNA", 241, 243], ["NS5", "DNA", 246, 249], ["MTase", "DNA", 250, 255], ["pGEX", "DNA", 257, 261], ["4T", "DNA", 262, 264], ["NS5", "DNA", 267, 270], ["RdRP", "DNA", 271, 275], ["pGEX", "DNA", 277, 281], ["4T", "DNA", 282, 284], ["DDX5", "DNA", 287, 291], ["pET", "DNA", 293, 296], ["24a", "DNA", 297, 300], ["pET", "DNA", 307, 310], ["24a", "DNA", 311, 314], ["NS3", "DNA", 315, 318], ["pET", "DNA", 320, 323], ["24a", "DNA", 324, 327], ["NS5", "DNA", 328, 331], ["MTase", "DNA", 332, 337], ["pET", "DNA", 343, 346], ["24a", "DNA", 347, 350], ["NS5", "DNA", 351, 354], ["RdRP", "DNA", 355, 359], ["Codon plus (DE3)-Rosetta 2 cells", "CELL_LINE", 423, 455], ["Escherichia coli", "SPECIES", 382, 398], ["Escherichia coli", "SPECIES", 382, 398], ["UTR-flanking luciferase reporter gene", "TREATMENT", 43, 80], ["Protein expression", "TEST", 129, 147], ["purification", "TEST", 152, 164], ["pCold", "TEST", 191, 196], ["DDX5", "TEST", 199, 203], ["pGEX", "TEST", 205, 209], ["pGEX", "TEST", 221, 225], ["NS3", "TEST", 231, 234], ["pGEX", "TEST", 236, 240], ["NS5", "TEST", 246, 249], ["MTase", "TEST", 250, 255], ["pGEX", "TEST", 257, 261], ["NS5", "TEST", 267, 270], ["RdRP", "TEST", 271, 275], ["pGEX", "TEST", 277, 281], ["DDX5", "TEST", 287, 291], ["pET", "TEST", 293, 296], ["core", "TEST", 301, 305], ["pET", "TEST", 307, 310], ["NS3", "TEST", 315, 318], ["pET", "TEST", 320, 323], ["NS5", "TEST", 328, 331], ["MTase", "TEST", 332, 337], ["pET", "TEST", 343, 346], ["NS5", "TEST", 351, 354], ["RdRP", "TEST", 355, 359], ["Escherichia coli expression strain", "PROBLEM", 382, 416], ["BL", "TEST", 417, 419], ["Escherichia coli", "OBSERVATION", 382, 398]]], ["A single colony was used to inoculate 10 ml of Luria-Bertani (LB) media containing ampicillin (100 lg/ml) or kanamycin (50 lg/ ml), and the culture was grown at 37\u00b0C overnight.", [["colony", "ANATOMY", 9, 15], ["ampicillin", "CHEMICAL", 83, 93], ["kanamycin", "CHEMICAL", 109, 118], ["ampicillin", "CHEMICAL", 83, 93], ["kanamycin", "CHEMICAL", 109, 118], ["ampicillin", "SIMPLE_CHEMICAL", 83, 93], ["kanamycin", "SIMPLE_CHEMICAL", 109, 118], ["Luria-Bertani", "SPECIES", 47, 60], ["A single colony", "TREATMENT", 0, 15], ["Luria-Bertani (LB) media", "TREATMENT", 47, 71], ["ampicillin", "TREATMENT", 83, 93], ["kanamycin", "TREATMENT", 109, 118], ["the culture", "TEST", 136, 147]]], ["The cultures were then diluted into the LB media containing ampicillin (100 lg/ml) and grown to an A 600 of 0.6 at 37\u00b0C, then protein expression was induced with 100 lM IPTG for 16-20 h at 21\u00b0C. The cells were harvested by centrifugation at 5000g for 20 min at 4\u00b0C and re-suspended in lysis buffer (100 mM NaCl, 20 mM Tris-HCl, pH 8.0, 0.1 mM PMSF).", [["cultures", "ANATOMY", 4, 12], ["cells", "ANATOMY", 199, 204], ["ampicillin", "CHEMICAL", 60, 70], ["IPTG", "CHEMICAL", 169, 173], ["NaCl", "CHEMICAL", 306, 310], ["Tris-HCl", "CHEMICAL", 318, 326], ["ampicillin", "CHEMICAL", 60, 70], ["IPTG", "CHEMICAL", 169, 173], ["NaCl", "CHEMICAL", 306, 310], ["Tris-HCl", "CHEMICAL", 318, 326], ["PMSF", "CHEMICAL", 343, 347], ["ampicillin", "SIMPLE_CHEMICAL", 60, 70], ["cells", "CELL", 199, 204], ["C", "SIMPLE_CHEMICAL", 263, 264], ["Tris-HCl", "SIMPLE_CHEMICAL", 318, 326], ["The cultures", "TEST", 0, 12], ["ampicillin", "TREATMENT", 60, 70], ["lysis buffer", "TREATMENT", 285, 297], ["NaCl", "TEST", 306, 310], ["Tris", "TEST", 318, 322], ["pH", "TEST", 328, 330]]], ["The cells were disrupted by sonication, and the supernatant was collected by centrifugation.", [["cells", "ANATOMY", 4, 9], ["supernatant", "ANATOMY", 48, 59], ["cells", "CELL", 4, 9], ["sonication", "OBSERVATION_MODIFIER", 28, 38]]], ["The supernatant was then subjected to affinity purification using Bio-Rad Profinity\u2122 IMAC or Profinity TM GST column (Bio-Rad).", [["supernatant", "ANATOMY", 4, 15], ["affinity purification", "TEST", 38, 59], ["Bio", "TEST", 66, 69], ["IMAC", "TEST", 85, 89]]], ["The proteins were then eluted, pooled together and further purified using size exclusion chromatography (Superdex75, GE Healthcare).", [["size exclusion chromatography", "TEST", 74, 103]]], ["Concentration of the purified proteins was determined by Bradford assay.Cytotoxicity assayThe cell viability of BHK-21 cells transfected with DDX5i, HA-DDX5 or DDX5 mutants plasmids was detected by CytoTox 96 \u00d2 NonRadioactive Cytotoxicity Assay (Promega) at 72 h after transfection.", [["cell", "ANATOMY", 94, 98], ["BHK-21 cells", "ANATOMY", 112, 124], ["plasmids", "ANATOMY", 173, 181], ["cell", "CELL", 94, 98], ["BHK-21 cells", "CELL", 112, 124], ["DDX5i", "GENE_OR_GENE_PRODUCT", 142, 147], ["HA-DDX5", "GENE_OR_GENE_PRODUCT", 149, 156], ["DDX5", "GENE_OR_GENE_PRODUCT", 160, 164], ["purified proteins", "PROTEIN", 21, 38], ["BHK-21 cells", "CELL_LINE", 112, 124], ["DDX5i, HA-DDX5 or DDX5 mutants plasmids", "DNA", 142, 181], ["BHK-21", "SPECIES", 112, 118], ["the purified proteins", "TEST", 17, 38], ["Cytotoxicity assay", "TEST", 72, 90], ["The cell viability", "TEST", 90, 108], ["BHK", "TEST", 112, 115], ["DDX5i", "TEST", 142, 147], ["HA", "PROBLEM", 149, 151], ["DDX5", "PROBLEM", 152, 156], ["DDX5 mutants plasmids", "PROBLEM", 160, 181], ["CytoTox", "TEST", 198, 205], ["NonRadioactive Cytotoxicity Assay", "TEST", 211, 244], ["cell viability", "OBSERVATION", 94, 108]]], ["The Cytotoxicity of Leptomycin B (LMB) on BHK-21 cells was detected by CytoTox 96 \u00d2 NonRadioactive Cytotoxicity Assay at 48 h after added to the cells with different the concentrations (0-20 ng/ml).Antibodies and reagentsThe DDX5-specific polyclonal antibody was purchased from Santa Cruz Biotechnology (USA), anti-b-actin, anti-MYC, anti-GST and anti-HIS monoclonal antibodies were purchased from Abmart Company (Shanghai, China).", [["BHK-21 cells", "ANATOMY", 42, 54], ["cells", "ANATOMY", 145, 150], ["Leptomycin B", "CHEMICAL", 20, 32], ["LMB", "CHEMICAL", 34, 37], ["DDX5", "CHEMICAL", 225, 229], ["Leptomycin B", "CHEMICAL", 20, 32], ["LMB", "CHEMICAL", 34, 37], ["Leptomycin B", "SIMPLE_CHEMICAL", 20, 32], ["LMB", "SIMPLE_CHEMICAL", 34, 37], ["BHK-21 cells", "CELL", 42, 54], ["cells", "CELL", 145, 150], ["DDX5", "GENE_OR_GENE_PRODUCT", 225, 229], ["anti-b-actin", "GENE_OR_GENE_PRODUCT", 310, 322], ["anti-MYC", "GENE_OR_GENE_PRODUCT", 324, 332], ["anti-GST", "GENE_OR_GENE_PRODUCT", 334, 342], ["BHK-21 cells", "CELL_LINE", 42, 54], ["DDX5", "PROTEIN", 225, 229], ["polyclonal antibody", "PROTEIN", 239, 258], ["Santa Cruz Biotechnology (USA), anti-b-actin", "PROTEIN", 278, 322], ["anti-MYC", "PROTEIN", 324, 332], ["anti-GST and anti-HIS monoclonal antibodies", "PROTEIN", 334, 377], ["anti-HIS", "SPECIES", 347, 355], ["Leptomycin B (LMB", "TREATMENT", 20, 37], ["BHK", "TEST", 42, 45], ["CytoTox", "TEST", 71, 78], ["NonRadioactive Cytotoxicity Assay", "TEST", 84, 117], ["Antibodies", "TEST", 198, 208], ["The DDX5", "TEST", 221, 229], ["specific polyclonal antibody", "TEST", 230, 258], ["anti-b-actin", "TREATMENT", 310, 322], ["anti-MYC", "TREATMENT", 324, 332], ["anti-GST", "TREATMENT", 334, 342], ["anti-HIS monoclonal antibodies", "TREATMENT", 347, 377], ["polyclonal antibody", "OBSERVATION", 239, 258]]], ["Anti-MYC-HRP and Anti-HA-HRP monoclonal antibodies were purchased from cell signaling (USA).", [["cell", "ANATOMY", 71, 75], ["Anti-MYC-HRP", "GENE_OR_GENE_PRODUCT", 0, 12], ["Anti-HA-HRP", "GENE_OR_GENE_PRODUCT", 17, 28], ["cell", "CELL", 71, 75], ["Anti-MYC", "PROTEIN", 0, 8], ["HRP", "PROTEIN", 9, 12], ["Anti-HA", "PROTEIN", 17, 24], ["HRP monoclonal antibodies", "PROTEIN", 25, 50], ["Anti-MYC", "TEST", 0, 8], ["HRP", "TEST", 9, 12], ["Anti-HA", "TEST", 17, 24], ["HRP monoclonal antibodies", "TEST", 25, 50]]], ["Leptomycin B (LMB) was purchased from Santa Cruz Biotechnology (USA).", [["Leptomycin B", "CHEMICAL", 0, 12], ["LMB", "CHEMICAL", 14, 17], ["Leptomycin B", "CHEMICAL", 0, 12], ["LMB", "CHEMICAL", 14, 17], ["Leptomycin B", "SIMPLE_CHEMICAL", 0, 12], ["LMB", "SIMPLE_CHEMICAL", 14, 17], ["Leptomycin B (LMB", "TREATMENT", 0, 17]]], ["The monoclonal antibody against the JEV envelope glycoprotein was described previously (Ishag et al., 2012b) .", [["JEV", "ORGANISM", 36, 39], ["monoclonal antibody", "PROTEIN", 4, 23], ["JEV envelope glycoprotein", "PROTEIN", 36, 61], ["JEV", "SPECIES", 36, 39], ["The monoclonal antibody", "TREATMENT", 0, 23], ["the JEV envelope glycoprotein", "PROBLEM", 32, 61], ["monoclonal antibody", "OBSERVATION", 4, 23]]], ["To produce anti-core, NS3 and NS5 polyclonal antibodies of mice source, the BALB/c mice free of pathogens was inoculated with 50 lg of NS5-RdRp protein emulsified with equal amount of freund's complete adjuvant via subcutaneous injection.", [["subcutaneous", "ANATOMY", 215, 227], ["anti-core", "GENE_OR_GENE_PRODUCT", 11, 20], ["NS3", "GENE_OR_GENE_PRODUCT", 22, 25], ["NS5", "GENE_OR_GENE_PRODUCT", 30, 33], ["mice", "ORGANISM", 59, 63], ["BALB/c mice", "ORGANISM", 76, 87], ["NS5", "ORGANISM", 135, 138], ["freund", "SIMPLE_CHEMICAL", 184, 190], ["anti-core", "PROTEIN", 11, 20], ["NS3", "PROTEIN", 22, 25], ["NS5 polyclonal antibodies", "PROTEIN", 30, 55], ["NS5", "PROTEIN", 135, 138], ["RdRp protein", "PROTEIN", 139, 151], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 83, 87], ["anti-core", "TREATMENT", 11, 20], ["NS3", "TREATMENT", 22, 25], ["NS5 polyclonal antibodies", "TREATMENT", 30, 55], ["mice source", "PROBLEM", 59, 70], ["the BALB", "TEST", 72, 80], ["pathogens", "PROBLEM", 96, 105], ["NS5", "TREATMENT", 135, 138], ["RdRp protein emulsified", "TREATMENT", 139, 162], ["subcutaneous injection", "TREATMENT", 215, 237]]], ["Booster doses were subsequently given at 1, 2 and 3 weeks later with 50 lg of core, NS3 and NS5-RdRp emulsified with incomplete adjuvant.", [["NS3", "GENE_OR_GENE_PRODUCT", 84, 87], ["NS5", "GENE_OR_GENE_PRODUCT", 92, 95], ["NS3", "PROTEIN", 84, 87], ["NS5", "PROTEIN", 92, 95], ["RdRp", "PROTEIN", 96, 100], ["Booster doses", "TREATMENT", 0, 13], ["NS3", "TREATMENT", 84, 87], ["NS5", "TREATMENT", 92, 95], ["RdRp emulsified", "TREATMENT", 96, 111], ["incomplete adjuvant", "TREATMENT", 117, 136]]], ["Finally, the serum of the mice was collected.", [["serum", "ANATOMY", 13, 18], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["mice", "ORGANISM", 26, 30], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 26, 30]]], ["The serum of the mice without immunized any protein was collected as the negative serum.", [["serum", "ANATOMY", 4, 9], ["serum", "ANATOMY", 82, 87], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["mice", "ORGANISM", 17, 21], ["serum", "ORGANISM_SUBSTANCE", 82, 87], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 17, 21], ["The serum", "TEST", 0, 9]]], ["Both immunoblot and ELISA were performed to evaluate the immunoreactivity between JEV core, NS3 and NS5 proteins and their polyclonal antibodies.", [["JEV", "ORGANISM", 82, 85], ["NS3", "GENE_OR_GENE_PRODUCT", 92, 95], ["NS5", "GENE_OR_GENE_PRODUCT", 100, 103], ["JEV core, NS3 and NS5 proteins", "PROTEIN", 82, 112], ["polyclonal antibodies", "PROTEIN", 123, 144], ["JEV", "SPECIES", 82, 85], ["Both immunoblot and ELISA", "TEST", 0, 25], ["the immunoreactivity", "TEST", 53, 73], ["JEV core", "TEST", 82, 90], ["NS3", "TEST", 92, 95], ["NS5 proteins", "TEST", 100, 112], ["their polyclonal antibodies", "TEST", 117, 144]]], ["The animal used in this study and animal experiment was approved by Department of Science and Technology of Jiangsu Province and in compliance with the Nanjing Agricultural University Institutional Animal Care and Use Committee.", [["this study", "TEST", 19, 29]]], ["The license number was SYXK (SU) 2010-0005.Plaque assayThe viral culture supernatants with 10-fold dilutions (from 10 2 to 10 6 ) were added into 6-well plate with confluent monolayer of BHK-21 cells.", [["Plaque", "ANATOMY", 43, 49], ["supernatants", "ANATOMY", 73, 85], ["monolayer", "ANATOMY", 174, 183], ["BHK-21 cells", "ANATOMY", 187, 199], ["monolayer", "CELL", 174, 183], ["BHK-21 cells", "CELL", 187, 199], ["BHK-21 cells", "CELL_LINE", 187, 199], ["BHK-21", "SPECIES", 187, 193], ["Plaque assay", "TEST", 43, 55], ["The viral culture supernatants", "TEST", 55, 85], ["fold dilutions", "TEST", 94, 108], ["confluent monolayer of BHK", "PROBLEM", 164, 190], ["viral", "OBSERVATION_MODIFIER", 59, 64], ["confluent monolayer", "OBSERVATION", 164, 183]]], ["The plate was then incubated at 37\u00b0C for 2 h, with rocking at every 15-min interval.", [["plate", "OBSERVATION_MODIFIER", 4, 9]]], ["The excess virus inocula were removed by rinsing the wells with PBS for three times.", [["The excess virus inocula", "TREATMENT", 0, 24], ["PBS", "TREATMENT", 64, 67], ["excess", "OBSERVATION_MODIFIER", 4, 10], ["virus inocula", "OBSERVATION", 11, 24]]], ["Subsequently, overlay medium (2% low melting-point agarose with DMEM medium containing 2% FBS) was added to each well and further Table 1 The primers of the plasmids used in the study (the restriction endonucleases sites were underlined and italic, T7 promoter and tobramycin aptamer tag sequences were underlined in the forward and reverse primers). incubated at 37\u00b0C with 5% CO 2 for 3 days.", [["tobramycin", "CHEMICAL", 265, 275], ["tobramycin", "CHEMICAL", 265, 275], ["CO 2", "CHEMICAL", 377, 381], ["FBS", "ORGANISM_SUBSTANCE", 90, 93], ["tobramycin", "SIMPLE_CHEMICAL", 265, 275], ["plasmids", "DNA", 157, 165], ["restriction endonucleases sites", "DNA", 189, 220], ["underlined and italic, T7 promoter", "DNA", 226, 260], ["tobramycin aptamer tag sequences", "DNA", 265, 297], ["forward and reverse primers", "DNA", 321, 348], ["2% low melting-point agarose with DMEM medium", "TREATMENT", 30, 75], ["2% FBS", "TREATMENT", 87, 93], ["the plasmids", "TREATMENT", 153, 165], ["the study", "TEST", 174, 183], ["the restriction endonucleases sites", "TREATMENT", 185, 220], ["italic, T7 promoter", "TREATMENT", 241, 260], ["tobramycin aptamer tag sequences", "TREATMENT", 265, 297], ["medium", "OBSERVATION_MODIFIER", 22, 28]]], ["The cells were stained with 0.5% crystal violet.GST pull-down assay and competitive binding assay50 lL of glutathione-Sparse 4B beads (GE Healthcare) were resuspended in binding buffer (20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 0.5% NP-40).", [["cells", "ANATOMY", 4, 9], ["glutathione", "CHEMICAL", 106, 117], ["Tris-HCl", "CHEMICAL", 192, 200], ["NaCl", "CHEMICAL", 217, 221], ["glutathione", "CHEMICAL", 106, 117], ["Tris-HCl", "CHEMICAL", 192, 200], ["NaCl", "CHEMICAL", 217, 221], ["cells", "CELL", 4, 9], ["GST", "GENE_OR_GENE_PRODUCT", 48, 51], ["glutathione", "SIMPLE_CHEMICAL", 106, 117], ["Tris-HCl", "SIMPLE_CHEMICAL", 192, 200], ["GST", "PROTEIN", 48, 51], ["GST pull", "TEST", 48, 56], ["glutathione", "TEST", 106, 117], ["Sparse 4B beads (GE Healthcare", "TREATMENT", 118, 148], ["Tris", "TEST", 192, 196], ["pH", "TEST", 202, 204], ["NaCl", "TEST", 217, 221], ["NP", "TEST", 228, 230]]], ["The purified GST tagged proteins were incubated with the beads for 2 h at 4\u00b0C under gentle agitation.", [["agitation", "DISEASE", 91, 100], ["GST", "GENE_OR_GENE_PRODUCT", 13, 16], ["purified GST tagged proteins", "PROTEIN", 4, 32], ["The purified GST tagged proteins", "TREATMENT", 0, 32], ["the beads", "TREATMENT", 53, 62], ["gentle agitation", "PROBLEM", 84, 100], ["gentle agitation", "OBSERVATION", 84, 100]]], ["Unbounded proteins were washed away using washing buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% NP-40).", [["Tris-HCl", "CHEMICAL", 64, 72], ["NaCl", "CHEMICAL", 89, 93], ["Tris-HCl", "CHEMICAL", 64, 72], ["NaCl", "CHEMICAL", 89, 93], ["Tris-HCl", "SIMPLE_CHEMICAL", 64, 72], ["Unbounded proteins", "PROTEIN", 0, 18], ["pH", "TEST", 74, 76], ["NaCl", "TEST", 89, 93], ["NP", "TEST", 100, 102]]], ["Then the purified HIS-tagged proteins were then incubated with the beads for 3-4 h with gentle agitation at 4\u00b0C respectively.", [["agitation", "DISEASE", 95, 104], ["purified HIS-tagged proteins", "PROTEIN", 9, 37], ["gentle agitation", "PROBLEM", 88, 104]]], ["The beads were washed four times with 1 ml of washing buffer.", [["beads", "ANATOMY", 4, 9], ["The beads", "TREATMENT", 0, 9], ["washing buffer", "TREATMENT", 46, 60], ["beads", "OBSERVATION_MODIFIER", 4, 9]]], ["Finally the beads were resuspended in 200 lL of SDS-PAGE sample buffer, boiled and subjected to 12% or 15% SDS-PAGE gel, and then transferred to PVDF membrane.", [["beads", "ANATOMY", 12, 17], ["PVDF membrane", "ANATOMY", 145, 158], ["SDS-PAGE", "CHEMICAL", 48, 56], ["SDS", "CHEMICAL", 48, 51], ["PVDF", "CHEMICAL", 145, 149], ["membrane", "CELLULAR_COMPONENT", 150, 158], ["the beads", "TREATMENT", 8, 17]]], ["The presence of the targeted proteins was detected with the anti-DDX5 polyclonal antibody and anti-HIS monoclonal antibody, glutathione-Sparse 4B-beads with the GST proteins were used as control.GST pull-down assay and competitive binding assayIn competitive binding experiment, GST-DDX5 protein was first incubated with 50 lL of glutathione-Sparse 4B beads.", [["glutathione", "CHEMICAL", 124, 135], ["glutathione", "CHEMICAL", 330, 341], ["glutathione", "CHEMICAL", 124, 135], ["glutathione", "CHEMICAL", 330, 341], ["anti-DDX5", "GENE_OR_GENE_PRODUCT", 60, 69], ["glutathione", "SIMPLE_CHEMICAL", 124, 135], ["GST", "GENE_OR_GENE_PRODUCT", 161, 164], ["GST", "GENE_OR_GENE_PRODUCT", 195, 198], ["GST-DDX5", "GENE_OR_GENE_PRODUCT", 279, 287], ["glutathione", "SIMPLE_CHEMICAL", 330, 341], ["targeted proteins", "PROTEIN", 20, 37], ["anti-DDX5 polyclonal antibody", "PROTEIN", 60, 89], ["anti-HIS monoclonal antibody", "PROTEIN", 94, 122], ["glutathione-Sparse 4B-beads", "PROTEIN", 124, 151], ["GST proteins", "PROTEIN", 161, 173], ["GST", "PROTEIN", 195, 198], ["GST", "PROTEIN", 279, 282], ["DDX5 protein", "PROTEIN", 283, 295], ["the targeted proteins", "PROBLEM", 16, 37], ["the anti-DDX5 polyclonal antibody", "TEST", 56, 89], ["anti-HIS monoclonal antibody", "TEST", 94, 122], ["glutathione", "TEST", 124, 135], ["the GST proteins", "TREATMENT", 157, 173], ["GST pull", "TEST", 195, 203], ["DDX5 protein", "TEST", 283, 295], ["glutathione", "TEST", 330, 341], ["Sparse 4B beads", "PROBLEM", 342, 357], ["Sparse", "OBSERVATION_MODIFIER", 342, 348], ["4B beads", "OBSERVATION", 349, 357]]], ["After extensive washing by washing buffer, HIS-tagged core, NS3, NS5-Mtase or NS5-RdRp was incubated with the beads for 3-4 h with gentle agitation at 4\u00b0C followed by washing 5 times with washing buffer.", [["agitation", "DISEASE", 138, 147], ["NS3", "GENE_OR_GENE_PRODUCT", 60, 63], ["NS5-Mtase", "GENE_OR_GENE_PRODUCT", 65, 74], ["NS5", "GENE_OR_GENE_PRODUCT", 78, 81], ["NS3", "PROTEIN", 60, 63], ["NS5", "PROTEIN", 65, 68], ["Mtase", "PROTEIN", 69, 74], ["NS5", "PROTEIN", 78, 81], ["RdRp", "PROTEIN", 82, 86], ["HIS-tagged core", "TREATMENT", 43, 58], ["NS3", "TREATMENT", 60, 63], ["NS5-Mtase", "TREATMENT", 65, 74], ["NS5-RdRp", "TREATMENT", 78, 86], ["gentle agitation", "PROBLEM", 131, 147], ["washing buffer", "TREATMENT", 188, 202]]], ["The different amount of competitive protein (core, NS3, NS5-Mtase or NS5-RdRp) (10 lg-50 lg) were mixed with the beads.", [["NS3", "GENE_OR_GENE_PRODUCT", 51, 54], ["NS5-Mtase", "GENE_OR_GENE_PRODUCT", 56, 65], ["NS5-RdRp", "GENE_OR_GENE_PRODUCT", 69, 77], ["competitive protein", "PROTEIN", 24, 43], ["NS3", "PROTEIN", 51, 54], ["NS5", "PROTEIN", 56, 59], ["Mtase", "PROTEIN", 60, 65], ["NS5", "PROTEIN", 69, 72], ["RdRp", "PROTEIN", 73, 77], ["NS3", "TEST", 51, 54], ["NS5-Mtase", "TREATMENT", 56, 65], ["NS5-RdRp", "TREATMENT", 69, 77], ["lg", "TEST", 83, 85], ["different", "OBSERVATION_MODIFIER", 4, 13], ["amount", "OBSERVATION_MODIFIER", 14, 20], ["competitive protein", "OBSERVATION", 24, 43], ["beads", "OBSERVATION_MODIFIER", 113, 118]]], ["The mixture was incubated for 3-4 h with gentle agitation at 4\u00b0C. The mixture was centrifuged at 3000 rpm for 5 min, the supernatant and the beads were subjected to 12% or 15% SDS-PAGE gel and analyzed by Western blot using either anti-HIS monoclonal antibody, anti-NS3 or NS5 polyclonal antibody.Co-immunoprecipitation assayBHK-21 cells transfected with the plasmids as indicated or infected with JEV, 48 h later, The medium was removed and the cells were rinsed twice in cold phosphate-buffered saline, incubated for 3 h at 4\u00b0C in lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 0.2 mM PMSF, 1% NP-40) with gentle agitation and collected.", [["supernatant", "ANATOMY", 121, 132], ["beads", "ANATOMY", 141, 146], ["assayBHK-21 cells", "ANATOMY", 320, 337], ["plasmids", "ANATOMY", 359, 367], ["cells", "ANATOMY", 446, 451], ["agitation", "DISEASE", 48, 57], ["phosphate", "CHEMICAL", 478, 487], ["Tris-HCl", "CHEMICAL", 553, 561], ["NaCl", "CHEMICAL", 578, 582], ["dithiothreitol", "CHEMICAL", 600, 614], ["phosphate", "CHEMICAL", 478, 487], ["Tris-HCl", "CHEMICAL", 553, 561], ["NaCl", "CHEMICAL", 578, 582], ["EDTA", "CHEMICAL", 589, 593], ["dithiothreitol", "CHEMICAL", 600, 614], ["PMSF", "CHEMICAL", 623, 627], ["anti-NS3", "GENE_OR_GENE_PRODUCT", 261, 269], ["assayBHK-21 cells", "CELL", 320, 337], ["JEV", "ORGANISM", 398, 401], ["cells", "CELL", 446, 451], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 478, 503], ["C", "SIMPLE_CHEMICAL", 528, 529], ["Tris-HCl", "SIMPLE_CHEMICAL", 553, 561], ["EDTA", "SIMPLE_CHEMICAL", 589, 593], ["dithiothreitol", "SIMPLE_CHEMICAL", 600, 614], ["HIS monoclonal antibody", "PROTEIN", 236, 259], ["NS3", "PROTEIN", 266, 269], ["NS5 polyclonal antibody", "PROTEIN", 273, 296], ["assayBHK-21 cells", "CELL_LINE", 320, 337], ["plasmids", "DNA", 359, 367], ["JEV", "SPECIES", 398, 401], ["gentle agitation", "PROBLEM", 41, 57], ["the beads", "TREATMENT", 137, 146], ["anti-HIS monoclonal antibody", "TEST", 231, 259], ["anti-NS3", "TREATMENT", 261, 269], ["NS5 polyclonal antibody", "TEST", 273, 296], ["Co-immunoprecipitation assayBHK", "TEST", 297, 328], ["the plasmids", "TREATMENT", 355, 367], ["JEV", "PROBLEM", 398, 401], ["the cells", "TREATMENT", 442, 451], ["cold phosphate-buffered saline", "TREATMENT", 473, 503], ["C in lysis buffer", "TREATMENT", 528, 545], ["Tris", "TEST", 553, 557], ["HCl", "TEST", 558, 561], ["pH", "TEST", 563, 565], ["NaCl", "TEST", 578, 582], ["EDTA", "TEST", 589, 593], ["dithiothreitol", "TEST", 600, 614], ["PMSF", "TEST", 623, 627], ["NP", "TEST", 632, 634], ["gentle agitation", "PROBLEM", 644, 660]]], ["Cell debris was removed by centrifugation at 10,000g for 10 min at 4\u00b0C. Cell extracts were incubated with anti-MYC mAb coupled protein Gagarose beads or the beads (have been incubated with DDX5 polyclonal antibody) for 2 h at 4\u00b0C. The beads were washed five times with 1 ml of washing buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% NP-40).", [["Cell debris", "ANATOMY", 0, 11], ["Cell extracts", "ANATOMY", 72, 85], ["beads", "ANATOMY", 235, 240], ["Tris-HCl", "CHEMICAL", 299, 307], ["NaCl", "CHEMICAL", 324, 328], ["Tris-HCl", "CHEMICAL", 299, 307], ["NaCl", "CHEMICAL", 324, 328], ["Cell", "CELL", 0, 4], ["Cell extracts", "ORGANISM_SUBSTANCE", 72, 85], ["Tris-HCl", "SIMPLE_CHEMICAL", 299, 307], ["anti-MYC mAb", "PROTEIN", 106, 118], ["DDX5 polyclonal antibody", "PROTEIN", 189, 213], ["Cell debris", "PROBLEM", 0, 11], ["Cell extracts", "TREATMENT", 72, 85], ["anti-MYC mAb", "TREATMENT", 106, 118], ["protein Gagarose beads", "TREATMENT", 127, 149], ["DDX5 polyclonal antibody", "TREATMENT", 189, 213], ["The beads", "TREATMENT", 231, 240], ["washing buffer", "TREATMENT", 277, 291], ["Tris", "TEST", 299, 303], ["pH", "TEST", 309, 311], ["NaCl", "TEST", 324, 328], ["NP", "TEST", 335, 337], ["debris", "OBSERVATION", 5, 11], ["beads", "OBSERVATION_MODIFIER", 235, 240]]], ["The beads were resuspended in 200 lL of SDS-PAGE sample buffer and boiled and were separated by SDS-PAGE, and then transferred to PVDF membrane.", [["beads", "ANATOMY", 4, 9], ["PVDF membrane", "ANATOMY", 130, 143], ["SDS", "CHEMICAL", 40, 43], ["PVDF", "CHEMICAL", 130, 134], ["membrane", "CELLULAR_COMPONENT", 135, 143], ["The beads", "TREATMENT", 0, 9], ["beads", "OBSERVATION_MODIFIER", 4, 9]]], ["The proteins were analyzed by anti-DDX5, core, NS3, NS5 polyclonal antibodies or anti-MYC-HRP monoclonal antibody.Western blot and RT-PCR analysisCell lysates or proteins complexes for GST pulldown and Coimmunoprecipitation were separated by 12% or 15% SDS-PAGE and transferred to PVDF membrane (Millipore, USA) in a Trans-Blot SD semidry transfer cell (Bio-Rad, USA).", [["Cell lysates", "ANATOMY", 146, 158], ["PVDF membrane", "ANATOMY", 281, 294], ["cell", "ANATOMY", 348, 352], ["PVDF", "CHEMICAL", 281, 285], ["anti-DDX5", "GENE_OR_GENE_PRODUCT", 30, 39], ["NS3", "GENE_OR_GENE_PRODUCT", 47, 50], ["NS5", "GENE_OR_GENE_PRODUCT", 52, 55], ["anti-MYC", "GENE_OR_GENE_PRODUCT", 81, 89], ["HRP", "GENE_OR_GENE_PRODUCT", 90, 93], ["Cell lysates", "ORGANISM_SUBSTANCE", 146, 158], ["GST", "GENE_OR_GENE_PRODUCT", 185, 188], ["membrane", "CELLULAR_COMPONENT", 286, 294], ["cell", "CELL", 348, 352], ["anti-DDX5", "PROTEIN", 30, 39], ["NS3", "PROTEIN", 47, 50], ["NS5 polyclonal antibodies", "PROTEIN", 52, 77], ["anti-MYC", "PROTEIN", 81, 89], ["HRP monoclonal antibody", "PROTEIN", 90, 113], ["proteins complexes", "PROTEIN", 162, 180], ["GST", "PROTEIN", 185, 188], ["The proteins", "TEST", 0, 12], ["anti-DDX5", "TEST", 30, 39], ["core", "TEST", 41, 45], ["NS3", "TEST", 47, 50], ["NS5 polyclonal antibodies", "TEST", 52, 77], ["anti-MYC", "TEST", 81, 89], ["HRP monoclonal antibody", "TEST", 90, 113], ["Western blot", "TEST", 114, 126], ["RT-PCR analysis", "TEST", 131, 146], ["Cell lysates", "TEST", 146, 158], ["proteins complexes", "PROBLEM", 162, 180], ["GST pulldown", "TEST", 185, 197], ["Coimmunoprecipitation", "TEST", 202, 223], ["monoclonal antibody", "OBSERVATION", 94, 113]]], ["The membrane was blocked with 5% non-fat milk powder in TBST buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20), then probed with anti-core, NS3 or NS5 polyclonal antibodies, anti-JEV E (Ishag et al., 2012a; Ishag et al., 2012b) or anti-b-actin monoclonal antibodies, anti-HA monoclonal antibody-HRP or anti-MYC monoclonal antibody-HRP (Cell Signaling, USA).", [["membrane", "ANATOMY", 4, 12], ["fat milk", "ANATOMY", 37, 45], ["Cell", "ANATOMY", 346, 350], ["Tris-HCl", "CHEMICAL", 75, 83], ["NaCl", "CHEMICAL", 100, 104], ["Tris-HCl", "CHEMICAL", 75, 83], ["NaCl", "CHEMICAL", 100, 104], ["Tween 20", "CHEMICAL", 111, 119], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["fat milk", "ORGANISM_SUBSTANCE", 37, 45], ["Tris-HCl", "SIMPLE_CHEMICAL", 75, 83], ["anti-core", "GENE_OR_GENE_PRODUCT", 139, 148], ["NS3", "GENE_OR_GENE_PRODUCT", 150, 153], ["anti-JEV E", "SIMPLE_CHEMICAL", 184, 194], ["anti-b-actin", "GENE_OR_GENE_PRODUCT", 241, 253], ["HRP", "GENE_OR_GENE_PRODUCT", 305, 308], ["HRP", "SIMPLE_CHEMICAL", 341, 344], ["Cell", "CELL", 346, 350], ["anti-core", "PROTEIN", 139, 148], ["NS3", "PROTEIN", 150, 153], ["NS5 polyclonal antibodies", "PROTEIN", 157, 182], ["anti-JEV E", "PROTEIN", 184, 194], ["anti-b-actin monoclonal antibodies", "PROTEIN", 241, 275], ["anti-HA monoclonal antibody", "PROTEIN", 277, 304], ["HRP", "PROTEIN", 305, 308], ["anti-MYC monoclonal antibody", "PROTEIN", 312, 340], ["HRP", "PROTEIN", 341, 344], ["5% non-fat milk powder", "TREATMENT", 30, 52], ["pH", "TEST", 85, 87], ["NaCl", "TEST", 100, 104], ["anti-core", "TREATMENT", 139, 148], ["NS3", "TREATMENT", 150, 153], ["NS5 polyclonal antibodies", "TEST", 157, 182], ["anti-JEV E", "TEST", 184, 194], ["anti-b-actin monoclonal antibodies", "TEST", 241, 275], ["anti-HA monoclonal antibody", "TEST", 277, 304], ["HRP", "TEST", 305, 308], ["anti-MYC monoclonal antibody", "TEST", 312, 340]]], ["For the anti-HA monoclonal antibody-HRP, anti-MYC monoclonal antibody-HRP detection, they were directly visualized using enhanced chemiluminescence (GE Healthcare).", [["HRP", "GENE_OR_GENE_PRODUCT", 36, 39], ["HRP", "SIMPLE_CHEMICAL", 70, 73], ["anti-HA monoclonal antibody", "PROTEIN", 8, 35], ["HRP", "PROTEIN", 36, 39], ["anti-MYC monoclonal antibody", "PROTEIN", 41, 69], ["HRP", "PROTEIN", 70, 73], ["the anti-HA monoclonal antibody", "TEST", 4, 35], ["HRP", "TEST", 36, 39], ["anti-MYC monoclonal antibody", "TEST", 41, 69], ["HRP detection", "TEST", 70, 83]]], ["For the other antibodies, the bound antibody was detected using HRP-conjugated secondary antibodies, and visualized using enhanced chemiluminescence.Western blot and RT-PCR analysisJEV-specific RNA copy number which was expressed as a ratio to the cellular b-actin cDNA copies was quantified using quantitative PCR (Q-PCR).", [["cellular", "ANATOMY", 248, 256], ["HRP", "SIMPLE_CHEMICAL", 64, 67], ["cellular", "CELL", 248, 256], ["antibodies", "PROTEIN", 14, 24], ["HRP-conjugated secondary antibodies", "PROTEIN", 64, 99], ["cellular b-actin cDNA copies", "DNA", 248, 276], ["the other antibodies", "TEST", 4, 24], ["the bound antibody", "TEST", 26, 44], ["HRP", "TEST", 64, 67], ["enhanced chemiluminescence", "TEST", 122, 148], ["Western blot", "TEST", 149, 161], ["RT-PCR analysisJEV", "TEST", 166, 184], ["quantitative PCR", "TEST", 298, 314]]], ["The total RNA was extracted from JEV-infected BHK-21 cells with TRIzol reagent (Invitrogen) and purified according to the Manufacturer's recommendations.", [["BHK-21 cells", "ANATOMY", 46, 58], ["JEV", "ORGANISM", 33, 36], ["BHK-21 cells", "CELL", 46, 58], ["TRIzol", "ORGANISM", 64, 70], ["JEV-infected BHK-21 cells", "CELL_LINE", 33, 58], ["JEV", "SPECIES", 33, 36], ["BHK-21", "SPECIES", 46, 52], ["The total RNA", "TEST", 0, 13], ["JEV", "PROBLEM", 33, 36], ["TRIzol reagent", "TREATMENT", 64, 78], ["total RNA", "OBSERVATION_MODIFIER", 4, 13], ["infected BHK", "OBSERVATION", 37, 49]]], ["Intracellular JEV genome levels were quantified with the SYBR Green Probe 3-step QRT-PCR kit (Takara, China) and fluorescent quantization meter (ABI PRISM 7300 sequence detection system, Applied Biosystems).", [["Intracellular", "ANATOMY", 0, 13], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["JEV", "ORGANISM", 14, 17], ["JEV", "SPECIES", 14, 17], ["Intracellular JEV genome levels", "TEST", 0, 31], ["the SYBR", "TEST", 53, 61], ["step QRT", "TEST", 76, 84], ["JEV genome", "OBSERVATION", 14, 24]]], ["For cDNA preparation, total RNA (1 lg) was reverse transcribed with first strand cDNA synthesis kit (Takara, China).", [["total RNA", "RNA", 22, 31], ["cDNA preparation", "TREATMENT", 4, 20], ["total RNA", "TREATMENT", 22, 31], ["first strand cDNA synthesis kit", "TREATMENT", 68, 99]]], ["Triplicate cDNA samples were amplified with the RT-PCR kit.", [["samples", "ANATOMY", 16, 23], ["cDNA samples", "DNA", 11, 23], ["Triplicate cDNA samples", "TEST", 0, 23], ["the RT-PCR kit", "TEST", 44, 58]]], ["The primer for the JEV NS1 and b-actin were the following: NS1 sense primer: 5 0 -acactcgtcagatcacaggttca-3 0 ; antisense primer: 5 0 -gccagaaacatcaccagaagg-3 0 , b-actin sense primer: 5 0 -catccgtaaagacctctatgccaac-3 0 , antisense primer, 5 0 -atggagccaccgatccaca-3 0 and cellular b-actin mRNA from the same RNA extract was used as an internal control in BHK-21 cells as the previous study (Ishag et al., 2012a; Ishag et al., 2012b) .Western blot and RT-PCR analysis2.10.", [["cellular", "ANATOMY", 273, 281], ["BHK-21 cells", "ANATOMY", 356, 368], ["JEV", "ORGANISM", 19, 22], ["NS1", "GENE_OR_GENE_PRODUCT", 23, 26], ["b-actin", "GENE_OR_GENE_PRODUCT", 31, 38], ["NS1", "GENE_OR_GENE_PRODUCT", 59, 62], ["b-actin", "GENE_OR_GENE_PRODUCT", 163, 170], ["atggagccaccgatccaca-3 0", "GENE_OR_GENE_PRODUCT", 245, 268], ["cellular", "CELL", 273, 281], ["b-actin", "GENE_OR_GENE_PRODUCT", 282, 289], ["BHK-21 cells", "CELL", 356, 368], ["JEV NS1", "PROTEIN", 19, 26], ["b-actin", "PROTEIN", 31, 38], ["NS1", "PROTEIN", 59, 62], ["antisense primer: 5 0 -gccagaaacatcaccagaagg-3 0", "DNA", 112, 160], ["b-actin sense primer: 5 0 -catccgtaaagacctctatgccaac-3 0", "DNA", 163, 219], ["antisense primer", "DNA", 222, 238], ["5 0", "DNA", 240, 243], ["-atggagccaccgatccaca-3 0 and cellular b-actin mRNA", "RNA", 244, 294], ["BHK-21 cells", "CELL_LINE", 356, 368], ["JEV NS1", "SPECIES", 19, 26], ["the JEV NS1", "TREATMENT", 15, 26], ["acactcgtcagatcacaggttca", "TEST", 82, 105], ["antisense primer", "TEST", 112, 128], ["gccagaaacatcaccagaagg", "TEST", 135, 156], ["catccgtaaagacctctatgccaac", "TEST", 190, 215], ["antisense primer", "TEST", 222, 238], ["atggagccaccgatccaca", "TEST", 245, 264], ["cellular b-actin mRNA", "TREATMENT", 273, 294], ["an internal control in BHK", "TREATMENT", 333, 359], ["the previous study", "TEST", 372, 390], ["Western blot", "TEST", 435, 447], ["RT", "TEST", 452, 454], ["PCR analysis2", "TEST", 455, 468]]], ["In vitro RNA transcription and the interaction of JEV 5 0 and 3 0 UTR with DDX5Western blot and RT-PCR analysisTo synthesize JEV replicon, GAPDH-luciferase, JEV 5 0 , 3 0 UTR and control RNAs in vitro, the purified plasmids DNA was first linearized with KpnI or BamHI enzyme.", [["plasmids", "ANATOMY", 215, 223], ["JEV 5", "ORGANISM", 50, 55], ["JEV", "ORGANISM", 125, 128], ["GAPDH", "GENE_OR_GENE_PRODUCT", 139, 144], ["luciferase", "GENE_OR_GENE_PRODUCT", 145, 155], ["JEV 5", "ORGANISM", 157, 162], ["DNA", "CELLULAR_COMPONENT", 224, 227], ["KpnI", "GENE_OR_GENE_PRODUCT", 254, 258], ["BamHI", "GENE_OR_GENE_PRODUCT", 262, 267], ["JEV 5 0 and 3 0 UTR", "DNA", 50, 69], ["RT-PCR analysisTo", "DNA", 96, 113], ["JEV replicon", "DNA", 125, 137], ["GAPDH-luciferase, JEV 5 0 , 3 0 UTR", "DNA", 139, 174], ["purified plasmids DNA", "DNA", 206, 227], ["KpnI", "DNA", 254, 258], ["BamHI enzyme", "PROTEIN", 262, 274], ["JEV", "SPECIES", 125, 128], ["DDX5Western blot", "TEST", 75, 91], ["RT-PCR analysisTo synthesize JEV replicon", "TREATMENT", 96, 137], ["GAPDH-luciferase", "TREATMENT", 139, 155], ["the purified plasmids DNA", "TREATMENT", 202, 227], ["KpnI", "TREATMENT", 254, 258], ["BamHI enzyme", "TEST", 262, 274], ["JEV replicon", "OBSERVATION", 125, 137]]], ["JEV 5 0 , 3 0 UTR and control RNA were generated by in vitro transcription using Riboprobe \u00d2 System-T7 Kit (Promega, China) following a standard method in a 20 lL reaction mixture containing 4 lL 5 \u00c2 transcription buffer, 2 lL RNasin \u00d2 RNA Inhibitor (40U/lL), 1 lL each NTP (10 mM), 1 lg of linearized DNA template and 1 lL T7 RNA polymerase (20 U/lL).", [["NTP", "CHEMICAL", 270, 273], ["NTP", "CHEMICAL", 270, 273], ["JEV 5", "ORGANISM", 0, 5], ["DNA", "CELLULAR_COMPONENT", 302, 305], ["JEV 5 0 , 3 0 UTR", "DNA", 0, 17], ["linearized DNA template", "DNA", 291, 314], ["lL T7 RNA polymerase", "PROTEIN", 321, 341], ["JEV", "SPECIES", 0, 3], ["JEV", "TEST", 0, 3], ["UTR and control RNA", "TREATMENT", 14, 33], ["Riboprobe \u00d2 System", "TREATMENT", 81, 99], ["a standard method", "TREATMENT", 134, 151], ["a 20 lL reaction mixture", "TREATMENT", 155, 179], ["transcription buffer", "TREATMENT", 200, 220], ["2 lL RNasin \u00d2 RNA Inhibitor", "TREATMENT", 222, 249], ["linearized DNA template", "TREATMENT", 291, 314], ["T7", "ANATOMY", 100, 102]]], ["10 lL of RNase-free DNaseI (1 U/lL) was added to the mixture and incubated at 37\u00b0C for 30 min.", [["DNaseI", "CHEMICAL", 20, 26], ["RNase", "GENE_OR_GENE_PRODUCT", 9, 14], ["DNaseI", "SIMPLE_CHEMICAL", 20, 26], ["RNase", "PROTEIN", 9, 14], ["DNaseI", "PROTEIN", 20, 26], ["RNase", "TEST", 9, 14], ["free DNaseI (1 U/lL)", "TREATMENT", 15, 35], ["RNase", "OBSERVATION", 9, 14], ["free DNaseI", "OBSERVATION", 15, 26]]], ["The RNA was quantified using spectrophotometry.", [["spectrophotometry", "TEST", 29, 46]]], ["5 lg RNA was added to the matrix beads conjugated with tobramycin respectively (Hartmuth et al., 2004) and incubated by head-over-tail rotation for 1-1.5 h.", [["matrix", "ANATOMY", 26, 32], ["head", "ANATOMY", 120, 124], ["tail", "ANATOMY", 130, 134], ["tobramycin", "CHEMICAL", 55, 65], ["tobramycin", "CHEMICAL", 55, 65], ["tobramycin", "SIMPLE_CHEMICAL", 55, 65], ["head", "ORGANISM_SUBDIVISION", 120, 124], ["5 lg RNA", "RNA", 0, 8], ["lg RNA", "TREATMENT", 2, 8], ["the matrix beads", "TREATMENT", 22, 38], ["tobramycin", "TREATMENT", 55, 65], ["head", "ANATOMY", 120, 124]]], ["The mixture was washed three times with PBS (prepared with DEPC-treated water), the supernatants of BHK-21 cell lysate or purified DDX5 mutants were added.", [["supernatants", "ANATOMY", 84, 96], ["BHK-21 cell lysate", "ANATOMY", 100, 118], ["DEPC", "CHEMICAL", 59, 63], ["DEPC", "CHEMICAL", 59, 63], ["PBS", "SIMPLE_CHEMICAL", 40, 43], ["DEPC", "SIMPLE_CHEMICAL", 59, 63], ["BHK-21 cell", "CELL", 100, 111], ["DDX5", "GENE_OR_GENE_PRODUCT", 131, 135], ["DDX5 mutants", "PROTEIN", 131, 143], ["The mixture", "TREATMENT", 0, 11], ["PBS", "TREATMENT", 40, 43], ["DEPC", "TREATMENT", 59, 63], ["the supernatants of BHK", "TREATMENT", 80, 103], ["cell lysate", "TREATMENT", 107, 118], ["purified DDX5 mutants", "TREATMENT", 122, 143]]], ["The mixture was incubated by head-over-tail rotation for 2 h and washed three times with PBS and subjected to SDS-PAGE for Western blot using anti-DDX5 polyclonal antibody, The RNA of JEV 5 0 and 3 0 UTR and control RNA were detected by 1% agarose (stained by Ethidium bromide).Confocal microscopy analysisBHK-21 cells were plated onto cover glass in a 6-well plate.", [["head", "ANATOMY", 29, 33], ["tail", "ANATOMY", 39, 43], ["analysisBHK-21 cells", "ANATOMY", 298, 318], ["Ethidium bromide", "CHEMICAL", 260, 276], ["Ethidium bromide", "CHEMICAL", 260, 276], ["head", "ORGANISM_SUBDIVISION", 29, 33], ["anti-DDX5", "GENE_OR_GENE_PRODUCT", 142, 151], ["JEV 5", "ORGANISM", 184, 189], ["agarose", "SIMPLE_CHEMICAL", 240, 247], ["Ethidium bromide", "SIMPLE_CHEMICAL", 260, 276], ["analysisBHK-21 cells", "CELL", 298, 318], ["anti-DDX5 polyclonal antibody", "PROTEIN", 142, 171], ["JEV 5 0 and 3 0 UTR", "DNA", 184, 203], ["analysisBHK-21 cells", "CELL_LINE", 298, 318], ["JEV", "SPECIES", 184, 187], ["PBS", "TREATMENT", 89, 92], ["Western blot", "TEST", 123, 135], ["anti-DDX5 polyclonal antibody", "TEST", 142, 171], ["JEV", "TEST", 184, 187], ["Ethidium bromide", "TREATMENT", 260, 276], ["Confocal microscopy analysisBHK", "TEST", 278, 309]]], ["In the following day, cells were infected with JEV (MOI = 0.01).", [["cells", "ANATOMY", 22, 27], ["cells", "CELL", 22, 27], ["JEV", "ORGANISM", 47, 50], ["JEV", "SPECIES", 47, 50], ["JEV (MOI", "TREATMENT", 47, 55]]], ["24 h later, cells were fixed with ethanol for 30 min at 4\u00b0C, the cells were then washed with 1% BSA/PBS, and endogenous proteins were directly stained with their antibodies respectively.", [["cells", "ANATOMY", 12, 17], ["cells", "ANATOMY", 65, 70], ["ethanol", "CHEMICAL", 34, 41], ["ethanol", "CHEMICAL", 34, 41], ["cells", "CELL", 12, 17], ["ethanol", "SIMPLE_CHEMICAL", 34, 41], ["cells", "CELL", 65, 70], ["BSA", "SIMPLE_CHEMICAL", 96, 99], ["PBS", "SIMPLE_CHEMICAL", 100, 103], ["endogenous proteins", "PROTEIN", 109, 128], ["antibodies", "PROTEIN", 162, 172], ["ethanol", "TREATMENT", 34, 41], ["1% BSA/PBS", "TEST", 93, 103], ["endogenous proteins", "PROBLEM", 109, 128]]], ["The cells were then treated for 60 min at room temperature with Rhodamineconjugated second antibodies (Dingguo, China).", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["Rhodamineconjugated second antibodies", "TREATMENT", 64, 101]]], ["For the viral RNA staining, cells were first infected with JEV (MOI = 0.01).", [["cells", "ANATOMY", 28, 33], ["cells", "CELL", 28, 33], ["JEV", "ORGANISM", 59, 62], ["JEV", "SPECIES", 59, 62], ["the viral RNA staining", "TEST", 4, 26], ["JEV (MOI", "TEST", 59, 67], ["viral RNA staining", "OBSERVATION", 8, 26]]], ["3 h later, the cells were treated with actinomycin D (Sigma, China) for 4 h (15 lg/ml) (Xu et al., 2010) to block cellular RNA transcription, then 5-ethynyl uridine (EU) was added.", [["cells", "ANATOMY", 15, 20], ["cellular", "ANATOMY", 114, 122], ["actinomycin D", "CHEMICAL", 39, 52], ["5-ethynyl uridine", "CHEMICAL", 147, 164], ["EU", "CHEMICAL", 166, 168], ["actinomycin D", "CHEMICAL", 39, 52], ["5-ethynyl uridine", "CHEMICAL", 147, 164], ["cells", "CELL", 15, 20], ["actinomycin D", "SIMPLE_CHEMICAL", 39, 52], ["cellular", "CELL", 114, 122], ["5-ethynyl uridine", "SIMPLE_CHEMICAL", 147, 164], ["EU", "SIMPLE_CHEMICAL", 166, 168], ["actinomycin D (Sigma, China)", "TREATMENT", 39, 67], ["block cellular RNA transcription", "TREATMENT", 108, 140], ["5-ethynyl uridine (EU)", "TREATMENT", 147, 169]]], ["The viral RNA was detected using the Click-iT \u00d2 RNA Imaging Kits (Invitrogen, China) according to the manufacturer's instructions.", [["viral RNA", "RNA", 4, 13], ["The viral RNA", "PROBLEM", 0, 13], ["the Click", "TEST", 33, 42], ["Imaging Kits", "TEST", 52, 64], ["viral RNA", "OBSERVATION", 4, 13]]], ["The nucleus was stained using 4 0 , 6-diamidino-2-phenylindole (DAPI).", [["nucleus", "ANATOMY", 4, 11], ["4 0 , 6-diamidino-2-phenylindole", "CHEMICAL", 30, 62], ["4 0 , 6-diamidino-2-phenylindole", "CHEMICAL", 30, 62], ["DAPI", "CHEMICAL", 64, 68], ["nucleus", "CELLULAR_COMPONENT", 4, 11], ["4 0 , 6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 30, 62], ["DAPI", "SIMPLE_CHEMICAL", 64, 68], ["diamidino", "TREATMENT", 38, 47], ["nucleus", "ANATOMY", 4, 11]]], ["The cover slips were mounted onto slide glass using PBS containing 50% glycerol.", [["glycerol", "CHEMICAL", 71, 79], ["glycerol", "CHEMICAL", 71, 79], ["glycerol", "SIMPLE_CHEMICAL", 71, 79], ["The cover slips", "TREATMENT", 0, 15], ["PBS", "TREATMENT", 52, 55], ["50% glycerol", "TREATMENT", 67, 79], ["slips", "OBSERVATION", 10, 15]]], ["Confocal images were obtained using a Zeiss LSM 710 scanning confocal microscope. .", [["Confocal images", "TEST", 0, 15]]], ["Western blot analysis of the JEV proteins and DDX5 expression level in infected BHK-21 cells after DDX5 knockdown.", [["BHK-21 cells", "ANATOMY", 80, 92], ["JEV", "ORGANISM", 29, 32], ["DDX5", "GENE_OR_GENE_PRODUCT", 46, 50], ["BHK-21 cells", "CELL", 80, 92], ["DDX5", "GENE_OR_GENE_PRODUCT", 99, 103], ["JEV proteins", "PROTEIN", 29, 41], ["DDX5", "PROTEIN", 46, 50], ["BHK-21 cells", "CELL_LINE", 80, 92], ["DDX5", "PROTEIN", 99, 103], ["JEV", "SPECIES", 29, 32], ["BHK-21", "SPECIES", 80, 86], ["blot analysis", "TEST", 8, 21], ["the JEV proteins", "TEST", 25, 41], ["expression level", "TEST", 51, 67], ["infected BHK", "PROBLEM", 71, 83], ["DDX5 knockdown", "TREATMENT", 99, 113], ["infected BHK", "OBSERVATION", 71, 83]]], ["Western blot of b-actin was served as the loading control.", [["b-actin", "GENE_OR_GENE_PRODUCT", 16, 23], ["b-actin", "PROTEIN", 16, 23], ["b-actin", "TREATMENT", 16, 23], ["the loading control", "TREATMENT", 38, 57]]], ["The influence of DDX5i on virus assembly or release.", [["DDX5i", "CHEMICAL", 17, 22], ["DDX5i", "GENE_OR_GENE_PRODUCT", 17, 22], ["DDX5i", "PROTEIN", 17, 22], ["DDX5i on virus assembly", "TREATMENT", 17, 40]]], ["(A, B) The BHK-21 cells was infected with JEV (MOI = 0.01) after DDX5 silence, the ratio of JEV RNA copy numbers between the supernatants and the cell lysates was detected by Q-PCR, and the ratio of the virus titers in supernatants and cell lysates were determined by plaque assay, the untargeted shRNA was used as the control.", [["BHK-21 cells", "ANATOMY", 11, 23], ["supernatants", "ANATOMY", 125, 137], ["cell lysates", "ANATOMY", 146, 158], ["supernatants", "ANATOMY", 219, 231], ["cell lysates", "ANATOMY", 236, 248], ["plaque", "ANATOMY", 268, 274], ["BHK-21 cells", "CELL", 11, 23], ["JEV", "ORGANISM", 42, 45], ["DDX5", "GENE_OR_GENE_PRODUCT", 65, 69], ["JEV", "ORGANISM", 92, 95], ["cell lysates", "ORGANISM_SUBSTANCE", 146, 158], ["cell lysates", "CELL", 236, 248], ["BHK-21 cells", "CELL_LINE", 11, 23], ["JEV RNA", "RNA", 92, 99], ["JEV", "SPECIES", 42, 45], ["JEV", "SPECIES", 92, 95], ["The BHK", "TEST", 7, 14], ["JEV", "PROBLEM", 42, 45], ["MOI", "TEST", 47, 50], ["JEV RNA copy numbers", "PROBLEM", 92, 112], ["the cell lysates", "TEST", 142, 158], ["Q-PCR", "TEST", 175, 180], ["the ratio", "TEST", 186, 195], ["the virus titers", "TEST", 199, 215], ["cell lysates", "TEST", 236, 248], ["plaque assay", "TEST", 268, 280], ["the untargeted shRNA", "TREATMENT", 282, 302], ["JEV RNA", "OBSERVATION", 92, 99], ["cell lysates", "OBSERVATION", 146, 158]]], ["The differences between means were considered significant at \u2044 p < 0.05, very significant \u2044\u2044 p < 0.01.Luciferase reporter assayFor the replicon luciferase reporter assay, BHK-21 cells were seeded in 24-well plates and transfected with DDX5 shRNA plasmid.", [["BHK-21 cells", "ANATOMY", 171, 183], ["luciferase", "GENE_OR_GENE_PRODUCT", 144, 154], ["BHK-21 cells", "CELL", 171, 183], ["DDX5", "GENE_OR_GENE_PRODUCT", 235, 239], ["BHK-21 cells", "CELL_LINE", 171, 183], ["DDX5 shRNA plasmid", "DNA", 235, 253], ["Luciferase reporter assay", "TEST", 102, 127], ["the replicon luciferase reporter assay", "TEST", 131, 169], ["BHK", "TEST", 171, 174], ["DDX5 shRNA plasmid", "TREATMENT", 235, 253]]], ["24 h later, the cells were transfected with 0.6 lg in vitro-transcribed JEV replicons RNA plus 0.2 lg of a firefly luciferase RNA in vitro transcribed from a luciferase T7 control (Promega) as an internal control using TransFast\u2122 (Promega).", [["cells", "ANATOMY", 16, 21], ["cells", "CELL", 16, 21], ["JEV", "ORGANISM", 72, 75], ["luciferase", "GENE_OR_GENE_PRODUCT", 115, 125], ["luciferase", "GENE_OR_GENE_PRODUCT", 158, 168], ["JEV replicons RNA", "RNA", 72, 89], ["firefly luciferase RNA", "RNA", 107, 129], ["luciferase T7 control", "DNA", 158, 179], ["JEV", "SPECIES", 72, 75], ["lg in vitro", "TREATMENT", 48, 59], ["a firefly luciferase RNA", "PROBLEM", 105, 129], ["a luciferase T7 control (Promega)", "TREATMENT", 156, 189], ["an internal control", "TREATMENT", 193, 212], ["TransFast\u2122 (Promega)", "TREATMENT", 219, 239], ["firefly luciferase", "OBSERVATION", 107, 125]]], ["At the indicated times post transfection, cell lysates were collected for the dualluciferase assay using Dual-Luciferase \u00d2 Reporter Assay System Kit and GloMax \u00d2 20/20 Luminometer instrumentation (Promega).Statistical analysisAll data were determined in triplicate and were representative of at least two separate experiments.", [["cell lysates", "ANATOMY", 42, 54], ["cell lysates", "CELL", 42, 54], ["cell lysates", "TEST", 42, 54], ["the dualluciferase assay", "TEST", 74, 98], ["Dual-Luciferase", "TREATMENT", 105, 120], ["GloMax", "TREATMENT", 153, 159], ["20/20 Luminometer instrumentation (Promega)", "TREATMENT", 162, 205], ["Statistical analysis", "TEST", 206, 226], ["All data", "TEST", 226, 234]]], ["The results represent the means \u00b1 standard deviations of triplicate determinations.", [["triplicate determinations", "TEST", 57, 82]]], ["All statistical analyses were performed by one-way ANOVA using a SPSS 16.0 software package (version 16.0, SPSS Inc., Chicago, IL, USA).Endogenous DDX5 plays important role in JEV replicationIt has been demonstrated that DDX5 is involved in the replication of several viruses (Chen et al., 2009; Goh et al., 2004) .", [["DDX5", "CHEMICAL", 147, 151], ["DDX5", "CHEMICAL", 221, 225], ["DDX5", "GENE_OR_GENE_PRODUCT", 147, 151], ["JEV", "ORGANISM", 176, 179], ["DDX5", "GENE_OR_GENE_PRODUCT", 221, 225], ["DDX5", "PROTEIN", 147, 151], ["DDX5", "PROTEIN", 221, 225], ["JEV", "SPECIES", 176, 179], ["All statistical analyses", "TEST", 0, 24], ["a SPSS", "TEST", 63, 69], ["version", "TEST", 93, 100], ["JEV replication", "OBSERVATION", 176, 191], ["several", "OBSERVATION_MODIFIER", 260, 267], ["viruses", "OBSERVATION", 268, 275]]], ["To determine whether DDX5 is required for JEV replication, we first used shRNA-mediated gene silence method (DDX5i) to decrease the expression of endogenous DDX5 in BHK-21 cells.", [["BHK-21 cells", "ANATOMY", 165, 177], ["DDX5", "GENE_OR_GENE_PRODUCT", 21, 25], ["JEV", "ORGANISM", 42, 45], ["DDX5", "GENE_OR_GENE_PRODUCT", 157, 161], ["BHK-21 cells", "CELL", 165, 177], ["DDX5", "PROTEIN", 21, 25], ["DDX5", "PROTEIN", 157, 161], ["BHK-21 cells", "CELL_LINE", 165, 177], ["JEV", "SPECIES", 42, 45], ["BHK-21", "SPECIES", 165, 171], ["DDX5", "TEST", 21, 25], ["JEV replication", "TREATMENT", 42, 57], ["shRNA-mediated gene silence method (DDX5i)", "TREATMENT", 73, 115], ["endogenous DDX5 in BHK", "PROBLEM", 146, 168]]], ["Western blot analysis using anti-DDX5 antibody demonstrated 90% decrease in protein expression level compared with the control untargeted The differences between means were considered significant at \u2044 p < 0.05, very significant \u2044\u2044 p < 0.01. shRNA (Fig. 1A) .", [["anti-DDX5 antibody", "GENE_OR_GENE_PRODUCT", 28, 46], ["anti-DDX5 antibody", "PROTEIN", 28, 46], ["blot analysis", "TEST", 8, 21], ["anti-DDX5 antibody", "TEST", 28, 46], ["90% decrease in protein expression level", "PROBLEM", 60, 100], ["protein expression", "OBSERVATION", 76, 94]]], ["24 h later, the cells previously transfected with DDX5i plasmid were infected with JEV (MOI = 0.01).", [["cells", "ANATOMY", 16, 21], ["cells", "CELL", 16, 21], ["DDX5i", "GENE_OR_GENE_PRODUCT", 50, 55], ["JEV", "ORGANISM", 83, 86], ["DDX5i plasmid", "DNA", 50, 63], ["JEV", "SPECIES", 83, 86], ["the cells", "PROBLEM", 12, 21], ["DDX5i plasmid", "TREATMENT", 50, 63], ["JEV (MOI", "TREATMENT", 83, 91]]], ["48 h later, the viral titers in the supernatants were detected.", [["supernatants", "ANATOMY", 36, 48], ["the viral titers", "TEST", 12, 28], ["viral titers", "OBSERVATION", 16, 28]]], ["The results showed that a reduction of endogenous DDX5 expression accounted for more than 13-fold decrease in virus titers (p < 0.01) compared with the control shRNA (Fig. 1B, C) .", [["DDX5", "GENE_OR_GENE_PRODUCT", 50, 54], ["DDX5", "PROTEIN", 50, 54], ["a reduction of endogenous DDX5 expression", "PROBLEM", 24, 65], ["13-fold decrease in virus titers", "PROBLEM", 90, 122]]], ["DDX5 knockdown also resulted in significant decrease of JEV genome RNA and viral proteins expression level as suggested by Q-PCR and Western blot analysis (Fig. 1D , E) compared with the control shRNA (p < 0.01).", [["DDX5", "CHEMICAL", 0, 4], ["DDX5", "GENE_OR_GENE_PRODUCT", 0, 4], ["JEV", "ORGANISM", 56, 59], ["DDX5", "PROTEIN", 0, 4], ["JEV genome RNA", "RNA", 56, 70], ["viral proteins", "PROTEIN", 75, 89], ["JEV", "SPECIES", 56, 59], ["significant decrease of JEV genome RNA", "PROBLEM", 32, 70], ["viral proteins expression level", "PROBLEM", 75, 106], ["Q-PCR", "TEST", 123, 128], ["Western blot analysis", "TEST", 133, 154], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["decrease", "OBSERVATION_MODIFIER", 44, 52], ["JEV genome RNA", "OBSERVATION", 56, 70]]], ["All the results showed that DDX5 is important for JEV replication.Endogenous DDX5 plays important role in JEV replicationWe next determined whether cellular DDX5 knockdown decreases JEV infection by affecting virus assembly or release.", [["cellular", "ANATOMY", 148, 156], ["DDX5", "CHEMICAL", 28, 32], ["DDX5", "CHEMICAL", 77, 81], ["DDX5", "CHEMICAL", 157, 161], ["JEV infection", "DISEASE", 182, 195], ["DDX5", "GENE_OR_GENE_PRODUCT", 28, 32], ["JEV", "ORGANISM", 50, 53], ["DDX5", "GENE_OR_GENE_PRODUCT", 77, 81], ["JEV", "ORGANISM", 106, 109], ["cellular", "CELL", 148, 156], ["DDX5", "GENE_OR_GENE_PRODUCT", 157, 161], ["JEV", "ORGANISM", 182, 185], ["DDX5", "PROTEIN", 28, 32], ["DDX5", "PROTEIN", 77, 81], ["DDX5", "PROTEIN", 157, 161], ["JEV", "SPECIES", 50, 53], ["JEV", "SPECIES", 106, 109], ["JEV", "SPECIES", 182, 185], ["JEV replication", "TREATMENT", 50, 65], ["JEV replicationWe", "TREATMENT", 106, 123], ["cellular DDX5 knockdown", "TREATMENT", 148, 171], ["JEV infection", "PROBLEM", 182, 195], ["JEV infection", "OBSERVATION", 182, 195]]], ["The BHK-21 cells were transfected with DDX5i plasmid before infected with JEV (MOI = 0.01).", [["BHK-21 cells", "ANATOMY", 4, 16], ["BHK-21 cells", "CELL", 4, 16], ["DDX5i", "GENE_OR_GENE_PRODUCT", 39, 44], ["JEV", "ORGANISM", 74, 77], ["BHK-21 cells", "CELL_LINE", 4, 16], ["DDX5i plasmid", "DNA", 39, 52], ["JEV", "SPECIES", 74, 77], ["The BHK", "TEST", 0, 7], ["DDX5i plasmid", "TREATMENT", 39, 52], ["JEV (MOI", "TREATMENT", 74, 82], ["21 cells", "OBSERVATION_MODIFIER", 8, 16]]], ["JEV RNA copy numbers of the cell lysates and the supernatants were detected by Q-PCR, although the RNA copy numbers in cell lysates were nearly 12-fold higher than that in the supernatants, the ratios between them were almost the same between the cells treated with DDX5i and the control cells (p > 0.05) ( Fig. 2A) , indicating that DDX5 knockdown did not affect the virus assembly.", [["cell lysates", "ANATOMY", 28, 40], ["supernatants", "ANATOMY", 49, 61], ["cell lysates", "ANATOMY", 119, 131], ["supernatants", "ANATOMY", 176, 188], ["cells", "ANATOMY", 247, 252], ["cells", "ANATOMY", 288, 293], ["DDX5", "CHEMICAL", 334, 338], ["JEV", "ORGANISM", 0, 3], ["cell lysates", "CELL", 28, 40], ["cell lysates", "CELL", 119, 131], ["cells", "CELL", 247, 252], ["cells", "CELL", 288, 293], ["DDX5", "GENE_OR_GENE_PRODUCT", 334, 338], ["DDX5i", "PROTEIN", 266, 271], ["DDX5", "PROTEIN", 334, 338], ["JEV", "SPECIES", 0, 3], ["the cell lysates", "TEST", 24, 40], ["the supernatants", "TEST", 45, 61], ["Q-PCR", "TEST", 79, 84], ["the RNA copy", "TEST", 95, 107], ["cell lysates", "TEST", 119, 131], ["the ratios", "TEST", 190, 200], ["DDX5i", "TREATMENT", 266, 271], ["DDX5 knockdown", "PROBLEM", 334, 348], ["the virus", "PROBLEM", 364, 373], ["cell lysates", "OBSERVATION", 28, 40], ["virus", "OBSERVATION", 368, 373]]], ["Meanwhile, the ratios of JEV infective titers between the supernatants and the cell lysates was also the same between DDX5i treated cells and the control cells (p > 0.05) (Fig. 2B) , indicating that DDX5 knockdown did not affect the virus release.", [["supernatants", "ANATOMY", 58, 70], ["cell lysates", "ANATOMY", 79, 91], ["cells", "ANATOMY", 132, 137], ["cells", "ANATOMY", 154, 159], ["DDX5", "CHEMICAL", 199, 203], ["DDX5i", "CHEMICAL", 118, 123], ["JEV", "ORGANISM", 25, 28], ["cell lysates", "ORGANISM_SUBSTANCE", 79, 91], ["cells", "CELL", 132, 137], ["cells", "CELL", 154, 159], ["DDX5", "GENE_OR_GENE_PRODUCT", 199, 203], ["DDX5i treated cells", "CELL_LINE", 118, 137], ["control cells", "CELL_TYPE", 146, 159], ["DDX5", "PROTEIN", 199, 203], ["JEV", "SPECIES", 25, 28], ["JEV infective titers", "PROBLEM", 25, 45], ["the supernatants", "TREATMENT", 54, 70], ["the cell lysates", "TEST", 75, 91], ["DDX5i treated cells", "TREATMENT", 118, 137], ["DDX5 knockdown", "PROBLEM", 199, 213], ["the virus release", "PROBLEM", 229, 246], ["JEV infective", "OBSERVATION", 25, 38], ["cell lysates", "OBSERVATION", 79, 91]]], ["Therefore, DDX5 silencing did not affect JEV assembly or release.DDX5 helicase activity is important for JEV replicationTo determine whether DDX5 helicase activity is important for JEV replication, DDX5 helicase-dead mutant lacking either ATPase activity (K144E) or RNA unwinding activity (S279L) Tanner and Linder, 2001 ) was used.", [["DDX5", "CHEMICAL", 11, 15], ["DDX5", "GENE_OR_GENE_PRODUCT", 11, 15], ["JEV", "ORGANISM", 41, 44], ["DDX5", "GENE_OR_GENE_PRODUCT", 65, 69], ["JEV", "ORGANISM", 105, 108], ["DDX5", "GENE_OR_GENE_PRODUCT", 141, 145], ["JEV", "ORGANISM", 181, 184], ["DDX5", "GENE_OR_GENE_PRODUCT", 198, 202], ["ATPase", "GENE_OR_GENE_PRODUCT", 239, 245], ["DDX5", "PROTEIN", 11, 15], ["DDX5", "PROTEIN", 65, 69], ["DDX5", "PROTEIN", 141, 145], ["DDX5 helicase", "PROTEIN", 198, 211], ["ATPase", "PROTEIN", 239, 245], ["K144E", "PROTEIN", 256, 261], ["JEV", "SPECIES", 41, 44], ["JEV", "SPECIES", 105, 108], ["JEV", "SPECIES", 181, 184], ["JEV replicationTo", "TREATMENT", 105, 122], ["JEV replication", "TREATMENT", 181, 196]]], ["BHK-21 cells were first transfected with DDX5i plasmid to decrease the endogenous DDX5 expression level.", [["BHK-21 cells", "ANATOMY", 0, 12], ["BHK-21 cells", "CELL", 0, 12], ["DDX5i", "GENE_OR_GENE_PRODUCT", 41, 46], ["DDX5", "GENE_OR_GENE_PRODUCT", 82, 86], ["BHK-21 cells", "CELL_LINE", 0, 12], ["DDX5i plasmid", "DNA", 41, 54], ["DDX5", "PROTEIN", 82, 86], ["BHK", "TEST", 0, 3], ["DDX5i plasmid", "TREATMENT", 41, 54], ["21 cells", "OBSERVATION_MODIFIER", 4, 12], ["endogenous DDX5 expression", "OBSERVATION", 71, 97]]], ["24 h later, the cells were then transfected with RNA interference-resistant plasmid (to exclude the influence of DDX5i plasmid): pCDNA3.1-DDX5r, pCDNA3.1-DDX5r-K144E or pCDNA3.1-DDX5r-S279L (Fig. 3A ) before the cells were infected (MOI = 0.01).", [["cells", "ANATOMY", 16, 21], ["plasmid", "ANATOMY", 76, 83], ["cells", "ANATOMY", 212, 217], ["cells", "CELL", 16, 21], ["DDX5i", "GENE_OR_GENE_PRODUCT", 113, 118], ["pCDNA3.1-DDX5r", "GENE_OR_GENE_PRODUCT", 129, 143], ["pCDNA3.1-DDX5r-K144E", "GENE_OR_GENE_PRODUCT", 145, 165], ["pCDNA3.1-DDX5r-S279L", "GENE_OR_GENE_PRODUCT", 169, 189], ["cells", "CELL", 212, 217], ["resistant plasmid", "DNA", 66, 83], ["DDX5i plasmid", "DNA", 113, 126], ["pCDNA3.1", "DNA", 129, 137], ["DDX5r", "DNA", 138, 143], ["pCDNA3.1", "DNA", 145, 153], ["DDX5r", "DNA", 154, 159], ["K144E", "DNA", 160, 165], ["pCDNA3.1", "DNA", 169, 177], ["DDX5r", "DNA", 178, 183], ["S279L", "DNA", 184, 189], ["RNA interference", "PROBLEM", 49, 65], ["resistant plasmid", "PROBLEM", 66, 83], ["DDX5i plasmid", "TREATMENT", 113, 126], ["DDX5r", "TEST", 138, 143], ["DDX5r", "TEST", 154, 159], ["K144E", "TEST", 160, 165], ["DDX5r", "TEST", 178, 183], ["the cells", "PROBLEM", 208, 217], ["MOI", "TEST", 233, 236]]], ["The virus titers were detected 2 days later by plaque assay, the results showed that overexpression of DDX5r-K144E, DDX5r-S279L and the control plasmid pcDNA3.1 after DDX5 knock down resulted in the reduction of JEV replication for 10-fold (p < 0.01), 12-fold (p < 0.01) and 13-fold (p < 0.01).", [["plaque", "ANATOMY", 47, 53], ["DDX5r-K144E", "GENE_OR_GENE_PRODUCT", 103, 114], ["DDX5r-S279L", "GENE_OR_GENE_PRODUCT", 116, 127], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 152, 160], ["DDX5", "GENE_OR_GENE_PRODUCT", 167, 171], ["JEV", "ORGANISM", 212, 215], ["DDX5r", "PROTEIN", 103, 108], ["K144E", "DNA", 109, 114], ["DDX5r", "PROTEIN", 116, 121], ["S279L", "DNA", 122, 127], ["control plasmid pcDNA3.1", "DNA", 136, 160], ["DDX5", "PROTEIN", 167, 171], ["JEV", "SPECIES", 212, 215], ["The virus titers", "TEST", 0, 16], ["plaque assay", "TEST", 47, 59], ["DDX5r", "TEST", 103, 108], ["DDX5r", "TEST", 116, 121], ["the control plasmid pcDNA3.1", "TREATMENT", 132, 160], ["JEV replication", "TREATMENT", 212, 227], ["JEV replication", "OBSERVATION", 212, 227]]], ["JEV replication was not significantly affected in DDX5r overexpressing cells and the control treated cells (Fig. 3B) .", [["cells", "ANATOMY", 71, 76], ["cells", "ANATOMY", 101, 106], ["JEV", "ORGANISM", 0, 3], ["cells", "CELL", 71, 76], ["cells", "CELL", 101, 106], ["DDX5r overexpressing cells", "CELL_LINE", 50, 76], ["control treated cells", "CELL_LINE", 85, 106], ["JEV", "SPECIES", 0, 3], ["JEV replication", "TREATMENT", 0, 15], ["overexpressing cells", "OBSERVATION", 56, 76]]], ["Meanwhile, the viral RNA level was also reduced in DDX5 mutants overexpression cells which is In vitro interaction analysis of DDX5 with JEV core, NS3, NS5-MTase and NS5-RdRp using GST-pull down experiment.", [["cells", "ANATOMY", 79, 84], ["DDX5", "GENE_OR_GENE_PRODUCT", 51, 55], ["cells", "CELL", 79, 84], ["DDX5", "GENE_OR_GENE_PRODUCT", 127, 131], ["JEV", "ORGANISM", 137, 140], ["NS3", "GENE_OR_GENE_PRODUCT", 147, 150], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 152, 161], ["NS5-RdRp", "GENE_OR_GENE_PRODUCT", 166, 174], ["GST", "GENE_OR_GENE_PRODUCT", 181, 184], ["DDX5 mutants overexpression cells", "CELL_LINE", 51, 84], ["DDX5", "PROTEIN", 127, 131], ["NS3", "PROTEIN", 147, 150], ["NS5", "PROTEIN", 152, 155], ["MTase", "PROTEIN", 156, 161], ["NS5", "PROTEIN", 166, 169], ["RdRp", "PROTEIN", 170, 174], ["GST", "PROTEIN", 181, 184], ["JEV", "SPECIES", 137, 140], ["the viral RNA level", "TEST", 11, 30], ["DDX5 mutants overexpression cells", "PROBLEM", 51, 84], ["JEV core", "TREATMENT", 137, 145], ["NS3", "TREATMENT", 147, 150], ["NS5-MTase", "TREATMENT", 152, 161], ["NS5-RdRp", "TREATMENT", 166, 174], ["GST", "TEST", 181, 184], ["viral RNA", "OBSERVATION", 15, 24], ["overexpression cells", "OBSERVATION", 64, 84]]], ["GST fused DDX5, was incubated with GST beads, then with His-tagged JEV core, NS3, NS5-MTase and NS5-RdRp, and then detected by Western blot analysis using anti-His and GST antibodies.", [["GST", "GENE_OR_GENE_PRODUCT", 0, 3], ["DDX5", "GENE_OR_GENE_PRODUCT", 10, 14], ["GST", "GENE_OR_GENE_PRODUCT", 35, 38], ["JEV", "ORGANISM", 67, 70], ["NS3", "GENE_OR_GENE_PRODUCT", 77, 80], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 82, 91], ["NS5-RdRp", "GENE_OR_GENE_PRODUCT", 96, 104], ["anti-His", "GENE_OR_GENE_PRODUCT", 155, 163], ["GST antibodies", "GENE_OR_GENE_PRODUCT", 168, 182], ["GST", "PROTEIN", 0, 3], ["DDX5", "PROTEIN", 10, 14], ["GST beads", "PROTEIN", 35, 44], ["His-tagged JEV core", "PROTEIN", 56, 75], ["NS3", "PROTEIN", 77, 80], ["NS5", "PROTEIN", 82, 85], ["MTase", "PROTEIN", 86, 91], ["NS5", "PROTEIN", 96, 99], ["RdRp", "PROTEIN", 100, 104], ["anti-His and GST antibodies", "PROTEIN", 155, 182], ["GST beads", "TREATMENT", 35, 44], ["NS3", "TEST", 77, 80], ["NS5", "TEST", 82, 85], ["NS5-RdRp", "TREATMENT", 96, 104], ["blot analysis", "TEST", 135, 148], ["anti", "TEST", 155, 159], ["His and GST antibodies", "TEST", 160, 182]]], ["The GST protein was used as the control.", [["GST", "GENE_OR_GENE_PRODUCT", 4, 7], ["GST protein", "PROTEIN", 4, 15], ["The GST protein", "TREATMENT", 0, 15]]], ["JEV core, NS3, NS5-MTase and NS5-RdRp interact with DDX5.", [["JEV", "ORGANISM", 0, 3], ["NS3", "GENE_OR_GENE_PRODUCT", 10, 13], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 15, 24], ["NS5-RdRp", "GENE_OR_GENE_PRODUCT", 29, 37], ["DDX5", "GENE_OR_GENE_PRODUCT", 52, 56], ["JEV core", "DNA", 0, 8], ["NS3", "PROTEIN", 10, 13], ["NS5", "PROTEIN", 15, 18], ["MTase", "PROTEIN", 19, 24], ["NS5", "PROTEIN", 29, 32], ["RdRp", "PROTEIN", 33, 37], ["DDX5", "PROTEIN", 52, 56], ["JEV", "SPECIES", 0, 3], ["JEV core", "TREATMENT", 0, 8], ["NS3", "TREATMENT", 10, 13], ["NS5", "TREATMENT", 15, 18], ["NS5", "TREATMENT", 29, 32]]], ["In vitro interaction analysis of JEV core, NS3, NS5-MTase and NS5-RdRp with DDX5 using GST-pull down experiment.", [["JEV", "ORGANISM", 33, 36], ["NS3", "GENE_OR_GENE_PRODUCT", 43, 46], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 48, 57], ["NS5-RdRp", "GENE_OR_GENE_PRODUCT", 62, 70], ["DDX5", "GENE_OR_GENE_PRODUCT", 76, 80], ["GST", "GENE_OR_GENE_PRODUCT", 87, 90], ["JEV core", "PROTEIN", 33, 41], ["NS3", "PROTEIN", 43, 46], ["NS5", "PROTEIN", 48, 51], ["MTase", "PROTEIN", 52, 57], ["NS5", "PROTEIN", 62, 65], ["RdRp", "PROTEIN", 66, 70], ["DDX5", "PROTEIN", 76, 80], ["GST", "PROTEIN", 87, 90], ["JEV", "SPECIES", 33, 36], ["JEV core", "TREATMENT", 33, 41], ["NS3", "TREATMENT", 43, 46], ["NS5-MTase", "TREATMENT", 48, 57], ["NS5", "TREATMENT", 62, 65], ["RdRp", "TREATMENT", 66, 70], ["DDX5", "TREATMENT", 76, 80], ["GST", "TEST", 87, 90]]], ["GST fused core, NS3, NS5-MTase and NS5-RdRp were incubated with GST beads, then with His-tagged DDX5, and then detected by western blot analysis using anti-His and GST antibodies.", [["His", "CHEMICAL", 85, 88], ["GST", "GENE_OR_GENE_PRODUCT", 0, 3], ["NS3", "GENE_OR_GENE_PRODUCT", 16, 19], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 21, 30], ["NS5-RdRp", "GENE_OR_GENE_PRODUCT", 35, 43], ["GST", "GENE_OR_GENE_PRODUCT", 64, 67], ["DDX5", "GENE_OR_GENE_PRODUCT", 96, 100], ["anti-His", "GENE_OR_GENE_PRODUCT", 151, 159], ["GST antibodies", "GENE_OR_GENE_PRODUCT", 164, 178], ["GST", "PROTEIN", 0, 3], ["NS3", "PROTEIN", 16, 19], ["NS5", "PROTEIN", 21, 24], ["MTase", "PROTEIN", 25, 30], ["NS5", "PROTEIN", 35, 38], ["RdRp", "PROTEIN", 39, 43], ["GST beads", "PROTEIN", 64, 73], ["His", "PROTEIN", 85, 88], ["DDX5", "PROTEIN", 96, 100], ["anti-His and GST antibodies", "PROTEIN", 151, 178], ["NS3", "TREATMENT", 16, 19], ["NS5-MTase", "TREATMENT", 21, 30], ["NS5-RdRp", "TREATMENT", 35, 43], ["GST beads", "TREATMENT", 64, 73], ["blot analysis", "TEST", 131, 144], ["anti", "TEST", 151, 155], ["His and GST antibodies", "TEST", 156, 178]]], ["The GST protein was used as the control.", [["GST", "GENE_OR_GENE_PRODUCT", 4, 7], ["GST protein", "PROTEIN", 4, 15], ["The GST protein", "TREATMENT", 0, 15]]], ["DDX5 interacts with JEV core, NS3, NS5-MTase and NS5-RdRp in BHK-21 cells.", [["BHK-21 cells", "ANATOMY", 61, 73], ["DDX5", "CHEMICAL", 0, 4], ["DDX5", "GENE_OR_GENE_PRODUCT", 0, 4], ["JEV", "ORGANISM", 20, 23], ["NS3", "GENE_OR_GENE_PRODUCT", 30, 33], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 35, 44], ["NS5", "GENE_OR_GENE_PRODUCT", 49, 52], ["BHK-21 cells", "CELL", 61, 73], ["DDX5", "PROTEIN", 0, 4], ["NS3", "PROTEIN", 30, 33], ["NS5", "PROTEIN", 35, 38], ["MTase", "PROTEIN", 39, 44], ["NS5", "PROTEIN", 49, 52], ["RdRp", "PROTEIN", 53, 57], ["BHK-21 cells", "CELL_LINE", 61, 73], ["JEV", "SPECIES", 20, 23], ["JEV core", "TREATMENT", 20, 28], ["NS3", "TREATMENT", 30, 33], ["NS5-MTase", "TREATMENT", 35, 44], ["NS5", "TEST", 49, 52], ["RdRp in BHK", "TREATMENT", 53, 64], ["21 cells", "OBSERVATION", 65, 73]]], ["BHK-21 cells were transfected with the different viral protein constructs tagged with MYC epitope.", [["BHK-21 cells", "ANATOMY", 0, 12], ["BHK-21 cells", "CELL", 0, 12], ["MYC", "GENE_OR_GENE_PRODUCT", 86, 89], ["BHK-21 cells", "CELL_LINE", 0, 12], ["viral protein constructs", "DNA", 49, 73], ["MYC epitope", "PROTEIN", 86, 97], ["BHK", "TEST", 0, 3], ["the different viral protein constructs", "TREATMENT", 35, 73], ["MYC epitope", "TREATMENT", 86, 97], ["21 cells", "OBSERVATION_MODIFIER", 4, 12], ["MYC epitope", "OBSERVATION", 86, 97]]], ["MYC-tagged viral protein was used to immunoprecipitate the endogenous DDX5 protein from the cell lysates.", [["cell lysates", "ANATOMY", 92, 104], ["MYC", "GENE_OR_GENE_PRODUCT", 0, 3], ["DDX5", "GENE_OR_GENE_PRODUCT", 70, 74], ["cell lysates", "ORGANISM_SUBSTANCE", 92, 104], ["MYC", "PROTEIN", 0, 3], ["tagged viral protein", "PROTEIN", 4, 24], ["endogenous DDX5 protein", "PROTEIN", 59, 82], ["MYC", "TEST", 0, 3], ["tagged viral protein", "PROBLEM", 4, 24], ["the endogenous DDX5 protein", "PROBLEM", 55, 82], ["the cell lysates", "TEST", 88, 104], ["cell lysates", "OBSERVATION", 92, 104]]], ["The immunoprecipitated proteins were detected with anti-DDX5 polyclonal antibody and anti-MYC-HRP monoclonal antibody.", [["anti-DDX5", "GENE_OR_GENE_PRODUCT", 51, 60], ["anti-MYC-HRP", "GENE_OR_GENE_PRODUCT", 85, 97], ["immunoprecipitated proteins", "PROTEIN", 4, 31], ["anti-DDX5 polyclonal antibody", "PROTEIN", 51, 80], ["anti-MYC", "PROTEIN", 85, 93], ["HRP monoclonal antibody", "PROTEIN", 94, 117], ["The immunoprecipitated proteins", "TEST", 0, 31], ["anti-DDX5 polyclonal antibody", "TEST", 51, 80], ["anti-MYC", "TEST", 85, 93], ["HRP monoclonal antibody", "TEST", 94, 117], ["monoclonal antibody", "OBSERVATION", 98, 117]]], ["The interaction of DDX5 with JEV core, NS3, NS5-MTase and NS5-RdRp in BHK-21 cells is not mediated by RNA or DNA.", [["BHK-21 cells", "ANATOMY", 70, 82], ["DDX5", "GENE_OR_GENE_PRODUCT", 19, 23], ["JEV", "ORGANISM", 29, 32], ["NS3", "GENE_OR_GENE_PRODUCT", 39, 42], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 44, 53], ["NS5", "GENE_OR_GENE_PRODUCT", 58, 61], ["BHK-21 cells", "CELL", 70, 82], ["DNA", "CELLULAR_COMPONENT", 109, 112], ["DDX5", "PROTEIN", 19, 23], ["NS3", "PROTEIN", 39, 42], ["NS5", "PROTEIN", 44, 47], ["MTase", "PROTEIN", 48, 53], ["NS5", "PROTEIN", 58, 61], ["RdRp", "PROTEIN", 62, 66], ["BHK-21 cells", "CELL_LINE", 70, 82], ["JEV", "SPECIES", 29, 32], ["DDX5", "TEST", 19, 23], ["JEV core", "TREATMENT", 29, 37], ["NS3", "TREATMENT", 39, 42], ["NS5-MTase", "TREATMENT", 44, 53], ["NS5", "TREATMENT", 58, 61], ["RdRp in BHK", "TREATMENT", 62, 73], ["DNA", "PROBLEM", 109, 112]]], ["BHK-21 cells were transfected with different MYC-tagged viral protein plasmid, MYC-tagged viral protein was used to immunoprecipitate the endogenous DDX5 protein from the cell lysates treated with RNase (100 lg/ml) and DNase (100 lg/ml).", [["BHK-21 cells", "ANATOMY", 0, 12], ["cell lysates", "ANATOMY", 171, 183], ["BHK-21 cells", "CELL", 0, 12], ["MYC", "GENE_OR_GENE_PRODUCT", 45, 48], ["MYC", "GENE_OR_GENE_PRODUCT", 79, 82], ["DDX5", "GENE_OR_GENE_PRODUCT", 149, 153], ["cell lysates", "ORGANISM_SUBSTANCE", 171, 183], ["RNase", "GENE_OR_GENE_PRODUCT", 197, 202], ["DNase", "GENE_OR_GENE_PRODUCT", 219, 224], ["BHK-21 cells", "CELL_LINE", 0, 12], ["MYC-tagged viral protein plasmid", "DNA", 45, 77], ["MYC", "PROTEIN", 79, 82], ["tagged viral protein", "PROTEIN", 83, 103], ["endogenous DDX5 protein", "PROTEIN", 138, 161], ["RNase", "PROTEIN", 197, 202], ["DNase", "PROTEIN", 219, 224], ["BHK", "TEST", 0, 3], ["different MYC", "TEST", 35, 48], ["tagged viral protein plasmid", "TREATMENT", 49, 77], ["MYC", "TEST", 79, 82], ["tagged viral protein", "PROBLEM", 83, 103], ["the cell lysates", "TREATMENT", 167, 183], ["RNase", "TREATMENT", 197, 202], ["DNase", "TREATMENT", 219, 224], ["21 cells", "OBSERVATION_MODIFIER", 4, 12]]], ["The cell lysates (input, 2%) were analyzed in parallel by Western blot.", [["cell lysates", "ANATOMY", 4, 16], ["cell lysates", "CELL", 4, 16], ["The cell lysates", "TEST", 0, 16], ["cell lysates", "OBSERVATION", 4, 16]]], ["Asterisks represent the nonspecific recognition. consistent with the results of plaque assay (Fig. 3C ) (p < 0.01).", [["plaque", "ANATOMY", 80, 86], ["the nonspecific recognition", "PROBLEM", 20, 47], ["plaque assay", "TEST", 80, 92], ["nonspecific", "OBSERVATION_MODIFIER", 24, 35], ["plaque", "OBSERVATION", 80, 86]]], ["The expression of endogenous DDX5 or DDX5 mutants were confirmed by Western blot analysis using anti-HA monoclonal antibody and anti-DDX5 polyclonal antibody (Fig. 3D) .", [["DDX5", "GENE_OR_GENE_PRODUCT", 29, 33], ["DDX5", "GENE_OR_GENE_PRODUCT", 37, 41], ["DDX5", "PROTEIN", 29, 33], ["DDX5 mutants", "PROTEIN", 37, 49], ["anti-HA monoclonal antibody", "PROTEIN", 96, 123], ["anti-DDX5 polyclonal antibody", "PROTEIN", 128, 157], ["endogenous DDX5", "PROBLEM", 18, 33], ["DDX5 mutants", "PROBLEM", 37, 49], ["blot analysis", "TEST", 76, 89], ["anti-HA monoclonal antibody", "TEST", 96, 123], ["anti-DDX5 polyclonal antibody", "TEST", 128, 157]]], ["Both of the results demonstrated that DDX5 helicase activity plays important roles in JEV replication.DDX5 helicase activity is important for JEV replicationThe cell viability of all DDX5 constructs on BHK-21 cells was determined by measuring the cytotoxicity using CytoTox 96 \u00d2 Non-Radioactive Cytotoxicity Assay Kit.", [["cell", "ANATOMY", 161, 165], ["BHK-21 cells", "ANATOMY", 202, 214], ["DDX5", "GENE_OR_GENE_PRODUCT", 38, 42], ["JEV", "ORGANISM", 86, 89], ["DDX5", "GENE_OR_GENE_PRODUCT", 102, 106], ["JEV", "ORGANISM", 142, 145], ["cell", "CELL", 161, 165], ["BHK-21 cells", "CELL", 202, 214], ["DDX5", "PROTEIN", 38, 42], ["DDX5", "PROTEIN", 102, 106], ["DDX5 constructs", "DNA", 183, 198], ["BHK-21 cells", "CELL_LINE", 202, 214], ["JEV", "SPECIES", 86, 89], ["JEV", "SPECIES", 142, 145], ["BHK-21", "SPECIES", 202, 208], ["DDX5 helicase activity", "TREATMENT", 38, 60], ["JEV replication", "TREATMENT", 86, 101], ["JEV replication", "TREATMENT", 142, 157], ["The cell viability", "TEST", 157, 175], ["BHK", "TEST", 202, 205], ["the cytotoxicity", "TEST", 243, 259], ["CytoTox", "TEST", 266, 273], ["Non-Radioactive Cytotoxicity Assay Kit", "TEST", 279, 317], ["JEV replication", "OBSERVATION", 86, 101], ["cell viability", "OBSERVATION", 161, 175]]], ["Our result demonstrated that the viability of BHK-21 cells was not significantly affected (Fig. 3E) .The interactions between DDX5 and viral proteins and the interaction interface mapping with competition binding experimentWe next determined whether DDX5 is involved in JEV replication by interacting with JEV proteins related to viral RNA replication.", [["BHK-21 cells", "ANATOMY", 46, 58], ["BHK-21 cells", "CELL", 46, 58], ["DDX5", "GENE_OR_GENE_PRODUCT", 126, 130], ["DDX5", "GENE_OR_GENE_PRODUCT", 250, 254], ["JEV", "ORGANISM", 270, 273], ["JEV", "ORGANISM", 306, 309], ["BHK-21 cells", "CELL_LINE", 46, 58], ["DDX5", "PROTEIN", 126, 130], ["viral proteins", "PROTEIN", 135, 149], ["DDX5", "PROTEIN", 250, 254], ["JEV proteins", "PROTEIN", 306, 318], ["JEV", "SPECIES", 270, 273], ["JEV", "SPECIES", 306, 309], ["the viability of BHK-21 cells", "TEST", 29, 58], ["DDX5", "TEST", 126, 130], ["viral proteins", "PROBLEM", 135, 149], ["JEV proteins", "TREATMENT", 306, 318], ["viral RNA replication", "TREATMENT", 330, 351]]], ["It has been shown that JEV core, NS3 and NS5 are involved in the JEV replication (Chen et al., 1997; Uchil and Satchidanandam, 2003a) .", [["JEV", "ORGANISM", 23, 26], ["NS3", "GENE_OR_GENE_PRODUCT", 33, 36], ["NS5", "GENE_OR_GENE_PRODUCT", 41, 44], ["JEV", "ORGANISM", 65, 68], ["NS3", "PROTEIN", 33, 36], ["NS5", "PROTEIN", 41, 44], ["JEV", "SPECIES", 23, 26], ["JEV", "SPECIES", 65, 68], ["NS3", "TREATMENT", 33, 36], ["NS5", "TREATMENT", 41, 44], ["JEV", "OBSERVATION", 23, 26], ["JEV replication", "OBSERVATION", 65, 80]]], ["In flavivirus, NS5 can be separated into two domains: methyltransferase (MTase) domain and RNA-dependent RNA polymerase (RdRp) domain (Ackermann and Padmanabhan, 2001; Egloff et al., 2002; Guyatt et al., 2001; Koonin, 1993) .", [["NS5", "GENE_OR_GENE_PRODUCT", 15, 18], ["MTase", "GENE_OR_GENE_PRODUCT", 73, 78], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 91, 119], ["NS5", "PROTEIN", 15, 18], ["methyltransferase (MTase) domain", "PROTEIN", 54, 86], ["RNA-dependent RNA polymerase (RdRp) domain", "PROTEIN", 91, 133], ["flavivirus", "PROBLEM", 3, 13], ["NS5", "TREATMENT", 15, 18], ["methyltransferase (MTase) domain", "TREATMENT", 54, 86], ["RNA-dependent RNA polymerase (RdRp) domain (Ackermann and Padmanabhan", "TREATMENT", 91, 160], ["flavivirus", "OBSERVATION", 3, 13]]], ["During JEV infection, the NS5 protein is not cleaved into MTase and RdRp (Yu et al., 2007) .", [["JEV infection", "DISEASE", 7, 20], ["JEV", "ORGANISM", 7, 10], ["NS5", "GENE_OR_GENE_PRODUCT", 26, 29], ["MTase", "GENE_OR_GENE_PRODUCT", 58, 63], ["NS5 protein", "PROTEIN", 26, 37], ["MTase", "PROTEIN", 58, 63], ["RdRp", "PROTEIN", 68, 72], ["JEV", "SPECIES", 7, 10], ["JEV infection", "PROBLEM", 7, 20], ["the NS5 protein", "TEST", 22, 37], ["JEV", "OBSERVATION_MODIFIER", 7, 10], ["infection", "OBSERVATION", 11, 20]]], ["In our study, we divided NS5 into two domains (MTase and RdRp domains) to detect their interactions with DDX5 in details.", [["MTase", "GENE_OR_GENE_PRODUCT", 47, 52], ["DDX5", "GENE_OR_GENE_PRODUCT", 105, 109], ["NS5", "PROTEIN", 25, 28], ["MTase", "PROTEIN", 47, 52], ["RdRp domains", "PROTEIN", 57, 69], ["DDX5", "PROTEIN", 105, 109], ["our study", "TEST", 3, 12], ["NS5", "TREATMENT", 25, 28], ["MTase and RdRp domains", "TREATMENT", 47, 69]]], ["We used GST-pulldown assay to monitor the interactions between JEV core, NS3, NS5-MTase or NS5-RdRp and DDX5 or vice versa.", [["GST", "GENE_OR_GENE_PRODUCT", 8, 11], ["JEV", "ORGANISM", 63, 66], ["NS3", "GENE_OR_GENE_PRODUCT", 73, 76], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 78, 87], ["NS5-RdRp", "GENE_OR_GENE_PRODUCT", 91, 99], ["DDX5", "GENE_OR_GENE_PRODUCT", 104, 108], ["GST", "PROTEIN", 8, 11], ["NS3", "PROTEIN", 73, 76], ["NS5", "PROTEIN", 78, 81], ["MTase", "PROTEIN", 82, 87], ["NS5", "PROTEIN", 91, 94], ["RdRp", "PROTEIN", 95, 99], ["DDX5", "PROTEIN", 104, 108], ["JEV", "SPECIES", 63, 66], ["GST", "TEST", 8, 11], ["pulldown assay", "TEST", 12, 26], ["JEV core", "TREATMENT", 63, 71], ["NS3", "TREATMENT", 73, 76], ["NS5", "TREATMENT", 78, 81], ["NS5", "TREATMENT", 91, 94], ["RdRp", "TREATMENT", 95, 99], ["DDX5", "TREATMENT", 104, 108]]], ["The results showed GST-DDX5 can interact with His-tagged JEV core, NS3, NS5-Mtase and NS5-RdRp, while GST protein can not (Fig. 4A) .", [["GST", "GENE_OR_GENE_PRODUCT", 19, 22], ["DDX5", "GENE_OR_GENE_PRODUCT", 23, 27], ["His-", "GENE_OR_GENE_PRODUCT", 46, 50], ["JEV", "ORGANISM", 57, 60], ["NS3", "GENE_OR_GENE_PRODUCT", 67, 70], ["NS5-Mtase", "GENE_OR_GENE_PRODUCT", 72, 81], ["NS5-RdRp", "GENE_OR_GENE_PRODUCT", 86, 94], ["GST", "GENE_OR_GENE_PRODUCT", 102, 105], ["GST", "PROTEIN", 19, 22], ["DDX5", "PROTEIN", 23, 27], ["His-tagged JEV core", "PROTEIN", 46, 65], ["NS3", "PROTEIN", 67, 70], ["NS5", "PROTEIN", 72, 75], ["Mtase", "PROTEIN", 76, 81], ["NS5", "PROTEIN", 86, 89], ["RdRp", "PROTEIN", 90, 94], ["GST protein", "PROTEIN", 102, 113], ["GST", "TEST", 19, 22], ["NS3", "TEST", 67, 70], ["NS5", "TEST", 72, 75], ["NS5-RdRp", "TREATMENT", 86, 94], ["GST protein", "TEST", 102, 113]]], ["GST-core, GST-NS3, GST-NS5-MTase and GST-NS5-RdRp can interact with His-tagged DDX5 (Fig. 4B) .The interactions between DDX5 and viral proteins and the interaction interface mapping with competition binding experimentWe next performed co-immunoprecipitation assay to confirm these interactions.", [["GST", "GENE_OR_GENE_PRODUCT", 0, 3], ["GST", "GENE_OR_GENE_PRODUCT", 10, 13], ["GST", "GENE_OR_GENE_PRODUCT", 19, 22], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 23, 32], ["GST", "GENE_OR_GENE_PRODUCT", 37, 40], ["NS5", "GENE_OR_GENE_PRODUCT", 41, 44], ["DDX5", "GENE_OR_GENE_PRODUCT", 79, 83], ["DDX5", "GENE_OR_GENE_PRODUCT", 120, 124], ["GST", "PROTEIN", 0, 3], ["GST", "PROTEIN", 10, 13], ["NS3", "PROTEIN", 14, 17], ["GST", "PROTEIN", 19, 22], ["NS5", "PROTEIN", 23, 26], ["MTase", "PROTEIN", 27, 32], ["GST", "PROTEIN", 37, 40], ["NS5", "PROTEIN", 41, 44], ["RdRp", "PROTEIN", 45, 49], ["His-tagged DDX5", "PROTEIN", 68, 83], ["Fig. 4B", "PROTEIN", 85, 92], ["DDX5", "PROTEIN", 120, 124], ["viral proteins", "PROTEIN", 129, 143], ["GST", "TEST", 0, 3], ["core", "TEST", 4, 8], ["GST", "TEST", 10, 13], ["NS3", "TEST", 14, 17], ["GST", "TEST", 19, 22], ["NS5", "TEST", 23, 26], ["MTase", "TEST", 27, 32], ["GST", "TEST", 37, 40], ["NS5-RdRp", "TREATMENT", 41, 49], ["DDX5", "TEST", 120, 124], ["viral proteins", "PROBLEM", 129, 143], ["co-immunoprecipitation assay", "TEST", 235, 263]]], ["The cells were transfected with either JEV core, NS3, NS5-MTase, or NS5-RdRp plasmids tagged with MYC epitope.The interactions between DDX5 and viral proteins and the interaction interface mapping with competition binding experimentThe MYC-tagged proteins were immunoprecipitated with anti-MYC monoclonal antibody conjugated beads and the coimmunoprecipitated endogenous DDX5 were detected in Western blot analysis using anti-DDX5 polyclonal antibody.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["JEV", "ORGANISM", 39, 42], ["NS3", "GENE_OR_GENE_PRODUCT", 49, 52], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 54, 63], ["NS5", "GENE_OR_GENE_PRODUCT", 68, 71], ["MYC", "GENE_OR_GENE_PRODUCT", 98, 101], ["DDX5", "GENE_OR_GENE_PRODUCT", 135, 139], ["MYC", "GENE_OR_GENE_PRODUCT", 236, 239], ["anti-MYC", "GENE_OR_GENE_PRODUCT", 285, 293], ["DDX5", "GENE_OR_GENE_PRODUCT", 371, 375], ["anti-DDX5", "GENE_OR_GENE_PRODUCT", 421, 430], ["JEV core, NS3, NS5-MTase, or NS5-RdRp plasmids", "DNA", 39, 85], ["MYC epitope", "PROTEIN", 98, 109], ["DDX5", "PROTEIN", 135, 139], ["viral proteins", "PROTEIN", 144, 158], ["MYC", "PROTEIN", 236, 239], ["anti-MYC monoclonal antibody", "PROTEIN", 285, 313], ["coimmunoprecipitated endogenous DDX5", "PROTEIN", 339, 375], ["anti-DDX5 polyclonal antibody", "PROTEIN", 421, 450], ["JEV", "SPECIES", 39, 42], ["JEV core", "TREATMENT", 39, 47], ["NS3", "TREATMENT", 49, 52], ["NS5-MTase", "TREATMENT", 54, 63], ["NS5-RdRp plasmids", "TREATMENT", 68, 85], ["MYC epitope", "PROBLEM", 98, 109], ["DDX5", "TEST", 135, 139], ["viral proteins", "PROBLEM", 144, 158], ["the interaction interface mapping", "TREATMENT", 163, 196], ["The MYC-tagged proteins", "TEST", 232, 255], ["anti-MYC monoclonal antibody conjugated beads", "TREATMENT", 285, 330], ["the coimmunoprecipitated endogenous DDX5", "PROBLEM", 335, 375], ["blot analysis", "TEST", 401, 414], ["anti-DDX5 polyclonal antibody", "TEST", 421, 450], ["RdRp plasmids", "OBSERVATION", 72, 85], ["MYC epitope", "OBSERVATION", 98, 109], ["endogenous DDX5", "OBSERVATION", 360, 375]]], ["The results showed JEV core, NS3, NS5-MTase, or NS5-RdRp could interact with endogenous DDX5 (Fig. 4C) .", [["JEV", "ORGANISM", 19, 22], ["NS3", "GENE_OR_GENE_PRODUCT", 29, 32], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 34, 43], ["NS5", "GENE_OR_GENE_PRODUCT", 48, 51], ["DDX5", "GENE_OR_GENE_PRODUCT", 88, 92], ["NS3", "PROTEIN", 29, 32], ["NS5", "PROTEIN", 34, 37], ["MTase", "PROTEIN", 38, 43], ["NS5", "PROTEIN", 48, 51], ["RdRp", "PROTEIN", 52, 56], ["endogenous DDX5", "PROTEIN", 77, 92], ["Fig. 4C", "PROTEIN", 94, 101], ["JEV", "SPECIES", 19, 22], ["JEV core", "TEST", 19, 27], ["NS3", "TEST", 29, 32], ["NS5", "TEST", 34, 37], ["NS5", "PROBLEM", 48, 51], ["RdRp", "PROBLEM", 52, 56]]], ["Since DDX5 is a nucleic acid-binding protein, it is possible that these interactions were mediated by RNA or DNA.", [["DDX5", "CHEMICAL", 6, 10], ["nucleic acid", "CHEMICAL", 16, 28], ["DDX5", "GENE_OR_GENE_PRODUCT", 6, 10], ["DNA", "CELLULAR_COMPONENT", 109, 112], ["DDX5", "PROTEIN", 6, 10], ["nucleic acid-binding protein", "PROTEIN", 16, 44], ["a nucleic acid-binding protein", "PROBLEM", 14, 44]]], ["To address this issue, we next examined the influence of RNA or DNA on the interaction between JEV core, NS3, NS5-MTase, NS5-RdRp and DDX5.", [["DNA", "CELLULAR_COMPONENT", 64, 67], ["JEV", "ORGANISM", 95, 98], ["NS3", "GENE_OR_GENE_PRODUCT", 105, 108], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 110, 119], ["NS5-RdRp", "GENE_OR_GENE_PRODUCT", 121, 129], ["DDX5", "GENE_OR_GENE_PRODUCT", 134, 138], ["NS3", "PROTEIN", 105, 108], ["NS5", "PROTEIN", 110, 113], ["MTase", "PROTEIN", 114, 119], ["NS5", "PROTEIN", 121, 124], ["RdRp", "PROTEIN", 125, 129], ["DDX5", "PROTEIN", 134, 138], ["RNA or DNA", "PROBLEM", 57, 67], ["JEV core", "TREATMENT", 95, 103], ["NS3", "TREATMENT", 105, 108], ["NS5-MTase", "TREATMENT", 110, 119], ["NS5", "TREATMENT", 121, 124], ["RdRp", "TREATMENT", 125, 129], ["DDX5", "TREATMENT", 134, 138]]], ["The co-immunoprecipitation was performed following RNase and DNase treatment.", [["RNase", "GENE_OR_GENE_PRODUCT", 51, 56], ["DNase", "GENE_OR_GENE_PRODUCT", 61, 66], ["RNase", "PROTEIN", 51, 56], ["DNase", "PROTEIN", 61, 66], ["The co-immunoprecipitation", "TREATMENT", 0, 26], ["RNase", "TREATMENT", 51, 56], ["DNase treatment", "TREATMENT", 61, 76]]], ["The results showed JEV core, NS3, NS5-MTase, NS5-RdRp and DDX5 interaction was also detected after RNase (100 lg/ml) and DNase (100 lg/ml) treatment, suggesting that the interaction between JEV proteins and DDX5 were not mediated by RNA or DNA (Fig. 4D) .The interactions between DDX5 and viral proteins and the interaction interface mapping with competition binding experimentBecause DDX5 can interact with JEV core, NS3, NS5-MTase, or NS5-RdRp proteins, we next tried to determine the interaction interface between JEV core, NS3, and NS5 (MTase and RdRp domains) proteins and DDX5 using competition binding experiment.", [["DDX5", "CHEMICAL", 385, 389], ["JEV", "ORGANISM", 19, 22], ["NS3", "GENE_OR_GENE_PRODUCT", 29, 32], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 34, 43], ["NS5", "GENE_OR_GENE_PRODUCT", 45, 48], ["DDX5", "GENE_OR_GENE_PRODUCT", 58, 62], ["RNase", "GENE_OR_GENE_PRODUCT", 99, 104], ["DNase", "GENE_OR_GENE_PRODUCT", 121, 126], ["JEV", "ORGANISM", 190, 193], ["DDX5", "GENE_OR_GENE_PRODUCT", 207, 211], ["DNA", "CELLULAR_COMPONENT", 240, 243], ["DDX5", "GENE_OR_GENE_PRODUCT", 280, 284], ["DDX5", "GENE_OR_GENE_PRODUCT", 385, 389], ["JEV", "ORGANISM", 408, 411], ["NS3", "GENE_OR_GENE_PRODUCT", 418, 421], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 423, 432], ["NS5", "GENE_OR_GENE_PRODUCT", 437, 440], ["JEV", "ORGANISM", 517, 520], ["NS3", "GENE_OR_GENE_PRODUCT", 527, 530], ["NS5", "GENE_OR_GENE_PRODUCT", 536, 539], ["MTase", "GENE_OR_GENE_PRODUCT", 541, 546], ["DDX5", "GENE_OR_GENE_PRODUCT", 578, 582], ["NS3", "PROTEIN", 29, 32], ["NS5", "PROTEIN", 34, 37], ["MTase", "PROTEIN", 38, 43], ["NS5", "PROTEIN", 45, 48], ["RdRp", "PROTEIN", 49, 53], ["DDX5", "PROTEIN", 58, 62], ["RNase", "PROTEIN", 99, 104], ["DNase", "PROTEIN", 121, 126], ["JEV proteins", "PROTEIN", 190, 202], ["DDX5", "PROTEIN", 207, 211], ["DDX5", "PROTEIN", 280, 284], ["viral proteins", "PROTEIN", 289, 303], ["DDX5", "PROTEIN", 385, 389], ["NS3", "PROTEIN", 418, 421], ["NS5", "PROTEIN", 423, 426], ["MTase", "PROTEIN", 427, 432], ["NS5", "PROTEIN", 437, 440], ["RdRp proteins", "PROTEIN", 441, 454], ["JEV core, NS3, and NS5 (MTase and RdRp domains", "PROTEIN", 517, 563], ["DDX5", "PROTEIN", 578, 582], ["JEV", "SPECIES", 19, 22], ["JEV", "SPECIES", 190, 193], ["JEV", "SPECIES", 408, 411], ["JEV", "SPECIES", 517, 520], ["JEV core", "TEST", 19, 27], ["NS3", "TEST", 29, 32], ["NS5", "TEST", 34, 37], ["NS5", "TEST", 45, 48], ["RdRp", "PROBLEM", 49, 53], ["DDX5 interaction", "PROBLEM", 58, 74], ["RNase", "TEST", 99, 104], ["DNase", "TREATMENT", 121, 126], ["treatment", "TREATMENT", 139, 148], ["JEV proteins", "TEST", 190, 202], ["DDX5", "TEST", 207, 211], ["DDX5", "TEST", 280, 284], ["viral proteins", "PROBLEM", 289, 303], ["the interaction interface mapping", "TREATMENT", 308, 341], ["JEV core", "TREATMENT", 408, 416], ["NS3", "TREATMENT", 418, 421], ["NS5-MTase", "TREATMENT", 423, 432], ["NS5-RdRp proteins", "TREATMENT", 437, 454], ["JEV core", "TREATMENT", 517, 525], ["NS3", "TREATMENT", 527, 530], ["NS5 (MTase and RdRp domains) proteins", "TREATMENT", 536, 573]]], ["The glutathione-Sparse 4B beads were first incubated with the GST-DDX5.", [["glutathione", "CHEMICAL", 4, 15], ["glutathione", "CHEMICAL", 4, 15], ["glutathione", "SIMPLE_CHEMICAL", 4, 15], ["GST", "GENE_OR_GENE_PRODUCT", 62, 65], ["DDX5", "GENE_OR_GENE_PRODUCT", 66, 70], ["GST", "PROTEIN", 62, 65], ["DDX5", "PROTEIN", 66, 70], ["The glutathione", "TREATMENT", 0, 15], ["Sparse 4B beads", "TREATMENT", 16, 31], ["the GST", "TEST", 58, 65]]], ["After unbound GST-DDX5 protein was washed away, JEV core, NS3 or NS5 (MTase or RdRp domains) was mixed with the beads.", [["GST", "GENE_OR_GENE_PRODUCT", 14, 17], ["DDX5", "GENE_OR_GENE_PRODUCT", 18, 22], ["JEV", "ORGANISM", 48, 51], ["NS3", "GENE_OR_GENE_PRODUCT", 58, 61], ["NS5", "GENE_OR_GENE_PRODUCT", 65, 68], ["MTase", "GENE_OR_GENE_PRODUCT", 70, 75], ["GST", "PROTEIN", 14, 17], ["DDX5 protein", "PROTEIN", 18, 30], ["NS3", "PROTEIN", 58, 61], ["NS5", "PROTEIN", 65, 68], ["MTase", "PROTEIN", 70, 75], ["RdRp domains", "PROTEIN", 79, 91], ["JEV", "SPECIES", 48, 51], ["unbound GST", "TEST", 6, 17], ["DDX5 protein", "TREATMENT", 18, 30], ["JEV core", "TREATMENT", 48, 56], ["NS3", "TREATMENT", 58, 61], ["NS5 (MTase", "TREATMENT", 65, 75], ["RdRp domains", "TREATMENT", 79, 91], ["the beads", "TREATMENT", 108, 117]]], ["The various amount of other viral protein was further incubated with the beads to compete the bound viral protein from DDX5.", [["DDX5", "GENE_OR_GENE_PRODUCT", 119, 123], ["viral protein", "PROTEIN", 28, 41], ["viral protein", "PROTEIN", 100, 113], ["DDX5", "PROTEIN", 119, 123], ["other viral protein", "PROBLEM", 22, 41], ["the beads", "TREATMENT", 69, 78], ["the bound viral protein", "PROBLEM", 90, 113], ["various", "OBSERVATION_MODIFIER", 4, 11], ["amount", "OBSERVATION_MODIFIER", 12, 18], ["viral protein", "OBSERVATION", 28, 41]]], ["The results showed the JEV core protein bound with DDX5 decreased gradually when the mixture was incubated with increasing amount of NS3.", [["JEV", "ORGANISM", 23, 26], ["DDX5", "GENE_OR_GENE_PRODUCT", 51, 55], ["NS3", "GENE_OR_GENE_PRODUCT", 133, 136], ["JEV core protein", "PROTEIN", 23, 39], ["DDX5", "PROTEIN", 51, 55], ["NS3", "PROTEIN", 133, 136], ["JEV", "SPECIES", 23, 26], ["the JEV core protein bound", "PROBLEM", 19, 45], ["DDX5", "PROBLEM", 51, 55], ["NS3", "PROBLEM", 133, 136], ["NS3", "OBSERVATION", 133, 136]]], ["Meanwhile, the amount of core protein in the supernatant increased (Fig. 5A) .", [["supernatant", "ANATOMY", 45, 56], ["core protein", "PROTEIN", 25, 37], ["core protein", "TEST", 25, 37], ["amount", "OBSERVATION_MODIFIER", 15, 21], ["core", "OBSERVATION_MODIFIER", 25, 29], ["protein", "OBSERVATION", 30, 37], ["increased", "OBSERVATION_MODIFIER", 57, 66]]], ["The similar results were observed when use NS5-RdRp to compete the core protein (Fig. 5B) , NS5-MTase could not compete with core protein (Fig. 5C ).", [["NS5-MTase", "GENE_OR_GENE_PRODUCT", 92, 101], ["NS5", "PROTEIN", 43, 46], ["RdRp", "PROTEIN", 47, 51], ["core protein", "PROTEIN", 67, 79], ["Fig. 5B", "PROTEIN", 81, 88], ["NS5", "PROTEIN", 92, 95], ["MTase", "PROTEIN", 96, 101], ["core protein", "PROTEIN", 125, 137], ["Fig. 5C", "PROTEIN", 139, 146], ["NS5-RdRp", "TREATMENT", 43, 51], ["NS5-MTase", "TREATMENT", 92, 101]]], ["Furthermore, NS3 could be pulled down from DDX5 by NS5-MTase protein (Fig. 5D ), but not by NS5-RdRp (Fig. 5E ).", [["NS3", "GENE_OR_GENE_PRODUCT", 13, 16], ["DDX5", "GENE_OR_GENE_PRODUCT", 43, 47], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 51, 60], ["NS5-RdRp", "GENE_OR_GENE_PRODUCT", 92, 100], ["NS3", "PROTEIN", 13, 16], ["DDX5", "PROTEIN", 43, 47], ["NS5", "PROTEIN", 51, 54], ["MTase protein", "PROTEIN", 55, 68], ["Fig. 5D", "PROTEIN", 70, 77], ["NS5", "PROTEIN", 92, 95], ["RdRp", "PROTEIN", 96, 100], ["Fig. 5E", "PROTEIN", 102, 109], ["NS3", "TREATMENT", 13, 16], ["DDX5", "TREATMENT", 43, 47], ["NS5-MTase protein (Fig. 5D", "TREATMENT", 51, 77]]], ["NS5-MTase could not be pulled down from DDX5 by NS5-RdRp (Fig. 5F ).", [["NS5-MTase", "GENE_OR_GENE_PRODUCT", 0, 9], ["DDX5", "GENE_OR_GENE_PRODUCT", 40, 44], ["NS5", "GENE_OR_GENE_PRODUCT", 48, 51], ["NS5", "PROTEIN", 0, 3], ["MTase", "PROTEIN", 4, 9], ["DDX5", "PROTEIN", 40, 44], ["NS5", "PROTEIN", 48, 51], ["RdRp", "PROTEIN", 52, 56], ["NS5-MTase", "TREATMENT", 0, 9]]], ["The analysis of the proteins in the supernatant was consistent with the results Fig. 5 .", [["supernatant", "ANATOMY", 36, 47], ["The analysis", "TEST", 0, 12], ["consistent with", "UNCERTAINTY", 52, 67]]], ["The interaction interface mapping between JEV core, NS3, and NS5 (MTase and RdRp domains) and DDX5 proteins.", [["JEV", "ORGANISM", 42, 45], ["NS3", "GENE_OR_GENE_PRODUCT", 52, 55], ["NS5", "GENE_OR_GENE_PRODUCT", 61, 64], ["MTase", "GENE_OR_GENE_PRODUCT", 66, 71], ["DDX5", "GENE_OR_GENE_PRODUCT", 94, 98], ["JEV core", "PROTEIN", 42, 50], ["NS3", "PROTEIN", 52, 55], ["NS5", "PROTEIN", 61, 64], ["MTase", "PROTEIN", 66, 71], ["RdRp domains", "PROTEIN", 76, 88], ["DDX5 proteins", "PROTEIN", 94, 107], ["The interaction interface mapping", "TEST", 0, 33], ["JEV core", "TEST", 42, 50], ["NS3", "TREATMENT", 52, 55], ["NS5 (MTase", "TREATMENT", 61, 71], ["RdRp domains", "TEST", 76, 88], ["DDX5 proteins", "PROBLEM", 94, 107]]], ["GST-DDX5 protein was first incubated with 50 lL of glutathione-Sparse 4B beads.", [["glutathione", "CHEMICAL", 51, 62], ["glutathione", "CHEMICAL", 51, 62], ["GST", "GENE_OR_GENE_PRODUCT", 0, 3], ["DDX5", "GENE_OR_GENE_PRODUCT", 4, 8], ["glutathione", "SIMPLE_CHEMICAL", 51, 62], ["GST", "PROTEIN", 0, 3], ["DDX5 protein", "PROTEIN", 4, 16], ["GST", "TEST", 0, 3], ["DDX5 protein", "TEST", 4, 16], ["glutathione", "TEST", 51, 62], ["Sparse 4B beads", "PROBLEM", 63, 78], ["Sparse", "OBSERVATION_MODIFIER", 63, 69], ["4B beads", "OBSERVATION", 70, 78]]], ["After extensive washing, HIS-tagged core, NS3, NS5-Mtase or NS5-RdRp was incubated with the beads for 3-4 h with gentle agitation followed by washing 5 times with washing buffer.", [["agitation", "DISEASE", 120, 129], ["NS3", "GENE_OR_GENE_PRODUCT", 42, 45], ["NS5-Mtase", "GENE_OR_GENE_PRODUCT", 47, 56], ["NS5", "GENE_OR_GENE_PRODUCT", 60, 63], ["HIS-tagged core", "DNA", 25, 40], ["NS3", "PROTEIN", 42, 45], ["NS5", "PROTEIN", 47, 50], ["Mtase", "PROTEIN", 51, 56], ["NS5", "PROTEIN", 60, 63], ["RdRp", "PROTEIN", 64, 68], ["extensive washing", "TREATMENT", 6, 23], ["HIS-tagged core", "TREATMENT", 25, 40], ["NS3", "TREATMENT", 42, 45], ["NS5-Mtase", "TREATMENT", 47, 56], ["NS5-RdRp", "TREATMENT", 60, 68], ["gentle agitation", "TREATMENT", 113, 129], ["washing buffer", "TREATMENT", 163, 177]]], ["The different amount of competition protein (core, NS3, NS5-Mtase or NS5-RdRp) (10 lg-50 lg) was mixed with the beads to determine the interaction interface of NS3/core (A), NS5-RdRp/core (B), NS5-MTase/core (C), NS5-MTase/NS3 (D), NS5-RdRp/NS3 (E) and NS5-RdRp/NS5-MTase (F).", [["NS3", "GENE_OR_GENE_PRODUCT", 51, 54], ["NS5-Mtase", "GENE_OR_GENE_PRODUCT", 56, 65], ["NS5-RdRp", "GENE_OR_GENE_PRODUCT", 69, 77], ["NS3/core (A)", "GENE_OR_GENE_PRODUCT", 160, 172], ["NS5", "GENE_OR_GENE_PRODUCT", 174, 177], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 193, 202], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 213, 222], ["NS3 (D)", "GENE_OR_GENE_PRODUCT", 223, 230], ["NS5-RdRp", "GENE_OR_GENE_PRODUCT", 232, 240], ["NS3 (E)", "GENE_OR_GENE_PRODUCT", 241, 248], ["NS5-RdRp", "GENE_OR_GENE_PRODUCT", 253, 261], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 262, 271], ["competition protein", "PROTEIN", 24, 43], ["NS3", "PROTEIN", 51, 54], ["NS5", "PROTEIN", 56, 59], ["Mtase", "PROTEIN", 60, 65], ["NS5", "PROTEIN", 69, 72], ["RdRp", "PROTEIN", 73, 77], ["NS3", "PROTEIN", 160, 163], ["A", "PROTEIN", 170, 171], ["NS5", "PROTEIN", 174, 177], ["RdRp", "PROTEIN", 178, 182], ["B", "PROTEIN", 189, 190], ["NS5", "PROTEIN", 193, 196], ["MTase", "PROTEIN", 197, 202], ["core (C)", "PROTEIN", 203, 211], ["NS5", "PROTEIN", 213, 216], ["MTase", "PROTEIN", 217, 222], ["NS3", "PROTEIN", 223, 226], ["D", "PROTEIN", 228, 229], ["NS5", "PROTEIN", 232, 235], ["RdRp", "PROTEIN", 236, 240], ["NS3", "PROTEIN", 241, 244], ["E", "PROTEIN", 246, 247], ["NS5", "PROTEIN", 253, 256], ["RdRp", "PROTEIN", 257, 261], ["NS5", "PROTEIN", 262, 265], ["MTase", "PROTEIN", 266, 271], ["F", "PROTEIN", 273, 274], ["competition protein", "TEST", 24, 43], ["NS3", "TEST", 51, 54], ["NS5", "TEST", 56, 59], ["Mtase", "TEST", 60, 65], ["NS5-RdRp", "TREATMENT", 69, 77], ["lg", "TEST", 83, 85], ["the beads", "TREATMENT", 108, 117], ["NS3", "TEST", 160, 163], ["NS5", "TEST", 174, 177], ["RdRp", "TEST", 178, 182], ["NS5", "TEST", 193, 196], ["MTase", "TEST", 197, 202], ["C", "TEST", 209, 210], ["NS5", "TEST", 213, 216], ["MTase", "TEST", 217, 222], ["NS3", "TEST", 223, 226], ["NS5", "TEST", 232, 235], ["RdRp", "TEST", 236, 240], ["NS5", "TREATMENT", 253, 256], ["different", "OBSERVATION_MODIFIER", 4, 13], ["amount", "OBSERVATION_MODIFIER", 14, 20], ["NS5", "ANATOMY", 213, 216], ["NS5", "ANATOMY", 232, 235], ["NS3", "ANATOMY", 241, 244]]], ["The mixture was incubated for 3-4 h with gentle agitation.", [["agitation", "DISEASE", 48, 57], ["gentle agitation", "PROBLEM", 41, 57]]], ["The mixture was centrifuged at 3000 rpm for 5 min, the supernatant and the beads were subjected to 12% or 15% SDS-PAGE gel and analyzed by western blot using either anti-HIS monoclonal antibody, anti-NS3 or NS5 polyclonal antibody.", [["supernatant", "ANATOMY", 55, 66], ["beads", "ANATOMY", 75, 80], ["anti-NS3", "GENE_OR_GENE_PRODUCT", 195, 203], ["HIS monoclonal antibody", "PROTEIN", 170, 193], ["NS3", "PROTEIN", 200, 203], ["NS5 polyclonal antibody", "PROTEIN", 207, 230], ["the beads", "TREATMENT", 71, 80], ["anti-HIS monoclonal antibody", "TEST", 165, 193], ["anti-NS3", "TREATMENT", 195, 203], ["NS5 polyclonal antibody", "TEST", 207, 230]]], ["Asterisks represent the nonspecific recognition. on the beads.", [["the nonspecific recognition", "PROBLEM", 20, 47], ["the beads", "TREATMENT", 52, 61], ["nonspecific", "OBSERVATION_MODIFIER", 24, 35], ["beads", "OBSERVATION_MODIFIER", 56, 61]]], ["Therefore, the results suggested that interaction site of core/NS3, core/NS5-RdRp or NS3/NS5-MTase on DDX5 might be close to each other, while the interaction site of NS5-MTase/core, NS3/NS5-RdRp or NS5-MTase/NS5-RdRp on DDX5 is not.", [["NS3", "GENE_OR_GENE_PRODUCT", 63, 66], ["NS5", "GENE_OR_GENE_PRODUCT", 73, 76], ["NS3", "GENE_OR_GENE_PRODUCT", 85, 88], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 89, 98], ["DDX5", "GENE_OR_GENE_PRODUCT", 102, 106], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 167, 176], ["NS3", "GENE_OR_GENE_PRODUCT", 183, 186], ["NS5", "GENE_OR_GENE_PRODUCT", 187, 190], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 199, 208], ["NS5", "GENE_OR_GENE_PRODUCT", 209, 212], ["DDX5", "GENE_OR_GENE_PRODUCT", 221, 225], ["NS3", "PROTEIN", 63, 66], ["NS5", "PROTEIN", 73, 76], ["RdRp", "PROTEIN", 77, 81], ["NS3", "PROTEIN", 85, 88], ["NS5", "PROTEIN", 89, 92], ["MTase", "PROTEIN", 93, 98], ["DDX5", "PROTEIN", 102, 106], ["NS5", "PROTEIN", 167, 170], ["MTase", "PROTEIN", 171, 176], ["NS3", "PROTEIN", 183, 186], ["NS5", "PROTEIN", 187, 190], ["RdRp", "PROTEIN", 191, 195], ["NS5", "PROTEIN", 199, 202], ["MTase", "PROTEIN", 203, 208], ["NS5", "PROTEIN", 209, 212], ["RdRp", "PROTEIN", 213, 217], ["DDX5", "DNA", 221, 225], ["core/NS3", "TREATMENT", 58, 66], ["core/NS5", "TREATMENT", 68, 76], ["RdRp", "TREATMENT", 77, 81], ["NS3", "TREATMENT", 85, 88], ["NS5-MTase", "TREATMENT", 89, 98], ["DDX5", "TREATMENT", 102, 106], ["NS5-MTase/core", "TREATMENT", 167, 181], ["NS3", "TREATMENT", 183, 186], ["NS5", "TREATMENT", 187, 190], ["RdRp", "TREATMENT", 191, 195], ["NS5-MTase", "TREATMENT", 199, 208], ["NS5", "TREATMENT", 209, 212], ["RdRp", "TREATMENT", 213, 217], ["DDX5", "TREATMENT", 221, 225]]], ["Meanwhile, all the purified recombinant proteins were analyzed by SDS-PAGE (Fig. S1 ).DDX5 was recruited from the nucleus to the cytoplasm during virus infectionAs previously reported, DDX5 is primarily localized in the nucleus (Choi and Lee, 2012) .", [["nucleus", "ANATOMY", 114, 121], ["cytoplasm", "ANATOMY", 129, 138], ["nucleus", "ANATOMY", 220, 227], ["infection", "DISEASE", 152, 161], ["DDX5", "GENE_OR_GENE_PRODUCT", 86, 90], ["nucleus", "CELLULAR_COMPONENT", 114, 121], ["cytoplasm", "ORGANISM_SUBSTANCE", 129, 138], ["DDX5", "GENE_OR_GENE_PRODUCT", 185, 189], ["nucleus", "CELLULAR_COMPONENT", 220, 227], ["purified recombinant proteins", "PROTEIN", 19, 48], ["DDX5", "PROTEIN", 86, 90], ["DDX5", "PROTEIN", 185, 189], ["virus infection", "PROBLEM", 146, 161], ["DDX5", "TEST", 185, 189], ["nucleus", "ANATOMY", 114, 121], ["virus infection", "OBSERVATION", 146, 161], ["nucleus", "ANATOMY", 220, 227]]], ["We detected the cellular localization of endogenous DDX5 in BHK-21 cells infected with JEV.", [["cellular", "ANATOMY", 16, 24], ["BHK-21 cells", "ANATOMY", 60, 72], ["cellular", "CELL", 16, 24], ["DDX5", "GENE_OR_GENE_PRODUCT", 52, 56], ["BHK-21 cells", "CELL", 60, 72], ["JEV", "ORGANISM", 87, 90], ["endogenous DDX5", "PROTEIN", 41, 56], ["BHK-21 cells", "CELL_LINE", 60, 72], ["BHK-21", "SPECIES", 60, 66], ["JEV", "SPECIES", 87, 90], ["endogenous DDX5 in BHK", "PROBLEM", 41, 63], ["JEV", "PROBLEM", 87, 90], ["endogenous DDX5", "OBSERVATION", 41, 56]]], ["Confocal microscopy analysis demonstrated endogenous DDX5 primarily localized in the nucleus in the uninfected cells, while some of DDX5 was recruited to the cytoplasm in JEV infected cells (MOI = 0.01), suggesting DDX5 could be recruited to the cytoplasm to participate in JEV replication (Fig. 6A) .", [["nucleus", "ANATOMY", 85, 92], ["cells", "ANATOMY", 111, 116], ["cytoplasm", "ANATOMY", 158, 167], ["cells", "ANATOMY", 184, 189], ["cytoplasm", "ANATOMY", 246, 255], ["JEV infected", "DISEASE", 171, 183], ["DDX5", "GENE_OR_GENE_PRODUCT", 53, 57], ["nucleus", "CELLULAR_COMPONENT", 85, 92], ["cells", "CELL", 111, 116], ["DDX5", "GENE_OR_GENE_PRODUCT", 132, 136], ["cytoplasm", "ORGANISM_SUBSTANCE", 158, 167], ["JEV", "ORGANISM", 171, 174], ["cells", "CELL", 184, 189], ["DDX5", "GENE_OR_GENE_PRODUCT", 215, 219], ["cytoplasm", "ORGANISM_SUBSTANCE", 246, 255], ["JEV", "ORGANISM", 274, 277], ["DDX5", "PROTEIN", 53, 57], ["uninfected cells", "CELL_TYPE", 100, 116], ["DDX5", "PROTEIN", 132, 136], ["JEV infected cells", "CELL_TYPE", 171, 189], ["DDX5", "PROTEIN", 215, 219], ["JEV", "SPECIES", 171, 174], ["JEV", "SPECIES", 274, 277], ["Confocal microscopy analysis", "TEST", 0, 28], ["endogenous DDX5", "PROBLEM", 42, 57], ["DDX5", "TEST", 132, 136], ["MOI", "TEST", 191, 194], ["DDX5", "PROBLEM", 215, 219], ["endogenous DDX5", "OBSERVATION", 42, 57], ["nucleus", "ANATOMY", 85, 92], ["uninfected cells", "OBSERVATION", 100, 116], ["JEV infected cells", "OBSERVATION", 171, 189]]], ["To investigate if the recruitment of DDX5 to the cytoplasm is necessary for JEV Fig. 6 .", [["cytoplasm", "ANATOMY", 49, 58], ["DDX5", "GENE_OR_GENE_PRODUCT", 37, 41], ["cytoplasm", "ORGANISM_SUBSTANCE", 49, 58], ["DDX5", "PROTEIN", 37, 41], ["JEV Fig.", "SPECIES", 76, 84]]], ["The localization of DDX5 in JEV infected BHK-21 cells.", [["BHK-21 cells", "ANATOMY", 41, 53], ["DDX5", "GENE_OR_GENE_PRODUCT", 20, 24], ["JEV", "ORGANISM", 28, 31], ["BHK-21 cells", "CELL", 41, 53], ["DDX5", "PROTEIN", 20, 24], ["JEV infected BHK-21 cells", "CELL_LINE", 28, 53], ["JEV", "SPECIES", 28, 31], ["BHK-21", "SPECIES", 41, 47], ["DDX5", "TEST", 20, 24], ["JEV infected BHK", "PROBLEM", 28, 44], ["JEV", "OBSERVATION", 28, 31], ["infected BHK", "OBSERVATION", 32, 44]]], ["Localization of endogenous DDX5 in BHK-21 cell infected, mock infected with JEV or LMB treated was detected using anti-DDX5 polyclonal antibody, the virus enveloped (E) protein was detected using anti-E monoclonal antibody.", [["BHK-21 cell", "ANATOMY", 35, 46], ["LMB", "CHEMICAL", 83, 86], ["LMB", "CHEMICAL", 83, 86], ["DDX5", "GENE_OR_GENE_PRODUCT", 27, 31], ["BHK-21 cell", "CELL", 35, 46], ["JEV", "ORGANISM", 76, 79], ["LMB", "CELL", 83, 86], ["anti-DDX5", "GENE_OR_GENE_PRODUCT", 114, 123], ["endogenous DDX5", "PROTEIN", 16, 31], ["BHK-21 cell", "CELL_LINE", 35, 46], ["anti-DDX5 polyclonal antibody", "PROTEIN", 114, 143], ["virus enveloped (E) protein", "PROTEIN", 149, 176], ["anti-E monoclonal antibody", "PROTEIN", 196, 222], ["BHK-21", "SPECIES", 35, 41], ["JEV", "SPECIES", 76, 79], ["endogenous DDX5 in BHK", "PROBLEM", 16, 38], ["JEV", "PROBLEM", 76, 79], ["LMB", "TREATMENT", 83, 86], ["anti-DDX5 polyclonal antibody", "TEST", 114, 143], ["the virus enveloped (E) protein", "TEST", 145, 176], ["anti-E monoclonal antibody", "TEST", 196, 222], ["endogenous DDX5", "OBSERVATION", 16, 31], ["21 cell", "OBSERVATION_MODIFIER", 39, 46], ["infected", "OBSERVATION_MODIFIER", 47, 55]]], ["LMB can inhibit JEV infection.", [["LMB", "CHEMICAL", 0, 3], ["JEV infection", "DISEASE", 16, 29], ["LMB", "CHEMICAL", 0, 3], ["LMB", "SIMPLE_CHEMICAL", 0, 3], ["JEV", "ORGANISM", 16, 19], ["JEV", "SPECIES", 16, 19], ["JEV infection", "PROBLEM", 16, 29], ["JEV", "OBSERVATION_MODIFIER", 16, 19], ["infection", "OBSERVATION", 20, 29]]], ["BHK-21 cell was infected with JEV (MOI = 0.01), then LMB (5 ng/ml) was added, the viral titers were detected by plaque assay at 48 hpi, the untreated cells were used as the control.", [["BHK-21 cell", "ANATOMY", 0, 11], ["plaque", "ANATOMY", 112, 118], ["cells", "ANATOMY", 150, 155], ["LMB", "CHEMICAL", 53, 56], ["LMB", "CHEMICAL", 53, 56], ["BHK-21 cell", "CELL", 0, 11], ["JEV", "ORGANISM", 30, 33], ["LMB", "SIMPLE_CHEMICAL", 53, 56], ["cells", "CELL", 150, 155], ["BHK-21 cell", "CELL_LINE", 0, 11], ["JEV", "SPECIES", 30, 33], ["BHK", "TEST", 0, 3], ["JEV (MOI", "TREATMENT", 30, 38], ["LMB", "TREATMENT", 53, 56], ["the viral titers", "TEST", 78, 94], ["plaque assay", "TEST", 112, 124], ["the untreated cells", "TREATMENT", 136, 155], ["21 cell", "OBSERVATION_MODIFIER", 4, 11]]], ["The Cytotoxicity of Leptomycin B (LMB) on BHK-21 cells was detected by CytoTox 96 \u00d2 NonRadioactive Cytotoxicity Assay at 48 h after added to the cells with different the concentrations (0-20 ng/ml).", [["BHK-21 cells", "ANATOMY", 42, 54], ["cells", "ANATOMY", 145, 150], ["Leptomycin B", "CHEMICAL", 20, 32], ["LMB", "CHEMICAL", 34, 37], ["Leptomycin B", "CHEMICAL", 20, 32], ["LMB", "CHEMICAL", 34, 37], ["Leptomycin B", "SIMPLE_CHEMICAL", 20, 32], ["LMB", "SIMPLE_CHEMICAL", 34, 37], ["BHK-21 cells", "CELL", 42, 54], ["cells", "CELL", 145, 150], ["BHK-21 cells", "CELL_LINE", 42, 54], ["Leptomycin B (LMB", "TREATMENT", 20, 37], ["BHK", "TEST", 42, 45], ["CytoTox", "TEST", 71, 78], ["NonRadioactive Cytotoxicity Assay", "TEST", 84, 117]]], ["DDX5 can interact with JEV core, NS3, NS5 proteins.", [["DDX5", "CHEMICAL", 0, 4], ["DDX5", "GENE_OR_GENE_PRODUCT", 0, 4], ["JEV", "ORGANISM", 23, 26], ["NS3", "GENE_OR_GENE_PRODUCT", 33, 36], ["NS5", "GENE_OR_GENE_PRODUCT", 38, 41], ["DDX5", "PROTEIN", 0, 4], ["NS3", "PROTEIN", 33, 36], ["NS5 proteins", "PROTEIN", 38, 50], ["JEV", "SPECIES", 23, 26], ["JEV core", "TREATMENT", 23, 31], ["NS3", "TREATMENT", 33, 36], ["NS5 proteins", "TREATMENT", 38, 50]]], ["BHK-21 cells was infected with JEV (MOI = 0.01).", [["BHK-21 cells", "ANATOMY", 0, 12], ["BHK-21 cells", "CELL", 0, 12], ["JEV", "ORGANISM", 31, 34], ["BHK-21 cells", "CELL_LINE", 0, 12], ["JEV", "SPECIES", 31, 34], ["BHK", "TEST", 0, 3], ["JEV (MOI", "TREATMENT", 31, 39], ["21 cells", "OBSERVATION_MODIFIER", 4, 12]]], ["48 h later, the anti-DDX5 polyclonal antibody was used to co-immunoprecipitate the proteins from the whole cell lysate treated with RNase (100 lg/ml) and DNase (100 lg/ml).", [["cell lysate", "ANATOMY", 107, 118], ["anti-DDX5", "GENE_OR_GENE_PRODUCT", 16, 25], ["cell", "CELL", 107, 111], ["RNase", "GENE_OR_GENE_PRODUCT", 132, 137], ["DNase", "GENE_OR_GENE_PRODUCT", 154, 159], ["anti-DDX5 polyclonal antibody", "PROTEIN", 16, 45], ["RNase", "PROTEIN", 132, 137], ["DNase", "PROTEIN", 154, 159], ["the anti-DDX5 polyclonal antibody", "TEST", 12, 45], ["the whole cell lysate", "TREATMENT", 97, 118], ["RNase", "TREATMENT", 132, 137], ["DNase", "TEST", 154, 159]]], ["The JEV core, NS3 and NS5 proteins were detected using their polyclonal antibodies respectively.", [["JEV", "ORGANISM", 4, 7], ["NS3", "GENE_OR_GENE_PRODUCT", 14, 17], ["NS5", "GENE_OR_GENE_PRODUCT", 22, 25], ["NS3", "PROTEIN", 14, 17], ["NS5 proteins", "PROTEIN", 22, 34], ["polyclonal antibodies", "PROTEIN", 61, 82], ["JEV", "SPECIES", 4, 7], ["The JEV core", "TEST", 0, 12], ["NS3 and NS5 proteins", "TEST", 14, 34]]], ["The cell lysates (input, 2%) were analyzed in parallel by western blot.", [["cell lysates", "ANATOMY", 4, 16], ["cell lysates", "CELL", 4, 16], ["The cell lysates", "TEST", 0, 16], ["cell lysates", "OBSERVATION", 4, 16]]], ["DDX5 colocalizes with the JEV core, NS3, NS5 proteins.", [["DDX5", "GENE_OR_GENE_PRODUCT", 0, 4], ["JEV", "ORGANISM", 26, 29], ["NS3", "GENE_OR_GENE_PRODUCT", 36, 39], ["NS5", "GENE_OR_GENE_PRODUCT", 41, 44], ["DDX5", "PROTEIN", 0, 4], ["NS3", "PROTEIN", 36, 39], ["NS5 proteins", "PROTEIN", 41, 53], ["JEV", "SPECIES", 26, 29], ["the JEV core", "TEST", 22, 34], ["NS5 proteins", "OBSERVATION", 41, 53]]], ["We infected the BHK-21 cells with JEV (MOI = 0.01) first.", [["BHK-21 cells", "ANATOMY", 16, 28], ["BHK-21 cells", "CELL", 16, 28], ["JEV", "ORGANISM", 34, 37], ["BHK-21 cells", "CELL_LINE", 16, 28], ["BHK-21", "SPECIES", 16, 22], ["JEV", "SPECIES", 34, 37], ["the BHK", "TEST", 12, 19], ["JEV (MOI", "TREATMENT", 34, 42], ["infected", "OBSERVATION", 3, 11], ["21 cells", "OBSERVATION_MODIFIER", 20, 28]]], ["48 h later, DDX5, JEV core, NS3 and NS5 proteins were detected using their polyclonal antibodies and the colocalization study was performed under confocal microscopy, the negative serum (the serum of unimmunized mouse) was used as the control.", [["serum", "ANATOMY", 180, 185], ["serum", "ANATOMY", 191, 196], ["DDX5", "GENE_OR_GENE_PRODUCT", 12, 16], ["JEV", "ORGANISM", 18, 21], ["NS3", "GENE_OR_GENE_PRODUCT", 28, 31], ["NS5", "GENE_OR_GENE_PRODUCT", 36, 39], ["serum", "ORGANISM_SUBSTANCE", 180, 185], ["serum", "ORGANISM_SUBSTANCE", 191, 196], ["mouse", "ORGANISM", 212, 217], ["DDX5", "PROTEIN", 12, 16], ["JEV core", "PROTEIN", 18, 26], ["NS3", "PROTEIN", 28, 31], ["NS5 proteins", "PROTEIN", 36, 48], ["polyclonal antibodies", "PROTEIN", 75, 96], ["mouse", "SPECIES", 212, 217], ["JEV", "SPECIES", 18, 21], ["mouse", "SPECIES", 212, 217], ["DDX5", "TEST", 12, 16], ["JEV core", "TEST", 18, 26], ["NS3 and NS5 proteins", "TEST", 28, 48], ["their polyclonal antibodies", "TEST", 69, 96], ["the colocalization study", "TEST", 101, 125], ["confocal microscopy", "TEST", 146, 165]]], ["DDX5 is not incorporated into the virions.", [["virions", "ANATOMY", 34, 41], ["DDX5", "CHEMICAL", 0, 4], ["DDX5", "GENE_OR_GENE_PRODUCT", 0, 4], ["DDX5", "PROTEIN", 0, 4], ["virions", "ANATOMY", 34, 41]]], ["BHK-21 cells were infected with JEV (MOI = 0.01) for 48 h, the anti-E monoclonal antibody was used to immunoprecipitate the mature virions in the medium, the proteins in the immunoprecipitated virions (IP) were detected with anti-DDX5, E or core antibodies.", [["BHK-21 cells", "ANATOMY", 0, 12], ["virions", "ANATOMY", 131, 138], ["virions", "ANATOMY", 193, 200], ["BHK-21 cells", "CELL", 0, 12], ["JEV", "ORGANISM", 32, 35], ["anti-DDX5", "GENE_OR_GENE_PRODUCT", 225, 234], ["E", "SIMPLE_CHEMICAL", 236, 237], ["BHK-21 cells", "CELL_LINE", 0, 12], ["anti-E monoclonal antibody", "PROTEIN", 63, 89], ["anti-DDX5", "PROTEIN", 225, 234], ["E", "PROTEIN", 236, 237], ["core antibodies", "PROTEIN", 241, 256], ["JEV", "SPECIES", 32, 35], ["BHK", "TEST", 0, 3], ["JEV (MOI", "TREATMENT", 32, 40], ["the anti-E monoclonal antibody", "TEST", 59, 89], ["21 cells", "OBSERVATION_MODIFIER", 4, 12]]], ["All cell lysates (input, 2%) were analyzed in parallel by western blot.", [["cell lysates", "ANATOMY", 4, 16], ["cell lysates", "CELL", 4, 16], ["All cell lysates", "TREATMENT", 0, 16], ["cell lysates", "OBSERVATION", 4, 16]]], ["The heavy chain of anti-E monoclonal antibody was labeled.DDX5 was recruited from the nucleus to the cytoplasm during virus infectionreplication, we used leptomycin B (LMB, 5 ng/ml) to inhibit nuclear export of DDX5 (Wang et al., 2009a) at 0 h post-infection (MOI = 0.01), 24 h later, Confocal microscopy analysis showed that DDX5 was not recruited to the cytoplasm during JEV infection after LMB treatment (Fig. 6A) .", [["nucleus", "ANATOMY", 86, 93], ["cytoplasm", "ANATOMY", 101, 110], ["nuclear", "ANATOMY", 193, 200], ["cytoplasm", "ANATOMY", 356, 365], ["leptomycin B", "CHEMICAL", 154, 166], ["LMB", "CHEMICAL", 168, 171], ["infection", "DISEASE", 249, 258], ["JEV infection", "DISEASE", 373, 386], ["LMB", "CHEMICAL", 393, 396], ["leptomycin B", "CHEMICAL", 154, 166], ["LMB", "CHEMICAL", 168, 171], ["LMB", "CHEMICAL", 393, 396], ["anti-E", "GENE_OR_GENE_PRODUCT", 19, 25], ["DDX5", "GENE_OR_GENE_PRODUCT", 58, 62], ["nucleus", "CELLULAR_COMPONENT", 86, 93], ["cytoplasm", "ORGANISM_SUBSTANCE", 101, 110], ["leptomycin B", "SIMPLE_CHEMICAL", 154, 166], ["LMB", "SIMPLE_CHEMICAL", 168, 171], ["nuclear", "CELLULAR_COMPONENT", 193, 200], ["DDX5", "GENE_OR_GENE_PRODUCT", 211, 215], ["DDX5", "GENE_OR_GENE_PRODUCT", 326, 330], ["cytoplasm", "ORGANISM_SUBSTANCE", 356, 365], ["JEV", "ORGANISM", 373, 376], ["LMB", "SIMPLE_CHEMICAL", 393, 396], ["heavy chain", "PROTEIN", 4, 15], ["anti-E monoclonal antibody", "PROTEIN", 19, 45], ["DDX5", "PROTEIN", 58, 62], ["DDX5", "PROTEIN", 211, 215], ["DDX5", "PROTEIN", 326, 330], ["JEV", "SPECIES", 373, 376], ["anti-E monoclonal antibody", "TEST", 19, 45], ["virus infectionreplication", "TREATMENT", 118, 144], ["leptomycin B (LMB", "TREATMENT", 154, 171], ["infection", "PROBLEM", 249, 258], ["MOI", "TEST", 260, 263], ["Confocal microscopy analysis", "TEST", 285, 313], ["DDX5", "PROBLEM", 326, 330], ["JEV infection", "PROBLEM", 373, 386], ["LMB treatment", "TREATMENT", 393, 406], ["heavy", "OBSERVATION_MODIFIER", 4, 9], ["chain", "OBSERVATION_MODIFIER", 10, 15], ["nucleus", "ANATOMY", 86, 93], ["infection", "OBSERVATION", 249, 258], ["JEV infection", "OBSERVATION", 373, 386]]], ["In the meantime, we determined the effect of LMB treatment on JEV infection, 5 ng/ml and 10 ng/ml LMB was added to the cell at 0 h post-infection, the virus titers was detected 2 days later by plaque assay.", [["cell", "ANATOMY", 119, 123], ["plaque", "ANATOMY", 193, 199], ["LMB", "CHEMICAL", 45, 48], ["JEV infection", "DISEASE", 62, 75], ["LMB", "CHEMICAL", 98, 101], ["LMB", "CHEMICAL", 45, 48], ["LMB", "CHEMICAL", 98, 101], ["LMB", "SIMPLE_CHEMICAL", 45, 48], ["JEV", "ORGANISM", 62, 65], ["LMB", "SIMPLE_CHEMICAL", 98, 101], ["cell", "CELL", 119, 123], ["JEV", "SPECIES", 62, 65], ["LMB treatment", "TREATMENT", 45, 58], ["JEV infection", "PROBLEM", 62, 75], ["LMB", "TREATMENT", 98, 101], ["infection", "PROBLEM", 136, 145], ["the virus titers", "TEST", 147, 163], ["plaque assay", "TEST", 193, 205], ["infection", "OBSERVATION", 136, 145], ["plaque", "OBSERVATION", 193, 199]]], ["The results showed that LMB can significant inhibit JEV infection compared with the untreated cells (Fig. 6B) , confirming that it is need to recruit DDX5 to the cytoplasm to participate in JEV replication.", [["cells", "ANATOMY", 94, 99], ["cytoplasm", "ANATOMY", 162, 171], ["LMB", "CHEMICAL", 24, 27], ["JEV infection", "DISEASE", 52, 65], ["LMB", "CHEMICAL", 24, 27], ["LMB", "SIMPLE_CHEMICAL", 24, 27], ["JEV", "ORGANISM", 52, 55], ["cells", "CELL", 94, 99], ["Fig. 6B", "CELL", 101, 108], ["DDX5", "GENE_OR_GENE_PRODUCT", 150, 154], ["cytoplasm", "ORGANISM_SUBSTANCE", 162, 171], ["JEV", "ORGANISM", 190, 193], ["untreated cells", "CELL_TYPE", 84, 99], ["DDX5", "PROTEIN", 150, 154], ["JEV", "SPECIES", 52, 55], ["JEV", "SPECIES", 190, 193], ["LMB", "PROBLEM", 24, 27], ["JEV infection", "PROBLEM", 52, 65], ["JEV replication", "TREATMENT", 190, 205], ["LMB", "ANATOMY", 24, 27], ["JEV", "OBSERVATION_MODIFIER", 52, 55], ["infection", "OBSERVATION", 56, 65], ["JEV replication", "OBSERVATION", 190, 205]]], ["Cytotoxicity assay showed that LMB can not induce significantly cytotoxicity on BHK-21 cells even at the concentration of 20 ng/ml (Fig. 6C) .DDX5 was recruited from the nucleus to the cytoplasm during virus infection3.5.", [["BHK-21 cells", "ANATOMY", 80, 92], ["nucleus", "ANATOMY", 170, 177], ["cytoplasm", "ANATOMY", 185, 194], ["LMB", "CHEMICAL", 31, 34], ["BHK-21", "CHEMICAL", 80, 86], ["infection", "DISEASE", 208, 217], ["LMB", "CHEMICAL", 31, 34], ["LMB", "SIMPLE_CHEMICAL", 31, 34], ["BHK-21 cells", "CELL", 80, 92], ["DDX5", "GENE_OR_GENE_PRODUCT", 142, 146], ["nucleus", "CELLULAR_COMPONENT", 170, 177], ["cytoplasm", "ORGANISM_SUBSTANCE", 185, 194], ["BHK-21 cells", "CELL_LINE", 80, 92], ["DDX5", "PROTEIN", 142, 146], ["BHK-21", "SPECIES", 80, 86], ["Cytotoxicity assay", "TEST", 0, 18], ["LMB", "PROBLEM", 31, 34], ["significantly cytotoxicity", "PROBLEM", 50, 76], ["BHK", "TEST", 80, 83], ["virus infection", "PROBLEM", 202, 217], ["nucleus", "ANATOMY", 170, 177], ["cytoplasm", "OBSERVATION_MODIFIER", 185, 194]]], ["DDX5 interacts with the JEV core, NS3, NS5 proteins and colocalizes with them during virus infection NS5 and NS3 have been hypothesized to seed the formation of virus replication complexes, and they may form replication complex together with 3 0 noncoding region of JEV genomic RNA (Uchil and Satchidanandam, 2003a) and the core protein can bind to the viral RNA to participate in virus replication (Khromykh and Westaway, 1996) .", [["DDX5", "CHEMICAL", 0, 4], ["infection", "DISEASE", 91, 100], ["DDX5", "GENE_OR_GENE_PRODUCT", 0, 4], ["JEV", "ORGANISM", 24, 27], ["NS3", "GENE_OR_GENE_PRODUCT", 34, 37], ["NS5", "GENE_OR_GENE_PRODUCT", 39, 42], ["NS5", "GENE_OR_GENE_PRODUCT", 101, 104], ["NS3", "GENE_OR_GENE_PRODUCT", 109, 112], ["JEV", "ORGANISM", 266, 269], ["DDX5", "PROTEIN", 0, 4], ["NS3", "PROTEIN", 34, 37], ["NS5 proteins", "PROTEIN", 39, 51], ["NS5", "PROTEIN", 101, 104], ["NS3", "PROTEIN", 109, 112], ["virus replication complexes", "PROTEIN", 161, 188], ["replication complex", "PROTEIN", 208, 227], ["3 0 noncoding region", "DNA", 242, 262], ["JEV genomic RNA", "DNA", 266, 281], ["viral RNA", "RNA", 353, 362], ["JEV", "SPECIES", 266, 269], ["NS3", "TREATMENT", 34, 37], ["NS5 proteins", "TREATMENT", 39, 51], ["virus infection NS5", "PROBLEM", 85, 104], ["NS3", "TREATMENT", 109, 112], ["virus replication complexes", "TREATMENT", 161, 188], ["the core protein", "PROBLEM", 320, 336], ["the viral RNA", "PROBLEM", 349, 362], ["virus replication", "OBSERVATION", 161, 178], ["JEV genomic RNA", "OBSERVATION", 266, 281], ["viral RNA", "OBSERVATION", 353, 362]]], ["Since GST-pulldown and co-immunoprecipitation experiments showed that DDX5 can interact with the JEV core, NS3, NS5-MTase and NS5-RdRp proteins.", [["DDX5", "CHEMICAL", 70, 74], ["GST", "GENE_OR_GENE_PRODUCT", 6, 9], ["DDX5", "GENE_OR_GENE_PRODUCT", 70, 74], ["JEV", "ORGANISM", 97, 100], ["NS3", "GENE_OR_GENE_PRODUCT", 107, 110], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 112, 121], ["NS5-RdRp", "GENE_OR_GENE_PRODUCT", 126, 134], ["GST", "PROTEIN", 6, 9], ["DDX5", "PROTEIN", 70, 74], ["NS3", "PROTEIN", 107, 110], ["NS5", "PROTEIN", 112, 115], ["MTase", "PROTEIN", 116, 121], ["NS5", "PROTEIN", 126, 129], ["RdRp proteins", "PROTEIN", 130, 143], ["JEV", "SPECIES", 97, 100], ["GST", "TEST", 6, 9], ["co-immunoprecipitation experiments", "TEST", 23, 57], ["the JEV core", "TREATMENT", 93, 105], ["NS3", "TREATMENT", 107, 110], ["NS5-MTase", "TREATMENT", 112, 121], ["NS5-RdRp proteins", "TREATMENT", 126, 143]]], ["We further determined if DDX5 can interact with these proteins during virus infection.", [["DDX5", "CHEMICAL", 25, 29], ["infection", "DISEASE", 76, 85], ["DDX5", "GENE_OR_GENE_PRODUCT", 25, 29], ["DDX5", "PROTEIN", 25, 29], ["DDX5", "PROBLEM", 25, 29], ["these proteins during virus infection", "PROBLEM", 48, 85]]], ["The BHK-21 cells were infected with JEV (MOI = 0.01).", [["BHK-21 cells", "ANATOMY", 4, 16], ["BHK-21 cells", "CELL", 4, 16], ["JEV", "ORGANISM", 36, 39], ["BHK-21 cells", "CELL_LINE", 4, 16], ["JEV", "SPECIES", 36, 39], ["The BHK", "TEST", 0, 7], ["JEV (MOI", "TEST", 36, 44], ["21 cells", "OBSERVATION_MODIFIER", 8, 16]]], ["24 h later, the anti-DDX5 polyclonal antibody was used to co-immunoprecipitate proteins from the whole cell lysate which was also treated with RNase (100 lg/ml) and DNase (100 lg/ml).", [["cell lysate", "ANATOMY", 103, 114], ["anti-DDX5", "GENE_OR_GENE_PRODUCT", 16, 25], ["cell lysate", "CELL", 103, 114], ["RNase", "GENE_OR_GENE_PRODUCT", 143, 148], ["DNase", "GENE_OR_GENE_PRODUCT", 165, 170], ["anti-DDX5 polyclonal antibody", "PROTEIN", 16, 45], ["RNase", "PROTEIN", 143, 148], ["DNase", "PROTEIN", 165, 170], ["the anti-DDX5 polyclonal antibody", "TEST", 12, 45], ["the whole cell lysate", "TREATMENT", 93, 114], ["RNase", "TREATMENT", 143, 148], ["DNase", "TREATMENT", 165, 170]]], ["The results showed JEV core, NS3, and NS5 proteins can be co-immunoprecipitated by DDX5 compared with the control IgG (Fig. 7A) , confirming that DDX5 interacts with viral proteins that are important for virus replication and the interaction between them was not mediated by RNA or DNA.", [["JEV", "ORGANISM", 19, 22], ["NS3", "GENE_OR_GENE_PRODUCT", 29, 32], ["NS5", "GENE_OR_GENE_PRODUCT", 38, 41], ["DDX5", "GENE_OR_GENE_PRODUCT", 83, 87], ["IgG (Fig. 7A", "GENE_OR_GENE_PRODUCT", 114, 126], ["DDX5", "GENE_OR_GENE_PRODUCT", 146, 150], ["DNA", "CELLULAR_COMPONENT", 282, 285], ["JEV core, NS3, and NS5 proteins", "PROTEIN", 19, 50], ["DDX5", "PROTEIN", 83, 87], ["IgG", "PROTEIN", 114, 117], ["Fig. 7A", "PROTEIN", 119, 126], ["DDX5", "PROTEIN", 146, 150], ["viral proteins", "PROTEIN", 166, 180], ["JEV", "SPECIES", 19, 22], ["JEV core", "TEST", 19, 27], ["NS3", "PROBLEM", 29, 32], ["NS5 proteins", "PROBLEM", 38, 50], ["the control IgG", "TEST", 102, 117], ["viral proteins", "PROBLEM", 166, 180], ["virus replication", "TREATMENT", 204, 221], ["DNA", "PROBLEM", 282, 285], ["viral proteins", "OBSERVATION", 166, 180]]], ["Furthermore, confocal microscopy analysis demonstrated that DDX5 colocalized with JEV core, NS3 and NS5 proteins mainly in the cytoplasm during virus infection.", [["cytoplasm", "ANATOMY", 127, 136], ["infection", "DISEASE", 150, 159], ["DDX5", "GENE_OR_GENE_PRODUCT", 60, 64], ["JEV", "ORGANISM", 82, 85], ["NS3", "GENE_OR_GENE_PRODUCT", 92, 95], ["NS5", "GENE_OR_GENE_PRODUCT", 100, 103], ["cytoplasm", "ORGANISM_SUBSTANCE", 127, 136], ["DDX5", "PROTEIN", 60, 64], ["JEV core, NS3 and NS5 proteins", "PROTEIN", 82, 112], ["JEV", "SPECIES", 82, 85], ["confocal microscopy analysis", "TEST", 13, 41], ["DDX5", "PROBLEM", 60, 64], ["JEV core", "TEST", 82, 90], ["NS3", "TREATMENT", 92, 95], ["NS5 proteins", "TEST", 100, 112], ["the cytoplasm during virus infection", "PROBLEM", 123, 159], ["cytoplasm", "OBSERVATION_MODIFIER", 127, 136], ["virus infection", "OBSERVATION", 144, 159]]], ["In uninfected cells, most of DDX5 still localized in the nucleus, the serum of the unimmunized mouse was used as the control (Fig. 7B) .DDX5 was recruited from the nucleus to the cytoplasm during virus infectionIt has been shown DDX3, another cellular helicase, can be incorporation into the virons of HBV, Herpes simplex virus type 1(HSV-1) and Human cytomegalovirus (HCMV) (Stegen et al., 2013; Varnum et al., 2004; Wang et al., 2009b) .", [["cells", "ANATOMY", 14, 19], ["nucleus", "ANATOMY", 57, 64], ["serum", "ANATOMY", 70, 75], ["nucleus", "ANATOMY", 164, 171], ["cytoplasm", "ANATOMY", 179, 188], ["cellular", "ANATOMY", 243, 251], ["infection", "DISEASE", 202, 211], ["Herpes simplex virus", "DISEASE", 307, 327], ["Human cytomegalovirus (HCMV)", "DISEASE", 346, 374], ["cells", "CELL", 14, 19], ["DDX5", "GENE_OR_GENE_PRODUCT", 29, 33], ["nucleus", "CELLULAR_COMPONENT", 57, 64], ["serum", "ORGANISM_SUBSTANCE", 70, 75], ["mouse", "ORGANISM", 95, 100], ["DDX5", "GENE_OR_GENE_PRODUCT", 136, 140], ["nucleus", "CELLULAR_COMPONENT", 164, 171], ["cytoplasm", "ORGANISM_SUBSTANCE", 179, 188], ["DDX3", "GENE_OR_GENE_PRODUCT", 229, 233], ["cellular", "CELL", 243, 251], ["HBV,", "ORGANISM", 302, 306], ["Herpes simplex virus type 1", "ORGANISM", 307, 334], ["HSV-1", "ORGANISM", 335, 340], ["Human", "ORGANISM", 346, 351], ["cytomegalovirus", "ORGANISM", 352, 367], ["HCMV", "ORGANISM", 369, 373], ["uninfected cells", "CELL_TYPE", 3, 19], ["DDX5", "PROTEIN", 29, 33], ["DDX5", "PROTEIN", 136, 140], ["DDX3", "PROTEIN", 229, 233], ["cellular helicase", "PROTEIN", 243, 260], ["mouse", "SPECIES", 95, 100], ["Herpes simplex virus type 1", "SPECIES", 307, 334], ["HSV-1", "SPECIES", 335, 340], ["Human", "SPECIES", 346, 351], ["mouse", "SPECIES", 95, 100], ["HBV", "SPECIES", 302, 305], ["Herpes simplex virus type 1", "SPECIES", 307, 334], ["HSV-1", "SPECIES", 335, 340], ["Human cytomegalovirus", "SPECIES", 346, 367], ["HCMV", "SPECIES", 369, 373], ["DDX5", "TEST", 29, 33], ["the unimmunized mouse", "TREATMENT", 79, 100], ["virus infection", "PROBLEM", 196, 211], ["DDX3", "PROBLEM", 229, 233], ["another cellular helicase", "PROBLEM", 235, 260], ["HBV", "PROBLEM", 302, 305], ["Herpes simplex virus type", "TEST", 307, 332], ["HSV", "TEST", 335, 338], ["Human cytomegalovirus", "PROBLEM", 346, 367], ["uninfected cells", "OBSERVATION", 3, 19], ["nucleus", "ANATOMY_MODIFIER", 57, 64], ["nucleus", "ANATOMY", 164, 171], ["virus infection", "OBSERVATION", 196, 211], ["DDX3", "OBSERVATION", 229, 233], ["HBV", "ANATOMY", 302, 305], ["cytomegalovirus", "OBSERVATION", 352, 367]]], ["We also Fig. 8 .", [["Fig", "OBSERVATION_MODIFIER", 8, 11]]], ["DDX5 can bind to JEV 5 0 , 3 0 UTR and colocalizes with viral RNA.", [["DDX5", "CHEMICAL", 0, 4], ["DDX5", "GENE_OR_GENE_PRODUCT", 0, 4], ["JEV 5", "ORGANISM", 17, 22], ["DDX5", "PROTEIN", 0, 4], ["JEV 5 0 , 3 0 UTR", "DNA", 17, 34], ["viral RNA", "RNA", 56, 65], ["viral RNA", "PROBLEM", 56, 65], ["viral RNA", "OBSERVATION", 56, 65]]], ["DDX5 can bind to JEV 3 0 UTR.", [["DDX5", "CHEMICAL", 0, 4], ["DDX5", "GENE_OR_GENE_PRODUCT", 0, 4], ["DDX5", "PROTEIN", 0, 4], ["JEV 3 0 UTR", "DNA", 17, 28]]], ["JEV 5 0 , 3 0 UTR and control RNA with Tobramycin Affinity Tag were first transcripted in vitro, and then incubated with tobramycin conjugated matrix beads.", [["tobramycin", "CHEMICAL", 121, 131], ["tobramycin", "CHEMICAL", 121, 131], ["JEV 5", "ORGANISM", 0, 5], ["Tag", "GENE_OR_GENE_PRODUCT", 59, 62], ["tobramycin", "SIMPLE_CHEMICAL", 121, 131], ["JEV 5 0 , 3 0 UTR", "DNA", 0, 17], ["Tobramycin Affinity Tag", "PROTEIN", 39, 62], ["JEV", "SPECIES", 0, 3], ["JEV", "TEST", 0, 3], ["Tobramycin Affinity Tag", "TREATMENT", 39, 62], ["tobramycin conjugated matrix beads", "TREATMENT", 121, 155]]], ["The mixture was then incubated with BHK-21 cell lysate, the protein bounded on beads was detected by Western blot using anti-DDX5 polyclonal antibody.", [["BHK-21 cell lysate", "ANATOMY", 36, 54], ["BHK-21 cell", "CELL", 36, 47], ["lysate", "ORGANISM_SUBSTANCE", 48, 54], ["anti-DDX5", "GENE_OR_GENE_PRODUCT", 120, 129], ["anti-DDX5 polyclonal antibody", "PROTEIN", 120, 149], ["BHK-21 cell lysate", "TREATMENT", 36, 54], ["the protein", "PROBLEM", 56, 67], ["beads", "TREATMENT", 79, 84], ["anti-DDX5 polyclonal antibody", "TEST", 120, 149], ["cell lysate", "OBSERVATION", 43, 54]]], ["All the RNAs were also analyzed by 1% agarose, 5% input were also analyzed in parallel by western blot.", [["agarose", "SIMPLE_CHEMICAL", 38, 45], ["RNAs", "RNA", 8, 12]]], ["DDX5 colocalizes with viral RNA.", [["DDX5", "GENE_OR_GENE_PRODUCT", 0, 4], ["DDX5", "PROTEIN", 0, 4], ["viral RNA", "RNA", 22, 31], ["viral RNA", "PROBLEM", 22, 31], ["viral RNA", "OBSERVATION", 22, 31]]], ["BHK-21 cells was infected with JEV (MOI = 0.01), endogenous DDX5 was detected by anti-DDX5 polyclonal antibody and the viral RNA was detected (red) using the Click-iT \u00d2 RNA Imaging Kit at 12hpi.", [["BHK-21 cells", "ANATOMY", 0, 12], ["BHK-21 cells", "CELL", 0, 12], ["JEV", "ORGANISM", 31, 34], ["DDX5", "GENE_OR_GENE_PRODUCT", 60, 64], ["BHK-21 cells", "CELL_LINE", 0, 12], ["endogenous DDX5", "PROTEIN", 49, 64], ["anti-DDX5 polyclonal antibody", "PROTEIN", 81, 110], ["viral RNA", "RNA", 119, 128], ["JEV", "SPECIES", 31, 34], ["BHK", "TEST", 0, 3], ["JEV (MOI", "TEST", 31, 39], ["endogenous DDX5", "TEST", 49, 64], ["anti-DDX5 polyclonal antibody", "TEST", 81, 110], ["the viral RNA", "PROBLEM", 115, 128], ["the Click", "TEST", 154, 163], ["Imaging Kit", "TEST", 173, 184], ["21 cells", "OBSERVATION_MODIFIER", 4, 12], ["viral RNA", "OBSERVATION", 119, 128]]], ["The mock-infected cells were also included as a control. determined whether DDX5 is also incorporated into JEV virions.", [["cells", "ANATOMY", 18, 23], ["virions", "ANATOMY", 111, 118], ["DDX5", "CHEMICAL", 76, 80], ["cells", "CELL", 18, 23], ["DDX5", "GENE_OR_GENE_PRODUCT", 76, 80], ["JEV", "ORGANISM", 107, 110], ["mock-infected cells", "CELL_LINE", 4, 23], ["DDX5", "PROTEIN", 76, 80], ["JEV", "SPECIES", 107, 110], ["infected cells", "PROBLEM", 9, 23], ["DDX5", "PROBLEM", 76, 80], ["infected cells", "OBSERVATION", 9, 23], ["JEV virions", "OBSERVATION", 107, 118]]], ["We infected the BHK-21 cells with JEV (MOI = 0.01) for 48 h, the anti-EDIII monoclonal antibody was used to co-immunoprecipitate the mature virions in the medium, and the Western blot analysis showed that DDX5 is not incorporated into the JEV virions (Fig. 7C) .DDX5 was recruited from the nucleus to the cytoplasm during virus infection3.6.", [["BHK-21 cells", "ANATOMY", 16, 28], ["virions", "ANATOMY", 140, 147], ["nucleus", "ANATOMY", 290, 297], ["cytoplasm", "ANATOMY", 305, 314], ["DDX5", "CHEMICAL", 205, 209], ["BHK-21 cells", "CELL", 16, 28], ["JEV", "ORGANISM", 34, 37], ["DDX5", "GENE_OR_GENE_PRODUCT", 205, 209], ["JEV", "ORGANISM", 239, 242], ["DDX5", "GENE_OR_GENE_PRODUCT", 262, 266], ["nucleus", "CELLULAR_COMPONENT", 290, 297], ["cytoplasm", "ORGANISM_SUBSTANCE", 305, 314], ["BHK-21 cells", "CELL_LINE", 16, 28], ["anti-EDIII monoclonal antibody", "PROTEIN", 65, 95], ["DDX5", "PROTEIN", 205, 209], ["DDX5", "PROTEIN", 262, 266], ["BHK-21", "SPECIES", 16, 22], ["JEV", "SPECIES", 34, 37], ["JEV", "SPECIES", 239, 242], ["the BHK", "TEST", 12, 19], ["JEV (MOI", "TREATMENT", 34, 42], ["the anti-EDIII monoclonal antibody", "TEST", 61, 95], ["the Western blot analysis", "TEST", 167, 192], ["DDX5", "PROBLEM", 205, 209], ["virus infection3.6", "PROBLEM", 322, 340], ["21 cells", "OBSERVATION_MODIFIER", 20, 28], ["JEV virions", "OBSERVATION", 239, 250], ["nucleus", "ANATOMY", 290, 297], ["cytoplasm", "OBSERVATION_MODIFIER", 305, 314]]], ["DDX5 can bind to JEV 3 0 UTR and colocalize with the viral RNA It has been shown that NS3 and NS5 of JEV can bind to 3 0 -UTR of viral RNA and engage in virus replication (Chen et al., 1997) .", [["DDX5", "CHEMICAL", 0, 4], ["DDX5", "GENE_OR_GENE_PRODUCT", 0, 4], ["NS3", "GENE_OR_GENE_PRODUCT", 86, 89], ["NS5", "GENE_OR_GENE_PRODUCT", 94, 97], ["JEV", "ORGANISM", 101, 104], ["DDX5", "PROTEIN", 0, 4], ["JEV 3 0 UTR", "DNA", 17, 28], ["viral RNA", "RNA", 53, 62], ["NS3", "PROTEIN", 86, 89], ["NS5", "PROTEIN", 94, 97], ["3 0 -UTR", "DNA", 117, 125], ["viral RNA", "RNA", 129, 138], ["JEV", "SPECIES", 101, 104], ["the viral RNA", "TREATMENT", 49, 62], ["NS3", "TREATMENT", 86, 89], ["NS5 of JEV", "TREATMENT", 94, 104], ["viral RNA", "TREATMENT", 129, 138], ["viral RNA", "OBSERVATION", 53, 62], ["NS3", "OBSERVATION", 86, 89], ["viral RNA", "OBSERVATION", 129, 138]]], ["We also determined whether DDX5 can bind to JEV 5 0 or/and 3 0 -UTR.", [["DDX5", "CHEMICAL", 27, 31], ["DDX5", "GENE_OR_GENE_PRODUCT", 27, 31], ["JEV 5 0", "ORGANISM", 44, 51], ["DDX5", "PROTEIN", 27, 31], ["JEV 5 0 or/and 3 0 -UTR", "DNA", 44, 67]]], ["We synthesized JEV-5 0 , 3 0 UTR and control RNA in vitro, and incubated RNAs with the Tobramycin Affinity Tag beads, the cell lysate was then incubated with the beads.", [["cell lysate", "ANATOMY", 122, 133], ["JEV", "ORGANISM", 15, 18], ["Tobramycin", "SIMPLE_CHEMICAL", 87, 97], ["Tag", "GENE_OR_GENE_PRODUCT", 107, 110], ["cell lysate", "CELL", 122, 133], ["JEV-5 0 , 3 0 UTR", "DNA", 15, 32], ["Tobramycin Affinity Tag beads", "PROTEIN", 87, 116], ["the Tobramycin Affinity Tag beads", "TREATMENT", 83, 116], ["the cell lysate", "TREATMENT", 118, 133], ["the beads", "TREATMENT", 158, 167]]], ["The Western blot results showed only JEV 3 0 UTR can pull down endogenous DDX5, while the control RNA can not (Fig. 8A) .DDX5 was recruited from the nucleus to the cytoplasm during virus infectionMeanwhile, we also found that DDX5 colocalized with the viral RNA by confocal microscopy analysis at 12hpi (Fig. 8B) , demonstrating DDX5 may be involved in JEV RNA synthesis.DDX5 is a positive regulator for viral RNA synthesis but not for viral protein translationSince 5 0 and 3 0 UTR of JEV are both involved in the first round of viral protein translation and virus RNA replication, we used a JEV replicon reporter system to determine whether DDX5 modulated viral translation and/or RNA replication.", [["nucleus", "ANATOMY", 149, 156], ["cytoplasm", "ANATOMY", 164, 173], ["DDX5", "CHEMICAL", 371, 375], ["DDX5", "CHEMICAL", 643, 647], ["DDX5", "GENE_OR_GENE_PRODUCT", 74, 78], ["DDX5", "GENE_OR_GENE_PRODUCT", 121, 125], ["nucleus", "CELLULAR_COMPONENT", 149, 156], ["cytoplasm", "ORGANISM_SUBSTANCE", 164, 173], ["DDX5", "GENE_OR_GENE_PRODUCT", 226, 230], ["DDX5", "GENE_OR_GENE_PRODUCT", 329, 333], ["JEV", "ORGANISM", 353, 356], ["DDX5", "GENE_OR_GENE_PRODUCT", 371, 375], ["JEV", "ORGANISM", 486, 489], ["JEV", "ORGANISM", 593, 596], ["DDX5", "GENE_OR_GENE_PRODUCT", 643, 647], ["JEV 3 0 UTR", "DNA", 37, 48], ["DDX5", "PROTEIN", 74, 78], ["control RNA", "RNA", 90, 101], ["DDX5", "PROTEIN", 121, 125], ["DDX5", "PROTEIN", 226, 230], ["viral RNA", "RNA", 252, 261], ["DDX5", "PROTEIN", 329, 333], ["JEV RNA", "RNA", 353, 360], ["DDX5", "PROTEIN", 371, 375], ["5 0 and 3 0 UTR", "DNA", 467, 482], ["DDX5", "PROTEIN", 643, 647], ["JEV", "SPECIES", 353, 356], ["JEV", "SPECIES", 486, 489], ["JEV", "SPECIES", 593, 596], ["The Western blot", "TEST", 0, 16], ["JEV", "PROBLEM", 37, 40], ["endogenous DDX5", "TREATMENT", 63, 78], ["virus infection", "PROBLEM", 181, 196], ["DDX5", "PROBLEM", 226, 230], ["the viral RNA", "PROBLEM", 248, 261], ["confocal microscopy analysis", "TEST", 265, 293], ["JEV RNA synthesis", "PROBLEM", 353, 370], ["a positive regulator", "PROBLEM", 379, 399], ["viral RNA synthesis", "PROBLEM", 404, 423], ["viral protein translation", "PROBLEM", 436, 461], ["JEV", "PROBLEM", 486, 489], ["viral protein translation", "TREATMENT", 530, 555], ["virus RNA replication", "TREATMENT", 560, 581], ["a JEV replicon reporter system", "TREATMENT", 591, 621], ["viral translation", "TREATMENT", 658, 675], ["RNA replication", "TREATMENT", 683, 698], ["nucleus", "ANATOMY", 149, 156], ["JEV RNA synthesis", "OBSERVATION", 353, 370], ["viral protein translation", "OBSERVATION", 530, 555]]], ["We constructed a luciferase-containing JEV replicon according to the previous study (Chien et al., 2011) .", [["luciferase", "GENE_OR_GENE_PRODUCT", 17, 27], ["JEV", "ORGANISM", 39, 42], ["luciferase", "PROTEIN", 17, 27], ["JEV", "SPECIES", 39, 42], ["a luciferase", "TREATMENT", 15, 27], ["JEV replicon", "TREATMENT", 39, 51], ["the previous study", "TEST", 65, 83], ["JEV replicon", "OBSERVATION", 39, 51]]], ["BHK-21 cells were first transfected with DDX5i shRNA plasmid to knockdown the expression of DDX5, the non-targeting shRNA was used as the control.", [["BHK-21 cells", "ANATOMY", 0, 12], ["BHK-21 cells", "CELL", 0, 12], ["DDX5i", "GENE_OR_GENE_PRODUCT", 41, 46], ["DDX5", "GENE_OR_GENE_PRODUCT", 92, 96], ["BHK-21 cells", "CELL_LINE", 0, 12], ["DDX5i shRNA plasmid", "DNA", 41, 60], ["DDX5", "PROTEIN", 92, 96], ["non-targeting shRNA", "DNA", 102, 121], ["BHK", "TEST", 0, 3], ["DDX5i shRNA plasmid", "TREATMENT", 41, 60], ["DDX5", "TREATMENT", 92, 96], ["the non-targeting shRNA", "TREATMENT", 98, 121], ["21 cells", "OBSERVATION_MODIFIER", 4, 12]]], ["The cells were then transfected with in vitro-transcribed luciferase-containing JEV-replicon RNA and firefly luciferase RNA as the internal control.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["luciferase", "GENE_OR_GENE_PRODUCT", 58, 68], ["JEV", "ORGANISM", 80, 83], ["luciferase", "GENE_OR_GENE_PRODUCT", 109, 119], ["luciferase", "PROTEIN", 58, 68], ["JEV-replicon RNA", "RNA", 80, 96], ["luciferase RNA", "RNA", 109, 123], ["JEV", "SPECIES", 80, 83], ["vitro-transcribed luciferase", "TREATMENT", 40, 68], ["JEV-replicon RNA", "TREATMENT", 80, 96], ["firefly luciferase RNA", "TREATMENT", 101, 123]]], ["The cells were harvested for dual luciferase assays at 3, 6, 12, 24, 48 and 72 h post transfection.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["luciferase", "GENE_OR_GENE_PRODUCT", 34, 44], ["luciferase", "PROTEIN", 34, 44], ["dual luciferase assays", "TEST", 29, 51]]], ["The results showed that there were two peaks of replicon luciferase activity corresponding to the first translation and the second replication peak (Fig. 9A) .", [["luciferase", "GENE_OR_GENE_PRODUCT", 57, 67], ["luciferase", "PROTEIN", 57, 67], ["two peaks of replicon luciferase activity", "PROBLEM", 35, 76], ["peaks", "OBSERVATION_MODIFIER", 39, 44], ["replicon luciferase activity", "OBSERVATION", 48, 76]]], ["The luciferase activities were nearly the same in the DDX5i and control treated BHK-21 cells in the first peak, while luciferase activities were lower for all of the time points in the DDX5i treated BHK-21 cells in the second peak.", [["BHK-21 cells", "ANATOMY", 80, 92], ["BHK-21 cells", "ANATOMY", 199, 211], ["DDX5i", "CHEMICAL", 185, 190], ["luciferase", "GENE_OR_GENE_PRODUCT", 4, 14], ["BHK-21 cells", "CELL", 80, 92], ["luciferase", "GENE_OR_GENE_PRODUCT", 118, 128], ["BHK-21 cells", "CELL", 199, 211], ["luciferase", "PROTEIN", 4, 14], ["DDX5i", "CELL_LINE", 54, 59], ["BHK-21 cells", "CELL_LINE", 80, 92], ["luciferase", "PROTEIN", 118, 128], ["DDX5i treated BHK-21 cells", "CELL_LINE", 185, 211], ["BHK-21", "SPECIES", 80, 86], ["The luciferase activities", "TEST", 0, 25], ["luciferase activities", "TEST", 118, 139]]], ["The data showed that viral RNA replication, but not the viral protein translation, was hampered by DDX5 knockdown.", [["DDX5", "GENE_OR_GENE_PRODUCT", 99, 103], ["DDX5", "PROTEIN", 99, 103], ["The data", "TEST", 0, 8], ["viral RNA replication", "PROBLEM", 21, 42], ["the viral protein translation", "PROBLEM", 52, 81], ["viral RNA replication", "OBSERVATION", 21, 42]]], ["Meanwhile, the luciferase activity derived from a control reporter, Renilla luciferase flanked by cellular GAPDH 5 0 and 3 0 UTRs did not significantly changed between the shDDX5 and control treated cells (Fig. 9B) , which means that the translation of cellular protein was not hampered by DDX5 knockdown.", [["cellular", "ANATOMY", 98, 106], ["cells", "ANATOMY", 199, 204], ["cellular", "ANATOMY", 253, 261], ["luciferase", "GENE_OR_GENE_PRODUCT", 15, 25], ["Renilla", "GENE_OR_GENE_PRODUCT", 68, 75], ["luciferase", "GENE_OR_GENE_PRODUCT", 76, 86], ["cellular", "CELL", 98, 106], ["GAPDH 5 0", "GENE_OR_GENE_PRODUCT", 107, 116], ["3", "GENE_OR_GENE_PRODUCT", 121, 122], ["cells", "CELL", 199, 204], ["Fig. 9B", "CELL", 206, 213], ["cellular", "CELL", 253, 261], ["DDX5", "GENE_OR_GENE_PRODUCT", 290, 294], ["luciferase", "PROTEIN", 15, 25], ["Renilla luciferase", "DNA", 68, 86], ["cellular GAPDH 5 0 and 3 0 UTRs", "DNA", 98, 129], ["shDDX5", "CELL_LINE", 172, 178], ["control treated cells", "CELL_LINE", 183, 204], ["cellular protein", "PROTEIN", 253, 269], ["DDX5", "PROTEIN", 290, 294], ["a control reporter", "TREATMENT", 48, 66], ["cellular GAPDH", "TEST", 98, 112], ["cellular protein", "PROBLEM", 253, 269]]], ["Collectively, our results strongly suggested that DDX5 is involved in viral RNA replication by binding to JEV 3 0 UTR.DiscussionThe high prevalence of disease caused by JEV and the limited efficacy of therapies stimulate the research for safer and more effective antiviral agents to treat JEV infection.", [["DDX5", "CHEMICAL", 50, 54], ["JEV", "DISEASE", 169, 172], ["JEV infection", "DISEASE", 289, 302], ["DDX5", "GENE_OR_GENE_PRODUCT", 50, 54], ["JEV", "ORGANISM", 169, 172], ["JEV", "ORGANISM", 289, 292], ["DDX5", "PROTEIN", 50, 54], ["JEV 3 0 UTR", "DNA", 106, 117], ["JEV", "SPECIES", 169, 172], ["JEV", "SPECIES", 289, 292], ["viral RNA replication", "TREATMENT", 70, 91], ["disease", "PROBLEM", 151, 158], ["JEV", "PROBLEM", 169, 172], ["therapies stimulate", "TREATMENT", 201, 220], ["antiviral agents", "TREATMENT", 263, 279], ["JEV infection", "PROBLEM", 289, 302], ["viral RNA replication", "OBSERVATION", 70, 91], ["high prevalence", "OBSERVATION_MODIFIER", 132, 147], ["disease", "OBSERVATION", 151, 158], ["infection", "OBSERVATION", 293, 302]]], ["However, viral resistance to antiviral agents has been a problem.", [["antiviral agents", "TREATMENT", 29, 45], ["viral resistance", "OBSERVATION", 9, 25]]], ["One possible solution to overcome this problem is to target host cellular factors important for the viral life cycle.", [["cellular", "ANATOMY", 65, 73], ["cellular", "CELL", 65, 73], ["host cellular factors", "PROTEIN", 60, 81], ["the viral life cycle", "TREATMENT", 96, 116]]], ["DDX5 plays important roles in many virus, such as SARS-CoV, influenza virus and HCV (Chen et al., 2009; Goh et al., 2004) , and other cellular helicases such as DDX3, DDX1, DDX56 are also involved in many virus replication and the assembly of virions (Xu et al., 2011; Xu and Hobman, 2012) .", [["cellular", "ANATOMY", 134, 142], ["DDX5", "CHEMICAL", 0, 4], ["SARS-CoV, influenza virus", "DISEASE", 50, 75], ["DDX5", "GENE_OR_GENE_PRODUCT", 0, 4], ["SARS-CoV", "ORGANISM", 50, 58], ["influenza virus", "ORGANISM", 60, 75], ["HCV", "ORGANISM", 80, 83], ["cellular", "CELL", 134, 142], ["DDX3", "GENE_OR_GENE_PRODUCT", 161, 165], ["DDX1", "GENE_OR_GENE_PRODUCT", 167, 171], ["DDX56", "GENE_OR_GENE_PRODUCT", 173, 178], ["DDX5", "PROTEIN", 0, 4], ["cellular helicases", "PROTEIN", 134, 152], ["DDX3", "PROTEIN", 161, 165], ["DDX1", "PROTEIN", 167, 171], ["DDX56", "PROTEIN", 173, 178], ["influenza virus", "SPECIES", 60, 75], ["SARS-CoV", "SPECIES", 50, 58], ["HCV", "SPECIES", 80, 83], ["many virus", "PROBLEM", 30, 40], ["SARS", "PROBLEM", 50, 54], ["influenza virus", "PROBLEM", 60, 75], ["HCV", "PROBLEM", 80, 83], ["virus", "OBSERVATION", 205, 210]]], ["Two studies reported novel DDX3 inhibitors against HIV infection Radi et al., 2012) .", [["HIV infection", "DISEASE", 51, 64], ["DDX3", "GENE_OR_GENE_PRODUCT", 27, 31], ["HIV", "ORGANISM", 51, 54], ["DDX3", "PROTEIN", 27, 31], ["HIV", "SPECIES", 51, 54], ["HIV", "SPECIES", 51, 54], ["Two studies", "TEST", 0, 11], ["novel DDX3 inhibitors", "TREATMENT", 21, 42], ["HIV infection", "PROBLEM", 51, 64]]], ["Therefore, the cellular helicases have been proposed as a promising target to design novel agents to control viral infection that poses major global health threats (Geiss et al., 2009; Kwong et al., 2005; Stankiewicz-Drogo\u0144 et al., 2010) .DiscussionIn our studies, we demonstrated that a reduction of endogenous DDX5 and DDX5 helicase-dead mutants all significantly reduced the viral load and synthesis of viral RNA, suggesting DDX5 and its helicase activity are required for JEV replication.", [["cellular", "ANATOMY", 15, 23], ["viral infection", "DISEASE", 109, 124], ["cellular", "CELL", 15, 23], ["DDX5", "GENE_OR_GENE_PRODUCT", 312, 316], ["DDX5", "GENE_OR_GENE_PRODUCT", 321, 325], ["DDX5", "GENE_OR_GENE_PRODUCT", 428, 432], ["JEV", "ORGANISM", 476, 479], ["cellular helicases", "PROTEIN", 15, 33], ["DDX5", "PROTEIN", 312, 316], ["DDX5 helicase", "PROTEIN", 321, 334], ["viral RNA", "RNA", 406, 415], ["DDX5", "PROTEIN", 428, 432], ["JEV", "SPECIES", 476, 479], ["the cellular helicases", "TREATMENT", 11, 33], ["novel agents", "TREATMENT", 85, 97], ["viral infection", "PROBLEM", 109, 124], ["our studies", "TEST", 252, 263], ["endogenous DDX5", "TREATMENT", 301, 316], ["DDX5 helicase", "TREATMENT", 321, 334], ["dead mutants", "PROBLEM", 335, 347], ["the viral load", "PROBLEM", 374, 388], ["synthesis of viral RNA", "PROBLEM", 393, 415], ["DDX5", "PROBLEM", 428, 432], ["JEV replication", "TREATMENT", 476, 491], ["viral", "OBSERVATION_MODIFIER", 109, 114], ["infection", "OBSERVATION", 115, 124], ["viral load", "OBSERVATION", 378, 388], ["viral RNA", "OBSERVATION", 406, 415]]], ["Our data also showed that DDX5 does not affect virus assembly and release or incorporate into the virions, implying its minimal influence on virus maturation.DiscussionIt has been shown JEV core, NS3 and NS5 proteins play important roles in viral genome replication (Chen et al., 1997; Uchil and Satchidanandam, 2003a) .", [["virions", "ANATOMY", 98, 105], ["DDX5", "CHEMICAL", 26, 30], ["DDX5", "GENE_OR_GENE_PRODUCT", 26, 30], ["JEV", "ORGANISM", 186, 189], ["NS3", "GENE_OR_GENE_PRODUCT", 196, 199], ["NS5", "GENE_OR_GENE_PRODUCT", 204, 207], ["DDX5", "PROTEIN", 26, 30], ["NS3", "PROTEIN", 196, 199], ["NS5 proteins", "PROTEIN", 204, 216], ["JEV", "SPECIES", 186, 189], ["Our data", "TEST", 0, 8], ["DDX5", "PROBLEM", 26, 30], ["virus", "PROBLEM", 47, 52], ["virus maturation", "TREATMENT", 141, 157], ["NS3 and NS5 proteins", "TREATMENT", 196, 216], ["minimal", "OBSERVATION_MODIFIER", 120, 127], ["viral genome", "OBSERVATION", 241, 253]]], ["By using GST-pulldown and coimmunoprecipitation, we demonstrated that DDX5 can interact with JEV core, NS3, NS5-MTase and NS5-RdRp, suggesting that DDX5 might act as a cofactor for JEV proteins in virus replication.", [["DDX5", "CHEMICAL", 70, 74], ["DDX5", "CHEMICAL", 148, 152], ["GST", "GENE_OR_GENE_PRODUCT", 9, 12], ["DDX5", "GENE_OR_GENE_PRODUCT", 70, 74], ["JEV", "ORGANISM", 93, 96], ["NS3", "GENE_OR_GENE_PRODUCT", 103, 106], ["NS5-MTase", "GENE_OR_GENE_PRODUCT", 108, 117], ["NS5-RdRp", "GENE_OR_GENE_PRODUCT", 122, 130], ["DDX5", "GENE_OR_GENE_PRODUCT", 148, 152], ["JEV", "ORGANISM", 181, 184], ["GST", "PROTEIN", 9, 12], ["DDX5", "PROTEIN", 70, 74], ["NS3", "PROTEIN", 103, 106], ["NS5", "PROTEIN", 108, 111], ["MTase", "PROTEIN", 112, 117], ["NS5", "PROTEIN", 122, 125], ["RdRp", "PROTEIN", 126, 130], ["DDX5", "PROTEIN", 148, 152], ["JEV proteins", "PROTEIN", 181, 193], ["JEV", "SPECIES", 93, 96], ["JEV", "SPECIES", 181, 184], ["GST-pulldown", "TREATMENT", 9, 21], ["coimmunoprecipitation", "TEST", 26, 47], ["JEV core", "TREATMENT", 93, 101], ["NS3", "TREATMENT", 103, 106], ["NS5-MTase", "TREATMENT", 108, 117], ["NS5-RdRp", "TREATMENT", 122, 130], ["JEV proteins in virus replication", "PROBLEM", 181, 214]]], ["It has been suggested that cellular proteins can bind to viral 5 0 and/or 3 0 UTR to modulate viral translation and/or replication (Chen et al., 1997) .", [["cellular", "ANATOMY", 27, 35], ["cellular", "CELL", 27, 35], ["5 0", "ORGANISM", 63, 66], ["cellular proteins", "PROTEIN", 27, 44], ["viral 5 0 and/or 3 0 UTR", "DNA", 57, 81], ["cellular proteins", "PROBLEM", 27, 44], ["viral", "TEST", 57, 62]]], ["Our studies showed that DDX5 can only interact with viral 3 0 UTR and colocalize with viral RNA.", [["DDX5", "CHEMICAL", 24, 28], ["DDX5", "GENE_OR_GENE_PRODUCT", 24, 28], ["DDX5", "PROTEIN", 24, 28], ["viral 3 0 UTR", "DNA", 52, 65], ["viral RNA", "RNA", 86, 95], ["Our studies", "TEST", 0, 11], ["DDX5", "PROBLEM", 24, 28], ["viral 3 0 UTR", "TREATMENT", 52, 65], ["viral RNA", "PROBLEM", 86, 95], ["viral RNA", "OBSERVATION", 86, 95]]], ["We further confirmed that DDX5 plays an important role in virus RNA replication but not in viral protein translation, which is consistent with its ability to bind to viral 3 0 UTR.", [["DDX5", "CHEMICAL", 26, 30], ["DDX5", "GENE_OR_GENE_PRODUCT", 26, 30], ["DDX5", "PROTEIN", 26, 30], ["viral 3 0 UTR", "DNA", 166, 179], ["virus RNA replication", "TREATMENT", 58, 79], ["viral protein translation", "PROBLEM", 91, 116], ["consistent with", "UNCERTAINTY", 127, 142]]], ["We performed the competition binding studies to map the interaction interfaces between DDX5 and viral proteins.", [["DDX5", "GENE_OR_GENE_PRODUCT", 87, 91], ["DDX5", "PROTEIN", 87, 91], ["viral proteins", "PROTEIN", 96, 110], ["the competition binding studies", "TEST", 13, 44], ["DDX5", "TEST", 87, 91], ["viral proteins", "PROBLEM", 96, 110], ["viral proteins", "OBSERVATION", 96, 110]]], ["The viral RNA replication is a quite dynamic process, and other host factors are also recruited by the viral proteins to facilitate this process (Lindenbach et al., 2005; Uchil and Satchidanandam, 2003a) .", [["viral proteins", "PROTEIN", 103, 117], ["The viral RNA replication", "PROBLEM", 0, 25], ["viral RNA replication", "OBSERVATION", 4, 25]]], ["We suspected that the interaction interfaces shown in our competition binding studies might not always exist during viral RNA replication. .", [["the interaction interfaces", "PROBLEM", 18, 44], ["viral RNA replication", "TREATMENT", 116, 137]]], ["The firefly luciferase reporter was used as the internal control.", [["luciferase", "GENE_OR_GENE_PRODUCT", 12, 22], ["firefly luciferase reporter", "DNA", 4, 31], ["The firefly luciferase reporter", "TEST", 0, 31], ["the internal control", "TREATMENT", 44, 64]]], ["At various times post transfection, cell lysates were collected for dualluciferase assays.", [["cell lysates", "ANATOMY", 36, 48], ["cell lysates", "CELL", 36, 48], ["cell lysates", "TEST", 36, 48], ["dualluciferase assays", "TEST", 68, 89]]], ["Renilla luciferase activity was normalized to that of firefly luciferase activity.", [["Renilla", "ORGANISM", 0, 7], ["luciferase", "GENE_OR_GENE_PRODUCT", 8, 18], ["luciferase", "GENE_OR_GENE_PRODUCT", 62, 72], ["luciferase", "PROTEIN", 8, 18], ["luciferase", "PROTEIN", 62, 72], ["Renilla luciferase activity", "TEST", 0, 27]]], ["Some negative-stranded RNA viruses use the host cytoplasm as the primary site of replication, they can also recruit nuclear factors and alter their nuclear-cytoplasm trafficking to enhance viral replication (Hiscox, 2003) .", [["cytoplasm", "ANATOMY", 48, 57], ["nuclear", "ANATOMY", 116, 123], ["nuclear", "ANATOMY", 148, 155], ["cytoplasm", "ANATOMY", 156, 165], ["cytoplasm", "ORGANISM_SUBSTANCE", 48, 57], ["nuclear", "CELLULAR_COMPONENT", 148, 155], ["cytoplasm", "ORGANISM_SUBSTANCE", 156, 165], ["nuclear factors", "PROTEIN", 116, 131], ["stranded RNA viruses", "PROBLEM", 14, 34], ["negative", "OBSERVATION_MODIFIER", 5, 13], ["-", "OBSERVATION_MODIFIER", 13, 14], ["stranded RNA viruses", "OBSERVATION", 14, 34], ["host cytoplasm", "OBSERVATION_MODIFIER", 43, 57], ["replication", "OBSERVATION", 81, 92]]], ["The host nucleus proteins could be recruited to cytoplasm to facilitate flaviviruses replication (Uchil and Satchidanandam, 2003b; Zebovitz et al., 1974) .", [["nucleus", "ANATOMY", 9, 16], ["cytoplasm", "ANATOMY", 48, 57], ["cytoplasm", "ORGANISM_SUBSTANCE", 48, 57], ["host nucleus proteins", "PROTEIN", 4, 25], ["flaviviruses replication", "TREATMENT", 72, 96], ["host nucleus", "OBSERVATION", 4, 16]]], ["It has been reported that DDX5 is redistributed into the cytoplasm during HCV infection (Goh et al., 2004) .", [["cytoplasm", "ANATOMY", 57, 66], ["HCV infection", "DISEASE", 74, 87], ["DDX5", "GENE_OR_GENE_PRODUCT", 26, 30], ["cytoplasm", "ORGANISM_SUBSTANCE", 57, 66], ["HCV", "ORGANISM", 74, 77], ["DDX5", "PROTEIN", 26, 30], ["HCV", "SPECIES", 74, 77], ["HCV infection", "PROBLEM", 74, 87], ["redistributed", "OBSERVATION_MODIFIER", 34, 47], ["cytoplasm", "OBSERVATION_MODIFIER", 57, 66], ["HCV", "OBSERVATION_MODIFIER", 74, 77], ["infection", "OBSERVATION", 78, 87]]], ["Consistent with this, our study showed that DDX5 might be recruited to the cytoplasm and colocalize with the JEV core, NS3 and NS5 and viral RNA during the infection to facilitate the unwinding the intermediate RNA duplexes.", [["cytoplasm", "ANATOMY", 75, 84], ["DDX5", "CHEMICAL", 44, 48], ["infection", "DISEASE", 156, 165], ["DDX5", "GENE_OR_GENE_PRODUCT", 44, 48], ["cytoplasm", "ORGANISM_SUBSTANCE", 75, 84], ["JEV", "ORGANISM", 109, 112], ["NS3", "GENE_OR_GENE_PRODUCT", 119, 122], ["NS5", "GENE_OR_GENE_PRODUCT", 127, 130], ["DDX5", "PROTEIN", 44, 48], ["JEV core, NS3 and NS5 and viral RNA", "RNA", 109, 144], ["intermediate RNA duplexes", "RNA", 198, 223], ["JEV", "SPECIES", 109, 112], ["our study", "TEST", 22, 31], ["DDX5", "PROBLEM", 44, 48], ["the JEV core", "TEST", 105, 117], ["NS3", "PROBLEM", 119, 122], ["NS5", "PROBLEM", 127, 130], ["viral RNA", "PROBLEM", 135, 144], ["the infection", "PROBLEM", 152, 165], ["viral RNA", "OBSERVATION", 135, 144], ["intermediate RNA duplexes", "OBSERVATION", 198, 223]]], ["Since LMB can inhibit all the CRM1-mediated export of proteins from the nucleus to the cytoplasm (Wang et al., 2009a) , we cannot rule out the trafficking of other cellular proteins inhibited by LMB which might also be important for virus replication.", [["nucleus", "ANATOMY", 72, 79], ["cytoplasm", "ANATOMY", 87, 96], ["cellular", "ANATOMY", 164, 172], ["LMB", "CHEMICAL", 6, 9], ["LMB", "CHEMICAL", 195, 198], ["LMB", "CHEMICAL", 6, 9], ["LMB", "CHEMICAL", 195, 198], ["LMB", "SIMPLE_CHEMICAL", 6, 9], ["CRM1", "GENE_OR_GENE_PRODUCT", 30, 34], ["nucleus", "CELLULAR_COMPONENT", 72, 79], ["cytoplasm", "ORGANISM_SUBSTANCE", 87, 96], ["cellular", "CELL", 164, 172], ["LMB", "SIMPLE_CHEMICAL", 195, 198], ["CRM1", "PROTEIN", 30, 34], ["cellular proteins", "PROTEIN", 164, 181], ["other cellular proteins", "PROBLEM", 158, 181], ["virus replication", "TREATMENT", 233, 250], ["nucleus", "ANATOMY", 72, 79]]], ["Our result showed that virus can still replicate at low titers after LMB treatment.", [["LMB", "CHEMICAL", 69, 72], ["LMB", "CHEMICAL", 69, 72], ["LMB", "SIMPLE_CHEMICAL", 69, 72], ["virus", "PROBLEM", 23, 28], ["LMB treatment", "TREATMENT", 69, 82], ["virus", "OBSERVATION", 23, 28]]], ["Considering that DDX5 shuttles between nucleus and cytoplasma, we speculated the small amount of DDX5 resides in cytoplasma after LMB treatment still exerts its role in virus replication.", [["nucleus", "ANATOMY", 39, 46], ["cytoplasma", "ANATOMY", 51, 61], ["cytoplasma", "ANATOMY", 113, 123], ["LMB", "CHEMICAL", 130, 133], ["LMB", "CHEMICAL", 130, 133], ["DDX5", "GENE_OR_GENE_PRODUCT", 17, 21], ["nucleus", "CELLULAR_COMPONENT", 39, 46], ["cytoplasma", "CELLULAR_COMPONENT", 51, 61], ["DDX5", "GENE_OR_GENE_PRODUCT", 97, 101], ["cytoplasma", "CANCER", 113, 123], ["LMB", "SIMPLE_CHEMICAL", 130, 133], ["DDX5", "PROTEIN", 17, 21], ["DDX5", "PROTEIN", 97, 101], ["DDX5 shuttles between nucleus and cytoplasma", "PROBLEM", 17, 61], ["the small amount of DDX5", "PROBLEM", 77, 101], ["LMB treatment", "TREATMENT", 130, 143], ["virus replication", "TREATMENT", 169, 186], ["small", "OBSERVATION_MODIFIER", 81, 86], ["amount", "OBSERVATION_MODIFIER", 87, 93]]], ["Meanwhile, it is also possible that DDX5 is only used to increase the efficiency of RNA separation so that the viral RdRp can transcribe viral RNA more efficiently during virus replication.DiscussionIn summary, our studies identified that DDX5 as a positive regulator for JEV replication, which will be useful for further understanding of cellular proteins involvement during JEV replication.", [["cellular", "ANATOMY", 339, 347], ["DDX5", "CHEMICAL", 36, 40], ["DDX5", "GENE_OR_GENE_PRODUCT", 36, 40], ["DDX5", "GENE_OR_GENE_PRODUCT", 239, 243], ["JEV", "ORGANISM", 272, 275], ["cellular", "CELL", 339, 347], ["JEV", "ORGANISM", 376, 379], ["DDX5", "PROTEIN", 36, 40], ["viral RdRp", "PROTEIN", 111, 121], ["viral RNA", "RNA", 137, 146], ["DDX5", "PROTEIN", 239, 243], ["cellular proteins", "PROTEIN", 339, 356], ["JEV", "SPECIES", 272, 275], ["JEV", "SPECIES", 376, 379], ["DDX5", "PROBLEM", 36, 40], ["RNA separation", "TREATMENT", 84, 98], ["the viral RdRp", "PROBLEM", 107, 121], ["viral RNA", "PROBLEM", 137, 146], ["virus replication", "TREATMENT", 171, 188], ["our studies", "TEST", 211, 222], ["JEV replication", "TREATMENT", 272, 287], ["cellular proteins involvement", "PROBLEM", 339, 368], ["JEV replication", "TREATMENT", 376, 391], ["is also possible", "UNCERTAINTY", 14, 30], ["RNA separation", "OBSERVATION", 84, 98], ["viral RdRp", "OBSERVATION", 111, 121]]], ["Our results also suggest that DDX5 could be served as a novel targets to design small inhibitors against Japanese encephalitis virus infection.", [["DDX5", "CHEMICAL", 30, 34], ["Japanese encephalitis virus infection", "DISEASE", 105, 142], ["DDX5", "GENE_OR_GENE_PRODUCT", 30, 34], ["Japanese encephalitis virus", "ORGANISM", 105, 132], ["DDX5", "PROTEIN", 30, 34], ["Japanese encephalitis virus", "SPECIES", 105, 132], ["Japanese encephalitis virus", "SPECIES", 105, 132], ["design small inhibitors", "TREATMENT", 73, 96], ["Japanese encephalitis virus infection", "PROBLEM", 105, 142]]]], "bafa2173dd5ac540e0d606352a73db4d29527cde": [["In the middle of the 19th century, it became clear that micro-organisms could cause disease.", [["micro-organisms", "PROBLEM", 56, 71], ["disease", "PROBLEM", 84, 91], ["middle", "ANATOMY_MODIFIER", 7, 13]]], ["Effective treatment, however, was not possible at that time; prevention and spread of infectious diseases depended solely on proper hygienic means.", [["infectious diseases", "DISEASE", 86, 105], ["Effective treatment", "TREATMENT", 0, 19], ["infectious diseases", "PROBLEM", 86, 105], ["infectious", "OBSERVATION", 86, 96]]], ["At the beginning of the 20th century, passive and active vaccination procedures were developed against a number of these pathogenic micro-organisms to prevent the diseases in question (rabies, diphtheria, tetanus, etc.) .", [["rabies, diphtheria, tetanus", "DISEASE", 185, 212], ["active vaccination procedures", "TREATMENT", 50, 79], ["these pathogenic micro-organisms", "PROBLEM", 115, 147], ["the diseases", "PROBLEM", 159, 171], ["rabies", "PROBLEM", 185, 191], ["diphtheria", "PROBLEM", 193, 203], ["tetanus", "PROBLEM", 205, 212], ["active", "OBSERVATION_MODIFIER", 50, 56], ["diseases", "OBSERVATION", 163, 171]]], ["Thanks to the discovery of antimicrobial chemicals (by Paul Ehrlich) and antibiotics (by Sir Alexander Fleming), the threat of infectious diseases seemed to be minimised.", [["infectious diseases", "DISEASE", 127, 146], ["Paul Ehrlich", "ORGANISM", 55, 67], ["antimicrobial chemicals", "TREATMENT", 27, 50], ["antibiotics", "TREATMENT", 73, 84], ["infectious diseases", "PROBLEM", 127, 146], ["infectious", "OBSERVATION", 127, 137]]], ["Large scale vaccination programmes against childhood diseases (diphtheria, whooping cough and polio), started in the early 1950s, raised hopes of finally being able to eradicate these diseases from the planet.", [["diphtheria", "DISEASE", 63, 73], ["whooping cough", "DISEASE", 75, 89], ["polio", "DISEASE", 94, 99], ["Large scale vaccination programmes", "TREATMENT", 0, 34], ["childhood diseases", "PROBLEM", 43, 61], ["diphtheria", "PROBLEM", 63, 73], ["whooping cough", "PROBLEM", 75, 89], ["polio", "PROBLEM", 94, 99], ["these diseases", "PROBLEM", 178, 192], ["scale", "OBSERVATION_MODIFIER", 6, 11]]], ["This approach was successful for smallpox (1980) .", [["smallpox", "DISEASE", 33, 41]]], ["However, new infectious diseases have emerged [e.g., Legionella, human immunodeficiency virus (HIV), Helicobacter, SARS, etc.] and new vaccines and antibiotics are needed.", [["infectious diseases", "DISEASE", 13, 32], ["Legionella, human immunodeficiency virus (HIV), Helicobacter, SARS", "DISEASE", 53, 119], ["human immunodeficiency virus", "ORGANISM", 65, 93], ["HIV", "ORGANISM", 95, 98], ["Helicobacter", "ORGANISM", 101, 113], ["human immunodeficiency virus", "SPECIES", 65, 93], ["human immunodeficiency virus", "SPECIES", 65, 93], ["HIV", "SPECIES", 95, 98], ["new infectious diseases", "PROBLEM", 9, 32], ["Legionella", "PROBLEM", 53, 63], ["human immunodeficiency virus (HIV)", "PROBLEM", 65, 99], ["Helicobacter, SARS", "PROBLEM", 101, 119], ["new vaccines", "TREATMENT", 131, 143], ["antibiotics", "TREATMENT", 148, 159], ["new", "OBSERVATION_MODIFIER", 9, 12], ["infectious", "OBSERVATION", 13, 23]]], ["Furthermore, due to intensive medical treatment with antibiotics and immunosuppressive drugs, hospital infections are a growing problem.", [["infections", "DISEASE", 103, 113], ["intensive medical treatment", "TREATMENT", 20, 47], ["antibiotics", "TREATMENT", 53, 64], ["immunosuppressive drugs", "TREATMENT", 69, 92], ["hospital infections", "PROBLEM", 94, 113], ["a growing problem", "PROBLEM", 118, 135]]], ["Bacteria hitherto deemed harmless are causing opportunistic infections in immunocompromised patients.", [["opportunistic infections", "DISEASE", 46, 70], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["Bacteria hitherto", "PROBLEM", 0, 17], ["opportunistic infections in immunocompromised patients", "PROBLEM", 46, 100], ["opportunistic", "OBSERVATION_MODIFIER", 46, 59], ["infections", "OBSERVATION", 60, 70], ["immunocompromised", "OBSERVATION", 74, 91]]], ["The pathogens have developed resistance to many antibiotics and sometimes no effective antibiotics are available to treat these patients.", [["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["The pathogens", "PROBLEM", 0, 13], ["many antibiotics", "TREATMENT", 43, 59], ["effective antibiotics", "TREATMENT", 77, 98]]]]}